{"9894672ce867c47c00c11568c97d4276e5471ebf": [["IntroductionParaesophageal hernia (PEH) is an uncommon type of hiatal hernia that affects mostly female patients over the age of 60 in the civilian population.", [["Paraesophageal hernia", "ANATOMY", 12, 33], ["PEH", "ANATOMY", 35, 38], ["hiatal hernia", "ANATOMY", 63, 76], ["Paraesophageal hernia", "DISEASE", 12, 33], ["PEH", "DISEASE", 35, 38], ["hiatal hernia", "DISEASE", 63, 76], ["Paraesophageal hernia", "PATHOLOGICAL_FORMATION", 12, 33], ["hiatal hernia", "PATHOLOGICAL_FORMATION", 63, 76], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["Paraesophageal hernia", "PROBLEM", 12, 33], ["hiatal hernia", "PROBLEM", 63, 76], ["Paraesophageal hernia", "OBSERVATION", 12, 33], ["uncommon type", "OBSERVATION_MODIFIER", 46, 59], ["hiatal hernia", "OBSERVATION", 63, 76]]], ["[1] [2] [3] [4] [5] [6] Despite the uncommon nature, patients with symptomatic PEHs usually undergo elective intervention when symptoms impinge upon their quality of life, or emergently, if the individual encounters symptoms of gastric volvulus or strangulation.", [["gastric", "ANATOMY", 228, 235], ["PEHs", "DISEASE", 79, 83], ["gastric volvulus", "DISEASE", 228, 244], ["strangulation", "DISEASE", 248, 261], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["patients", "ORGANISM", 53, 61], ["gastric volvulus", "PATHOLOGICAL_FORMATION", 228, 244], ["patients", "SPECIES", 53, 61], ["symptomatic PEHs", "PROBLEM", 67, 83], ["elective intervention", "TREATMENT", 100, 121], ["symptoms", "PROBLEM", 127, 135], ["gastric volvulus", "PROBLEM", 228, 244], ["strangulation", "PROBLEM", 248, 261], ["gastric", "ANATOMY", 228, 235], ["volvulus", "OBSERVATION", 236, 244], ["strangulation", "OBSERVATION", 248, 261]]], ["[7] [8] [9] PEH are usually repaired through a laparotomy, left thoracotomy, or laparoscopically.", [["[7] [8] [9]", "CHEMICAL", 0, 11], ["[7] [8] [9] PEH", "CHEMICAL", 0, 15], ["[7] [8] [9] PEH", "SIMPLE_CHEMICAL", 0, 15], ["a laparotomy", "TREATMENT", 45, 57], ["left thoracotomy", "TREATMENT", 59, 75], ["laparoscopically", "TREATMENT", 80, 96], ["laparotomy", "OBSERVATION", 47, 57], ["left", "ANATOMY_MODIFIER", 59, 63], ["thoracotomy", "OBSERVATION", 64, 75], ["laparoscopically", "OBSERVATION", 80, 96]]], ["Studies from the civilian population document significant decreases in perioperative mortality and morbidity in laparoscopic compared to open PEH repair.", [["PEH", "PATHOLOGICAL_FORMATION", 142, 145], ["Studies", "TEST", 0, 7], ["the civilian population", "TEST", 13, 36], ["significant decreases in perioperative mortality", "PROBLEM", 46, 94], ["morbidity", "PROBLEM", 99, 108], ["laparoscopic", "TREATMENT", 112, 124], ["open PEH repair", "TREATMENT", 137, 152], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["decreases", "OBSERVATION_MODIFIER", 58, 67], ["perioperative mortality", "OBSERVATION", 71, 94], ["laparoscopic", "OBSERVATION", 112, 124], ["PEH repair", "OBSERVATION", 142, 152]]], ["Over the past decade, the number of laparoscopic paraesophageal hernia repairs has surpassed the number of open paraesophageal hernia repairs in the private sector.", [["paraesophageal hernia", "ANATOMY", 49, 70], ["paraesophageal hernia", "ANATOMY", 112, 133], ["paraesophageal hernia", "DISEASE", 49, 70], ["paraesophageal hernia", "DISEASE", 112, 133], ["hernia", "PATHOLOGICAL_FORMATION", 127, 133], ["laparoscopic paraesophageal hernia repairs", "TREATMENT", 36, 78], ["open paraesophageal hernia repairs", "TREATMENT", 107, 141], ["laparoscopic", "OBSERVATION_MODIFIER", 36, 48], ["paraesophageal hernia", "OBSERVATION", 49, 70], ["repairs", "OBSERVATION", 71, 78], ["number", "OBSERVATION_MODIFIER", 97, 103], ["open", "OBSERVATION_MODIFIER", 107, 111], ["paraesophageal hernia", "OBSERVATION", 112, 133], ["repairs", "OBSERVATION", 134, 141]]], ["[1] [2] [3] [4] [5] [6] 10 However, there have not been any recent studies of paraesophageal hernia outcomes in the veteran population in the last decade.IntroductionThe Veterans Affairs Surgical Quality Improvement Program (VASQIP) database is a nationwide database that provides unique details on each patient.", [["paraesophageal hernia", "ANATOMY", 78, 99], ["paraesophageal hernia", "DISEASE", 78, 99], ["[1] [2] [3] [4] [5] [6] 10", "SIMPLE_CHEMICAL", 0, 26], ["paraesophageal hernia", "PATHOLOGICAL_FORMATION", 78, 99], ["patient", "ORGANISM", 304, 311], ["patient", "SPECIES", 304, 311], ["paraesophageal hernia", "PROBLEM", 78, 99], ["paraesophageal", "ANATOMY", 78, 92], ["hernia", "OBSERVATION", 93, 99]]], ["11 As the veterans are predominantly male, this study provides a unique opportunity to analyze the outcomes of paraesophageal hernia repair in the male population.", [["paraesophageal hernia", "ANATOMY", 111, 132], ["paraesophageal hernia", "DISEASE", 111, 132], ["veterans", "ORGANISM", 10, 18], ["paraesophageal hernia", "PATHOLOGICAL_FORMATION", 111, 132], ["this study", "TEST", 43, 53], ["paraesophageal hernia repair", "TREATMENT", 111, 139], ["predominantly", "OBSERVATION_MODIFIER", 23, 36], ["paraesophageal", "ANATOMY", 111, 125], ["hernia", "OBSERVATION", 126, 132]]], ["The VASQIP database allows a granular analysis of details such as the geographic location of the surgical facility and surgeon subspecialty versus the National Surgical Quality Improvement Program (NSQIP) .", [["VASQIP", "DNA", 4, 10]]], ["Previous studies have demonstrated variations in healthcare utilization, medical management, preventative medicine, and surgical outcomes.", [["Previous studies", "TEST", 0, 16], ["medical management", "TREATMENT", 73, 91], ["preventative medicine", "TREATMENT", 93, 114], ["surgical outcomes", "TREATMENT", 120, 137], ["variations", "OBSERVATION_MODIFIER", 35, 45]]], ["12, 13 This study aims to analyze the surgical outcomes of veterans who underwent PEH repair in the recent decade to elucidate any association between patient demographics, comorbidities, or geographic locations and morbidities.Patient SelectionVeterans who underwent paraesophageal hernia repair from 2010 to 2017 were identified using Current Procedural Terminology (CPT) codes from the VASQIP database.", [["paraesophageal hernia", "ANATOMY", 268, 289], ["paraesophageal hernia", "DISEASE", 268, 289], ["veterans", "ORGANISM", 59, 67], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["Patient", "SPECIES", 228, 235], ["This study", "TEST", 7, 17], ["PEH repair", "TREATMENT", 82, 92], ["comorbidities", "PROBLEM", 173, 186], ["morbidities", "PROBLEM", 216, 227], ["paraesophageal hernia repair", "TREATMENT", 268, 296], ["the VASQIP database", "TEST", 385, 404], ["repair", "OBSERVATION", 86, 92], ["paraesophageal", "ANATOMY", 268, 282], ["hernia", "OBSERVATION", 283, 289]]], ["CPT codes included 43332, 43333, 43334, 43335, 43336, and 43337 for open procedures (laparotomy, thoracotomy, or thoracoabdominal approaches) with or without mesh placement and 43281 and 43282 for laparoscopic procedures with or without mesh placement.", [["thoracoabdominal", "ANATOMY", 113, 129], ["open procedures", "TREATMENT", 68, 83], ["laparotomy", "TREATMENT", 85, 95], ["thoracotomy", "TREATMENT", 97, 108], ["thoracoabdominal approaches", "TREATMENT", 113, 140], ["mesh placement", "TREATMENT", 158, 172], ["laparoscopic procedures", "TREATMENT", 197, 220], ["mesh placement", "TREATMENT", 237, 251], ["laparotomy", "OBSERVATION", 85, 95], ["thoracotomy", "ANATOMY", 97, 108], ["thoracoabdominal", "ANATOMY", 113, 129], ["without", "UNCERTAINTY", 229, 236], ["mesh", "OBSERVATION", 237, 241]]], ["Patients were grouped into open versus laparoscopic cohorts.Data CollectionVASQIP data for each patient included age at the time of surgery, gender, ethnicity, body mass index (BMI), primary and secondary CPT codes, patient comorbidities, preoperative lab results, operative data, postoperative lab results, 30-day complications, 30-day mortality, 180-day mortality, hospital length of stay (LOS), surgeon specialty, and Veteran Affairs facility code.OutcomesThe outcomes included postoperative complications, including LOS, return to the operating room (OR), postoperative myocardial infarction (MI), pulmonary embolism (Patient Demographics and ComorbiditiesBetween 2010 and 2017, there were 1607 patients (81.5%) who underwent laparoscopic paraesophageal hernia repair (LPHR) and 366 patients (18.6%) who underwent open paraesophageal hernia repair (OPHR) in the VA hospitals nationwide.", [["body", "ANATOMY", 160, 164], ["myocardial", "ANATOMY", 574, 584], ["pulmonary", "ANATOMY", 602, 611], ["paraesophageal hernia", "ANATOMY", 743, 764], ["paraesophageal hernia", "ANATOMY", 823, 844], ["postoperative myocardial infarction", "DISEASE", 560, 595], ["MI", "DISEASE", 597, 599], ["pulmonary embolism", "DISEASE", 602, 620], ["paraesophageal hernia", "DISEASE", 743, 764], ["paraesophageal hernia", "DISEASE", 823, 844], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 96, 103], ["body", "ORGANISM_SUBDIVISION", 160, 164], ["patient", "ORGANISM", 216, 223], ["myocardial", "MULTI-TISSUE_STRUCTURE", 574, 584], ["pulmonary", "ORGAN", 602, 611], ["patients", "ORGANISM", 699, 707], ["patients", "ORGANISM", 787, 795], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 96, 103], ["patient", "SPECIES", 216, 223], ["patients", "SPECIES", 699, 707], ["patients", "SPECIES", 787, 795], ["laparoscopic cohorts", "TREATMENT", 39, 59], ["surgery", "TREATMENT", 132, 139], ["body mass index", "PROBLEM", 160, 175], ["primary and secondary CPT codes", "PROBLEM", 183, 214], ["patient comorbidities", "PROBLEM", 216, 237], ["postoperative complications", "PROBLEM", 481, 508], ["postoperative myocardial infarction", "PROBLEM", 560, 595], ["MI", "PROBLEM", 597, 599], ["pulmonary embolism", "PROBLEM", 602, 620], ["laparoscopic paraesophageal hernia repair", "TREATMENT", 730, 771], ["open paraesophageal hernia repair", "TREATMENT", 818, 851], ["myocardial", "ANATOMY", 574, 584], ["infarction", "OBSERVATION", 585, 595], ["pulmonary", "ANATOMY", 602, 611], ["embolism", "OBSERVATION", 612, 620], ["paraesophageal", "ANATOMY", 743, 757], ["hernia repair", "OBSERVATION", 758, 771], ["paraesophageal", "ANATOMY", 823, 837], ["hernia repair", "OBSERVATION", 838, 851]]], ["Overall, 84.1% of the patients were male and 75.7% were Caucasian.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["The mean age was 61 years old with an average BMI of 29.2.", [["an average BMI", "TEST", 35, 49]]], ["Gender, race, or average BMI were comparable between open and laparoscopic groups, but patients in the open group were significantly older and had higher comorbidities such as chronic obstructive pulmonary disease (COPD), functional dependency, hypertension (HTN) requiring medication, and higher American Society of Anesthesiologists (ASA) score (Table 1) .", [["pulmonary", "ANATOMY", 196, 205], ["chronic obstructive pulmonary disease", "DISEASE", 176, 213], ["COPD", "DISEASE", 215, 219], ["functional dependency", "DISEASE", 222, 243], ["hypertension", "DISEASE", 245, 257], ["HTN", "DISEASE", 259, 262], ["patients", "ORGANISM", 87, 95], ["pulmonary", "ORGAN", 196, 205], ["patients", "SPECIES", 87, 95], ["laparoscopic groups", "TREATMENT", 62, 81], ["higher comorbidities", "PROBLEM", 147, 167], ["chronic obstructive pulmonary disease", "PROBLEM", 176, 213], ["COPD)", "PROBLEM", 215, 220], ["functional dependency", "PROBLEM", 222, 243], ["hypertension", "PROBLEM", 245, 257], ["HTN", "PROBLEM", 259, 262], ["medication", "TREATMENT", 274, 284], ["Anesthesiologists (ASA)", "TREATMENT", 317, 340], ["laparoscopic", "OBSERVATION", 62, 74], ["chronic", "OBSERVATION_MODIFIER", 176, 183], ["obstructive", "OBSERVATION_MODIFIER", 184, 195], ["pulmonary", "ANATOMY", 196, 205], ["disease", "OBSERVATION", 206, 213], ["COPD", "OBSERVATION", 215, 219], ["functional dependency", "OBSERVATION", 222, 243], ["hypertension", "OBSERVATION", 245, 257]]], ["Notably, there was a higher chance of class III obesity (BMI > 40) in patients who underwent OPHR, though this was not statistically significant (Table 1) .Operative VariablesWhile the laparoscopic approach increased between 2010 and 2013 compared to 2014 and 2017 (83.6% versus 78.4%, p = 0.003), OPHR cases remained stable between the first half and second half of the data.", [["obesity", "DISEASE", 48, 55], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["class III obesity", "PROBLEM", 38, 55], ["BMI", "TEST", 57, 60], ["Operative Variables", "TEST", 156, 175], ["the laparoscopic approach", "TEST", 181, 206], ["p", "TEST", 286, 287], ["OPHR cases", "TEST", 298, 308], ["obesity", "OBSERVATION", 48, 55], ["laparoscopic", "OBSERVATION", 185, 197], ["stable", "OBSERVATION", 318, 324]]], ["In the OPHR group, the majority of patients underwent PEH repair through a laparotomy (66.4%) versus thoracotomy (19.7%; Table 2 ).", [["OPHR", "CANCER", 7, 11], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["PEH repair", "TREATMENT", 54, 64], ["a laparotomy", "TREATMENT", 73, 85], ["thoracotomy", "TREATMENT", 101, 112], ["repair", "OBSERVATION", 58, 64], ["laparotomy", "OBSERVATION", 75, 85], ["thoracotomy", "OBSERVATION", 101, 112]]], ["Overall, 33.1% of patients had PEH repair with mesh.", [["patients", "ORGANISM", 18, 26], ["PEH", "PATHOLOGICAL_FORMATION", 31, 34], ["patients", "SPECIES", 18, 26], ["PEH repair", "TREATMENT", 31, 41], ["mesh", "TREATMENT", 47, 51], ["repair", "OBSERVATION", 35, 41], ["mesh", "OBSERVATION", 47, 51]]], ["The OPHR group had a significantly higher number of emergent cases (5.2% versus 1.0%), longer operative times (3.9 h versus 3.7 h), and more intraoperative red blood cell (RBC) transfusions (6.3% versus 0.3%) than LPHR group (Table 2 ).Postoperative OutcomesThe overall mortality rate at 30 and 180 days was 0.51% and 0.71%, respectively.", [["red blood cell", "ANATOMY", 156, 170], ["RBC", "ANATOMY", 172, 175], ["OPHR", "CANCER", 4, 8], ["red blood cell", "CELL", 156, 170], ["RBC", "CELL", 172, 175], ["intraoperative red blood cell", "TEST", 141, 170], ["RBC", "TEST", 172, 175], ["transfusions", "TEST", 177, 189], ["mortality rate", "TEST", 270, 284]]], ["After univariable analysis, there was no significant difference in mortality rate between the two groups (0.44% in LPHR versus 0.82% in OPHR, p = 0.357).", [["univariable analysis", "TEST", 6, 26], ["mortality rate", "TEST", 67, 81], ["no", "UNCERTAINTY", 38, 40], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["difference", "OBSERVATION_MODIFIER", 53, 63]]], ["The LPHR group had a significantly shorter LOS (4.3 days versus 9.6 days, p < 0.001), lower postoperative blood transfusion (12% versus 23%, p < 0.001), and higher postoperative hematocrit (35.2% versus 31.4%, p < 0.001) than the OPHR group ( Table 3) .", [["blood", "ANATOMY", 106, 111], ["LPHR", "CANCER", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["a significantly shorter LOS", "PROBLEM", 19, 46], ["lower postoperative blood transfusion", "PROBLEM", 86, 123], ["p", "TEST", 141, 142], ["postoperative hematocrit", "TEST", 164, 188]]], ["The postoperative complications, including both severe and minor complications (return to the operating room within 30 days, reintubation, pneumonia, intubated for > 48 h, sepsis, and superficial surgical site infection (SSI)) were higher in the OPHR group than the LPHR group ( (Table 4) .Postoperative OutcomesSubanalysis in the open group showed no differences between abdominal approach versus thoracic approach in patient demographics, comorbidities, and postoperative complications (Table 5) .", [["site", "ANATOMY", 205, 209], ["abdominal", "ANATOMY", 372, 381], ["thoracic", "ANATOMY", 398, 406], ["pneumonia", "DISEASE", 139, 148], ["sepsis", "DISEASE", 172, 178], ["superficial surgical site infection", "DISEASE", 184, 219], ["OPHR", "CANCER", 246, 250], ["abdominal", "ORGANISM_SUBDIVISION", 372, 381], ["patient", "ORGANISM", 419, 426], ["patient", "SPECIES", 419, 426], ["The postoperative complications", "PROBLEM", 0, 31], ["both severe and minor complications", "PROBLEM", 43, 78], ["reintubation", "TREATMENT", 125, 137], ["pneumonia", "PROBLEM", 139, 148], ["intubated", "TREATMENT", 150, 159], ["sepsis", "PROBLEM", 172, 178], ["superficial surgical site infection", "PROBLEM", 184, 219], ["Postoperative OutcomesSubanalysis", "TEST", 290, 323], ["differences between abdominal approach", "PROBLEM", 352, 390], ["thoracic approach", "TREATMENT", 398, 415], ["comorbidities", "PROBLEM", 441, 454], ["postoperative complications", "PROBLEM", 460, 487], ["postoperative complications", "OBSERVATION", 4, 31], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["minor", "OBSERVATION_MODIFIER", 59, 64], ["complications", "OBSERVATION", 65, 78], ["pneumonia", "OBSERVATION", 139, 148], ["sepsis", "OBSERVATION", 172, 178], ["superficial", "OBSERVATION_MODIFIER", 184, 195], ["surgical site", "OBSERVATION", 196, 209], ["infection", "OBSERVATION", 210, 219], ["abdominal", "ANATOMY", 372, 381], ["thoracic", "ANATOMY", 398, 406]]], ["Specifically, postoperative pulmonary complications, including postoperative pneumonia, reintubation, and ventilator dependence > 48 h, were similar between the two groups (11.11% in abdominal approach versus 8.33% in thoracic approach, p = 0.4994).Regional Analysis in TrendThe number of patients who underwent OPHR and LPHR were sorted into regional VISN divisions and plotted in Fig 1.", [["pulmonary", "ANATOMY", 28, 37], ["abdominal", "ANATOMY", 183, 192], ["thoracic", "ANATOMY", 218, 226], ["postoperative pulmonary complications", "DISEASE", 14, 51], ["pneumonia", "DISEASE", 77, 86], ["ventilator dependence", "DISEASE", 106, 127], ["pulmonary", "ORGAN", 28, 37], ["abdominal", "ORGANISM_SUBDIVISION", 183, 192], ["thoracic", "ORGAN", 218, 226], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["postoperative pulmonary complications", "PROBLEM", 14, 51], ["postoperative pneumonia", "PROBLEM", 63, 86], ["reintubation", "TREATMENT", 88, 100], ["ventilator dependence", "PROBLEM", 106, 127], ["abdominal approach", "TEST", 183, 201], ["Regional Analysis", "TEST", 249, 266], ["OPHR", "TEST", 312, 316], ["LPHR", "TREATMENT", 321, 325], ["postoperative", "OBSERVATION_MODIFIER", 14, 27], ["pulmonary", "ANATOMY", 28, 37], ["complications", "OBSERVATION", 38, 51], ["postoperative", "OBSERVATION_MODIFIER", 63, 76], ["pneumonia", "OBSERVATION", 77, 86], ["reintubation", "OBSERVATION", 88, 100], ["ventilator dependence", "OBSERVATION", 106, 127], ["abdominal", "ANATOMY", 183, 192], ["thoracic", "ANATOMY", 218, 226]]], ["As noted previously, the open repair consists of 18.6% of paraesophageal hernia repairs nationwide.", [["paraesophageal hernia", "ANATOMY", 58, 79], ["paraesophageal hernia", "DISEASE", 58, 79], ["hernia", "PATHOLOGICAL_FORMATION", 73, 79], ["the open repair", "TREATMENT", 21, 36], ["paraesophageal hernia repairs", "TREATMENT", 58, 87], ["repair", "OBSERVATION", 30, 36], ["paraesophageal", "ANATOMY", 58, 72], ["hernia repairs", "OBSERVATION", 73, 87]]], ["The regional percentage of OPHR ranges from 6.7 to 31.2% (Table 6 ) depending on the VISN.", [["OPHR", "PROTEIN", 27, 31], ["OPHR", "TEST", 27, 31], ["regional", "OBSERVATION_MODIFIER", 4, 12], ["percentage", "OBSERVATION_MODIFIER", 13, 23]]], ["Chi-square analysis of regional percentage of OPHR versus national average showed that VISN 5 (28.6%, p = 0.045), 10 (25%, p = 0.026), and 15 (31.2%, p = 0.006) had significantly higher OPHR compared to the national average (Table 6 ).", [["Chi-square analysis", "TEST", 0, 19], ["OPHR", "TEST", 46, 50], ["VISN", "TEST", 87, 91], ["p", "TEST", 102, 103], ["p", "TEST", 123, 124], ["p", "TEST", 150, 151], ["significantly higher OPHR", "PROBLEM", 165, 190], ["regional", "OBSERVATION_MODIFIER", 23, 31], ["percentage", "OBSERVATION_MODIFIER", 32, 42]]], ["In VISN 5, VA hospitals in West Virginia (59.3%, n = 27) had a significantly higher (Fig. 2) .", [["a significantly higher (Fig", "PROBLEM", 61, 88]]], ["Analysis of surgeon specialty and surgical approach showed that LPHR were performed primarily by general surgeons, with 17.8% of laparoscopic repairs performed by thoracic surgeons nationally.", [["thoracic", "ANATOMY", 163, 171], ["surgical approach", "TEST", 34, 51], ["laparoscopic repairs", "TREATMENT", 129, 149], ["thoracic", "ANATOMY", 163, 171]]], ["The percentage of LPHR completed by thoracic surgeons ranges from 0% in numerous states to 86.3% in Connecticut (19 out of 22 cases).", [["thoracic", "ANATOMY", 36, 44], ["LPHR", "PROTEIN", 18, 22], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["thoracic", "ANATOMY", 36, 44]]], ["OPHR were coded mostly under general surgery (66.3%), with general surgeons performing 78.1% through an abdominal approach, 5.0% through a thoracic approach, and 16.9% via a thoracoabdominal approach.", [["abdominal", "ANATOMY", 104, 113], ["thoracic", "ANATOMY", 139, 147], ["thoracoabdominal", "ANATOMY", 174, 190], ["abdominal", "ORGANISM_SUBDIVISION", 104, 113], ["general surgery", "TREATMENT", 29, 44], ["an abdominal approach", "TREATMENT", 101, 122], ["a thoracic approach", "TREATMENT", 137, 156], ["a thoracoabdominal approach", "TREATMENT", 172, 199], ["abdominal", "ANATOMY", 104, 113], ["thoracic", "ANATOMY", 139, 147], ["thoracoabdominal", "ANATOMY", 174, 190]]], ["Of note, all OPHR in Connecticut (6 cases) and Delaware (1 case) were performed by thoracic surgeons, regardless of the types of approach.", [["thoracic", "ANATOMY", 83, 91], ["thoracic", "ANATOMY", 83, 91]]], ["There was no correlation of surgeon specialties with states that had significantly higher percentages of OPHR.", [["OPHR", "DISEASE", 105, 109]]], ["For example, OPHR in West Virginia and Connecticut was performed 100% by general surgeons while 94% (14 out of 15 cases) were performed by thoracic surgeons in Georgia, regardless of approaches.", [["thoracic", "ANATOMY", 139, 147]]], ["Table 8 compares the open PEHR outcomes of high volume facilities to the low volume facilities (defined as less than 5 cases and < 18.6% open cases, national average).", [["the open PEHR outcomes", "TREATMENT", 17, 39], ["high volume facilities", "TREATMENT", 43, 65]]], ["There were no differences between the patient comorbidities and postoperative outcomes besides higher rate of postoperative UTI in facilities with lower volume of open PEHR (Table 8 ).DiscussionThis retrospective study of the VASQIP database is the first analysis of paraesophageal hernia repair short-term outcomes in the veteran population.", [["paraesophageal hernia", "ANATOMY", 267, 288], ["UTI", "DISEASE", 124, 127], ["paraesophageal hernia", "DISEASE", 267, 288], ["patient", "ORGANISM", 38, 45], ["paraesophageal hernia", "PATHOLOGICAL_FORMATION", 267, 288], ["patient", "SPECIES", 38, 45], ["the patient comorbidities", "PROBLEM", 34, 59], ["postoperative outcomes", "PROBLEM", 64, 86], ["postoperative UTI", "PROBLEM", 110, 127], ["open PEHR", "TREATMENT", 163, 172], ["paraesophageal hernia repair", "TREATMENT", 267, 295], ["no", "UNCERTAINTY", 11, 13], ["UTI", "OBSERVATION", 124, 127], ["paraesophageal", "ANATOMY", 267, 281], ["hernia", "OBSERVATION", 282, 288]]], ["Patients who underwent laparoscopic paraesophageal hernia repair had lower morbidities and mortalities than the open repair group which is consistent with publications in the civilian population.", [["paraesophageal hernia", "ANATOMY", 36, 57], ["paraesophageal hernia", "DISEASE", 36, 57], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["laparoscopic paraesophageal hernia repair", "TREATMENT", 23, 64], ["lower morbidities and mortalities", "PROBLEM", 69, 102], ["the open repair group", "TREATMENT", 108, 129], ["laparoscopic", "OBSERVATION_MODIFIER", 23, 35], ["paraesophageal", "ANATOMY", 36, 50], ["hernia", "OBSERVATION", 51, 57], ["lower morbidities", "OBSERVATION_MODIFIER", 69, 86], ["repair", "OBSERVATION", 117, 123], ["consistent with", "UNCERTAINTY", 139, 154], ["publications", "OBSERVATION", 155, 167]]], ["[1] [2] [3] [4] [5] [6] The VASQIP database provides a special opportunity to analyze paraesophageal hernia repair outcomes in a predominantly male veteran patient population compared to a majority of female patients undergoing PEH repair (> 60%) in the private sector.", [["paraesophageal hernia", "ANATOMY", 86, 107], ["paraesophageal hernia", "DISEASE", 86, 107], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["paraesophageal hernia", "PATHOLOGICAL_FORMATION", 86, 107], ["patient", "ORGANISM", 156, 163], ["patients", "ORGANISM", 208, 216], ["patient", "SPECIES", 156, 163], ["patients", "SPECIES", 208, 216], ["The VASQIP database", "TEST", 24, 43], ["paraesophageal hernia repair", "TREATMENT", 86, 114], ["PEH repair", "TREATMENT", 228, 238], ["paraesophageal", "ANATOMY", 86, 100], ["hernia", "OBSERVATION", 101, 107], ["repair", "OBSERVATION", 232, 238]]], ["[1] [2] [3] [4] [5] [6] Presently, veterans are primarily Caucasian males over the age of 60.", [["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["veterans", "ORGANISM", 35, 43]]], ["As veterans have a higher rate of smoking than the average American, the number of tobacco smokers at the time of surgery (17.1%) and consequently patients with COPD (13.8%) were higher than that reported in the civilian population (9.7% tobacco smoker and 5.6% COPD).", [["smoking", "CHEMICAL", 34, 41], ["COPD", "DISEASE", 161, 165], ["COPD", "DISEASE", 262, 266], ["veterans", "ORGANISM", 3, 11], ["tobacco", "ORGANISM", 83, 90], ["patients", "ORGANISM", 147, 155], ["tobacco", "ORGANISM", 238, 245], ["patients", "SPECIES", 147, 155], ["tobacco", "SPECIES", 83, 90], ["tobacco", "SPECIES", 238, 245], ["surgery", "TREATMENT", 114, 121], ["COPD", "PROBLEM", 161, 165], ["5.6% COPD)", "PROBLEM", 257, 267], ["COPD", "OBSERVATION", 161, 165]]], ["3 Compared to the mostly female patient population in the NSQIP database, veterans who underwent paraesophageal hernia repair were more likely to have chronic heart failure (CHF), history of myocardial infarction (MI), prior cardiac surgery, and alcohol abuse.", [["paraesophageal hernia", "ANATOMY", 97, 118], ["heart", "ANATOMY", 159, 164], ["myocardial", "ANATOMY", 191, 201], ["cardiac", "ANATOMY", 225, 232], ["paraesophageal hernia", "DISEASE", 97, 118], ["chronic heart failure", "DISEASE", 151, 172], ["CHF", "DISEASE", 174, 177], ["myocardial infarction", "DISEASE", 191, 212], ["MI", "DISEASE", 214, 216], ["alcohol abuse", "DISEASE", 246, 259], ["alcohol", "CHEMICAL", 246, 253], ["patient", "ORGANISM", 32, 39], ["veterans", "ORGANISM", 74, 82], ["heart", "ORGAN", 159, 164], ["myocardial", "MULTI-TISSUE_STRUCTURE", 191, 201], ["patient", "SPECIES", 32, 39], ["paraesophageal hernia repair", "TREATMENT", 97, 125], ["chronic heart failure", "PROBLEM", 151, 172], ["CHF", "PROBLEM", 174, 177], ["myocardial infarction", "PROBLEM", 191, 212], ["MI", "PROBLEM", 214, 216], ["prior cardiac surgery", "TREATMENT", 219, 240], ["paraesophageal", "ANATOMY", 97, 111], ["hernia repair", "OBSERVATION", 112, 125], ["chronic", "OBSERVATION_MODIFIER", 151, 158], ["heart", "ANATOMY", 159, 164], ["failure", "OBSERVATION", 165, 172], ["CHF", "OBSERVATION", 174, 177], ["myocardial", "ANATOMY", 191, 201], ["infarction", "OBSERVATION", 202, 212], ["cardiac", "ANATOMY", 225, 232], ["surgery", "OBSERVATION", 233, 240]]], ["3 Despite increased comorbidities in the veteran population, paraesophageal hernia repair outcomes at VA hospitals are comparable to approaches and outcomes in the private sector.", [["paraesophageal hernia", "ANATOMY", 61, 82], ["paraesophageal hernia", "DISEASE", 61, 82], ["paraesophageal hernia", "PATHOLOGICAL_FORMATION", 61, 82], ["increased comorbidities in the veteran population", "PROBLEM", 10, 59], ["paraesophageal hernia repair", "TREATMENT", 61, 89], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["comorbidities", "OBSERVATION", 20, 33], ["paraesophageal", "ANATOMY", 61, 75], ["hernia repair", "OBSERVATION", 76, 89]]], ["Mungo 3 This study demonstrated that VA hospitals have adopted laparoscopic paraesophageal hernia repair with similar rates, including 81.5% of LPHR, 12.3% transabdominal OPHR, 3.6% transthoracic OPHR, and 2.6% thoracoabdominal OPHR.", [["paraesophageal hernia", "ANATOMY", 76, 97], ["transabdominal", "ANATOMY", 156, 170], ["thoracoabdominal", "ANATOMY", 211, 227], ["paraesophageal hernia", "DISEASE", 76, 97], ["LPHR", "DISEASE", 144, 148], ["hernia", "PATHOLOGICAL_FORMATION", 91, 97], ["This study", "TEST", 8, 18], ["laparoscopic paraesophageal hernia repair", "TREATMENT", 63, 104], ["LPHR", "TEST", 144, 148], ["transabdominal OPHR", "TEST", 156, 175], ["transthoracic OPHR", "TEST", 182, 200], ["2.6% thoracoabdominal OPHR", "TREATMENT", 206, 232], ["laparoscopic", "OBSERVATION_MODIFIER", 63, 75], ["paraesophageal hernia", "OBSERVATION", 76, 97], ["repair", "OBSERVATION", 98, 104], ["thoracoabdominal", "ANATOMY", 211, 227]]], ["Moreover, the 30-day mortality rates were 0.4% in the LPHR group and 0.8% in the OPHR group, which are lower than the NSQIP database analysis that reported a 30-day mortality of 0.5% in the LPHR group and 4.1% in the OPHR group.", [["LPHR", "DISEASE", 190, 194], ["LPHR", "CANCER", 54, 58], ["OPHR", "CANCER", 81, 85], ["LPHR", "CANCER", 190, 194], ["OPHR", "CANCER", 217, 221], ["mortality rates", "TEST", 21, 36], ["the NSQIP database analysis", "TEST", 114, 141]]], ["3 The mortality rates in the VASQIP database may be lower than large database analysis due to the overall smaller sample size of OPHR.", [["The mortality rates", "TEST", 2, 21], ["the VASQIP database", "TEST", 25, 44], ["large database analysis", "TEST", 63, 86], ["smaller", "OBSERVATION_MODIFIER", 106, 113], ["sample", "OBSERVATION_MODIFIER", 114, 120], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["Also, our data is more recent than other database studies from two decades ago which may simply reflect better postoperative intensive care programs.", [["other database studies", "TEST", 35, 57], ["may simply reflect", "UNCERTAINTY", 85, 103]]], ["[1] [2] [3] LPHR consistently provides significantly shorter LOS, decreased postoperative pain, and fewer perioperative complications in the literature.", [["postoperative pain", "DISEASE", 76, 94], ["[1] [2] [3] LPHR", "CHEMICAL", 0, 16], ["[1] [2] [3] LPHR", "SIMPLE_CHEMICAL", 0, 16], ["significantly shorter LOS", "PROBLEM", 39, 64], ["decreased postoperative pain", "PROBLEM", 66, 94], ["fewer perioperative complications in the literature", "PROBLEM", 100, 151], ["decreased", "OBSERVATION_MODIFIER", 66, 75], ["postoperative pain", "OBSERVATION", 76, 94], ["fewer", "OBSERVATION_MODIFIER", 100, 105], ["perioperative", "OBSERVATION_MODIFIER", 106, 119], ["complications", "OBSERVATION", 120, 133]]], ["[1] [2] [3] [4] [5] [6] After adjusting for patient comorbidities and operative variables, multivariable regression analysis showed that patients undergoing an open repair had significantly higher number of VASQIP complications, specifically a higher chance of returning to the operating room within 30 days, intraoperative and postoperative blood transfusions, and postoperative pneumonia than the LPHR group.", [["blood", "ANATOMY", 342, 347], ["pneumonia", "DISEASE", 380, 389], ["[1] [2] [3] [4] [5", "SIMPLE_CHEMICAL", 0, 18], ["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 137, 145], ["blood", "ORGANISM_SUBSTANCE", 342, 347], ["LPHR", "CANCER", 399, 403], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 137, 145], ["patient comorbidities", "PROBLEM", 44, 65], ["operative variables", "TEST", 70, 89], ["multivariable regression analysis", "TEST", 91, 124], ["an open repair", "TREATMENT", 157, 171], ["VASQIP complications", "PROBLEM", 207, 227], ["postoperative blood transfusions", "TREATMENT", 328, 360], ["postoperative pneumonia", "PROBLEM", 366, 389], ["repair", "OBSERVATION", 165, 171], ["postoperative", "OBSERVATION_MODIFIER", 366, 379], ["pneumonia", "OBSERVATION", 380, 389]]], ["Although an analysis of the Nationwide Inpatient Sample (NIS) database from 1999 to 2008 reported that thoracotomy PEH repairs had the longest length of stay and increased rate of prolonged postoperative ventilator use and pulmonary embolism, the rate of postoperative pulmonary complications in this database did not differ between the types of surgical approach (Table 5) .", [["pulmonary", "ANATOMY", 223, 232], ["pulmonary", "ANATOMY", 269, 278], ["pulmonary embolism", "DISEASE", 223, 241], ["postoperative pulmonary complications", "DISEASE", 255, 292], ["pulmonary", "ORGAN", 223, 232], ["pulmonary", "ORGAN", 269, 278], ["an analysis", "TEST", 9, 20], ["thoracotomy PEH repairs", "TREATMENT", 103, 126], ["prolonged postoperative ventilator use", "TREATMENT", 180, 218], ["pulmonary embolism", "PROBLEM", 223, 241], ["postoperative pulmonary complications", "PROBLEM", 255, 292], ["surgical approach", "TREATMENT", 346, 363], ["thoracotomy", "OBSERVATION", 103, 114], ["repairs", "OBSERVATION", 119, 126], ["increased", "OBSERVATION_MODIFIER", 162, 171], ["prolonged", "OBSERVATION_MODIFIER", 180, 189], ["postoperative ventilator", "OBSERVATION", 190, 214], ["pulmonary", "ANATOMY", 223, 232], ["embolism", "OBSERVATION", 233, 241], ["postoperative", "OBSERVATION_MODIFIER", 255, 268], ["pulmonary", "ANATOMY", 269, 278], ["complications", "OBSERVATION", 279, 292], ["surgical", "OBSERVATION", 346, 354]]], ["1 LPHR can be technically challenging, but laparoscopic repairs have become the standard of care and are offered to elderly patients with significant comorbidities and in emergent settings.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["laparoscopic repairs", "TREATMENT", 43, 63], ["significant comorbidities", "PROBLEM", 138, 163], ["laparoscopic", "OBSERVATION", 43, 55]]], ["14, 15 The laparoscopic approach not only had less postoperative morbidities and mortalities, it had significantly less operative time and intraoperative blood transfusion than open repairs ( Table 2 ).", [["blood", "ANATOMY", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["The laparoscopic approach", "TREATMENT", 7, 32], ["intraoperative blood transfusion", "TREATMENT", 139, 171], ["open repairs", "TREATMENT", 177, 189], ["laparoscopic", "OBSERVATION", 11, 23]]], ["The trend from open to laparoscopic repairs in the private sector has been replicated in the VA hospitals with increasing numbers of LPHR.", [["laparoscopic repairs", "TREATMENT", 23, 43], ["LPHR", "PROBLEM", 133, 137], ["laparoscopic repairs", "OBSERVATION", 23, 43], ["increasing", "OBSERVATION_MODIFIER", 111, 121], ["numbers", "OBSERVATION_MODIFIER", 122, 129]]], ["[1] [2] [3] [4] [5] [6] The majority of VA hospitals provide laparoscopic paraesophageal hernia repair as the standard of care, while there are VA hospitals in certain regions of the country that perform a higher percentage of open repairs.", [["paraesophageal hernia", "ANATOMY", 74, 95], ["paraesophageal hernia", "DISEASE", 74, 95], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["laparoscopic paraesophageal hernia repair", "TREATMENT", 61, 102], ["open repairs", "TREATMENT", 227, 239], ["paraesophageal hernia", "OBSERVATION", 74, 95], ["open repairs", "OBSERVATION", 227, 239]]], ["The VASQIP database provided a unique opportunity to investigate the trends in regional practice since each patient entry is accompanied by a VA hospital facility code.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115]]], ["Chi-Square analysis highlighted VISN 5, 10, and 15 with a significantly higher percentage of OPHR and VISN 23 had a significantly lower percentage than the national average.", [["Square analysis", "TEST", 4, 19], ["VISN", "TEST", 32, 36], ["VISN", "TEST", 102, 106], ["significantly", "OBSERVATION_MODIFIER", 116, 129], ["lower", "OBSERVATION_MODIFIER", 130, 135], ["percentage", "OBSERVATION_MODIFIER", 136, 146]]], ["This data further highlights the differences in regional practices.", [["This data", "TEST", 0, 9]]], ["Paraesophageal repairs in Connecticut were performed mostly by thoracic surgeons regardless of surgical approaches (86% of LPHR and 100% of OPHR), compared to 100% of repairs completed by general surgeons in Colorado, District of Columbia, Kansas, Maine, Montana, Nebraska, Nevada, New Jersey, Virginia, North Dakota, Puerto Rico, and West Virginia.", [["Paraesophageal", "ANATOMY", 0, 14], ["thoracic", "ANATOMY", 63, 71], ["Paraesophageal repairs", "TREATMENT", 0, 22], ["surgical approaches", "TREATMENT", 95, 114], ["LPHR", "TEST", 123, 127], ["repairs", "TREATMENT", 167, 174], ["repairs", "OBSERVATION", 15, 22], ["thoracic", "ANATOMY", 63, 71], ["surgical", "OBSERVATION", 95, 103]]], ["This data shows that the surgical subspecialty and approaches varied arbitrarily by different facilities and may indicate that surgical approach depends on the surgeon's practice pattern and training.LimitationsThis study has a few limitations as a retrospective database study.", [["This data", "TEST", 0, 9], ["This study", "TEST", 211, 221], ["a retrospective database study", "TEST", 247, 277], ["surgical", "OBSERVATION", 127, 135]]], ["Due to the limitation of the variables in the database, we cannot be certain that patients who met the inclusion criteria for the study did not have a prior paraesophageal hernia repair.", [["paraesophageal", "ANATOMY", 157, 171], ["paraesophageal hernia", "DISEASE", 157, 178], ["patients", "ORGANISM", 82, 90], ["hernia", "PATHOLOGICAL_FORMATION", 172, 178], ["patients", "SPECIES", 82, 90], ["the study", "TEST", 126, 135], ["a prior paraesophageal hernia repair", "TREATMENT", 149, 185], ["paraesophageal", "ANATOMY", 157, 171], ["hernia", "OBSERVATION", 172, 178], ["repair", "OBSERVATION", 179, 185]]], ["A prior hernia repair may sway the decision for the type of surgical approach and increase operative risk.", [["hernia", "ANATOMY", 8, 14], ["hernia", "PATHOLOGICAL_FORMATION", 8, 14], ["A prior hernia repair", "TREATMENT", 0, 21], ["surgical approach", "TREATMENT", 60, 77], ["increase operative risk", "PROBLEM", 82, 105], ["hernia", "OBSERVATION", 8, 14], ["surgical", "OBSERVATION", 60, 68]]], ["In addition, the database was unable to discern the rationale behind elective open paraesophageal hernia repair approach.", [["paraesophageal hernia", "ANATOMY", 83, 104], ["elective open paraesophageal hernia repair approach", "TREATMENT", 69, 120], ["paraesophageal hernia", "OBSERVATION", 83, 104], ["repair", "OBSERVATION", 105, 111]]], ["The database could not differentiate if the surgical approach was dictated by surgeon preference, adhesions from prior surgeries, or anatomic considerations.", [["adhesions", "PROBLEM", 98, 107], ["prior surgeries", "TREATMENT", 113, 128], ["adhesions", "OBSERVATION", 98, 107], ["surgeries", "OBSERVATION", 119, 128]]], ["As patient demographics did not vary significantly across regions, the number of open procedures in certain regions in the United States remained relatively high.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["open procedures", "TREATMENT", 81, 96], ["open", "OBSERVATION_MODIFIER", 81, 85], ["procedures", "OBSERVATION", 86, 96], ["high", "OBSERVATION", 157, 161]]], ["This may indicate that the type of surgical approach is more likely due to surgeon preference and not anatomical considerations or adhesive disease.", [["surgical approach", "TREATMENT", 35, 52], ["adhesive disease", "PROBLEM", 131, 147], ["surgical", "OBSERVATION", 35, 43], ["more likely", "UNCERTAINTY", 56, 67], ["adhesive disease", "OBSERVATION", 131, 147]]], ["Lastly, this database does not provide detailed follow-up to analyze any symptom or radiographic recurrence.", [["any symptom", "PROBLEM", 69, 80], ["radiographic recurrence", "PROBLEM", 84, 107]]], ["This data would be valuable information in the future to document the true value of each operative approach.ConclusionVeterans undergoing LPHR experience similar outcomes and the same benefits as patients in the private sector.", [["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204]]], ["The results document that Veterans should be offered a laparoscopic approach to paraesophageal repair regardless of BMI or age.", [["paraesophageal", "ANATOMY", 80, 94], ["paraesophageal", "PATHOLOGICAL_FORMATION", 80, 94], ["a laparoscopic approach", "TREATMENT", 53, 76], ["paraesophageal repair", "TREATMENT", 80, 101], ["laparoscopic", "OBSERVATION", 55, 67], ["paraesophageal repair", "OBSERVATION", 80, 101]]], ["The differences in the percentage of open paraesophageal hernia repair between various regions appear to be driven by surgeon preference and not patient demographics or comorbidities.", [["paraesophageal hernia", "ANATOMY", 42, 63], ["paraesophageal hernia", "DISEASE", 42, 63], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["open paraesophageal hernia repair", "TREATMENT", 37, 70], ["comorbidities", "PROBLEM", 169, 182], ["percentage", "OBSERVATION_MODIFIER", 23, 33], ["open", "OBSERVATION_MODIFIER", 37, 41], ["paraesophageal hernia", "OBSERVATION", 42, 63], ["repair", "OBSERVATION", 64, 70]]]], "86b48dbedbb546bdf43a405dbaf73615ec5689cc": [["P otentially reversible pulmonary failure secondary to diseases such as avian flu, ARDS, severe acute respiratory syndrome, pulmonary embolism, and bacterial pneumonia claims many lives in the United States every year.", [["pulmonary", "ANATOMY", 24, 33], ["pulmonary", "ANATOMY", 124, 133], ["pulmonary failure", "DISEASE", 24, 41], ["avian flu", "DISEASE", 72, 81], ["ARDS", "DISEASE", 83, 87], ["acute respiratory syndrome", "DISEASE", 96, 122], ["pulmonary embolism", "DISEASE", 124, 142], ["bacterial pneumonia", "DISEASE", 148, 167], ["pulmonary", "ORGAN", 24, 33], ["pulmonary", "ORGAN", 124, 133], ["avian flu", "SPECIES", 72, 81], ["P otentially reversible pulmonary failure", "PROBLEM", 0, 41], ["diseases", "PROBLEM", 55, 63], ["avian flu", "PROBLEM", 72, 81], ["ARDS", "PROBLEM", 83, 87], ["severe acute respiratory syndrome", "PROBLEM", 89, 122], ["pulmonary embolism", "PROBLEM", 124, 142], ["bacterial pneumonia", "PROBLEM", 148, 167], ["reversible", "OBSERVATION_MODIFIER", 13, 23], ["pulmonary", "ANATOMY", 24, 33], ["failure", "OBSERVATION", 34, 41], ["diseases", "OBSERVATION", 55, 63], ["avian", "OBSERVATION_MODIFIER", 72, 77], ["flu", "OBSERVATION", 78, 81], ["ARDS", "OBSERVATION", 83, 87], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory syndrome", "OBSERVATION", 102, 122], ["pulmonary", "ANATOMY", 124, 133], ["embolism", "OBSERVATION", 134, 142], ["bacterial", "OBSERVATION_MODIFIER", 148, 157], ["pneumonia", "OBSERVATION", 158, 167]]], ["1 In addition to this already formidable population, we now live in a world where the specter of bioterrorism with an aerosolized agent could multiply this number many fold at any time, literally overnight.", [["an aerosolized agent", "TREATMENT", 115, 135], ["formidable", "OBSERVATION_MODIFIER", 30, 40], ["population", "OBSERVATION", 41, 51]]], ["Although multiorgan failure may result in the demise of a patient with any of these conditions, many patients die from isolated pulmonary insufficiency that is potentially reversible.", [["multiorgan", "ANATOMY", 9, 19], ["pulmonary", "ANATOMY", 128, 137], ["multiorgan failure", "DISEASE", 9, 27], ["pulmonary insufficiency", "DISEASE", 128, 151], ["multiorgan", "ORGAN", 9, 19], ["patient", "ORGANISM", 58, 65], ["patients", "ORGANISM", 101, 109], ["pulmonary", "ORGAN", 128, 137], ["patient", "SPECIES", 58, 65], ["patients", "SPECIES", 101, 109], ["multiorgan failure", "PROBLEM", 9, 27], ["these conditions", "PROBLEM", 78, 94], ["isolated pulmonary insufficiency", "PROBLEM", 119, 151], ["multiorgan failure", "OBSERVATION", 9, 27], ["pulmonary", "ANATOMY", 128, 137], ["insufficiency", "OBSERVATION", 138, 151]]], ["The high mortality and increasing size of this population underscores the need for new and improved treatments for potentially reversible pulmonary failure.", [["pulmonary", "ANATOMY", 138, 147], ["pulmonary failure", "DISEASE", 138, 155], ["pulmonary", "ORGAN", 138, 147], ["The high mortality", "PROBLEM", 0, 18], ["potentially reversible pulmonary failure", "PROBLEM", 115, 155], ["high", "OBSERVATION_MODIFIER", 4, 8], ["mortality", "OBSERVATION_MODIFIER", 9, 18], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["size", "OBSERVATION_MODIFIER", 34, 38], ["reversible", "OBSERVATION_MODIFIER", 127, 137], ["pulmonary", "ANATOMY", 138, 147], ["failure", "OBSERVATION", 148, 155]]]], "28c0a41c6da54e50ce02900be189cb8bcd379e16": [["Epidemiology rheumatic diseases 1 therefore, people with rheumatic disease may be at higher risk for a more severe course with COVID-19, including hospitalisation, complications and death.", [["rheumatic diseases", "DISEASE", 13, 31], ["rheumatic disease", "DISEASE", 57, 74], ["death", "DISEASE", 182, 187], ["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["Epidemiology rheumatic diseases", "PROBLEM", 0, 31], ["rheumatic disease", "PROBLEM", 57, 74], ["COVID", "TEST", 127, 132], ["complications", "PROBLEM", 164, 177], ["death", "PROBLEM", 182, 187], ["rheumatic", "OBSERVATION", 13, 22], ["rheumatic", "OBSERVATION", 57, 66]]], ["Importantly, some medications used to treat rheumatic diseases, such as hydroxychloroquine and interleukin-6 (IL-6) inhibitors, are being studied for the prevention and/or treatment of COVID-19 and its complications including cytokine-storm.", [["rheumatic diseases", "DISEASE", 44, 62], ["hydroxychloroquine", "CHEMICAL", 72, 90], ["COVID-19", "CHEMICAL", 185, 193], ["hydroxychloroquine", "CHEMICAL", 72, 90], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 72, 90], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 95, 108], ["IL-6", "GENE_OR_GENE_PRODUCT", 110, 114], ["cytokine", "PROTEIN", 226, 234], ["some medications", "TREATMENT", 13, 29], ["rheumatic diseases", "PROBLEM", 44, 62], ["hydroxychloroquine", "TREATMENT", 72, 90], ["interleukin-6 (IL-6) inhibitors", "TREATMENT", 95, 126], ["COVID", "TREATMENT", 185, 190], ["its complications", "PROBLEM", 198, 215], ["rheumatic diseases", "OBSERVATION", 44, 62]]], ["[2] [3] [4] At present, the implications of COVID-19 for people living with rheumatic diseases remain poorly understood.", [["rheumatic diseases", "DISEASE", 76, 94], ["[2] [3] [4", "SIMPLE_CHEMICAL", 0, 10], ["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["COVID", "TEST", 44, 49], ["rheumatic diseases", "PROBLEM", 76, 94], ["rheumatic", "OBSERVATION", 76, 85]]]], "6e8f66d12dfaf4f01e5261fe2a21883f8fba28b4": [["better tackle these diseases and prevent them from assuming epidemic and pandemic levels.", [["these diseases", "PROBLEM", 14, 28], ["epidemic and pandemic levels", "PROBLEM", 60, 88], ["diseases", "OBSERVATION", 20, 28]]]], "8c4bcff580c73de53f04e6b56b2acf4379e53104": [["IntroductionIt is well established that the renin-angiotensin system (RAS) is an important factor in the regulation of blood pressure (BP).", [["blood", "ANATOMY", 119, 124], ["angiotensin", "CHEMICAL", 50, 61], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 44, 68], ["RAS", "GENE_OR_GENE_PRODUCT", 70, 73], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["BP", "SIMPLE_CHEMICAL", 135, 137], ["renin", "PROTEIN", 44, 49], ["the renin-angiotensin system", "TREATMENT", 40, 68], ["blood pressure", "TEST", 119, 133], ["BP", "TEST", 135, 137]]], ["Classically, angiotensinogen (AGT) is hydrolyzed by renin to form the decapeptide Angiotensin (Ang)-I which is then converted by angiotensinconverting enzyme (ACE) into the biologically active peptide Ang-II.", [["Angiotensin", "CHEMICAL", 82, 93], ["Ang", "CHEMICAL", 95, 98], ["Ang-II", "CHEMICAL", 201, 207], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 13, 28], ["AGT", "GENE_OR_GENE_PRODUCT", 30, 33], ["renin", "GENE_OR_GENE_PRODUCT", 52, 57], ["Angiotensin (Ang)-I", "GENE_OR_GENE_PRODUCT", 82, 101], ["angiotensinconverting enzyme", "GENE_OR_GENE_PRODUCT", 129, 157], ["ACE", "SIMPLE_CHEMICAL", 159, 162], ["Ang-II", "GENE_OR_GENE_PRODUCT", 201, 207], ["angiotensinogen", "PROTEIN", 13, 28], ["AGT", "PROTEIN", 30, 33], ["renin", "PROTEIN", 52, 57], ["decapeptide Angiotensin (Ang)-I", "PROTEIN", 70, 101], ["angiotensinconverting enzyme", "PROTEIN", 129, 157], ["ACE", "PROTEIN", 159, 162], ["angiotensinogen (AGT)", "TREATMENT", 13, 34], ["the decapeptide Angiotensin", "TREATMENT", 66, 93], ["angiotensinconverting enzyme (ACE)", "TREATMENT", 129, 163]]], ["Ang-II leads to elevations in BP by promoting vasoconstriction, renal sodium and water reabsorption, increasing cardiac output, sympathetic tone, arginine vasopressin release, and stimulating the sensation of thirst in the central nervous system (CNS) (Reid et al. 1978; Phillips 1987) .", [["renal", "ANATOMY", 64, 69], ["cardiac", "ANATOMY", 112, 119], ["central nervous system", "ANATOMY", 223, 245], ["CNS", "ANATOMY", 247, 250], ["Ang-II", "CHEMICAL", 0, 6], ["sodium", "CHEMICAL", 70, 76], ["arginine vasopressin", "CHEMICAL", 146, 166], ["sodium", "CHEMICAL", 70, 76], ["arginine", "CHEMICAL", 146, 154], ["Ang-II", "GENE_OR_GENE_PRODUCT", 0, 6], ["BP", "SIMPLE_CHEMICAL", 30, 32], ["renal", "ORGAN", 64, 69], ["sodium", "SIMPLE_CHEMICAL", 70, 76], ["water", "SIMPLE_CHEMICAL", 81, 86], ["cardiac", "ORGAN", 112, 119], ["arginine vasopressin", "GENE_OR_GENE_PRODUCT", 146, 166], ["central nervous system", "ANATOMICAL_SYSTEM", 223, 245], ["CNS", "ANATOMICAL_SYSTEM", 247, 250], ["Ang-II", "PROTEIN", 0, 6], ["BP", "PROTEIN", 30, 32], ["elevations in BP", "PROBLEM", 16, 32], ["vasoconstriction", "PROBLEM", 46, 62], ["renal sodium", "TREATMENT", 64, 76], ["water reabsorption", "TREATMENT", 81, 99], ["increasing cardiac output", "PROBLEM", 101, 126], ["sympathetic tone", "PROBLEM", 128, 144], ["arginine vasopressin release", "TREATMENT", 146, 174], ["thirst", "PROBLEM", 209, 215], ["vasoconstriction", "OBSERVATION", 46, 62], ["renal", "ANATOMY", 64, 69], ["sympathetic tone", "OBSERVATION", 128, 144], ["central", "ANATOMY_MODIFIER", 223, 230], ["nervous system", "ANATOMY", 231, 245]]], ["While Ang-II can interact with both AT1 and AT2 receptor subtypes (Table 1) , these effects of Ang-II are mediated mainly by AT1 receptors (AT1R).", [["Ang-II", "CHEMICAL", 6, 12], ["Ang-II", "CHEMICAL", 95, 101], ["Ang-II", "GENE_OR_GENE_PRODUCT", 6, 12], ["AT1", "GENE_OR_GENE_PRODUCT", 36, 39], ["AT2 receptor", "GENE_OR_GENE_PRODUCT", 44, 56], ["Table 1", "GENE_OR_GENE_PRODUCT", 67, 74], ["Ang-II", "GENE_OR_GENE_PRODUCT", 95, 101], ["AT1 receptors", "GENE_OR_GENE_PRODUCT", 125, 138], ["AT1R", "GENE_OR_GENE_PRODUCT", 140, 144], ["Ang-II", "PROTEIN", 6, 12], ["AT1", "PROTEIN", 36, 39], ["Ang-II", "PROTEIN", 95, 101], ["AT1 receptors", "PROTEIN", 125, 138], ["AT1R", "PROTEIN", 140, 144], ["Ang-II", "TREATMENT", 95, 101]]], ["The ACE/Ang-II/AT1R axis has long been thought to be the main path for the RAS in controlling the regulation of cardiovascular function.", [["cardiovascular", "ANATOMY", 112, 126], ["Ang-II", "CHEMICAL", 8, 14], ["ACE", "GENE_OR_GENE_PRODUCT", 4, 7], ["Ang-II", "GENE_OR_GENE_PRODUCT", 8, 14], ["AT1R", "GENE_OR_GENE_PRODUCT", 15, 19], ["RAS", "GENE_OR_GENE_PRODUCT", 75, 78], ["cardiovascular", "ANATOMICAL_SYSTEM", 112, 126], ["ACE", "PROTEIN", 4, 7], ["AT1R", "PROTEIN", 15, 19], ["RAS", "PROTEIN", 75, 78], ["The ACE/Ang-II/AT1R axis", "TREATMENT", 0, 24], ["cardiovascular function", "OBSERVATION", 112, 135]]], ["Therefore, pharmacological inhibition of ACE and specific blockade of AT1R have been the major therapeutic strategies for the treatment of hypertension and other cardiovascular diseases (Cushman and Ondetti 1981; Eberhardt et al. 1993 ).", [["cardiovascular", "ANATOMY", 162, 176], ["hypertension", "DISEASE", 139, 151], ["cardiovascular diseases", "DISEASE", 162, 185], ["ACE", "GENE_OR_GENE_PRODUCT", 41, 44], ["AT1R", "GENE_OR_GENE_PRODUCT", 70, 74], ["cardiovascular", "ANATOMICAL_SYSTEM", 162, 176], ["ACE", "PROTEIN", 41, 44], ["AT1R", "PROTEIN", 70, 74], ["ACE", "TREATMENT", 41, 44], ["specific blockade of AT1R", "TREATMENT", 49, 74], ["hypertension", "PROBLEM", 139, 151], ["other cardiovascular diseases", "PROBLEM", 156, 185], ["hypertension", "OBSERVATION", 139, 151], ["cardiovascular", "ANATOMY", 162, 176]]], ["However, the idea has been challenged in the last few years, with many components such as (pro)renin receptor (Nguyen and Danser 2008) , Ang-(1-7) Ocaranza et al. 2006) , ACE2 ) and the G-protein-coupled receptor Mas (Santos et al. 2003) added to the classical RAS and others like Ang-(1-12) (Trask et al. 2008) , ACE3 (Rella et al. 2007 ), Ang-A (Jankowski et al. 2007 ) and the non-AT1 non-AT2 binding site (Karamyan and Speth 2008) awaiting to be recognized.IntroductionACE2, one of the new elements of the RAS, was identified by 2 groups in 2000 (Donoghue et al. 2000; Tipnis et al. 2000) .", [["Ang", "CHEMICAL", 137, 140], ["Ang-(1-12", "CHEMICAL", 281, 290], ["Ang", "CHEMICAL", 341, 344], ["renin receptor", "GENE_OR_GENE_PRODUCT", 95, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 171, 175], ["G-protein-coupled receptor Mas", "GENE_OR_GENE_PRODUCT", 186, 216], ["RAS", "GENE_OR_GENE_PRODUCT", 261, 264], ["Ang-(1-12", "GENE_OR_GENE_PRODUCT", 281, 290], ["Ang-A", "GENE_OR_GENE_PRODUCT", 341, 346], ["AT2", "GENE_OR_GENE_PRODUCT", 392, 395], ["RAS", "GENE_OR_GENE_PRODUCT", 510, 513], ["renin receptor", "PROTEIN", 95, 109], ["ACE2", "PROTEIN", 171, 175], ["G-protein-coupled receptor Mas", "PROTEIN", 186, 216], ["RAS", "PROTEIN", 261, 264], ["AT2 binding site", "DNA", 392, 408], ["RAS", "DNA", 510, 513], ["Ang", "TEST", 137, 140], ["ACE2", "TEST", 171, 175], ["the G-protein-coupled receptor Mas", "TREATMENT", 182, 216], ["Ang", "TEST", 281, 284], ["the non-AT1 non-AT2 binding site", "TREATMENT", 376, 408], ["IntroductionACE2", "TREATMENT", 461, 477], ["new", "OBSERVATION_MODIFIER", 490, 493]]], ["The human ACE2 (hACE2) protein is a typical zinc metallopeptidase comprising 805 amino acids.", [["amino acids", "CHEMICAL", 81, 92], ["zinc", "CHEMICAL", 44, 48], ["amino acids", "CHEMICAL", 81, 92], ["human", "ORGANISM", 4, 9], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["hACE2", "GENE_OR_GENE_PRODUCT", 16, 21], ["amino acids", "AMINO_ACID", 81, 92], ["human ACE2 (hACE2) protein", "PROTEIN", 4, 30], ["zinc metallopeptidase", "PROTEIN", 44, 65], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human ACE2 (hACE2) protein", "TREATMENT", 0, 30], ["a typical zinc metallopeptidase", "TREATMENT", 34, 65], ["amino acids", "TREATMENT", 81, 92]]], ["As a homologue of ACE, ACE2 shares 42% sequence identity with ACE in the metalloprotease catalytic regions (Tipnis et al. 2000) , but unlike ACE, the carboxypeptidase hydrolyses its substrates by removing a single amino acid from their respective C-terminal.", [["amino acid", "CHEMICAL", 214, 224], ["amino acid", "CHEMICAL", 214, 224], ["ACE", "GENE_OR_GENE_PRODUCT", 18, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["ACE", "GENE_OR_GENE_PRODUCT", 62, 65], ["ACE", "GENE_OR_GENE_PRODUCT", 141, 144], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 150, 166], ["amino acid", "AMINO_ACID", 214, 224], ["ACE", "PROTEIN", 18, 21], ["ACE2", "PROTEIN", 23, 27], ["ACE", "PROTEIN", 62, 65], ["metalloprotease catalytic regions", "PROTEIN", 73, 106], ["ACE", "PROTEIN", 141, 144], ["carboxypeptidase", "PROTEIN", 150, 166], ["C-terminal", "PROTEIN", 247, 257], ["ACE", "TREATMENT", 18, 21], ["ACE2 shares", "TREATMENT", 23, 34], ["ACE in the metalloprotease catalytic regions", "TREATMENT", 62, 106], ["ACE", "TREATMENT", 141, 144], ["the carboxypeptidase hydrolyses", "TREATMENT", 146, 177], ["a single amino acid", "TREATMENT", 205, 224]]], ["ACE2 is able to cleave the decapeptide Ang-I and octapeptide Ang-II to Ang-(1-9) and Ang-(1-7), respectively (Tipnis et al. 2000; Vickers et al. 2002; Danilczyk et al. 2003) .", [["Ang", "CHEMICAL", 39, 42], ["Ang-II", "CHEMICAL", 61, 67], ["Ang-(1-9", "CHEMICAL", 71, 79], ["Ang", "CHEMICAL", 85, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["octapeptide Ang-II", "GENE_OR_GENE_PRODUCT", 49, 67], ["Ang-(1-9", "GENE_OR_GENE_PRODUCT", 71, 79], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 85, 93], ["ACE2", "PROTEIN", 0, 4], ["decapeptide Ang-I", "PROTEIN", 27, 44], ["the decapeptide Ang", "TREATMENT", 23, 42], ["octapeptide Ang", "TREATMENT", 49, 64], ["Ang", "TEST", 71, 74], ["Ang", "TEST", 85, 88]]], ["The affinity for Ang-I is poor in comparison with ACE, therefore the conversion of Ang-I to Ang-(1-9) is not of physiological importance, except maybe under conditions in which ACE activity is inhibited (Guy et al. 2005) or Ang-I levels are increased.", [["Ang", "CHEMICAL", 17, 20], ["Ang-I", "CHEMICAL", 83, 88], ["Ang-(1-9", "CHEMICAL", 92, 100], ["Ang", "CHEMICAL", 224, 227], ["Ang-I", "GENE_OR_GENE_PRODUCT", 17, 22], ["ACE", "GENE_OR_GENE_PRODUCT", 50, 53], ["Ang-I", "GENE_OR_GENE_PRODUCT", 83, 88], ["Ang-(1-9", "GENE_OR_GENE_PRODUCT", 92, 100], ["ACE", "GENE_OR_GENE_PRODUCT", 177, 180], ["Ang-I", "GENE_OR_GENE_PRODUCT", 224, 229], ["Ang-I", "PROTEIN", 17, 22], ["ACE", "PROTEIN", 177, 180], ["ACE", "TREATMENT", 50, 53], ["Ang-I to Ang", "TREATMENT", 83, 95], ["Ang-I levels", "TEST", 224, 236], ["increased", "OBSERVATION_MODIFIER", 241, 250]]], ["It has been established that ACE2 has approximately a 400-fold greater affinity for Ang-II than Ang-I (Vickers et al. 2002) .", [["Ang-II", "CHEMICAL", 84, 90], ["Ang", "CHEMICAL", 96, 99], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["Ang-II", "GENE_OR_GENE_PRODUCT", 84, 90], ["Ang-I", "GENE_OR_GENE_PRODUCT", 96, 101], ["ACE2", "PROTEIN", 29, 33], ["ACE2", "TEST", 29, 33]]], ["Hence, the major role of ACE2 in Ang peptides metabolism is the production of Ang-(1-7).", [["Ang", "CHEMICAL", 33, 36], ["Ang-(1-7", "CHEMICAL", 78, 86], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["Ang peptides", "GENE_OR_GENE_PRODUCT", 33, 45], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 78, 86], ["ACE2", "PROTEIN", 25, 29], ["Ang", "TEST", 78, 81], ["peptides metabolism", "OBSERVATION", 37, 56]]], ["ACE2 also participates in the metabolism of other peptides non related to the RAS: apelin-13, neurotensin, kinetensin, dynorphin, [des-Arg 9 ]-bradykinin, and [Lys-des-Arg 9 ]-bradykinin (Vickers et al. 2002) .", [["neurotensin", "CHEMICAL", 94, 105], ["kinetensin", "CHEMICAL", 107, 117], ["dynorphin", "CHEMICAL", 119, 128], ["[des-Arg 9 ]-bradykinin", "CHEMICAL", 130, 153], ["Lys-des-Arg 9 ]-bradykinin", "CHEMICAL", 160, 186], ["neurotensin", "CHEMICAL", 94, 105], ["[des-Arg 9 ]-bradykinin", "CHEMICAL", 130, 153], ["[Lys-des-Arg 9 ]-bradykinin", "CHEMICAL", 159, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAS", "GENE_OR_GENE_PRODUCT", 78, 81], ["apelin-13", "GENE_OR_GENE_PRODUCT", 83, 92], ["neurotensin", "GENE_OR_GENE_PRODUCT", 94, 105], ["kinetensin", "GENE_OR_GENE_PRODUCT", 107, 117], ["dynorphin", "GENE_OR_GENE_PRODUCT", 119, 128], ["[des-Arg 9 ]-bradykinin", "SIMPLE_CHEMICAL", 130, 153], ["[Lys-des-Arg 9 ]-bradykinin", "SIMPLE_CHEMICAL", 159, 186], ["ACE2", "PROTEIN", 0, 4], ["RAS", "PROTEIN", 78, 81], ["ACE2", "TREATMENT", 0, 4], ["other peptides", "PROBLEM", 44, 58], ["apelin", "TEST", 83, 89], ["neurotensin", "TREATMENT", 94, 105], ["kinetensin", "TREATMENT", 107, 117], ["dynorphin", "TREATMENT", 119, 128], ["bradykinin", "PROBLEM", 143, 153], ["bradykinin", "TREATMENT", 176, 186]]], ["However, the implications of ACE2-mediated metabolism of these peptides have not been investigated yet.IntroductionThe distribution of ACE2 has been addressed by several groups.", [["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["ACE2", "PROTEIN", 29, 33], ["ACE2", "PROTEIN", 135, 139], ["ACE2", "TEST", 29, 33], ["these peptides", "TREATMENT", 57, 71], ["ACE2", "PROBLEM", 135, 139]]], ["High ACE2 gene expression was initially reported in the heart, kidney and testis (Donoghue et al. 2000; Tipnis et al. 2000) .", [["heart", "ANATOMY", 56, 61], ["kidney", "ANATOMY", 63, 69], ["testis", "ANATOMY", 74, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["heart", "ORGAN", 56, 61], ["kidney", "ORGAN", 63, 69], ["testis", "ORGAN", 74, 80], ["ACE2", "PROTEIN", 5, 9], ["High ACE2 gene expression", "PROBLEM", 0, 25], ["heart", "ANATOMY", 56, 61], ["kidney", "ANATOMY", 63, 69], ["testis", "ANATOMY", 74, 80]]], ["Later studies showed ACE2 expression in a wide variety of tissues, including the brain and most of the cardiovascular-relevant tissues (Igase et al. 2005; Sakima et al. 2005; Doobay et al. 2007) , and the current consensus is that the distribution of the protein is ubiquitous.IntroductionAng-(1-7), the main product of Ang-II degradation by ACE2, has opposite properties to Ang-II.", [["tissues", "ANATOMY", 58, 65], ["brain", "ANATOMY", 81, 86], ["cardiovascular", "ANATOMY", 103, 117], ["tissues", "ANATOMY", 127, 134], ["IntroductionAng-(1-7)", "CHEMICAL", 277, 298], ["Ang-II", "CHEMICAL", 320, 326], ["Ang-II", "CHEMICAL", 375, 381], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["tissues", "TISSUE", 58, 65], ["brain", "ORGAN", 81, 86], ["cardiovascular", "ANATOMICAL_SYSTEM", 103, 117], ["tissues", "TISSUE", 127, 134], ["IntroductionAng-(1-7)", "SIMPLE_CHEMICAL", 277, 298], ["Ang-II", "GENE_OR_GENE_PRODUCT", 320, 326], ["ACE2", "GENE_OR_GENE_PRODUCT", 342, 346], ["Ang-II", "GENE_OR_GENE_PRODUCT", 375, 381], ["ACE2", "PROTEIN", 21, 25], ["Ang-II", "PROTEIN", 320, 326], ["ACE2", "PROTEIN", 342, 346], ["Ang-II", "PROTEIN", 375, 381], ["Later studies", "TEST", 0, 13], ["ACE2 expression", "PROBLEM", 21, 36], ["ACE2 expression", "OBSERVATION", 21, 36], ["brain", "ANATOMY", 81, 86], ["cardiovascular", "ANATOMY", 103, 117]]], ["By acting through Mas (Santos et al. 2003) , Ang-(1-7) promotes vasodilation, antiproliferation and antihypertrophy (Santos et al. 2000; Santos et al. 2003; Ferrario et al. 2005a) .", [["Ang-(1-7)", "CHEMICAL", 45, 54], ["Mas", "GENE_OR_GENE_PRODUCT", 18, 21], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 45, 53], ["Ang", "TEST", 45, 48]]], ["Accumulating evidence indicate that Ang-(1-7) has beneficial effects in cardiovascular diseases.", [["cardiovascular", "ANATOMY", 72, 86], ["Ang-(1-7)", "CHEMICAL", 36, 45], ["cardiovascular diseases", "DISEASE", 72, 95], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 36, 44], ["cardiovascular", "ANATOMICAL_SYSTEM", 72, 86], ["Ang", "TEST", 36, 39], ["cardiovascular diseases", "PROBLEM", 72, 95], ["Ang", "OBSERVATION", 36, 39], ["cardiovascular", "ANATOMY", 72, 86], ["diseases", "OBSERVATION", 87, 95]]], ["By cleaving Ang-II into Ang-(1-7), ACE2 may play a pivotal role in counter-regulating the actions of the well documented ACE/Ang-II/AT1R axis and be beneficial for the cardiovascular system.IntroductionIt has been shown that ACE2 gene is localized in a hypertension-related quantitative trait locus on the X chromosome (Crackower et al. 2002) , suggesting that ACE2 is a putative candidate gene for hypertension.", [["cardiovascular system", "ANATOMY", 168, 189], ["X chromosome", "ANATOMY", 306, 318], ["Ang-II", "CHEMICAL", 12, 18], ["Ang-(1-7", "CHEMICAL", 24, 32], ["Ang", "CHEMICAL", 125, 128], ["hypertension", "DISEASE", 253, 265], ["hypertension", "DISEASE", 399, 411], ["Ang-II", "GENE_OR_GENE_PRODUCT", 12, 18], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 24, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["ACE", "GENE_OR_GENE_PRODUCT", 121, 124], ["Ang-II", "GENE_OR_GENE_PRODUCT", 125, 131], ["AT1R", "GENE_OR_GENE_PRODUCT", 132, 136], ["cardiovascular", "ANATOMICAL_SYSTEM", 168, 182], ["system", "ANATOMICAL_SYSTEM", 183, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 225, 229], ["X chromosome", "CELLULAR_COMPONENT", 306, 318], ["ACE2", "GENE_OR_GENE_PRODUCT", 361, 365], ["Ang-II", "PROTEIN", 12, 18], ["ACE2", "PROTEIN", 35, 39], ["ACE", "PROTEIN", 121, 124], ["AT1R", "PROTEIN", 132, 136], ["ACE2 gene", "DNA", 225, 234], ["hypertension-related quantitative trait locus", "DNA", 253, 298], ["X chromosome", "DNA", 306, 318], ["ACE2", "PROTEIN", 361, 365], ["Ang", "TEST", 24, 27], ["ACE/Ang-II/AT1R axis", "TREATMENT", 121, 141], ["a hypertension", "PROBLEM", 251, 265], ["quantitative trait locus", "PROBLEM", 274, 298], ["hypertension", "PROBLEM", 399, 411], ["cardiovascular system", "ANATOMY", 168, 189], ["hypertension", "OBSERVATION", 253, 265], ["hypertension", "OBSERVATION", 399, 411]]], ["In addition, several studies have shown a strong association of the ACE2 gene polymorphism to hypertension in female Chinese patients with metabolic syndrome (Zhong et al. 2006) or essential hypertension (Yi et al. 2006; Fan et al. 2007) .", [["hypertension", "DISEASE", 94, 106], ["metabolic syndrome", "DISEASE", 139, 157], ["essential hypertension", "DISEASE", 181, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["patients", "ORGANISM", 125, 133], ["ACE2 gene", "DNA", 68, 77], ["patients", "SPECIES", 125, 133], ["several studies", "TEST", 13, 28], ["the ACE2 gene polymorphism", "PROBLEM", 64, 90], ["hypertension", "PROBLEM", 94, 106], ["metabolic syndrome", "PROBLEM", 139, 157], ["essential hypertension", "PROBLEM", 181, 203], ["hypertension", "OBSERVATION", 94, 106], ["metabolic syndrome", "OBSERVATION", 139, 157], ["hypertension", "OBSERVATION", 191, 203]]], ["Other studies demonstrated that polymorphism of the ACE2 gene is associated with left ventricular hypertrophy in patients with hypertrophic cardiomyopathy, but the association is independent of BP (Lieb et al. 2006; van der Merwe et al. 2008; Wang et al. 2008) .", [["left ventricular", "ANATOMY", 81, 97], ["left ventricular hypertrophy", "DISEASE", 81, 109], ["hypertrophic cardiomyopathy", "DISEASE", 127, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 81, 97], ["patients", "ORGANISM", 113, 121], ["ACE2 gene", "DNA", 52, 61], ["patients", "SPECIES", 113, 121], ["Other studies", "TEST", 0, 13], ["left ventricular hypertrophy", "PROBLEM", 81, 109], ["hypertrophic cardiomyopathy", "PROBLEM", 127, 154], ["BP", "TEST", 194, 196], ["left ventricular", "ANATOMY", 81, 97], ["hypertrophy", "OBSERVATION", 98, 109], ["hypertrophic", "OBSERVATION_MODIFIER", 127, 139], ["cardiomyopathy", "OBSERVATION", 140, 154]]], ["Finally, an association between ACE2 polymorphisms and coronary heart disease and myocardial infarction was observed in Chinese Han population (Yang et al. 2006) .", [["coronary", "ANATOMY", 55, 63], ["heart", "ANATOMY", 64, 69], ["myocardial", "ANATOMY", 82, 92], ["coronary heart disease", "DISEASE", 55, 77], ["myocardial infarction", "DISEASE", 82, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 55, 69], ["myocardial", "MULTI-TISSUE_STRUCTURE", 82, 92], ["ACE2", "PROTEIN", 32, 36], ["ACE2 polymorphisms", "PROBLEM", 32, 50], ["coronary heart disease", "PROBLEM", 55, 77], ["myocardial infarction", "PROBLEM", 82, 103], ["coronary heart", "ANATOMY", 55, 69], ["disease", "OBSERVATION", 70, 77], ["myocardial", "ANATOMY", 82, 92], ["infarction", "OBSERVATION", 93, 103]]], ["These studies support the idea that ACE2 plays a critical role in the regulation of BP and cardiovascular function.IntroductionHere, we will review the evidence for the involvement of ACE2 in the regulation of cardiovascular function.", [["cardiovascular", "ANATOMY", 91, 105], ["cardiovascular", "ANATOMY", 210, 224], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["BP", "SIMPLE_CHEMICAL", 84, 86], ["cardiovascular", "ANATOMICAL_SYSTEM", 91, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["cardiovascular", "ANATOMICAL_SYSTEM", 210, 224], ["ACE2", "PROTEIN", 36, 40], ["ACE2", "PROTEIN", 184, 188], ["These studies", "TEST", 0, 13], ["BP", "TEST", 84, 86], ["ACE2", "PROBLEM", 184, 188], ["cardiovascular function", "OBSERVATION", 91, 114], ["cardiovascular function", "OBSERVATION", 210, 233]]], ["Following a summary of the recently discovered properties of ACE2 in the periphery (i.e. in the heart, kidney and lung), we will focus on the central role of this enzyme and discuss its potential as a new target for the treatment of hypertension and other cardiovascular diseases.ACE2 in the peripheryACE2 is highly expressed in the heart, kidney and vasculature (Harmer et al. 2002) .", [["heart", "ANATOMY", 96, 101], ["kidney", "ANATOMY", 103, 109], ["lung", "ANATOMY", 114, 118], ["cardiovascular", "ANATOMY", 256, 270], ["heart", "ANATOMY", 333, 338], ["kidney", "ANATOMY", 340, 346], ["vasculature", "ANATOMY", 351, 362], ["hypertension", "DISEASE", 233, 245], ["cardiovascular diseases", "DISEASE", 256, 279], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["heart", "ORGAN", 96, 101], ["kidney", "ORGAN", 103, 109], ["lung", "ORGAN", 114, 118], ["cardiovascular", "ANATOMICAL_SYSTEM", 256, 270], ["ACE2", "GENE_OR_GENE_PRODUCT", 280, 284], ["peripheryACE2", "GENE_OR_GENE_PRODUCT", 292, 305], ["heart", "ORGAN", 333, 338], ["kidney", "ORGAN", 340, 346], ["vasculature", "MULTI-TISSUE_STRUCTURE", 351, 362], ["ACE2", "PROTEIN", 61, 65], ["ACE2", "PROTEIN", 280, 284], ["peripheryACE2", "PROTEIN", 292, 305], ["this enzyme", "TEST", 158, 169], ["hypertension", "PROBLEM", 233, 245], ["other cardiovascular diseases", "PROBLEM", 250, 279], ["ACE2 in the peripheryACE2", "TREATMENT", 280, 305], ["periphery", "ANATOMY_MODIFIER", 73, 82], ["heart", "ANATOMY", 96, 101], ["kidney", "ANATOMY", 103, 109], ["lung", "ANATOMY", 114, 118], ["hypertension", "OBSERVATION", 233, 245], ["cardiovascular diseases", "OBSERVATION", 256, 279], ["heart", "ANATOMY", 333, 338], ["kidney", "ANATOMY", 340, 346], ["vasculature", "ANATOMY", 351, 362]]], ["In the kidney, it is predominantly expressed in the proximal tubular brush border (Tikellis et al. 2003; Hamming et al. 2004) , where ACE is also present (Sibony et al. 1993 ).", [["kidney", "ANATOMY", 7, 13], ["tubular brush border", "ANATOMY", 61, 81], ["kidney", "ORGAN", 7, 13], ["tubular brush border", "TISSUE", 61, 81], ["ACE", "GENE_OR_GENE_PRODUCT", 134, 137], ["ACE", "TREATMENT", 134, 137], ["kidney", "ANATOMY", 7, 13], ["predominantly", "OBSERVATION_MODIFIER", 21, 34], ["expressed", "OBSERVATION", 35, 44], ["proximal", "ANATOMY_MODIFIER", 52, 60], ["tubular", "ANATOMY_MODIFIER", 61, 68], ["brush", "ANATOMY_MODIFIER", 69, 74], ["border", "ANATOMY_MODIFIER", 75, 81]]], ["It has also been shown in distal tubules and to a much lesser extent in glomeruli (Ye et al. 2004; Gembardt et al. 2005; Li et al. 2005) .", [["distal tubules", "ANATOMY", 26, 40], ["glomeruli", "ANATOMY", 72, 81], ["tubules", "TISSUE", 33, 40], ["glomeruli", "TISSUE", 72, 81], ["distal", "ANATOMY_MODIFIER", 26, 32], ["tubules", "OBSERVATION", 33, 40], ["lesser", "OBSERVATION_MODIFIER", 55, 61], ["extent", "OBSERVATION_MODIFIER", 62, 68], ["glomeruli", "ANATOMY", 72, 81]]], ["In the heart, ACE2 is localized to the endothelial and smooth muscle cells of intra-myocardial vessels, as well as on cardiac myocytes (Donoghue et al. 2000; Tipnis et al. 2000; Burrell et al. 2005) .", [["heart", "ANATOMY", 7, 12], ["endothelial", "ANATOMY", 39, 50], ["smooth muscle cells", "ANATOMY", 55, 74], ["intra-myocardial vessels", "ANATOMY", 78, 102], ["cardiac myocytes", "ANATOMY", 118, 134], ["heart", "ORGAN", 7, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["endothelial", "CELL", 39, 50], ["smooth muscle cells", "CELL", 55, 74], ["intra-myocardial vessels", "MULTI-TISSUE_STRUCTURE", 78, 102], ["cardiac myocytes", "CELL", 118, 134], ["ACE2", "PROTEIN", 14, 18], ["endothelial and smooth muscle cells", "CELL_TYPE", 39, 74], ["heart", "ANATOMY", 7, 12], ["ACE2", "ANATOMY", 14, 18], ["endothelial", "ANATOMY", 39, 50], ["smooth muscle cells", "OBSERVATION", 55, 74], ["intra-myocardial vessels", "ANATOMY", 78, 102], ["cardiac myocytes", "ANATOMY", 118, 134]]], ["The enzyme has also been found in the thoracic aorta, carotid arteries, and veins (Igase et al. 2005; Sluimer et al. 2008) .", [["thoracic aorta", "ANATOMY", 38, 52], ["carotid arteries", "ANATOMY", 54, 70], ["veins", "ANATOMY", 76, 81], ["thoracic aorta", "MULTI-TISSUE_STRUCTURE", 38, 52], ["carotid arteries", "MULTI-TISSUE_STRUCTURE", 54, 70], ["veins", "MULTI-TISSUE_STRUCTURE", 76, 81], ["The enzyme", "TEST", 0, 10], ["thoracic aorta", "ANATOMY", 38, 52], ["carotid arteries", "ANATOMY", 54, 70], ["veins", "ANATOMY", 76, 81]]], ["Since its discovery in 2000, accumulating evidence has indicated that ACE2 plays a significant role in the regulation of BP, renal and cardiac functions, and its altered expression is associated with major cardiac and renal pathophysiologies.", [["renal", "ANATOMY", 125, 130], ["cardiac", "ANATOMY", 135, 142], ["cardiac", "ANATOMY", 206, 213], ["renal", "ANATOMY", 218, 223], ["cardiac and renal pathophysiologies", "DISEASE", 206, 241], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["BP", "SIMPLE_CHEMICAL", 121, 123], ["renal", "MULTI-TISSUE_STRUCTURE", 125, 130], ["cardiac", "ORGAN", 135, 142], ["cardiac", "ORGAN", 206, 213], ["renal", "ORGAN", 218, 223], ["ACE2", "PROTEIN", 70, 74], ["BP", "TEST", 121, 123], ["major cardiac and renal pathophysiologies", "PROBLEM", 200, 241], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["renal", "ANATOMY", 125, 130], ["cardiac", "ANATOMY", 135, 142], ["renal", "ANATOMY", 218, 223], ["pathophysiologies", "OBSERVATION", 224, 241]]], ["It has been hypothesized that disruption of the balance between ACE and ACE2 would result in abnormal BP control (Yagil and Yagil 2003) , therefore ACE2 might protect against increases in BP and ACE2 deficiency might lead to hypertension.", [["hypertension", "DISEASE", 225, 237], ["ACE", "GENE_OR_GENE_PRODUCT", 64, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["BP", "SIMPLE_CHEMICAL", 188, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 195, 199], ["ACE", "PROTEIN", 64, 67], ["ACE2", "PROTEIN", 72, 76], ["ACE2", "PROTEIN", 148, 152], ["BP", "PROTEIN", 188, 190], ["ACE2", "PROTEIN", 195, 199], ["ACE and ACE2", "TREATMENT", 64, 76], ["abnormal BP control", "PROBLEM", 93, 112], ["ACE2", "TREATMENT", 148, 152], ["BP", "TEST", 188, 190], ["ACE2 deficiency", "PROBLEM", 195, 210], ["hypertension", "PROBLEM", 225, 237], ["ACE2 deficiency", "OBSERVATION", 195, 210], ["hypertension", "OBSERVATION", 225, 237]]], ["Indeed, patients with hypertension showed marked ACE up-regulation and ACE2 down-regulation in both heart and kidney (Wakahara et al. 2007; Koka et al. 2008) .", [["heart", "ANATOMY", 100, 105], ["kidney", "ANATOMY", 110, 116], ["hypertension", "DISEASE", 22, 34], ["patients", "ORGANISM", 8, 16], ["ACE", "GENE_OR_GENE_PRODUCT", 49, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["heart", "ORGAN", 100, 105], ["kidney", "ORGAN", 110, 116], ["ACE", "PROTEIN", 49, 52], ["ACE2", "PROTEIN", 71, 75], ["patients", "SPECIES", 8, 16], ["hypertension", "PROBLEM", 22, 34], ["marked ACE up", "PROBLEM", 42, 55], ["ACE2", "TEST", 71, 75], ["hypertension", "OBSERVATION", 22, 34], ["marked", "OBSERVATION_MODIFIER", 42, 48], ["both", "ANATOMY_MODIFIER", 95, 99], ["heart", "ANATOMY", 100, 105], ["kidney", "ANATOMY", 110, 116]]], ["ACE2 levels have been reported in the kidneys of three hypertensive rat strains (Crackower et al. 2002) .", [["kidneys", "ANATOMY", 38, 45], ["hypertensive", "DISEASE", 55, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["kidneys", "ORGAN", 38, 45], ["rat", "ORGANISM", 68, 71], ["ACE2", "PROTEIN", 0, 4], ["rat", "SPECIES", 68, 71], ["ACE2 levels", "TEST", 0, 11], ["three hypertensive rat strains", "PROBLEM", 49, 79], ["kidneys", "ANATOMY", 38, 45]]], ["In salt-sensitive Sabra hypertensive (SBH/y) rats, ACE2 mRNA and protein expression are lower than that in salt-resistant Sabra normotensive (SBN/y) rats.ACE2 in the peripheryFollowing salt loading, an additional increase in BP was observed in SBH/y rats, which was correlated with a further decrease in ACE2 expression.", [["periphery", "ANATOMY", 166, 175], ["hypertensive", "DISEASE", 24, 36], ["salt", "SIMPLE_CHEMICAL", 3, 7], ["SBH/y) rats", "ORGANISM", 38, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["salt", "SIMPLE_CHEMICAL", 107, 111], ["SBN/y) rats", "ORGANISM", 142, 153], ["ACE2", "GENE_OR_GENE_PRODUCT", 154, 158], ["salt", "SIMPLE_CHEMICAL", 185, 189], ["BP", "SIMPLE_CHEMICAL", 225, 227], ["SBH/y rats", "ORGANISM", 244, 254], ["ACE2", "GENE_OR_GENE_PRODUCT", 304, 308], ["ACE2 mRNA", "RNA", 51, 60], ["ACE2", "PROTEIN", 154, 158], ["BP", "PROTEIN", 225, 227], ["ACE2", "PROTEIN", 304, 308], ["rats", "SPECIES", 45, 49], ["rats", "SPECIES", 149, 153], ["rats", "SPECIES", 250, 254], ["salt", "TEST", 3, 7], ["hypertensive", "PROBLEM", 24, 36], ["ACE2 mRNA", "TEST", 51, 60], ["protein expression", "TEST", 65, 83], ["salt", "TEST", 107, 111], ["normotensive", "PROBLEM", 128, 140], ["ACE2", "TREATMENT", 154, 158], ["salt loading", "TREATMENT", 185, 197], ["an additional increase in BP", "TREATMENT", 199, 227], ["a further decrease in ACE2 expression", "TREATMENT", 282, 319], ["salt loading", "OBSERVATION", 185, 197], ["increase", "OBSERVATION_MODIFIER", 213, 221], ["ACE2 expression", "OBSERVATION", 304, 319]]], ["In addition, a significant decrease of ACE2 expression was also observed in the kidneys of both spontaneously hypertensive rats (SHR) and spontaneously hypertensive-stroke prone (SHRSP) rats as compared to their Wistar-Kyoto (WKY) controls.", [["kidneys", "ANATOMY", 80, 87], ["hypertensive", "DISEASE", 110, 122], ["hypertensive-stroke", "DISEASE", 152, 171], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["kidneys", "ORGAN", 80, 87], ["rats", "ORGANISM", 123, 127], ["rats", "ORGANISM", 186, 190], ["Wistar-Kyoto (WKY) controls", "ORGANISM", 212, 239], ["ACE2", "PROTEIN", 39, 43], ["rats", "SPECIES", 123, 127], ["rats", "SPECIES", 186, 190], ["a significant decrease of ACE2 expression", "PROBLEM", 13, 54], ["spontaneously hypertensive", "PROBLEM", 138, 164], ["stroke prone (SHRSP) rats", "PROBLEM", 165, 190], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["ACE2 expression", "OBSERVATION", 39, 54], ["kidneys", "ANATOMY", 80, 87], ["both", "ANATOMY_MODIFIER", 91, 95], ["spontaneously", "OBSERVATION_MODIFIER", 96, 109], ["hypertensive", "OBSERVATION", 110, 122]]], ["Similar observations were made by Zhong et al. showing that SHR have lower cardiac and renal ACE2 mRNA and protein (Zhong et al. 2004) .", [["cardiac", "ANATOMY", 75, 82], ["renal", "ANATOMY", 87, 92], ["cardiac", "ORGAN", 75, 82], ["renal", "ORGAN", 87, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["renal ACE2 mRNA", "RNA", 87, 102], ["lower cardiac and renal ACE2 mRNA", "PROBLEM", 69, 102], ["lower", "ANATOMY_MODIFIER", 69, 74], ["cardiac", "ANATOMY", 75, 82], ["renal ACE2", "ANATOMY", 87, 97]]], ["Chronic all-trans retinoic acid treatment increases gene and protein expression of ACE2 in both heart and kidney, resulting in the reduction of BP and the attenuation of myocardial damage in SHR (Zhong et al. 2004) .", [["heart", "ANATOMY", 96, 101], ["kidney", "ANATOMY", 106, 112], ["myocardial", "ANATOMY", 170, 180], ["retinoic acid", "CHEMICAL", 18, 31], ["myocardial damage", "DISEASE", 170, 187], ["all-trans retinoic acid", "CHEMICAL", 8, 31], ["-trans retinoic acid", "SIMPLE_CHEMICAL", 11, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["heart", "ORGAN", 96, 101], ["kidney", "ORGAN", 106, 112], ["BP", "SIMPLE_CHEMICAL", 144, 146], ["myocardial", "MULTI-TISSUE_STRUCTURE", 170, 180], ["ACE2", "PROTEIN", 83, 87], ["BP", "PROTEIN", 144, 146], ["Chronic all-trans retinoic acid treatment", "TREATMENT", 0, 41], ["ACE2", "TEST", 83, 87], ["the reduction of BP", "PROBLEM", 127, 146], ["myocardial damage in SHR", "PROBLEM", 170, 194], ["retinoic acid", "OBSERVATION", 18, 31], ["both", "ANATOMY_MODIFIER", 91, 95], ["heart", "ANATOMY", 96, 101], ["kidney", "ANATOMY", 106, 112], ["reduction", "OBSERVATION_MODIFIER", 131, 140], ["attenuation", "OBSERVATION_MODIFIER", 155, 166], ["myocardial", "ANATOMY", 170, 180], ["damage", "OBSERVATION", 181, 187]]], ["Treatments with ACE inhibitors or AT1R blockers increased cardiac and renal ACE2 expression and/or activity and decreased BP in Lew.Tg (mRen2) congenic hypertensive rats (Jessup et al. 2006) .", [["cardiac", "ANATOMY", 58, 65], ["renal", "ANATOMY", 70, 75], ["hypertensive", "DISEASE", 152, 164], ["ACE", "GENE_OR_GENE_PRODUCT", 16, 19], ["AT1R", "GENE_OR_GENE_PRODUCT", 34, 38], ["cardiac", "ORGAN", 58, 65], ["renal", "ORGAN", 70, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["BP", "SIMPLE_CHEMICAL", 122, 124], ["rats", "ORGANISM", 165, 169], ["ACE2", "PROTEIN", 76, 80], ["BP", "PROTEIN", 122, 124], ["rats", "SPECIES", 165, 169], ["ACE inhibitors", "TREATMENT", 16, 30], ["AT1R blockers", "TREATMENT", 34, 47], ["cardiac and renal ACE2 expression", "TREATMENT", 58, 91], ["decreased BP in Lew.Tg (mRen2)", "TREATMENT", 112, 142], ["congenic hypertensive rats", "PROBLEM", 143, 169], ["renal", "ANATOMY", 70, 75]]], ["Over-expression of ACE2 in vascular smooth muscle using the SM22 promoter reduced BP in SHRSP rats, and attenuated the pressor response to Ang-II in these animals (Rentzsch et al. 2008) .", [["vascular smooth muscle", "ANATOMY", 27, 49], ["Ang-II", "CHEMICAL", 139, 145], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["vascular smooth muscle", "TISSUE", 27, 49], ["SM22", "GENE_OR_GENE_PRODUCT", 60, 64], ["BP", "SIMPLE_CHEMICAL", 82, 84], ["SHRSP rats", "ORGANISM", 88, 98], ["Ang-II", "GENE_OR_GENE_PRODUCT", 139, 145], ["ACE2", "PROTEIN", 19, 23], ["SM22 promoter", "DNA", 60, 73], ["BP", "PROTEIN", 82, 84], ["rats", "SPECIES", 94, 98], ["SHRSP", "SPECIES", 88, 93], ["the SM22 promoter", "TREATMENT", 56, 73], ["vascular", "ANATOMY", 27, 35], ["smooth muscle", "ANATOMY", 36, 49]]], ["Altogether, these studies suggest an important role for ACE2 in the regulation of BP.ACE2 in the peripheryCrackower et al. first demonstrated that loss of ACE2 in mice results in contractile dysfunction, increased Ang-II levels and up-regulation of hypoxia-induced genes in the heart (Crackower et al. 2002) .", [["periphery", "ANATOMY", 97, 106], ["contractile", "ANATOMY", 179, 190], ["heart", "ANATOMY", 278, 283], ["contractile dysfunction", "DISEASE", 179, 202], ["Ang-II", "CHEMICAL", 214, 220], ["hypoxia", "DISEASE", 249, 256], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["BP", "SIMPLE_CHEMICAL", 82, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 155, 159], ["mice", "ORGANISM", 163, 167], ["Ang-II", "GENE_OR_GENE_PRODUCT", 214, 220], ["heart", "ORGAN", 278, 283], ["ACE2", "PROTEIN", 56, 60], ["BP", "PROTEIN", 82, 84], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 155, 159], ["Ang-II", "PROTEIN", 214, 220], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 163, 167], ["these studies", "TEST", 12, 25], ["ACE2", "TREATMENT", 56, 60], ["BP", "TEST", 82, 84], ["loss of ACE2 in mice", "PROBLEM", 147, 167], ["contractile dysfunction", "PROBLEM", 179, 202], ["increased Ang-II levels", "PROBLEM", 204, 227], ["hypoxia", "PROBLEM", 249, 256], ["induced genes in the heart", "PROBLEM", 257, 283], ["periphery", "ANATOMY_MODIFIER", 97, 106], ["loss", "OBSERVATION_MODIFIER", 147, 151], ["contractile dysfunction", "OBSERVATION", 179, 202], ["increased", "OBSERVATION_MODIFIER", 204, 213], ["hypoxia", "OBSERVATION", 249, 256], ["heart", "ANATOMY", 278, 283]]], ["The cardiac phenotype was completely rescued by genetic ablation of ACE in ACE2 knockout (ACE2 -/y ) mice (Crackower et al. 2002) , suggesting that cardiac function is modulated by the balance between ACE and ACE2.", [["cardiac", "ANATOMY", 4, 11], ["cardiac", "ANATOMY", 148, 155], ["cardiac", "ORGAN", 4, 11], ["ACE", "GENE_OR_GENE_PRODUCT", 68, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["cardiac", "ORGAN", 148, 155], ["ACE", "GENE_OR_GENE_PRODUCT", 201, 204], ["ACE2", "GENE_OR_GENE_PRODUCT", 209, 213], ["ACE", "PROTEIN", 68, 71], ["ACE2", "PROTEIN", 75, 79], ["ACE2", "PROTEIN", 90, 94], ["ACE", "PROTEIN", 201, 204], ["ACE2", "PROTEIN", 209, 213], ["mice", "SPECIES", 101, 105], ["ACE", "TREATMENT", 68, 71], ["ACE2", "TEST", 90, 94], ["ACE and ACE2", "TREATMENT", 201, 213], ["cardiac", "ANATOMY", 4, 11], ["cardiac", "ANATOMY", 148, 155], ["function", "OBSERVATION", 156, 164]]], ["Although these cardiac abnormalities failed to be detected by Yamamoto et al. in their own ACE2 -/y mouse, the authors reported the development of cardiac hypertrophy and dilatation associated with reduced cardiac contractility in response to chronic pressure overload, induced by transverse aortic constriction (Yamamoto et al. 2006) .", [["cardiac", "ANATOMY", 15, 22], ["cardiac", "ANATOMY", 147, 154], ["cardiac", "ANATOMY", 206, 213], ["aortic", "ANATOMY", 292, 298], ["cardiac abnormalities", "DISEASE", 15, 36], ["cardiac hypertrophy", "DISEASE", 147, 166], ["pressure overload", "DISEASE", 251, 268], ["cardiac", "ORGAN", 15, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["cardiac", "ORGAN", 147, 154], ["cardiac", "ORGAN", 206, 213], ["aortic", "MULTI-TISSUE_STRUCTURE", 292, 298], ["ACE2", "PROTEIN", 91, 95], ["mouse", "SPECIES", 100, 105], ["these cardiac abnormalities", "PROBLEM", 9, 36], ["cardiac hypertrophy", "PROBLEM", 147, 166], ["dilatation", "PROBLEM", 171, 181], ["reduced cardiac contractility", "PROBLEM", 198, 227], ["chronic pressure overload", "PROBLEM", 243, 268], ["transverse aortic constriction", "PROBLEM", 281, 311], ["cardiac", "ANATOMY", 15, 22], ["abnormalities", "OBSERVATION", 23, 36], ["cardiac", "ANATOMY", 147, 154], ["hypertrophy", "OBSERVATION", 155, 166], ["dilatation", "OBSERVATION", 171, 181], ["reduced", "OBSERVATION_MODIFIER", 198, 205], ["cardiac contractility", "OBSERVATION", 206, 227], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["pressure overload", "OBSERVATION", 251, 268], ["transverse aortic", "ANATOMY", 281, 298], ["constriction", "OBSERVATION_MODIFIER", 299, 311]]], ["These authors also observed increased cardiac Ang-II levels and that inhibition of the AT1R attenuated the hypertrophic response.", [["cardiac", "ANATOMY", 38, 45], ["Ang-II", "CHEMICAL", 46, 52], ["Ang-II", "GENE_OR_GENE_PRODUCT", 46, 52], ["AT1R", "GENE_OR_GENE_PRODUCT", 87, 91], ["Ang-II", "PROTEIN", 46, 52], ["AT1R", "PROTEIN", 87, 91], ["the hypertrophic response", "PROBLEM", 103, 128], ["cardiac", "ANATOMY", 38, 45], ["Ang", "OBSERVATION", 46, 49], ["hypertrophic response", "OBSERVATION", 107, 128]]], ["Recently, Oudit et al. showed that loss of ACE2 leads to a progressive age-dependent dilated cardiomyopathy, associated with increased Ang-II-mediated oxidative stress (Oudit et al. 2007 ).", [["dilated cardiomyopathy", "DISEASE", 85, 107], ["Ang-II", "CHEMICAL", 135, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["Ang-II", "GENE_OR_GENE_PRODUCT", 135, 141], ["ACE2", "PROTEIN", 43, 47], ["Ang-II", "PROTEIN", 135, 141], ["loss of ACE2 leads", "PROBLEM", 35, 53], ["a progressive age-dependent dilated cardiomyopathy", "PROBLEM", 57, 107], ["increased Ang-II-mediated oxidative stress", "PROBLEM", 125, 167], ["loss", "OBSERVATION_MODIFIER", 35, 39], ["progressive", "OBSERVATION_MODIFIER", 59, 70], ["dependent", "OBSERVATION_MODIFIER", 75, 84], ["dilated", "OBSERVATION_MODIFIER", 85, 92], ["cardiomyopathy", "OBSERVATION", 93, 107], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["Ang", "OBSERVATION", 135, 138], ["oxidative stress", "OBSERVATION", 151, 167]]], ["Using similarly engineered mice, Gurley et al. failed to see a cardiac phenotype but observed a small elevation of baseline BP in knockout C57Bl/6 mice, no changes in ACE2 -/y with a 129/SvEv background and variable changes in mixed animals (Gurley et al. 2006; Gurley and Coffman 2008) , suggesting that the role of ACE2 could be modulated by genetic factors.", [["cardiac", "ANATOMY", 63, 70], ["mice", "ORGANISM", 27, 31], ["C57Bl/6 mice", "ORGANISM", 139, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["SvEv", "GENE_OR_GENE_PRODUCT", 187, 191], ["ACE2", "GENE_OR_GENE_PRODUCT", 317, 321], ["BP", "PROTEIN", 124, 126], ["ACE2", "PROTEIN", 167, 171], ["ACE2", "PROTEIN", 317, 321], ["genetic factors", "PROTEIN", 344, 359], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 27, 31], ["a cardiac phenotype", "PROBLEM", 61, 80], ["a small elevation", "PROBLEM", 94, 111], ["baseline BP", "TEST", 115, 126], ["ACE2", "TEST", 167, 171], ["variable changes in mixed animals", "PROBLEM", 207, 240], ["cardiac", "ANATOMY", 63, 70], ["small", "OBSERVATION_MODIFIER", 96, 101], ["elevation", "OBSERVATION", 102, 111], ["variable", "OBSERVATION_MODIFIER", 207, 215]]], ["In addition, deletion of the ACE2 gene in male mice leads to Ang-IIdependent development of glomerular mesangial expansion (Oudit et al. 2006) .", [["glomerular mesangial", "ANATOMY", 92, 112], ["Ang", "CHEMICAL", 61, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["male mice", "ORGANISM", 42, 51], ["Ang-IIdependent", "GENE_OR_GENE_PRODUCT", 61, 76], ["glomerular mesangial", "TISSUE", 92, 112], ["ACE2 gene", "DNA", 29, 38], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["the ACE2 gene", "TREATMENT", 25, 38], ["glomerular mesangial expansion", "PROBLEM", 92, 122], ["glomerular", "ANATOMY_MODIFIER", 92, 102], ["mesangial expansion", "OBSERVATION", 103, 122]]], ["Altogether, these findings suggest an important role for ACE2 in counteracting the effects of accumulating Ang-II.", [["Ang-II", "CHEMICAL", 107, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["Ang-II", "GENE_OR_GENE_PRODUCT", 107, 113], ["ACE2", "PROTEIN", 57, 61], ["Ang-II", "PROTEIN", 107, 113], ["ACE2", "PROBLEM", 57, 61]]], ["However, transgenic mice with ACE2 expression targeted to myocardial cells developed spontaneous episodes of ventricular tachycardia and fibrillation leading to a fatal outcome (Donoghue et al. 2003) , suggesting that ACE2 possibly influences the electrical pathways of the heart.ACE2 in the peripheryEarly increases and late decreases in cardiac ACE2 expression were observed in experimental myocardial infarction in rats (Ocaranza et al. 2006) .", [["myocardial cells", "ANATOMY", 58, 74], ["ventricular", "ANATOMY", 109, 120], ["heart", "ANATOMY", 274, 279], ["periphery", "ANATOMY", 292, 301], ["cardiac", "ANATOMY", 339, 346], ["myocardial", "ANATOMY", 393, 403], ["ventricular tachycardia", "DISEASE", 109, 132], ["fibrillation", "DISEASE", 137, 149], ["myocardial infarction", "DISEASE", 393, 414], ["mice", "ORGANISM", 20, 24], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["myocardial cells", "CELL", 58, 74], ["ventricular", "ORGAN", 109, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["heart", "ORGAN", 274, 279], ["ACE2", "GENE_OR_GENE_PRODUCT", 280, 284], ["cardiac", "ORGAN", 339, 346], ["ACE2", "GENE_OR_GENE_PRODUCT", 347, 351], ["myocardial", "MULTI-TISSUE_STRUCTURE", 393, 403], ["rats", "ORGANISM", 418, 422], ["ACE2", "PROTEIN", 30, 34], ["myocardial cells", "CELL_TYPE", 58, 74], ["ACE2", "PROTEIN", 218, 222], ["ACE2", "PROTEIN", 280, 284], ["ACE2", "PROTEIN", 347, 351], ["mice", "SPECIES", 20, 24], ["rats", "SPECIES", 418, 422], ["mice", "SPECIES", 20, 24], ["ACE2 expression", "TREATMENT", 30, 45], ["myocardial cells", "PROBLEM", 58, 74], ["ventricular tachycardia", "PROBLEM", 109, 132], ["fibrillation", "PROBLEM", 137, 149], ["a fatal outcome", "PROBLEM", 161, 176], ["ACE2", "PROBLEM", 218, 222], ["Early increases", "PROBLEM", 301, 316], ["late decreases in cardiac ACE2 expression", "PROBLEM", 321, 362], ["experimental myocardial infarction", "PROBLEM", 380, 414], ["ventricular", "ANATOMY", 109, 120], ["tachycardia", "OBSERVATION", 121, 132], ["fibrillation", "OBSERVATION", 137, 149], ["fatal", "OBSERVATION_MODIFIER", 163, 168], ["heart", "ANATOMY", 274, 279], ["periphery", "ANATOMY_MODIFIER", 292, 301], ["increases", "OBSERVATION_MODIFIER", 307, 316], ["late", "OBSERVATION_MODIFIER", 321, 325], ["decreases", "OBSERVATION_MODIFIER", 326, 335], ["cardiac", "ANATOMY", 339, 346], ["ACE2 expression", "OBSERVATION", 347, 362], ["myocardial", "ANATOMY", 393, 403], ["infarction", "OBSERVATION", 404, 414]]], ["Cardiac hypertrophy, fibrosis and hypertension have been associated with significant increases in cardiac ACE2 gene expression and activity in rats (Burchill et al. 2008) .", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 98, 105], ["Cardiac hypertrophy", "DISEASE", 0, 19], ["fibrosis", "DISEASE", 21, 29], ["hypertension", "DISEASE", 34, 46], ["Cardiac", "MULTI-TISSUE_STRUCTURE", 0, 7], ["cardiac", "ORGAN", 98, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["rats", "ORGANISM", 143, 147], ["ACE2", "PROTEIN", 106, 110], ["rats", "SPECIES", 143, 147], ["Cardiac hypertrophy", "PROBLEM", 0, 19], ["fibrosis", "PROBLEM", 21, 29], ["hypertension", "PROBLEM", 34, 46], ["significant increases in cardiac ACE2 gene expression", "PROBLEM", 73, 126], ["hypertrophy", "OBSERVATION", 8, 19], ["fibrosis", "OBSERVATION", 21, 29], ["hypertension", "OBSERVATION", 34, 46], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["increases", "OBSERVATION_MODIFIER", 85, 94], ["cardiac", "ANATOMY", 98, 105], ["ACE2", "OBSERVATION", 106, 110]]], ["Increased ACE2 was also observed in cardiac tissue of patients with ischemic heart failure (Zisman et al. 2003) .", [["cardiac tissue", "ANATOMY", 36, 50], ["heart", "ANATOMY", 77, 82], ["ischemic heart failure", "DISEASE", 68, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["cardiac tissue", "TISSUE", 36, 50], ["patients", "ORGANISM", 54, 62], ["heart", "ORGAN", 77, 82], ["ACE2", "PROTEIN", 10, 14], ["patients", "SPECIES", 54, 62], ["Increased ACE2", "PROBLEM", 0, 14], ["ischemic heart failure", "PROBLEM", 68, 90], ["ACE2", "OBSERVATION", 10, 14], ["cardiac tissue", "ANATOMY", 36, 50], ["ischemic", "OBSERVATION_MODIFIER", 68, 76], ["heart", "ANATOMY", 77, 82], ["failure", "OBSERVATION", 83, 90]]], ["Moreover, blocking the effects of Ang-II by ACE inhibitors or AT1R blockers increased cardiac ACE2 expression in myocardial infarcted animals (Ishiyama et al. 2004; Ferrario et al. 2005c; Karram et al. 2005; Ocaranza et al. 2006; Burchill et al. 2008) , suggesting that ACE2 contribute to the cardio-protective effects of ACE inhibitors and AT1R antagonists.", [["cardiac", "ANATOMY", 86, 93], ["myocardial", "ANATOMY", 113, 123], ["Ang-II", "CHEMICAL", 34, 40], ["Ang-II", "GENE_OR_GENE_PRODUCT", 34, 40], ["ACE", "GENE_OR_GENE_PRODUCT", 44, 47], ["AT1R", "GENE_OR_GENE_PRODUCT", 62, 66], ["cardiac", "ORGAN", 86, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["myocardial", "MULTI-TISSUE_STRUCTURE", 113, 123], ["ACE2", "GENE_OR_GENE_PRODUCT", 270, 274], ["ACE", "GENE_OR_GENE_PRODUCT", 322, 325], ["AT1R antagonists", "GENE_OR_GENE_PRODUCT", 341, 357], ["Ang-II", "PROTEIN", 34, 40], ["ACE2", "PROTEIN", 94, 98], ["ACE2", "PROTEIN", 270, 274], ["Ang-II", "TREATMENT", 34, 40], ["ACE inhibitors", "TREATMENT", 44, 58], ["AT1R blockers", "TREATMENT", 62, 75], ["cardiac ACE2 expression", "TREATMENT", 86, 109], ["myocardial infarcted animals", "PROBLEM", 113, 141], ["ACE2", "PROBLEM", 270, 274], ["ACE inhibitors", "TREATMENT", 322, 336], ["AT1R antagonists", "TREATMENT", 341, 357], ["myocardial infarcted", "ANATOMY", 113, 133], ["cardio", "ANATOMY", 293, 299]]], ["These observations may imply that up-regulation of ACE2 is a compensatory response to the ischemic and hypertrophy insult.", [["ischemic and hypertrophy insult", "DISEASE", 90, 121], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["ACE2", "PROTEIN", 51, 55], ["ACE2", "TEST", 51, 55], ["the ischemic and hypertrophy insult", "PROBLEM", 86, 121], ["compensatory response", "OBSERVATION", 61, 82], ["ischemic", "OBSERVATION_MODIFIER", 90, 98], ["hypertrophy", "OBSERVATION", 103, 114]]], ["This concept is supported by several studies showing that cardiac over-expression of ACE2 by lentiviral delivery exerts protective effects over: Ang-II-induced cardiac hypertrophy and fibrosis in Sprague-Dawley rats (Huentelman et al. 2005) , hypertension in SHR (Diez-Freire et al. 2006 ) and a protective influence on the heart during myocardial infarction (Der Sarkissian et al. 2008) .ACE2 in the peripheryOther studies support the assumption that ACE2 provides renal protective effects.", [["cardiac", "ANATOMY", 58, 65], ["cardiac", "ANATOMY", 160, 167], ["heart", "ANATOMY", 324, 329], ["myocardial", "ANATOMY", 337, 347], ["periphery", "ANATOMY", 401, 410], ["renal", "ANATOMY", 466, 471], ["Ang-II", "CHEMICAL", 145, 151], ["cardiac hypertrophy", "DISEASE", 160, 179], ["fibrosis", "DISEASE", 184, 192], ["hypertension", "DISEASE", 243, 255], ["myocardial infarction", "DISEASE", 337, 358], ["cardiac", "ORGAN", 58, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["lentiviral", "ORGANISM", 93, 103], ["Ang-II", "GENE_OR_GENE_PRODUCT", 145, 151], ["cardiac", "ORGAN", 160, 167], ["Sprague-Dawley rats", "ORGANISM", 196, 215], ["heart", "ORGAN", 324, 329], ["myocardial", "MULTI-TISSUE_STRUCTURE", 337, 347], ["ACE2", "GENE_OR_GENE_PRODUCT", 389, 393], ["ACE2", "GENE_OR_GENE_PRODUCT", 452, 456], ["renal", "ORGAN", 466, 471], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 389, 393], ["ACE2", "PROTEIN", 452, 456], ["Sprague-Dawley rats", "SPECIES", 196, 215], ["Sprague-Dawley rats", "SPECIES", 196, 215], ["several studies", "TEST", 29, 44], ["ACE2", "PROBLEM", 85, 89], ["lentiviral delivery", "TREATMENT", 93, 112], ["cardiac hypertrophy", "PROBLEM", 160, 179], ["fibrosis", "PROBLEM", 184, 192], ["hypertension", "PROBLEM", 243, 255], ["SHR", "PROBLEM", 259, 262], ["myocardial infarction", "PROBLEM", 337, 358], ["Other studies", "TEST", 410, 423], ["ACE2", "TREATMENT", 452, 456], ["renal protective effects", "TREATMENT", 466, 490], ["cardiac", "ANATOMY", 58, 65], ["cardiac", "ANATOMY", 160, 167], ["hypertrophy", "OBSERVATION", 168, 179], ["fibrosis", "OBSERVATION", 184, 192], ["hypertension", "OBSERVATION", 243, 255], ["heart", "ANATOMY", 324, 329], ["myocardial", "ANATOMY", 337, 347], ["infarction", "OBSERVATION", 348, 358], ["periphery", "ANATOMY_MODIFIER", 401, 410], ["renal", "ANATOMY", 466, 471], ["protective", "OBSERVATION", 472, 482]]], ["Decreased ACE2 levels in the kidney have been shown in several diabetic animal models and patients with diabetes (Tikellis et al. 2003; Ye et al. 2006; Mizuiri et al. 2008) .", [["kidney", "ANATOMY", 29, 35], ["diabetic", "DISEASE", 63, 71], ["diabetes", "DISEASE", 104, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["kidney", "ORGAN", 29, 35], ["patients", "ORGANISM", 90, 98], ["ACE2", "PROTEIN", 10, 14], ["patients", "SPECIES", 90, 98], ["Decreased ACE2 levels in the kidney", "PROBLEM", 0, 35], ["diabetes", "PROBLEM", 104, 112], ["ACE2", "OBSERVATION", 10, 14], ["kidney", "ANATOMY", 29, 35], ["several", "OBSERVATION_MODIFIER", 55, 62], ["diabetic", "OBSERVATION", 63, 71]]], ["Chronic blockade of ACE2 in streptozotocin-treated mice increased albuminuria and worsened glomerular injury, which was associated with enhanced ACE expression in both glomeruli and vasculature (Soler et al. 2007 ).", [["glomerular", "ANATOMY", 91, 101], ["glomeruli", "ANATOMY", 168, 177], ["vasculature", "ANATOMY", 182, 193], ["streptozotocin", "CHEMICAL", 28, 42], ["albuminuria", "DISEASE", 66, 77], ["glomerular injury", "DISEASE", 91, 108], ["streptozotocin", "CHEMICAL", 28, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["streptozotocin", "SIMPLE_CHEMICAL", 28, 42], ["mice", "ORGANISM", 51, 55], ["glomerular", "TISSUE", 91, 101], ["ACE", "GENE_OR_GENE_PRODUCT", 145, 148], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 168, 177], ["vasculature", "MULTI-TISSUE_STRUCTURE", 182, 193], ["ACE2", "PROTEIN", 20, 24], ["ACE", "PROTEIN", 145, 148], ["mice", "SPECIES", 51, 55], ["Chronic blockade of ACE2 in streptozotocin", "TREATMENT", 0, 42], ["mice increased albuminuria", "PROBLEM", 51, 77], ["worsened glomerular injury", "PROBLEM", 82, 108], ["enhanced ACE expression", "PROBLEM", 136, 159], ["blockade", "OBSERVATION", 8, 16], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["albuminuria", "OBSERVATION", 66, 77], ["worsened", "OBSERVATION_MODIFIER", 82, 90], ["glomerular injury", "OBSERVATION", 91, 108], ["enhanced", "OBSERVATION_MODIFIER", 136, 144], ["ACE expression", "OBSERVATION", 145, 159], ["both", "ANATOMY_MODIFIER", 163, 167], ["glomeruli", "ANATOMY", 168, 177], ["vasculature", "ANATOMY", 182, 193]]], ["Inhibition of ACE2 in db/db mice also increased albuminuria and glomerular deposition of fibronectin (Ye et al. 2006) .", [["glomerular", "ANATOMY", 64, 74], ["albuminuria", "DISEASE", 48, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["db/db mice", "ORGANISM", 22, 32], ["glomerular", "TISSUE", 64, 74], ["fibronectin", "GENE_OR_GENE_PRODUCT", 89, 100], ["ACE2", "PROTEIN", 14, 18], ["fibronectin", "PROTEIN", 89, 100], ["mice", "SPECIES", 28, 32], ["ACE2 in db/db mice", "TREATMENT", 14, 32], ["increased albuminuria", "PROBLEM", 38, 59], ["glomerular deposition of fibronectin", "TREATMENT", 64, 100], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["albuminuria", "OBSERVATION", 48, 59], ["glomerular deposition", "OBSERVATION", 64, 85]]], ["In line with the beneficial effects of RAS blockade on cardiac ACE2, treatment with ACE inhibitors or AT1R blockers increased renal ACE2 levels and/or activity and reduced renal damage (Tikellis et al. 2003; Ferrario et al. 2005b; Jessup et al. 2006) .ACE2 in the peripheryACE2 also plays a protective role in the vasculature.", [["cardiac", "ANATOMY", 55, 62], ["renal", "ANATOMY", 126, 131], ["renal", "ANATOMY", 172, 177], ["vasculature", "ANATOMY", 314, 325], ["renal damage", "DISEASE", 172, 184], ["peripheryACE2", "CHEMICAL", 264, 277], ["RAS", "GENE_OR_GENE_PRODUCT", 39, 42], ["cardiac", "ORGAN", 55, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["ACE", "GENE_OR_GENE_PRODUCT", 84, 87], ["AT1R", "GENE_OR_GENE_PRODUCT", 102, 106], ["renal", "ORGAN", 126, 131], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["renal", "ORGAN", 172, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 252, 256], ["peripheryACE2", "GENE_OR_GENE_PRODUCT", 264, 277], ["vasculature", "MULTI-TISSUE_STRUCTURE", 314, 325], ["RAS", "PROTEIN", 39, 42], ["ACE2", "PROTEIN", 63, 67], ["ACE2", "PROTEIN", 132, 136], ["ACE2", "PROTEIN", 252, 256], ["peripheryACE2", "PROTEIN", 264, 277], ["RAS blockade", "TREATMENT", 39, 51], ["cardiac ACE2", "TREATMENT", 55, 67], ["ACE inhibitors", "TREATMENT", 84, 98], ["AT1R blockers", "TREATMENT", 102, 115], ["renal ACE2 levels", "TEST", 126, 143], ["reduced renal damage", "PROBLEM", 164, 184], ["ACE2 in the peripheryACE2", "TREATMENT", 252, 277], ["renal", "ANATOMY", 172, 177], ["damage", "OBSERVATION", 178, 184], ["protective", "OBSERVATION_MODIFIER", 291, 301], ["vasculature", "ANATOMY", 314, 325]]], ["Lower ACE2 activity has been shown in stable advanced, and in ruptured, atherosclerotic lesions (Sluimer et al. 2008) .", [["atherosclerotic lesions", "ANATOMY", 72, 95], ["atherosclerotic", "DISEASE", 72, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 72, 95], ["ACE2", "PROTEIN", 6, 10], ["Lower ACE2 activity", "PROBLEM", 0, 19], ["ruptured, atherosclerotic lesions", "PROBLEM", 62, 95], ["stable", "OBSERVATION_MODIFIER", 38, 44], ["ruptured", "OBSERVATION_MODIFIER", 62, 70], ["atherosclerotic", "OBSERVATION_MODIFIER", 72, 87], ["lesions", "OBSERVATION", 88, 95]]], ["Local overexpression of ACE2 in a rabbit model of atherosclerosis attenuated the progression of early atherosclerotic lesions and resulted in stable plaque compositions at late stage (Dong et al. 2008) .", [["atherosclerotic lesions", "ANATOMY", 102, 125], ["plaque", "ANATOMY", 149, 155], ["atherosclerosis", "DISEASE", 50, 65], ["atherosclerotic lesions", "DISEASE", 102, 125], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["rabbit", "ORGANISM", 34, 40], ["early", "PATHOLOGICAL_FORMATION", 96, 101], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 102, 125], ["plaque", "PATHOLOGICAL_FORMATION", 149, 155], ["ACE2", "PROTEIN", 24, 28], ["rabbit", "SPECIES", 34, 40], ["rabbit", "SPECIES", 34, 40], ["Local overexpression of ACE2", "PROBLEM", 0, 28], ["atherosclerosis", "PROBLEM", 50, 65], ["early atherosclerotic lesions", "PROBLEM", 96, 125], ["stable plaque compositions", "PROBLEM", 142, 168], ["overexpression", "OBSERVATION", 6, 20], ["ACE2", "ANATOMY", 24, 28], ["atherosclerosis", "OBSERVATION", 50, 65], ["progression", "OBSERVATION_MODIFIER", 81, 92], ["early", "OBSERVATION_MODIFIER", 96, 101], ["atherosclerotic", "OBSERVATION_MODIFIER", 102, 117], ["lesions", "OBSERVATION", 118, 125], ["stable", "OBSERVATION_MODIFIER", 142, 148], ["plaque", "OBSERVATION", 149, 155], ["late stage", "OBSERVATION_MODIFIER", 172, 182]]], ["Systemic blockade of AT1R increases ACE2 and Ang-(1-7) levels in both thoracic aorta and carotid artery of SHR, which are associated with attenuation of hypertrophic remodeling and neointima in these areas (Igase et al. 2005; Igase et al. 2008) .", [["thoracic aorta", "ANATOMY", 70, 84], ["carotid artery", "ANATOMY", 89, 103], ["neointima", "ANATOMY", 181, 190], ["Ang-(1-7)", "CHEMICAL", 45, 54], ["AT1R", "GENE_OR_GENE_PRODUCT", 21, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 45, 53], ["thoracic aorta", "MULTI-TISSUE_STRUCTURE", 70, 84], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 89, 103], ["neointima", "PATHOLOGICAL_FORMATION", 181, 190], ["AT1R", "PROTEIN", 21, 25], ["ACE2", "PROTEIN", 36, 40], ["Systemic blockade of AT1R", "TREATMENT", 0, 25], ["ACE2", "TEST", 36, 40], ["Ang", "TEST", 45, 48], ["hypertrophic remodeling and neointima in these areas", "PROBLEM", 153, 205], ["blockade", "OBSERVATION", 9, 17], ["AT1R", "OBSERVATION", 21, 25], ["both", "ANATOMY_MODIFIER", 65, 69], ["thoracic aorta", "ANATOMY", 70, 84], ["carotid artery", "ANATOMY", 89, 103], ["SHR", "OBSERVATION", 107, 110], ["attenuation", "OBSERVATION_MODIFIER", 138, 149], ["hypertrophic", "OBSERVATION_MODIFIER", 153, 165], ["remodeling", "OBSERVATION", 166, 176], ["neointima", "OBSERVATION_MODIFIER", 181, 190]]], ["These observations suggest that locally generated Ang-(1-7) through increased ACE2 expression may contribute to the reversal of vascular hypertrophy.ACE2 in the peripheryIn addition to its interaction with the cardiovascular system, ACE2 was also identified as a functional receptor for the Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV) (Li et al. 2003) , and is expressed in type I and type II alveolar epithelial cells, bronchiolar epithelial cells, endothelial cells and arterial smooth muscle cells of the lung (Hamming et al. 2004) .", [["vascular", "ANATOMY", 128, 136], ["periphery", "ANATOMY", 161, 170], ["cardiovascular system", "ANATOMY", 210, 231], ["alveolar epithelial cells", "ANATOMY", 408, 433], ["bronchiolar epithelial cells", "ANATOMY", 435, 463], ["endothelial cells", "ANATOMY", 465, 482], ["arterial smooth muscle cells", "ANATOMY", 487, 515], ["lung", "ANATOMY", 523, 527], ["Ang-(1-7", "CHEMICAL", 50, 58], ["vascular hypertrophy", "DISEASE", 128, 148], ["Acute Respiratory Syndrome (SARS) coronavirus", "DISEASE", 298, 343], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 50, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["vascular", "MULTI-TISSUE_STRUCTURE", 128, 136], ["ACE2", "GENE_OR_GENE_PRODUCT", 149, 153], ["ACE2", "GENE_OR_GENE_PRODUCT", 233, 237], ["CoV", "ORGANISM", 345, 348], ["alveolar epithelial cells", "CELL", 408, 433], ["bronchiolar epithelial cells", "CELL", 435, 463], ["endothelial cells", "CELL", 465, 482], ["arterial smooth muscle cells", "CELL", 487, 515], ["lung", "ORGAN", 523, 527], ["ACE2", "PROTEIN", 78, 82], ["ACE2", "PROTEIN", 149, 153], ["ACE2", "PROTEIN", 233, 237], ["type I and type II alveolar epithelial cells", "CELL_TYPE", 389, 433], ["bronchiolar epithelial cells", "CELL_TYPE", 435, 463], ["endothelial cells", "CELL_TYPE", 465, 482], ["arterial smooth muscle cells", "CELL_TYPE", 487, 515], ["Severe Acute Respiratory Syndrome (SARS) coronavirus", "SPECIES", 291, 343], ["CoV", "SPECIES", 345, 348], ["These observations", "TEST", 0, 18], ["Ang", "TEST", 50, 53], ["increased ACE2 expression", "PROBLEM", 68, 93], ["vascular hypertrophy", "PROBLEM", 128, 148], ["ACE2", "TEST", 233, 237], ["a functional receptor", "TREATMENT", 261, 282], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 287, 324], ["SARS) coronavirus", "PROBLEM", 326, 343], ["type I and type II alveolar epithelial cells", "PROBLEM", 389, 433], ["bronchiolar epithelial cells", "PROBLEM", 435, 463], ["vascular", "ANATOMY", 128, 136], ["hypertrophy", "OBSERVATION", 137, 148], ["periphery", "ANATOMY_MODIFIER", 161, 170], ["cardiovascular system", "ANATOMY", 210, 231], ["Severe", "OBSERVATION_MODIFIER", 291, 297], ["Acute", "OBSERVATION_MODIFIER", 298, 303], ["Respiratory Syndrome", "OBSERVATION", 304, 324], ["alveolar", "ANATOMY_MODIFIER", 408, 416], ["epithelial cells", "OBSERVATION", 417, 433], ["bronchiolar", "ANATOMY_MODIFIER", 435, 446], ["epithelial cells", "OBSERVATION", 447, 463], ["endothelial cells", "OBSERVATION", 465, 482], ["arterial", "ANATOMY_MODIFIER", 487, 495], ["smooth muscle cells", "OBSERVATION", 496, 515], ["lung", "ANATOMY", 523, 527]]], ["Down-regulation of ACE2 was found in the lungs of mice after acute lung injury, including SARS-CoV infection and loss of ACE2 expression in mutant mice, precipitates severe acute lung failure .", [["lungs", "ANATOMY", 41, 46], ["lung", "ANATOMY", 67, 71], ["lung", "ANATOMY", 179, 183], ["lung injury", "DISEASE", 67, 78], ["SARS-CoV infection", "DISEASE", 90, 108], ["acute lung failure", "DISEASE", 173, 191], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["lungs", "ORGAN", 41, 46], ["mice", "ORGANISM", 50, 54], ["lung", "ORGAN", 67, 71], ["SARS-CoV", "ORGANISM", 90, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["mice", "ORGANISM", 147, 151], ["lung", "ORGAN", 179, 183], ["ACE2", "PROTEIN", 19, 23], ["ACE2", "PROTEIN", 121, 125], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 50, 54], ["SARS-CoV", "SPECIES", 90, 98], ["mice", "SPECIES", 147, 151], ["ACE2", "TEST", 19, 23], ["acute lung injury", "PROBLEM", 61, 78], ["SARS", "PROBLEM", 90, 94], ["CoV infection", "PROBLEM", 95, 108], ["loss of ACE2 expression", "PROBLEM", 113, 136], ["severe acute lung failure", "PROBLEM", 166, 191], ["lungs", "ANATOMY", 41, 46], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["lung", "ANATOMY", 67, 71], ["injury", "OBSERVATION", 72, 78], ["CoV", "OBSERVATION_MODIFIER", 95, 98], ["infection", "OBSERVATION", 99, 108], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["lung", "ANATOMY", 179, 183], ["failure", "OBSERVATION", 184, 191]]], ["Treatment with recombinant ACE2 protein attenuates acute lung failure in wild-type as well as in ACE2 knockout mice , suggesting that ACE2 plays a protective role in acute lung injury.ACE2 in the peripheryIn summary, these studies indicate that peripheral ACE2 exerts a pivotal role in BP regulation as well as in cardiovascular, renal and pulmonary function.ACE2 in the brainThe distribution of ACE2 in the brain was at first controversial as original reports failed to identify the carboxypeptidase in the CNS (Donoghue et al. 2000; Tipnis et al. 2000) .", [["lung", "ANATOMY", 57, 61], ["lung", "ANATOMY", 172, 176], ["periphery", "ANATOMY", 196, 205], ["cardiovascular", "ANATOMY", 314, 328], ["renal", "ANATOMY", 330, 335], ["pulmonary", "ANATOMY", 340, 349], ["brain", "ANATOMY", 371, 376], ["brain", "ANATOMY", 408, 413], ["CNS", "ANATOMY", 508, 511], ["acute lung failure", "DISEASE", 51, 69], ["acute lung injury", "DISEASE", 166, 183], ["cardiovascular, renal and pulmonary function", "DISEASE", 314, 358], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["lung", "ORGAN", 57, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["mice", "ORGANISM", 111, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["lung", "ORGAN", 172, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["ACE2", "GENE_OR_GENE_PRODUCT", 256, 260], ["BP", "SIMPLE_CHEMICAL", 286, 288], ["cardiovascular", "ANATOMICAL_SYSTEM", 314, 328], ["renal", "MULTI-TISSUE_STRUCTURE", 330, 335], ["pulmonary", "ORGAN", 340, 349], ["ACE2", "GENE_OR_GENE_PRODUCT", 359, 363], ["brain", "ORGAN", 371, 376], ["ACE2", "GENE_OR_GENE_PRODUCT", 396, 400], ["brain", "ORGAN", 408, 413], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 484, 500], ["CNS", "ANATOMICAL_SYSTEM", 508, 511], ["recombinant ACE2 protein", "PROTEIN", 15, 39], ["ACE2", "PROTEIN", 97, 101], ["ACE2", "PROTEIN", 134, 138], ["ACE2", "PROTEIN", 184, 188], ["peripheral ACE2", "PROTEIN", 245, 260], ["BP", "PROTEIN", 286, 288], ["ACE2", "PROTEIN", 359, 363], ["ACE2", "PROTEIN", 396, 400], ["carboxypeptidase", "PROTEIN", 484, 500], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["Treatment", "TREATMENT", 0, 9], ["recombinant ACE2 protein attenuates", "TREATMENT", 15, 50], ["acute lung failure", "PROBLEM", 51, 69], ["acute lung injury", "PROBLEM", 166, 183], ["these studies", "TEST", 217, 230], ["peripheral ACE2", "PROBLEM", 245, 260], ["BP regulation", "TREATMENT", 286, 299], ["ACE2", "TEST", 359, 363], ["ACE2 in the brain", "PROBLEM", 396, 413], ["the carboxypeptidase", "TEST", 480, 500], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["lung", "ANATOMY", 57, 61], ["failure", "OBSERVATION", 62, 69], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["lung", "ANATOMY", 172, 176], ["injury", "OBSERVATION", 177, 183], ["periphery", "ANATOMY_MODIFIER", 196, 205], ["peripheral", "ANATOMY_MODIFIER", 245, 255], ["renal", "ANATOMY", 330, 335], ["pulmonary", "ANATOMY", 340, 349], ["brain", "ANATOMY", 371, 376], ["distribution", "OBSERVATION_MODIFIER", 380, 392], ["ACE2", "OBSERVATION", 396, 400], ["brain", "ANATOMY", 408, 413], ["CNS", "ANATOMY", 508, 511]]], ["Later, low levels of ACE2 mRNA were shown in the human brain using quantitative real-time RT-PCR (Harmer et al. 2002) , while immuno-histochemistry showed that ACE2 protein expression was restricted to endothelial and arterial smooth muscle cells (Hamming et al. 2004) .", [["brain", "ANATOMY", 55, 60], ["endothelial", "ANATOMY", 202, 213], ["arterial smooth muscle cells", "ANATOMY", 218, 246], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["human", "ORGANISM", 49, 54], ["brain", "ORGAN", 55, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 160, 164], ["endothelial", "CELL", 202, 213], ["arterial smooth muscle cells", "CELL", 218, 246], ["ACE2 mRNA", "RNA", 21, 30], ["ACE2", "PROTEIN", 160, 164], ["arterial smooth muscle cells", "CELL_TYPE", 218, 246], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["low levels of ACE2 mRNA", "PROBLEM", 7, 30], ["immuno-histochemistry", "TEST", 126, 147], ["ACE2 protein expression", "PROBLEM", 160, 183], ["human brain", "ANATOMY", 49, 60], ["protein expression", "OBSERVATION", 165, 183], ["arterial", "ANATOMY_MODIFIER", 218, 226], ["smooth muscle", "ANATOMY", 227, 240]]], ["In addition, studies performed in brain primary cell cultures reported that ACE2 was expressed predominantly in glial cells , although this observation could be dependent on the culture conditions and the difficulty of maintaining live neurons in such cultures.", [["brain primary cell cultures", "ANATOMY", 34, 61], ["glial cells", "ANATOMY", 112, 123], ["neurons", "ANATOMY", 236, 243], ["cultures", "ANATOMY", 252, 260], ["brain primary cell cultures", "CELL", 34, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["glial cells", "CELL", 112, 123], ["neurons", "CELL", 236, 243], ["brain primary cell cultures", "CELL_LINE", 34, 61], ["ACE2", "PROTEIN", 76, 80], ["glial cells", "CELL_TYPE", 112, 123], ["live neurons", "CELL_TYPE", 231, 243], ["studies", "TEST", 13, 20], ["brain primary cell cultures", "TEST", 34, 61], ["ACE2", "TEST", 76, 80], ["the culture conditions", "TEST", 174, 196], ["such cultures", "TEST", 247, 260], ["glial cells", "OBSERVATION", 112, 123]]], ["SARS-CoV has been detected in brains of infected patients, almost exclusively in neurons, suggesting the distribution of ACE2 to the CNS (Ding et al. 2004; Gu et al. 2005; Xu et al. 2005) .", [["brains", "ANATOMY", 30, 36], ["neurons", "ANATOMY", 81, 88], ["CNS", "ANATOMY", 133, 136], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["brains", "ORGAN", 30, 36], ["patients", "ORGANISM", 49, 57], ["neurons", "CELL", 81, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["CNS", "ANATOMICAL_SYSTEM", 133, 136], ["ACE2", "PROTEIN", 121, 125], ["patients", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["CoV", "OBSERVATION", 5, 8], ["infected", "OBSERVATION", 40, 48], ["CNS", "ANATOMY", 133, 136]]], ["Indeed, we recently demonstrated the presence of the ACE2 protein and mRNA in the mouse brain, predominantly in neurons (Doobay et al. 2007 ).", [["brain", "ANATOMY", 88, 93], ["neurons", "ANATOMY", 112, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["mouse", "ORGANISM", 82, 87], ["brain", "ORGAN", 88, 93], ["neurons", "CELL", 112, 119], ["ACE2 protein", "PROTEIN", 53, 65], ["mRNA", "RNA", 70, 74], ["mouse", "SPECIES", 82, 87], ["mouse", "SPECIES", 82, 87], ["the ACE2 protein", "TEST", 49, 65], ["mRNA in the mouse brain", "PROBLEM", 70, 93], ["mouse brain", "ANATOMY", 82, 93], ["neurons", "ANATOMY", 112, 119]]], ["Using a selective antibody, we found that ACE2 is widespread throughout the brain, present in nuclei involved in the central regulation of cardiovascular function like the cardiorespiratory neurons of the brainstem, as well as in non-cardiovascular areas such as the motor cortex and raphe (Doobay et al. 2007 ).", [["brain", "ANATOMY", 76, 81], ["nuclei", "ANATOMY", 94, 100], ["cardiovascular", "ANATOMY", 139, 153], ["cardiorespiratory neurons", "ANATOMY", 172, 197], ["brainstem", "ANATOMY", 205, 214], ["non-cardiovascular areas", "ANATOMY", 230, 254], ["motor cortex", "ANATOMY", 267, 279], ["raphe", "ANATOMY", 284, 289], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["brain", "ORGAN", 76, 81], ["nuclei", "CELLULAR_COMPONENT", 94, 100], ["cardiovascular", "ANATOMICAL_SYSTEM", 139, 153], ["brainstem", "ORGAN", 205, 214], ["motor cortex", "MULTI-TISSUE_STRUCTURE", 267, 279], ["raphe", "MULTI-TISSUE_STRUCTURE", 284, 289], ["ACE2", "PROTEIN", 42, 46], ["cardiorespiratory neurons", "CELL_TYPE", 172, 197], ["a selective antibody", "TEST", 6, 26], ["ACE2", "TEST", 42, 46], ["widespread", "OBSERVATION_MODIFIER", 50, 60], ["brain", "ANATOMY", 76, 81], ["central", "ANATOMY_MODIFIER", 117, 124], ["cardiovascular function", "OBSERVATION", 139, 162], ["cardiorespiratory neurons", "OBSERVATION", 172, 197], ["brainstem", "ANATOMY", 205, 214], ["non-cardiovascular", "ANATOMY", 230, 248], ["areas", "ANATOMY_MODIFIER", 249, 254], ["motor cortex", "ANATOMY", 267, 279], ["raphe", "ANATOMY_MODIFIER", 284, 289]]], ["Our observation was later confirmed by Lin et al. showing the presence of ACE2 mRNA and protein in the mouse brainstem (Lin et al. 2008) .", [["brainstem", "ANATOMY", 109, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["mouse", "ORGANISM", 103, 108], ["brainstem", "ORGAN", 109, 118], ["ACE2 mRNA", "RNA", 74, 83], ["mouse", "SPECIES", 103, 108], ["mouse", "SPECIES", 103, 108], ["Our observation", "TEST", 0, 15], ["ACE2 mRNA and protein in the mouse brainstem", "PROBLEM", 74, 118], ["mouse brainstem", "ANATOMY", 103, 118]]], ["While these findings suggest that ACE2 is a new component of the brain RAS, they also imply that the involvement of ACE2 in the CNS is beyond the regulation of cardiovascular function.ACE2 in the brainThere is much information to show that a hyperactive brain RAS plays a critical role in the development and maintenance of hypertension (Buggy et al. 1984; Fink et al. 1987; Gutkind et al. 1988; Gyurko et al. 1993; Ambuhl et al. 1995) .", [["brain", "ANATOMY", 65, 70], ["CNS", "ANATOMY", 128, 131], ["cardiovascular", "ANATOMY", 160, 174], ["brain", "ANATOMY", 254, 259], ["hyperactive", "DISEASE", 242, 253], ["hypertension", "DISEASE", 324, 336], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["brain", "ORGAN", 65, 70], ["RAS", "GENE_OR_GENE_PRODUCT", 71, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["cardiovascular", "ANATOMICAL_SYSTEM", 160, 174], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["brain", "ORGAN", 254, 259], ["RAS", "GENE_OR_GENE_PRODUCT", 260, 263], ["ACE2", "PROTEIN", 34, 38], ["ACE2", "PROTEIN", 116, 120], ["ACE2", "PROTEIN", 184, 188], ["hyperactive brain RAS", "PROTEIN", 242, 263], ["ACE2", "PROBLEM", 34, 38], ["ACE2 in the CNS", "PROBLEM", 116, 131], ["ACE2", "TREATMENT", 184, 188], ["a hyperactive brain RAS", "PROBLEM", 240, 263], ["hypertension", "PROBLEM", 324, 336], ["new", "OBSERVATION_MODIFIER", 44, 47], ["brain", "ANATOMY", 65, 70], ["CNS", "ANATOMY", 128, 131], ["cardiovascular function", "OBSERVATION", 160, 183], ["hyperactive", "OBSERVATION", 242, 253], ["hypertension", "OBSERVATION", 324, 336]]], ["In normotensive models, Ang-II acting on brain AT1R (Fink et al. 1987; Gutkind et al. 1988) induces an increase in BP mediated by enhanced sympathetic outflow (Falcon et al. 1978; Blume et al. 1999) , vasopressin release (Unger et al. 1981 ) and cardiac baroreflex resetting (McDonald et al. 1980) (Table 1 ).", [["brain", "ANATOMY", 41, 46], ["cardiac", "ANATOMY", 246, 253], ["Ang-II", "CHEMICAL", 24, 30], ["vasopressin", "CHEMICAL", 201, 212], ["vasopressin", "CHEMICAL", 201, 212], ["Ang-II", "GENE_OR_GENE_PRODUCT", 24, 30], ["brain", "ORGAN", 41, 46], ["AT1R", "GENE_OR_GENE_PRODUCT", 47, 51], ["BP", "SIMPLE_CHEMICAL", 115, 117], ["sympathetic outflow", "MULTI-TISSUE_STRUCTURE", 139, 158], ["vasopressin", "SIMPLE_CHEMICAL", 201, 212], ["cardiac", "ORGAN", 246, 253], ["Ang-II", "PROTEIN", 24, 30], ["brain AT1R", "PROTEIN", 41, 51], ["BP", "PROTEIN", 115, 117], ["an increase in BP", "PROBLEM", 100, 117], ["vasopressin release", "TREATMENT", 201, 220], ["cardiac baroreflex resetting", "TREATMENT", 246, 274], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["sympathetic outflow", "ANATOMY", 139, 158], ["cardiac", "ANATOMY", 246, 253]]], ["In SHR, up-regulation of brain RAS components (AGT, Ang-II, ACE and AT1R) precedes and sustains the development of hypertension (McDonald et al. 1980; Okuno et al. 1983; Hermann et al. 1984; Casto and Phillips 1986; Gutkind et al. 1988; Tamura et al. 1996) .", [["brain", "ANATOMY", 25, 30], ["hypertension", "DISEASE", 115, 127], ["brain", "ORGAN", 25, 30], ["RAS", "GENE_OR_GENE_PRODUCT", 31, 34], ["AGT", "GENE_OR_GENE_PRODUCT", 47, 50], ["Ang-II", "GENE_OR_GENE_PRODUCT", 52, 58], ["ACE", "GENE_OR_GENE_PRODUCT", 60, 63], ["AT1R", "GENE_OR_GENE_PRODUCT", 68, 72], ["brain RAS components", "PROTEIN", 25, 45], ["AGT", "PROTEIN", 47, 50], ["Ang-II", "PROTEIN", 52, 58], ["ACE", "PROTEIN", 60, 63], ["AT1R", "PROTEIN", 68, 72], ["brain RAS components", "PROBLEM", 25, 45], ["AGT", "TEST", 47, 50], ["Ang", "TEST", 52, 55], ["ACE and AT1R)", "TREATMENT", 60, 73], ["hypertension", "PROBLEM", 115, 127], ["brain", "ANATOMY", 25, 30], ["hypertension", "OBSERVATION", 115, 127]]], ["Although the precise mechanisms by which Ang-II triggers hypertension is not known, it seems to involve increased sympathetic vasomotor tone and altered cardiac baroreflex function (Chapleau and Abboud 2001) .ACE2 in the brainThe latest working model of the brain RAS (Fig. 1) includes ACE2, Ang-(1-7) and Mas, therefore forming a new arm for this system (Phillips and de Oliveira 2008) .", [["sympathetic vasomotor", "ANATOMY", 114, 135], ["cardiac", "ANATOMY", 153, 160], ["brain", "ANATOMY", 221, 226], ["brain", "ANATOMY", 258, 263], ["Ang-II", "CHEMICAL", 41, 47], ["hypertension", "DISEASE", 57, 69], ["Ang", "CHEMICAL", 292, 295], ["Ang-II", "GENE_OR_GENE_PRODUCT", 41, 47], ["cardiac", "ORGAN", 153, 160], ["ACE2", "GENE_OR_GENE_PRODUCT", 209, 213], ["brain", "ORGAN", 221, 226], ["brain", "ORGAN", 258, 263], ["RAS", "GENE_OR_GENE_PRODUCT", 264, 267], ["ACE2", "GENE_OR_GENE_PRODUCT", 286, 290], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 292, 300], ["Mas", "GENE_OR_GENE_PRODUCT", 306, 309], ["Ang-II", "PROTEIN", 41, 47], ["ACE2", "PROTEIN", 209, 213], ["brain RAS", "PROTEIN", 258, 267], ["ACE2", "PROTEIN", 286, 290], ["Ang", "PROTEIN", 292, 295], ["hypertension", "PROBLEM", 57, 69], ["increased sympathetic vasomotor tone", "PROBLEM", 104, 140], ["altered cardiac baroreflex function", "PROBLEM", 145, 180], ["ACE2", "TEST", 209, 213], ["ACE2", "TEST", 286, 290], ["Ang", "TEST", 292, 295], ["hypertension", "OBSERVATION", 57, 69], ["vasomotor tone", "OBSERVATION", 126, 140], ["cardiac", "ANATOMY", 153, 160], ["baroreflex function", "OBSERVATION", 161, 180], ["brain", "ANATOMY", 221, 226], ["brain", "ANATOMY", 258, 263]]], ["While the physiological role of central ACE2 is just beginning to be addressed, there is considerable evidence for a role of Ang-(1-7) in the brain.", [["brain", "ANATOMY", 142, 147], ["Ang-(1-7", "CHEMICAL", 125, 133], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 125, 133], ["brain", "ORGAN", 142, 147], ["central ACE2", "PROTEIN", 32, 44], ["Ang", "TEST", 125, 128], ["central ACE2", "OBSERVATION", 32, 44], ["considerable evidence for", "UNCERTAINTY", 89, 114], ["Ang", "OBSERVATION", 125, 128], ["brain", "ANATOMY", 142, 147]]], ["This peptide is mainly present in central nuclei related to BP regulation, such as brainstem areas and hypothalamus (Chappell et al. 1989) , and exerts synergistic or opposite effects to Ang-II (Moriguchi et al. 1995; Santos et al. 2000; Gironacci et al. 2004; Becker et al. 2005) .", [["central nuclei", "ANATOMY", 34, 48], ["brainstem areas", "ANATOMY", 83, 98], ["hypothalamus", "ANATOMY", 103, 115], ["Ang-II", "CHEMICAL", 187, 193], ["central nuclei", "CELLULAR_COMPONENT", 34, 48], ["BP", "SIMPLE_CHEMICAL", 60, 62], ["brainstem areas", "MULTI-TISSUE_STRUCTURE", 83, 98], ["hypothalamus", "MULTI-TISSUE_STRUCTURE", 103, 115], ["Ang-II", "GENE_OR_GENE_PRODUCT", 187, 193], ["BP", "PROTEIN", 60, 62], ["BP regulation", "TEST", 60, 73], ["brainstem areas and hypothalamus", "PROBLEM", 83, 115], ["central nuclei", "OBSERVATION", 34, 48], ["BP regulation", "OBSERVATION", 60, 73], ["brainstem", "ANATOMY", 83, 92], ["hypothalamus", "ANATOMY", 103, 115]]], ["Ang-(1-7) has been shown to act as an important neuromodulator of cardiac baroreflex mechanisms, leading to an increased sensitivity of this system (Campagnole- Santos et al. 1992; Santos et al. 2003 ).", [["cardiac", "ANATOMY", 66, 73], ["Ang-(1-7)", "CHEMICAL", 0, 9], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 0, 8], ["cardiac", "ORGAN", 66, 73], ["Ang", "TEST", 0, 3], ["an increased sensitivity of this system", "PROBLEM", 108, 147], ["cardiac", "ANATOMY", 66, 73], ["increased", "OBSERVATION_MODIFIER", 111, 120]]], ["In addition, central Ang-(1-7) prevents norepinephrine release (Gironacci et al. 2004 ) and induces depressor responses (Moriguchi et al. 1995; Dobruch et al. 2003; H\u00f6cht et al. 2008) in hypertensive rats, increases bradykinin levels (Lu et al. 2008) , potentiates the hypotensive effects of bradykinin (Bomtempo et al. 1998 ) and increases vasopressin (Moriguchi et al. 1994 ) and nitric oxide (NO) release (Gironacci et al. 2000) .", [["Ang-(1-7)", "CHEMICAL", 21, 30], ["norepinephrine", "CHEMICAL", 40, 54], ["hypertensive", "DISEASE", 187, 199], ["bradykinin", "CHEMICAL", 216, 226], ["hypotensive", "DISEASE", 269, 280], ["bradykinin", "CHEMICAL", 292, 302], ["vasopressin", "CHEMICAL", 341, 352], ["nitric oxide", "CHEMICAL", 382, 394], ["NO", "CHEMICAL", 396, 398], ["norepinephrine", "CHEMICAL", 40, 54], ["bradykinin", "CHEMICAL", 216, 226], ["bradykinin", "CHEMICAL", 292, 302], ["vasopressin", "CHEMICAL", 341, 352], ["nitric oxide", "CHEMICAL", 382, 394], ["NO", "CHEMICAL", 396, 398], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 21, 29], ["norepinephrine", "SIMPLE_CHEMICAL", 40, 54], ["rats", "ORGANISM", 200, 204], ["bradykinin", "SIMPLE_CHEMICAL", 216, 226], ["bradykinin", "SIMPLE_CHEMICAL", 292, 302], ["vasopressin", "SIMPLE_CHEMICAL", 341, 352], ["nitric oxide", "SIMPLE_CHEMICAL", 382, 394], ["NO", "SIMPLE_CHEMICAL", 396, 398], ["rats", "SPECIES", 200, 204], ["central Ang", "TREATMENT", 13, 24], ["norepinephrine release", "TREATMENT", 40, 62], ["depressor responses", "PROBLEM", 100, 119], ["hypertensive rats", "PROBLEM", 187, 204], ["increases bradykinin levels", "PROBLEM", 206, 233], ["the hypotensive effects", "PROBLEM", 265, 288], ["bradykinin", "TREATMENT", 292, 302], ["increases vasopressin", "TREATMENT", 331, 352], ["nitric oxide", "TREATMENT", 382, 394], ["central", "ANATOMY_MODIFIER", 13, 20], ["Ang", "ANATOMY", 21, 24]]], ["These effects are mediated by Mas (Gironacci et al. 2004; H\u00f6cht et al. 2008 ) which has been identified as the first Ang-(1-7) binding site (Santos et al. 2003) .", [["Ang", "CHEMICAL", 117, 120], ["Mas", "GENE_OR_GENE_PRODUCT", 30, 33], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 117, 125], ["Ang-(1-7) binding site", "DNA", 117, 139]]], ["The brain was also the first organ in which this receptor was found to be highly expressed (Young et al. 1988 ).", [["brain", "ANATOMY", 4, 9], ["organ", "ANATOMY", 29, 34], ["brain", "ORGAN", 4, 9], ["organ", "ORGAN", 29, 34], ["brain", "ANATOMY", 4, 9]]], ["Moreover, Becker et al. recently showed the presence of Mas in cardiovascular and hydroelectrolytic control areas of the rat brain supporting the role of the Ang-(1-7) receptor in these processes (Becker et al. 2007 ).ACE2 in the brainRecent data have emerged, showing the participation of ACE2 in the brain RAS.", [["cardiovascular", "ANATOMY", 63, 77], ["brain", "ANATOMY", 125, 130], ["brain", "ANATOMY", 302, 307], ["Ang", "CHEMICAL", 158, 161], ["Mas", "GENE_OR_GENE_PRODUCT", 56, 59], ["cardiovascular", "ANATOMICAL_SYSTEM", 63, 77], ["rat", "ORGANISM", 121, 124], ["brain", "ORGAN", 125, 130], ["Ang-(1-7) receptor", "GENE_OR_GENE_PRODUCT", 158, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["ACE2", "GENE_OR_GENE_PRODUCT", 290, 294], ["brain", "ORGAN", 302, 307], ["RAS", "GENE_OR_GENE_PRODUCT", 308, 311], ["Mas", "PROTEIN", 56, 59], ["Ang-(1-7) receptor", "PROTEIN", 158, 176], ["ACE2", "PROTEIN", 218, 222], ["ACE2", "PROTEIN", 290, 294], ["brain RAS", "PROTEIN", 302, 311], ["rat", "SPECIES", 121, 124], ["rat", "SPECIES", 121, 124], ["Mas in cardiovascular and hydroelectrolytic control areas of the rat brain", "PROBLEM", 56, 130], ["ACE2", "TREATMENT", 218, 222], ["Mas", "OBSERVATION", 56, 59], ["cardiovascular", "ANATOMY", 63, 77], ["hydroelectrolytic control", "OBSERVATION", 82, 107], ["rat", "ANATOMY_MODIFIER", 121, 124], ["brain", "ANATOMY", 125, 130], ["Ang", "OBSERVATION", 158, 161], ["brain", "ANATOMY", 302, 307]]], ["Using SELDI-TOF Mass Spectrometry, Elased et al. reported that the mouse brain is the seat of high ACE2 activity while ACE activity appears to be low in the CNS (Elased et al. 2008) .", [["brain", "ANATOMY", 73, 78], ["CNS", "ANATOMY", 157, 160], ["mouse", "ORGANISM", 67, 72], ["brain", "ORGAN", 73, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["ACE", "GENE_OR_GENE_PRODUCT", 119, 122], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["ACE2", "PROTEIN", 99, 103], ["ACE", "PROTEIN", 119, 122], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["SELDI-TOF Mass Spectrometry", "TREATMENT", 6, 33], ["ACE activity", "PROBLEM", 119, 131], ["brain", "ANATOMY", 73, 78], ["CNS", "ANATOMY", 157, 160]]], ["Although these data indicate that central ACE2 is active and plays a predominant role in the processing of Ang-II into Ang-(1-7) in the brain, they are also challenging the importance of ACE in the CNS.", [["brain", "ANATOMY", 136, 141], ["CNS", "ANATOMY", 198, 201], ["Ang-II", "CHEMICAL", 107, 113], ["Ang-(1-7", "CHEMICAL", 119, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["Ang-II", "GENE_OR_GENE_PRODUCT", 107, 113], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 119, 127], ["brain", "ORGAN", 136, 141], ["ACE", "GENE_OR_GENE_PRODUCT", 187, 190], ["CNS", "ANATOMICAL_SYSTEM", 198, 201], ["ACE2", "PROTEIN", 42, 46], ["Ang-II", "PROTEIN", 107, 113], ["ACE", "PROTEIN", 187, 190], ["these data", "TEST", 9, 19], ["Ang", "TEST", 119, 122], ["ACE", "TREATMENT", 187, 190], ["central", "ANATOMY_MODIFIER", 34, 41], ["active", "OBSERVATION_MODIFIER", 50, 56], ["brain", "ANATOMY", 136, 141], ["CNS", "ANATOMY", 198, 201]]], ["Surprisingly, the authors suggested that central ACE2 is more important than ACE activity in normal conditions while it may be otherwise in pathological situations.", [["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["ACE", "GENE_OR_GENE_PRODUCT", 77, 80], ["central ACE2", "PROTEIN", 41, 53], ["ACE", "PROTEIN", 77, 80], ["central ACE2", "PROBLEM", 41, 53]]], ["This is in disagreement with previous observations showing that the physiological importance of central Ang-(1-7) is unveiled in pathological conditions and that its role is limited in normal situations (Dobruch et al. 2003) .", [["Ang-(1-7", "CHEMICAL", 104, 112], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 104, 112], ["previous observations", "TEST", 29, 50], ["central Ang", "TREATMENT", 96, 107]]], ["Moreover, in humans, the expression of ACE2 mRNA was reported to be at least 10-fold lower than ACE in the brain (Harmer et al. 2002) .", [["brain", "ANATOMY", 107, 112], ["humans", "ORGANISM", 13, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["ACE", "GENE_OR_GENE_PRODUCT", 96, 99], ["brain", "ORGAN", 107, 112], ["ACE2 mRNA", "RNA", 39, 48], ["humans", "SPECIES", 13, 19], ["humans", "SPECIES", 13, 19], ["ACE2 mRNA", "TEST", 39, 48], ["brain", "ANATOMY", 107, 112]]], ["Although it is possible that mRNA levels do not correlate with ACE2 activity, validation of the SELDI-TOF Mass Spectrometry technique with current methodologies is needed.", [["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["ACE2", "PROTEIN", 63, 67], ["mRNA levels", "TEST", 29, 40], ["ACE2 activity", "TEST", 63, 76], ["the SELDI-TOF Mass Spectrometry technique", "TREATMENT", 92, 133], ["current methodologies", "TREATMENT", 139, 160]]], ["Finally, the authors' report that ACE2 activity was restricted to the murine hypothalamus is conflicting with our own observations showing widespread distribution of this carboxypeptidase throughout the mouse CNS (Doobay et al. 2007 ) and their recent report of ACE2 expression in the brainstem (Lin et al. 2008 ).ACE2 in the brainSeveral studies have described the interactions between ACE2 and other components of the RAS in the periphery (Tikellis et al. 2003; Ferrario et al. 2005b; Jessup et al. 2006 ) but very few have addressed these relations in the brain.", [["hypothalamus", "ANATOMY", 77, 89], ["CNS", "ANATOMY", 209, 212], ["brainstem", "ANATOMY", 285, 294], ["brain", "ANATOMY", 559, 564], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["murine", "ORGANISM", 70, 76], ["hypothalamus", "ORGAN", 77, 89], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 171, 187], ["mouse", "ORGANISM", 203, 208], ["CNS", "ANATOMICAL_SYSTEM", 209, 212], ["ACE2", "GENE_OR_GENE_PRODUCT", 262, 266], ["brainstem", "ORGAN", 285, 294], ["ACE2", "GENE_OR_GENE_PRODUCT", 314, 318], ["ACE2", "GENE_OR_GENE_PRODUCT", 387, 391], ["RAS", "GENE_OR_GENE_PRODUCT", 420, 423], ["brain", "ORGAN", 559, 564], ["ACE2", "PROTEIN", 34, 38], ["carboxypeptidase", "PROTEIN", 171, 187], ["ACE2", "PROTEIN", 262, 266], ["ACE2", "PROTEIN", 314, 318], ["ACE2", "PROTEIN", 387, 391], ["RAS", "PROTEIN", 420, 423], ["murine", "SPECIES", 70, 76], ["mouse", "SPECIES", 203, 208], ["mouse", "SPECIES", 203, 208], ["ACE2 activity", "PROBLEM", 34, 47], ["this carboxypeptidase", "TREATMENT", 166, 187], ["ACE2 expression in the brainstem", "PROBLEM", 262, 294], ["ACE2", "TEST", 314, 318], ["the brainSeveral studies", "TEST", 322, 346], ["widespread", "OBSERVATION_MODIFIER", 139, 149], ["distribution", "OBSERVATION_MODIFIER", 150, 162], ["brainstem", "ANATOMY", 285, 294], ["periphery", "ANATOMY_MODIFIER", 431, 440], ["brain", "ANATOMY", 559, 564]]], ["Using transgenic mice over-expressing the rat AT1a receptor selectively in the brain (NSE-AT1a mouse) (Lazartigues et al. 2002) or mice with chronic expression of both human renin and human AGT genes (R + A + mouse) (Merrill et al. 1996; Davisson et al. 1998) , we previously showed that over-expression of these central RAS components increases ACE2 protein expression in the subfornical organ (SFO) and differentially changed the expression in the brainstem (Doobay et al. 2007) , supporting the idea that ACE2 acts as a compensatory mechanism to limit brain RAS hyperactivity.", [["brain", "ANATOMY", 79, 84], ["subfornical organ", "ANATOMY", 377, 394], ["SFO", "ANATOMY", 396, 399], ["brainstem", "ANATOMY", 450, 459], ["brain", "ANATOMY", 555, 560], ["hyperactivity", "DISEASE", 565, 578], ["mice", "ORGANISM", 17, 21], ["rat", "ORGANISM", 42, 45], ["AT1a receptor", "GENE_OR_GENE_PRODUCT", 46, 59], ["brain", "ORGAN", 79, 84], ["NSE", "GENE_OR_GENE_PRODUCT", 86, 89], ["mouse", "ORGANISM", 95, 100], ["mice", "ORGANISM", 131, 135], ["human", "ORGANISM", 168, 173], ["renin", "GENE_OR_GENE_PRODUCT", 174, 179], ["human", "ORGANISM", 184, 189], ["AGT", "GENE_OR_GENE_PRODUCT", 190, 193], ["R + A", "GENE_OR_GENE_PRODUCT", 201, 206], ["RAS", "GENE_OR_GENE_PRODUCT", 321, 324], ["ACE2", "GENE_OR_GENE_PRODUCT", 346, 350], ["subfornical organ", "ORGAN", 377, 394], ["SFO", "ANATOMICAL_SYSTEM", 396, 399], ["brainstem", "ORGAN", 450, 459], ["ACE2", "GENE_OR_GENE_PRODUCT", 508, 512], ["brain", "ORGAN", 555, 560], ["RAS", "GENE_OR_GENE_PRODUCT", 561, 564], ["rat AT1a receptor", "PROTEIN", 42, 59], ["NSE", "PROTEIN", 86, 89], ["human renin and human AGT genes", "DNA", 168, 199], ["central RAS components", "PROTEIN", 313, 335], ["ACE2", "PROTEIN", 346, 350], ["ACE2", "PROTEIN", 508, 512], ["RAS", "PROTEIN", 561, 564], ["mice", "SPECIES", 17, 21], ["rat", "SPECIES", 42, 45], ["mouse", "SPECIES", 95, 100], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 184, 189], ["mouse", "SPECIES", 209, 214], ["mice", "SPECIES", 17, 21], ["rat", "SPECIES", 42, 45], ["mouse", "SPECIES", 95, 100], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 184, 189], ["transgenic mice", "TREATMENT", 6, 21], ["both human renin", "TREATMENT", 163, 179], ["human AGT genes", "TEST", 184, 199], ["these central RAS components", "PROBLEM", 307, 335], ["ACE2 protein expression", "PROBLEM", 346, 369], ["the expression in the brainstem", "PROBLEM", 428, 459], ["brain RAS hyperactivity", "PROBLEM", 555, 578], ["brain", "ANATOMY", 79, 84], ["central", "ANATOMY_MODIFIER", 313, 320], ["protein expression", "OBSERVATION", 351, 369], ["subfornical organ", "ANATOMY", 377, 394], ["brainstem", "ANATOMY", 450, 459], ["hyperactivity", "OBSERVATION", 565, 578]]], ["In support of this concept, Lin et al. using a gene silencing approach demonstrated that a reduction in AT1R mRNA is associated with a reduction in ACE2 mRNA in the brainstem (Lin et al. 2008) .", [["brainstem", "ANATOMY", 165, 174], ["AT1R", "GENE_OR_GENE_PRODUCT", 104, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["brainstem", "ORGAN", 165, 174], ["AT1R mRNA", "RNA", 104, 113], ["ACE2 mRNA", "RNA", 148, 157], ["a gene silencing approach", "TREATMENT", 45, 70], ["a reduction in AT1R mRNA", "TREATMENT", 89, 113], ["a reduction in ACE2 mRNA in the brainstem", "PROBLEM", 133, 174], ["reduction", "OBSERVATION_MODIFIER", 91, 100], ["AT1R mRNA", "OBSERVATION", 104, 113], ["reduction", "OBSERVATION_MODIFIER", 135, 144], ["ACE2 mRNA", "OBSERVATION", 148, 157], ["brainstem", "ANATOMY", 165, 174]]], ["Moreover, we recently showed, for the first time, that ACE2 over-expression in the SFO resulted in the down-regulation of AT1R in this region (Feng et al. 2008b) , suggesting that the carboxypeptidase can affect AT1R transcription and/or internalization.", [["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["SFO", "SIMPLE_CHEMICAL", 83, 86], ["AT1R", "GENE_OR_GENE_PRODUCT", 122, 126], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 184, 200], ["AT1R", "GENE_OR_GENE_PRODUCT", 212, 216], ["ACE2", "PROTEIN", 55, 59], ["SFO", "PROTEIN", 83, 86], ["AT1R", "PROTEIN", 122, 126], ["carboxypeptidase", "PROTEIN", 184, 200], ["AT1R", "PROTEIN", 212, 216], ["ACE2", "TEST", 55, 59], ["the carboxypeptidase", "TREATMENT", 180, 200], ["AT1R transcription", "TREATMENT", 212, 230]]], ["However, the lack of available tools to manipulate ACE2 expression has only allowed investigations of the effects of the classic RAS components on ACE2 and additional studies are needed to address the other side of the story.ACE2 in the brainAs mentioned previously, ACE2 also participates in the metabolism of non-RAS peptides including Apelin-13, neurotensin and bradykinin fragments (Vickers et al. 2002) .", [["brainAs", "ANATOMY", 237, 244], ["neurotensin", "CHEMICAL", 349, 360], ["bradykinin", "CHEMICAL", 365, 375], ["neurotensin", "CHEMICAL", 349, 360], ["bradykinin", "CHEMICAL", 365, 375], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["RAS", "GENE_OR_GENE_PRODUCT", 129, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 147, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 225, 229], ["brainAs", "CANCER", 237, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 267, 271], ["non-RAS peptides", "GENE_OR_GENE_PRODUCT", 311, 327], ["Apelin-13", "GENE_OR_GENE_PRODUCT", 338, 347], ["neurotensin", "GENE_OR_GENE_PRODUCT", 349, 360], ["bradykinin", "GENE_OR_GENE_PRODUCT", 365, 375], ["ACE2", "PROTEIN", 51, 55], ["RAS components", "PROTEIN", 129, 143], ["ACE2", "PROTEIN", 147, 151], ["ACE2", "PROTEIN", 225, 229], ["ACE2", "PROTEIN", 267, 271], ["ACE2", "TEST", 147, 151], ["additional studies", "TEST", 156, 174], ["ACE2", "TEST", 225, 229], ["non-RAS peptides", "PROBLEM", 311, 327], ["Apelin", "TEST", 338, 344], ["neurotensin and bradykinin fragments", "TREATMENT", 349, 385]]], ["In the brain, Apelin-13 contributes to increase BP (Seyedabadi et al. 2002; Kagiyama et al. 2005) and seems to oppose the vasopressin antidiuretic response (Llorens-Cortes and Kordon 2008), while neurotensin (Carraway and Leeman 1973) and bradykinin produce hypotensive effects.", [["brain", "ANATOMY", 7, 12], ["Apelin-13", "CHEMICAL", 14, 23], ["vasopressin", "CHEMICAL", 122, 133], ["neurotensin", "CHEMICAL", 196, 207], ["bradykinin", "CHEMICAL", 239, 249], ["hypotensive", "DISEASE", 258, 269], ["Apelin-13", "CHEMICAL", 14, 23], ["vasopressin", "CHEMICAL", 122, 133], ["neurotensin", "CHEMICAL", 196, 207], ["bradykinin", "CHEMICAL", 239, 249], ["brain", "ORGAN", 7, 12], ["Apelin-13", "GENE_OR_GENE_PRODUCT", 14, 23], ["BP", "SIMPLE_CHEMICAL", 48, 50], ["vasopressin", "SIMPLE_CHEMICAL", 122, 133], ["neurotensin", "GENE_OR_GENE_PRODUCT", 196, 207], ["bradykinin", "SIMPLE_CHEMICAL", 239, 249], ["Apelin-13", "PROTEIN", 14, 23], ["Apelin", "TEST", 14, 20], ["increase BP", "PROBLEM", 39, 50], ["the vasopressin antidiuretic response", "TREATMENT", 118, 155], ["bradykinin", "TREATMENT", 239, 249], ["hypotensive effects", "PROBLEM", 258, 277], ["brain", "ANATOMY", 7, 12], ["Apelin", "ANATOMY", 14, 20]]], ["However, despite the identification of these peptides as ACE2 substrates, there has not been any study addressing the impact of the enzyme on these neuromediators or, vice versa, the role of these peptides in the actions of ACE2 in the brain.From gene deletion to gene therapyAmong the three ACE2 -/y models generated, one showed a modest but significant increase in BP that appeared to be dependent upon the C57Bl/6 genetic background (Gurley et al. 2006) .", [["brain", "ANATOMY", 236, 241], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 224, 228], ["brain", "ORGAN", 236, 241], ["ACE2", "GENE_OR_GENE_PRODUCT", 292, 296], ["BP", "SIMPLE_CHEMICAL", 367, 369], ["ACE2", "PROTEIN", 57, 61], ["ACE2", "PROTEIN", 224, 228], ["ACE2", "PROTEIN", 292, 296], ["BP", "PROTEIN", 367, 369], ["any study", "TEST", 93, 102], ["the enzyme", "TEST", 128, 138], ["these peptides", "TEST", 191, 205], ["gene deletion", "TREATMENT", 247, 260], ["gene therapy", "TREATMENT", 264, 276], ["significant increase in BP", "PROBLEM", 343, 369], ["brain", "ANATOMY", 236, 241], ["significant", "OBSERVATION_MODIFIER", 343, 354], ["increase", "OBSERVATION", 355, 363]]], ["These original observations led us to reconsider the role of endogenous ACE2 in the central regulation of BP.", [["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["BP", "GENE_OR_GENE_PRODUCT", 106, 108], ["endogenous ACE2", "PROTEIN", 61, 76], ["BP", "PROTEIN", 106, 108], ["endogenous ACE2", "TREATMENT", 61, 76], ["BP", "TEST", 106, 108]]], ["Using the same ACE2 -/y mouse model, we investigated spontaneous baroreceptor reflex and autonomic function.", [["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["ACE2", "PROTEIN", 15, 19], ["mouse", "SPECIES", 24, 29], ["the same ACE2 -/y mouse model", "TREATMENT", 6, 35], ["spontaneous baroreceptor reflex", "PROBLEM", 53, 84], ["autonomic function", "OBSERVATION", 89, 107]]], ["We observed that ACE2 gene deletion resulted in impaired resting baroreflex sensitivity (Whitaker et al. 2007) , increased sympathetic tone and decreased parasympathetic tone (Xia et al., unpublished data) .", [["impaired resting baroreflex sensitivity", "DISEASE", 48, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["ACE2 gene deletion", "DNA", 17, 35], ["ACE2 gene deletion", "PROBLEM", 17, 35], ["impaired resting baroreflex sensitivity", "PROBLEM", 48, 87], ["increased sympathetic tone", "PROBLEM", 113, 139], ["decreased parasympathetic tone", "PROBLEM", 144, 174], ["sympathetic tone", "OBSERVATION", 123, 139], ["decreased", "OBSERVATION_MODIFIER", 144, 153], ["parasympathetic tone", "OBSERVATION", 154, 174]]], ["Interestingly, these observations are consistent with subjects presenting a hyperactive RAS like in hypertension and heart failure models (Zucker 2006; Grassi et al. 2007 ).", [["heart", "ANATOMY", 117, 122], ["hypertension", "DISEASE", 100, 112], ["heart failure", "DISEASE", 117, 130], ["RAS", "GENE_OR_GENE_PRODUCT", 88, 91], ["heart", "ORGAN", 117, 122], ["a hyperactive RAS", "PROBLEM", 74, 91], ["hypertension", "PROBLEM", 100, 112], ["heart failure models", "PROBLEM", 117, 137], ["consistent with", "UNCERTAINTY", 38, 53], ["hyperactive", "OBSERVATION", 76, 87], ["hypertension", "OBSERVATION", 100, 112], ["heart", "ANATOMY", 117, 122], ["failure", "OBSERVATION", 123, 130]]], ["However, measurement of Ang-II levels in the plasma and the brain of these mice showed no differences between wildtype and ACE2 -/y genotypes, suggesting that alteration of baroreflex and autonomic function are not triggered by increased Ang-II levels in the CNS or at the periphery.", [["plasma", "ANATOMY", 45, 51], ["brain", "ANATOMY", 60, 65], ["CNS", "ANATOMY", 259, 262], ["Ang-II", "CHEMICAL", 24, 30], ["Ang-II", "CHEMICAL", 238, 244], ["Ang-II", "GENE_OR_GENE_PRODUCT", 24, 30], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["brain", "ORGAN", 60, 65], ["mice", "ORGANISM", 75, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 123, 127], ["Ang-II", "GENE_OR_GENE_PRODUCT", 238, 244], ["CNS", "ANATOMICAL_SYSTEM", 259, 262], ["Ang-II", "PROTEIN", 24, 30], ["ACE2", "PROTEIN", 123, 127], ["Ang-II", "PROTEIN", 238, 244], ["mice", "SPECIES", 75, 79], ["Ang-II levels", "TEST", 24, 37], ["the plasma", "TEST", 41, 51], ["wildtype", "TEST", 110, 118], ["ACE2", "TEST", 123, 127], ["baroreflex and autonomic function", "PROBLEM", 173, 206], ["increased Ang-II levels in the CNS", "PROBLEM", 228, 262], ["brain", "ANATOMY", 60, 65], ["no", "UNCERTAINTY", 87, 89], ["autonomic function", "OBSERVATION", 188, 206], ["CNS", "ANATOMY", 259, 262], ["periphery", "ANATOMY_MODIFIER", 273, 282]]], ["Previous studies in the periphery have shown the beneficial effects of AT1R blockers in increasing ACE2 mRNA, suggesting that AT1R inhibit ACE2 expression (Ferrario et al. 2005c ).", [["AT1R", "GENE_OR_GENE_PRODUCT", 71, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["AT1R", "GENE_OR_GENE_PRODUCT", 126, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["AT1R", "PROTEIN", 71, 75], ["ACE2 mRNA", "RNA", 99, 108], ["AT1R", "PROTEIN", 126, 130], ["ACE2", "PROTEIN", 139, 143], ["Previous studies", "TEST", 0, 16], ["AT1R blockers", "TREATMENT", 71, 84], ["increasing ACE2 mRNA", "PROBLEM", 88, 108], ["AT1R inhibit ACE2 expression", "PROBLEM", 126, 154]]], ["In addition, our recent observation that ACE2 over-expression in the brain results in reduced AT1R levels (Feng et al. 2008b) , implies that ACE2 is also capable of modulating the expression level of RAS components.", [["brain", "ANATOMY", 69, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["brain", "ORGAN", 69, 74], ["AT1R", "GENE_OR_GENE_PRODUCT", 94, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["RAS", "GENE_OR_GENE_PRODUCT", 200, 203], ["ACE2", "PROTEIN", 41, 45], ["AT1R", "PROTEIN", 94, 98], ["ACE2", "PROTEIN", 141, 145], ["RAS components", "PROTEIN", 200, 214], ["ACE2", "TEST", 41, 45], ["reduced AT1R levels", "PROBLEM", 86, 105], ["brain", "ANATOMY", 69, 74]]], ["Therefore, it is conceivable that ACE2 deletion would result in AT1R up-regulation in the brain of ACE2 -/y mice which could then account for the impaired autonomic and baroreflex function in this model.", [["brain", "ANATOMY", 90, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["AT1R", "GENE_OR_GENE_PRODUCT", 64, 68], ["brain", "ORGAN", 90, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["ACE2", "PROTEIN", 34, 38], ["AT1R", "PROTEIN", 64, 68], ["ACE2", "PROTEIN", 99, 103], ["mice", "SPECIES", 108, 112], ["ACE2 deletion", "PROBLEM", 34, 47], ["AT1R", "TEST", 64, 68], ["ACE2", "TEST", 99, 103], ["the impaired autonomic and baroreflex function", "PROBLEM", 142, 188], ["brain", "ANATOMY", 90, 95], ["impaired", "OBSERVATION", 146, 154], ["baroreflex function", "OBSERVATION", 169, 188]]], ["In support of this hypothesis, preliminary data show that central blockade of AT1R by intracerebroventricular administration of losartan restored baroreflex sensitivity and decreased BP in ACE2 null mice but not in wildtypes (Whitaker et al. 2007; Xia et al., unpublished data) , emphasizing the critical role of ACE2 in the central regulation of BP.", [["losartan", "CHEMICAL", 128, 136], ["losartan", "CHEMICAL", 128, 136], ["AT1R", "GENE_OR_GENE_PRODUCT", 78, 82], ["intracerebroventricular", "IMMATERIAL_ANATOMICAL_ENTITY", 86, 109], ["losartan", "SIMPLE_CHEMICAL", 128, 136], ["BP", "SIMPLE_CHEMICAL", 183, 185], ["ACE2", "GENE_OR_GENE_PRODUCT", 189, 193], ["ACE2", "GENE_OR_GENE_PRODUCT", 313, 317], ["BP", "SIMPLE_CHEMICAL", 347, 349], ["AT1R", "PROTEIN", 78, 82], ["BP", "PROTEIN", 183, 185], ["ACE2", "PROTEIN", 189, 193], ["ACE2", "PROTEIN", 313, 317], ["BP", "PROTEIN", 347, 349], ["mice", "SPECIES", 199, 203], ["preliminary data", "TEST", 31, 47], ["central blockade of AT1R", "TREATMENT", 58, 82], ["losartan", "TREATMENT", 128, 136], ["baroreflex sensitivity", "PROBLEM", 146, 168], ["decreased BP in ACE2 null mice", "PROBLEM", 173, 203], ["BP", "TEST", 347, 349]]], ["Additional evidence were recently provided by Diz et al. showing that inhibition of ACE2 activity in the nucleus of the solitary tract attenuates baroreflex function for heart rate control in response to increases in BP (Diz et al. 2008) .From gene deletion to gene therapyRecently, we and others have developed viral vectors to over-express ACE2 in the brain with the ultimate goal of reducing brain RAS hyperactivity associated with cardiovascular diseases.", [["nucleus", "ANATOMY", 105, 112], ["solitary tract", "ANATOMY", 120, 134], ["heart", "ANATOMY", 170, 175], ["brain", "ANATOMY", 354, 359], ["brain", "ANATOMY", 395, 400], ["cardiovascular", "ANATOMY", 435, 449], ["hyperactivity", "DISEASE", 405, 418], ["cardiovascular diseases", "DISEASE", 435, 458], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["nucleus", "CELLULAR_COMPONENT", 105, 112], ["solitary tract", "ORGAN", 120, 134], ["heart", "ORGAN", 170, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 342, 346], ["brain", "ORGAN", 354, 359], ["brain", "ORGAN", 395, 400], ["RAS", "GENE_OR_GENE_PRODUCT", 401, 404], ["cardiovascular", "ANATOMICAL_SYSTEM", 435, 449], ["ACE2", "PROTEIN", 84, 88], ["ACE2", "PROTEIN", 342, 346], ["RAS", "PROTEIN", 401, 404], ["ACE2 activity", "PROBLEM", 84, 97], ["heart rate control", "TREATMENT", 170, 188], ["BP", "TEST", 217, 219], ["viral vectors", "PROBLEM", 312, 325], ["ACE2 in the brain", "PROBLEM", 342, 359], ["reducing brain RAS hyperactivity", "PROBLEM", 386, 418], ["cardiovascular diseases", "PROBLEM", 435, 458], ["ACE2 activity", "OBSERVATION", 84, 97], ["nucleus", "ANATOMY_MODIFIER", 105, 112], ["solitary tract", "ANATOMY", 120, 134], ["increases", "OBSERVATION_MODIFIER", 204, 213], ["viral", "OBSERVATION", 312, 317], ["brain", "ANATOMY", 354, 359], ["hyperactivity", "OBSERVATION", 405, 418], ["cardiovascular diseases", "OBSERVATION", 435, 458]]], ["Pioneering this type of experiments with ACE2 at the periphery, Dr. Raizada's group first showed that ACE2 expression was reduced by 40% in the rostral ventrolateral medulla (RVLM) of SHR compared to normotensive WKY rats (Yamazato et al. 2007 ).", [["rostral ventrolateral medulla", "ANATOMY", 144, 173], ["RVLM", "ANATOMY", 175, 179], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 152, 173], ["RVLM", "MULTI-TISSUE_STRUCTURE", 175, 179], ["WKY rats", "ORGANISM", 213, 221], ["ACE2", "PROTEIN", 41, 45], ["ACE2", "PROTEIN", 102, 106], ["rats", "SPECIES", 217, 221], ["ACE2", "TEST", 41, 45], ["ACE2 expression", "PROBLEM", 102, 117], ["SHR", "PROBLEM", 184, 187], ["periphery", "ANATOMY_MODIFIER", 53, 62], ["rostral", "ANATOMY_MODIFIER", 144, 151], ["ventrolateral", "ANATOMY_MODIFIER", 152, 165], ["medulla", "ANATOMY", 166, 173], ["RVLM", "ANATOMY", 175, 179]]], ["Interestingly, the authors showed that lentivirus-mediated ACE2 over-expression targeted to the RVLM resulted in the reduction of hypertension in SHR starting 4 weeks after infection.", [["hypertension", "DISEASE", 130, 142], ["infection", "DISEASE", 173, 182], ["lentivirus", "ORGANISM", 39, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["RVLM", "SIMPLE_CHEMICAL", 96, 100], ["ACE2", "PROTEIN", 59, 63], ["lentivirus", "SPECIES", 39, 49], ["lentivirus-mediated ACE2", "TREATMENT", 39, 63], ["hypertension in SHR", "PROBLEM", 130, 149], ["infection", "PROBLEM", 173, 182], ["lentivirus", "OBSERVATION", 39, 49], ["RVLM", "ANATOMY", 96, 100], ["reduction", "OBSERVATION_MODIFIER", 117, 126], ["hypertension", "OBSERVATION", 130, 142]]], ["Although lentivirus-mediated gene expression can occur as early as 3 days post infection, the delayed anti-hypertensive response observed in this study could be due to an insufficient degree of transgene expression.", [["infection", "DISEASE", 79, 88], ["lentivirus", "ORGANISM", 9, 19], ["lentivirus", "SPECIES", 9, 19], ["lentivirus", "PROBLEM", 9, 19], ["infection", "PROBLEM", 79, 88], ["the delayed anti-hypertensive response", "PROBLEM", 90, 128], ["this study", "TEST", 141, 151], ["transgene expression", "PROBLEM", 194, 214], ["lentivirus", "OBSERVATION", 9, 19], ["infection", "OBSERVATION", 79, 88], ["transgene expression", "OBSERVATION", 194, 214]]], ["Indeed, while the lentivirus increased the carboxypeptidase expression by 45% in the RVLM compared to untreated SHR, ACE2 protein levels remained 22% lower than that of WKY rats (Yamazato et al. 2007 ).", [["lentivirus", "ORGANISM", 18, 28], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 43, 59], ["RVLM", "SIMPLE_CHEMICAL", 85, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 117, 121], ["WKY rats", "ORGANISM", 169, 177], ["carboxypeptidase", "PROTEIN", 43, 59], ["ACE2", "PROTEIN", 117, 121], ["rats", "SPECIES", 173, 177], ["lentivirus", "SPECIES", 18, 28], ["the lentivirus", "PROBLEM", 14, 28], ["the carboxypeptidase expression", "TREATMENT", 39, 70], ["untreated SHR", "PROBLEM", 102, 115], ["ACE2 protein levels", "TEST", 117, 136], ["lentivirus", "OBSERVATION", 18, 28], ["RVLM", "ANATOMY", 85, 89]]], ["The mechanism by which ACE2 mediated the reduction of hypertension was not addressed in this study; however, because injection of Ang-(1-7) in the RVLM has previously been shown to increase BP (Silva et al. 1993) , it is unlikely that this peptide mediated the anti-hypertensive response in SHR.", [["hypertension", "DISEASE", 54, 66], ["Ang-(1-7)", "CHEMICAL", 130, 139], ["RVLM", "CHEMICAL", 147, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 130, 138], ["RVLM", "SIMPLE_CHEMICAL", 147, 151], ["BP", "SIMPLE_CHEMICAL", 190, 192], ["ACE2", "PROTEIN", 23, 27], ["hypertension", "PROBLEM", 54, 66], ["this study", "TEST", 88, 98], ["Ang", "TEST", 130, 133], ["BP", "TEST", 190, 192], ["this peptide", "PROBLEM", 235, 247], ["reduction", "OBSERVATION_MODIFIER", 41, 50], ["hypertension", "OBSERVATION", 54, 66], ["RVLM", "ANATOMY", 147, 151]]], ["This decrease was probably resulting from the degradation of Ang-II by ACE2 and/or down-regulation of AT1R in this brain region.", [["brain", "ANATOMY", 115, 120], ["Ang-II", "CHEMICAL", 61, 67], ["Ang-II", "GENE_OR_GENE_PRODUCT", 61, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["AT1R", "GENE_OR_GENE_PRODUCT", 102, 106], ["brain", "ORGAN", 115, 120], ["Ang-II", "PROTEIN", 61, 67], ["ACE2", "PROTEIN", 71, 75], ["AT1R", "PROTEIN", 102, 106], ["ACE2", "TEST", 71, 75], ["brain", "ANATOMY", 115, 120], ["region", "ANATOMY_MODIFIER", 121, 127]]], ["This interpretation is consistent with our own work, using an adenovirus coding for ACE2 (Feng et al. 2008b ).", [["adenovirus", "ORGANISM", 62, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["ACE2", "PROTEIN", 84, 88], ["an adenovirus", "TREATMENT", 59, 72], ["ACE2", "PROBLEM", 84, 88], ["consistent with", "UNCERTAINTY", 23, 38]]], ["While we showed that ACE2 over-expression in the SFO prevented the Ang-II-mediated pressor and drinking responses, administration of an Ang-(1-7) receptor antagonist failed to restore the enhanced BP response.", [["Ang-II", "CHEMICAL", 67, 73], ["Ang", "CHEMICAL", 136, 139], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["SFO", "SIMPLE_CHEMICAL", 49, 52], ["Ang-II", "GENE_OR_GENE_PRODUCT", 67, 73], ["Ang-(1-7) receptor antagonist", "GENE_OR_GENE_PRODUCT", 136, 165], ["BP", "SIMPLE_CHEMICAL", 197, 199], ["ACE2", "PROTEIN", 21, 25], ["Ang-II", "PROTEIN", 67, 73], ["BP", "PROTEIN", 197, 199], ["ACE2", "TEST", 21, 25], ["the Ang-II-mediated pressor", "TREATMENT", 63, 90], ["an Ang-(1-7) receptor antagonist", "TREATMENT", 133, 165], ["the enhanced BP response", "PROBLEM", 184, 208]]], ["On the other hand, we demonstrated that adenovirus-mediated ACE2 over-expression resulted in the down-regulation of AT1R in the SFO, thus impairing Ang-II downstream signaling (Feng et al. 2008b ).", [["Ang", "CHEMICAL", 148, 151], ["adenovirus", "ORGANISM", 40, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["AT1R", "GENE_OR_GENE_PRODUCT", 116, 120], ["SFO", "SIMPLE_CHEMICAL", 128, 131], ["Ang-II", "GENE_OR_GENE_PRODUCT", 148, 154], ["ACE2", "PROTEIN", 60, 64], ["AT1R", "PROTEIN", 116, 120], ["Ang-II", "PROTEIN", 148, 154], ["adenovirus", "PROBLEM", 40, 50], ["adenovirus", "OBSERVATION", 40, 50], ["SFO", "ANATOMY", 128, 131]]], ["In addition, using this adenovirus, we showed that over-expression of ACE2 in the paraventricular nucleus (PVN) attenuates the increased sympathetic vasomotor tone resulting from Ang-II infusion in ACE2 -/y mice, and reduced the associated oxidative stress in the PVN and downstream nuclei (Xia et al. 2008) .From gene deletion to gene therapyAlthough these studies provide the first evidence for the beneficial effects of ACE2 overexpression in the CNS, long term and high level expression is needed to dissect the mechanism(s) of action and the regulation of this enzyme in the brain.New strategies and new toolsDetermination of the role of ACE2 in the CNS (and at the periphery) has been impaired by the lack of tools to manipulate its expression and mechanism of action.New strategies and new toolsTwo pharmacological antagonists have been generated and reported as highly selective at inhibiting ACE2 activity, however, their use has been limited (Dales et al. 2002; Huang et al. 2003 ).", [["paraventricular nucleus", "ANATOMY", 82, 105], ["sympathetic vasomotor", "ANATOMY", 137, 158], ["nuclei", "ANATOMY", 283, 289], ["CNS", "ANATOMY", 450, 453], ["brain", "ANATOMY", 580, 585], ["CNS", "ANATOMY", 655, 658], ["Ang-II", "CHEMICAL", 179, 185], ["adenovirus", "ORGANISM", 24, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["paraventricular nucleus", "MULTI-TISSUE_STRUCTURE", 82, 105], ["PVN", "MULTI-TISSUE_STRUCTURE", 107, 110], ["sympathetic vasomotor", "TISSUE", 137, 158], ["Ang-II", "GENE_OR_GENE_PRODUCT", 179, 185], ["ACE2", "GENE_OR_GENE_PRODUCT", 198, 202], ["PVN", "SIMPLE_CHEMICAL", 264, 267], ["nuclei", "CELLULAR_COMPONENT", 283, 289], ["ACE2", "GENE_OR_GENE_PRODUCT", 423, 427], ["CNS", "ANATOMICAL_SYSTEM", 450, 453], ["brain", "ORGAN", 580, 585], ["ACE2", "GENE_OR_GENE_PRODUCT", 643, 647], ["CNS", "ANATOMICAL_SYSTEM", 655, 658], ["ACE2", "GENE_OR_GENE_PRODUCT", 901, 905], ["ACE2", "PROTEIN", 70, 74], ["ACE2", "PROTEIN", 198, 202], ["ACE2", "PROTEIN", 423, 427], ["ACE2", "PROTEIN", 643, 647], ["ACE2", "PROTEIN", 901, 905], ["mice", "SPECIES", 207, 211], ["this adenovirus", "TREATMENT", 19, 34], ["the increased sympathetic vasomotor tone", "PROBLEM", 123, 163], ["Ang-II infusion", "TREATMENT", 179, 194], ["ACE2", "TEST", 198, 202], ["the associated oxidative stress in the PVN", "PROBLEM", 225, 267], ["gene deletion", "TREATMENT", 314, 327], ["gene therapy", "TREATMENT", 331, 343], ["these studies", "TEST", 352, 365], ["ACE2 overexpression", "TREATMENT", 423, 442], ["this enzyme", "TEST", 561, 572], ["New strategies", "PROBLEM", 586, 600], ["New strategies", "PROBLEM", 774, 788], ["Two pharmacological antagonists", "TREATMENT", 802, 833], ["paraventricular nucleus", "ANATOMY", 82, 105], ["increased", "OBSERVATION_MODIFIER", 127, 136], ["sympathetic vasomotor tone", "OBSERVATION", 137, 163], ["oxidative stress", "OBSERVATION", 240, 256], ["PVN", "ANATOMY", 264, 267], ["CNS", "ANATOMY", 450, 453], ["brain", "ANATOMY", 580, 585], ["new", "OBSERVATION_MODIFIER", 605, 608], ["CNS", "ANATOMY", 655, 658], ["impaired", "OBSERVATION", 691, 699]]], ["The first one, originally known as compound 16 or C16, was generated by Millennium Pharmaceuticals and became known as MLN4760.", [["MLN4760", "CHEMICAL", 119, 126], ["MLN4760", "CHEMICAL", 119, 126], ["C16", "SIMPLE_CHEMICAL", 50, 53], ["MLN4760", "SIMPLE_CHEMICAL", 119, 126]]], ["Although capable of inhibiting ACE2 in the picomolar range and presenting excellent selectivity versus ACE and carboxypeptidase A (Dales et al. 2002) , its non-commercial status and intellectual property rights have confined its use to a limited number of investigators.", [["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["ACE", "GENE_OR_GENE_PRODUCT", 103, 106], ["carboxypeptidase A", "GENE_OR_GENE_PRODUCT", 111, 129], ["ACE2", "PROTEIN", 31, 35], ["ACE", "PROTEIN", 103, 106], ["ACE", "TREATMENT", 103, 106], ["excellent selectivity", "OBSERVATION", 74, 95]]], ["The second compound, DX600, is a peptide inhibitor, commercially available, showing mixed competitive and noncompetitive inhibition of the carboxypeptidase with very high potency (Ki= 2.8 nM) (Huang et al. 2003) .", [["DX600", "CHEMICAL", 21, 26], ["DX600", "CHEMICAL", 21, 26], ["DX600", "SIMPLE_CHEMICAL", 21, 26], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 139, 155], ["carboxypeptidase", "PROTEIN", 139, 155], ["a peptide inhibitor", "TREATMENT", 31, 50], ["the carboxypeptidase", "TREATMENT", 135, 155], ["Ki", "TEST", 180, 182]]], ["This inhibitor has been used extensively in-vitro (Li et al. 2005; Elased et al. 2008) and although data indicate that it might be effective in-vivo, the doses needed and the associated cost make it prohibitive for this type of experiments.New strategies and new toolsRecently, using a virtual screening technique based on the structure of ACE2, Ferreira et al. identified two selective ACE2 activators: Xanthenone and resorcinolnaphthalein, both capable of enhancing ACE2 activity in a dose-dependent manner with EC 50 values of 20.", [["EC", "ANATOMY", 514, 516], ["Xanthenone", "CHEMICAL", 404, 414], ["resorcinolnaphthalein", "CHEMICAL", 419, 440], ["Xanthenone", "CHEMICAL", 404, 414], ["resorcinolnaphthalein", "CHEMICAL", 419, 440], ["ACE2", "GENE_OR_GENE_PRODUCT", 340, 344], ["ACE2", "GENE_OR_GENE_PRODUCT", 387, 391], ["Xanthenone", "SIMPLE_CHEMICAL", 404, 414], ["resorcinolnaphthalein", "SIMPLE_CHEMICAL", 419, 440], ["ACE2", "GENE_OR_GENE_PRODUCT", 468, 472], ["EC", "CELL", 514, 516], ["ACE2", "PROTEIN", 340, 344], ["ACE2", "PROTEIN", 387, 391], ["ACE2", "PROTEIN", 468, 472], ["This inhibitor", "TREATMENT", 0, 14], ["New strategies", "PROBLEM", 240, 254], ["a virtual screening technique", "TEST", 284, 313], ["Xanthenone", "TREATMENT", 404, 414], ["resorcinolnaphthalein", "TREATMENT", 419, 440], ["selective", "OBSERVATION_MODIFIER", 377, 386], ["ACE2 activators", "OBSERVATION", 387, 402], ["enhancing", "OBSERVATION_MODIFIER", 458, 467], ["ACE2 activity", "OBSERVATION", 468, 481]]], ["Interestingly, these agents were also able to increase ACE2 mRNA levels by 2-fold, suggesting that the beneficial effects of these compounds might result from both increased ACE2 gene transcription and modulation of ACE2 activity.", [["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 174, 178], ["ACE2", "GENE_OR_GENE_PRODUCT", 216, 220], ["ACE2 mRNA", "RNA", 55, 64], ["ACE2", "PROTEIN", 174, 178], ["ACE2", "PROTEIN", 216, 220], ["ACE2 mRNA levels", "TEST", 55, 71], ["these compounds", "PROBLEM", 125, 140], ["increased ACE2 gene transcription", "TREATMENT", 164, 197], ["ACE2 activity", "TREATMENT", 216, 229]]], ["While there has not been any study of the effects of these compounds on central ACE2 expression and/or activity, in-vivo studies showed that chronic subcutaneous infusion of Xanthenone decreased BP, improved cardiac function and reversed fibrosis in SHR (Hernandez Prada et al. 2008) .", [["subcutaneous", "ANATOMY", 149, 161], ["cardiac", "ANATOMY", 208, 215], ["Xanthenone", "CHEMICAL", 174, 184], ["fibrosis", "DISEASE", 238, 246], ["Xanthenone", "CHEMICAL", 174, 184], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["Xanthenone", "SIMPLE_CHEMICAL", 174, 184], ["BP", "SIMPLE_CHEMICAL", 195, 197], ["cardiac", "ORGAN", 208, 215], ["ACE2", "PROTEIN", 80, 84], ["BP", "PROTEIN", 195, 197], ["any study", "TEST", 25, 34], ["central ACE2 expression", "TREATMENT", 72, 95], ["chronic subcutaneous infusion", "TREATMENT", 141, 170], ["Xanthenone decreased BP", "TREATMENT", 174, 197], ["reversed fibrosis", "PROBLEM", 229, 246], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["reversed", "OBSERVATION_MODIFIER", 229, 237], ["fibrosis", "OBSERVATION", 238, 246]]], ["These findings suggest that the development of ACE2 activators may provide a new approach for investigating the role of ACE2 in the CNS.New strategies and new toolsUsing a genetic approach, we recently developed a new transgenic mouse model where the full open reading frame of the human ACE2 gene is under the control of a synapsin promoter ( Fig. 2A) , allowing the hACE2 protein to be expressed specifically in neurons.", [["CNS", "ANATOMY", 132, 135], ["neurons", "ANATOMY", 414, 421], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 120, 124], ["CNS", "ANATOMICAL_SYSTEM", 132, 135], ["mouse", "ORGANISM", 229, 234], ["human", "ORGANISM", 282, 287], ["ACE2", "GENE_OR_GENE_PRODUCT", 288, 292], ["synapsin", "GENE_OR_GENE_PRODUCT", 324, 332], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 344, 351], ["hACE2", "GENE_OR_GENE_PRODUCT", 368, 373], ["neurons", "CELL", 414, 421], ["ACE2", "PROTEIN", 47, 51], ["ACE2", "PROTEIN", 120, 124], ["open reading frame", "DNA", 256, 274], ["human ACE2 gene", "DNA", 282, 297], ["synapsin promoter", "DNA", 324, 341], ["hACE2 protein", "PROTEIN", 368, 381], ["mouse", "SPECIES", 229, 234], ["human", "SPECIES", 282, 287], ["mouse", "SPECIES", 229, 234], ["human", "SPECIES", 282, 287], ["ACE2 activators", "PROBLEM", 47, 62], ["New strategies", "PROBLEM", 136, 150], ["a new transgenic mouse model", "PROBLEM", 212, 240], ["the human ACE2 gene", "TREATMENT", 278, 297], ["a synapsin promoter", "TREATMENT", 322, 341], ["the hACE2 protein", "TREATMENT", 364, 381], ["CNS", "ANATOMY", 132, 135], ["new", "OBSERVATION_MODIFIER", 214, 217], ["transgenic mouse model", "OBSERVATION", 218, 240]]], ["These mice are characterized by high ACE2 expression and activity, restricted to the CNS.", [["CNS", "ANATOMY", 85, 88], ["mice", "ORGANISM", 6, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["CNS", "ANATOMICAL_SYSTEM", 85, 88], ["ACE2", "PROTEIN", 37, 41], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["high", "OBSERVATION_MODIFIER", 32, 36], ["ACE2 expression", "OBSERVATION", 37, 52], ["CNS", "ANATOMY", 85, 88]]], ["Interestingly, syn-hACE2 transgenic mice are protected against RAS overactivity, as illustrated by the absence of neurogenic hypertension following chronic infusion of a subpressor dose of Ang-II (Feng et al. 2008a ).", [["hypertension", "DISEASE", 125, 137], ["Ang-II", "CHEMICAL", 189, 195], ["syn-hACE2 transgenic mice", "ORGANISM", 15, 40], ["RAS", "GENE_OR_GENE_PRODUCT", 63, 66], ["Ang-II", "GENE_OR_GENE_PRODUCT", 189, 195], ["syn-hACE2", "PROTEIN", 15, 24], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["RAS overactivity", "PROBLEM", 63, 79], ["neurogenic hypertension", "PROBLEM", 114, 137], ["chronic infusion", "TREATMENT", 148, 164], ["a subpressor dose", "TREATMENT", 168, 185], ["overactivity", "OBSERVATION", 67, 79], ["neurogenic", "OBSERVATION_MODIFIER", 114, 124], ["hypertension", "OBSERVATION", 125, 137]]], ["This anti-hypertensive response was prevented by co-infusion of an Ang-(1-7) receptor inhibitor, and associated with increased NO synthases expression throughout the brain (Feng et al., unpublished data) .", [["brain", "ANATOMY", 166, 171], ["Ang", "CHEMICAL", 67, 70], ["NO", "CHEMICAL", 127, 129], ["NO", "CHEMICAL", 127, 129], ["Ang-(1-7) receptor", "GENE_OR_GENE_PRODUCT", 67, 85], ["NO synthases", "GENE_OR_GENE_PRODUCT", 127, 139], ["brain", "ORGAN", 166, 171], ["NO synthases", "PROTEIN", 127, 139], ["an Ang-(1-7) receptor inhibitor", "TREATMENT", 64, 95], ["synthases expression throughout the brain", "PROBLEM", 130, 171], ["synthases expression", "OBSERVATION", 130, 150], ["brain", "ANATOMY", 166, 171]]], ["These observations suggest that, although impaired Ang-II signaling may participate to the reduced high BP level in syn-hACE2 mice, Ang-(1-7) is the major mediator for this response, leading to enhanced NO synthase expression which would favor NO release, thus reinforcing autonomic and baroreflex functions towards the prevention of neurogenic hypertension in this model.", [["Ang-II", "CHEMICAL", 51, 57], ["Ang-(1-7", "CHEMICAL", 132, 140], ["NO", "CHEMICAL", 203, 205], ["NO", "CHEMICAL", 244, 246], ["neurogenic hypertension", "DISEASE", 334, 357], ["NO", "CHEMICAL", 203, 205], ["NO", "CHEMICAL", 244, 246], ["Ang-II", "GENE_OR_GENE_PRODUCT", 51, 57], ["BP", "SIMPLE_CHEMICAL", 104, 106], ["syn-hACE2 mice", "ORGANISM", 116, 130], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 132, 140], ["NO synthase", "GENE_OR_GENE_PRODUCT", 203, 214], ["NO", "SIMPLE_CHEMICAL", 244, 246], ["Ang-II", "PROTEIN", 51, 57], ["BP", "PROTEIN", 104, 106], ["NO synthase", "PROTEIN", 203, 214], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["the reduced high BP level", "PROBLEM", 87, 112], ["Ang", "TEST", 132, 135], ["synthase expression", "PROBLEM", 206, 225], ["autonomic and baroreflex functions", "PROBLEM", 273, 307], ["neurogenic hypertension", "PROBLEM", 334, 357], ["neurogenic hypertension", "OBSERVATION", 334, 357]]], ["In support to the alteration of Ang-II signaling in syn-hACE2 mice, is the blunted drinking response in this model following Ang-II infusion.", [["Ang-II", "CHEMICAL", 32, 38], ["Ang-II", "CHEMICAL", 125, 131], ["Ang-II", "GENE_OR_GENE_PRODUCT", 32, 38], ["syn-hACE2 mice", "ORGANISM", 52, 66], ["Ang-II", "GENE_OR_GENE_PRODUCT", 125, 131], ["Ang-II", "PROTEIN", 32, 38], ["mice", "SPECIES", 62, 66], ["Ang-II infusion", "TREATMENT", 125, 140]]], ["As demonstrated early on by Fitzsimons (Fitzsimons 1971) , Ang-(1-7) has no effect on water intake and this could be confirmed in syn-hACE2 by the inability of the Ang-(1-7) blocker to restore the high drinking behavior observed in non-transgenic littermates (Feng et al., unpublished data) .", [["Ang-(1-7)", "CHEMICAL", 59, 68], ["Ang-(1-7)", "CHEMICAL", 164, 173], ["Fitzsimons", "SIMPLE_CHEMICAL", 28, 38], ["Ang-(1-7", "SIMPLE_CHEMICAL", 59, 67], ["water", "SIMPLE_CHEMICAL", 86, 91], ["syn-hACE2", "SIMPLE_CHEMICAL", 130, 139], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 164, 172], ["non-transgenic littermates", "ORGANISM", 232, 258], ["Ang", "TEST", 59, 62], ["the Ang", "TREATMENT", 160, 167], ["blocker", "TREATMENT", 174, 181]]], ["Therefore, syn-hACE2 transgenic mice constitute a new interesting model to elucidate the participation of central ACE2 in various physiological responses originating in the brain and associated to a hyperactive RAS.", [["brain", "ANATOMY", 173, 178], ["syn-hACE2 transgenic mice", "ORGANISM", 11, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 114, 118], ["brain", "ORGAN", 173, 178], ["RAS", "GENE_OR_GENE_PRODUCT", 211, 214], ["syn-hACE2", "PROTEIN", 11, 20], ["ACE2", "PROTEIN", 114, 118], ["RAS", "PROTEIN", 211, 214], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["central ACE2", "PROBLEM", 106, 118], ["a hyperactive RAS", "PROBLEM", 197, 214], ["brain", "ANATOMY", 173, 178], ["hyperactive", "OBSERVATION", 199, 210]]], ["It is likely that this model will be very useful to assess the benefits of central ACE2 in cardiovascular pathologies such as heart failure and stroke, but also in neurological affections like Alzheimer's disease, depression, stress and impaired cognition (Phillips and de Oliveira 2008) .New strategies and new toolsOver the last 2 decades, the characterization of the responses mediated by the brain RAS has been challenging due to the difficulty in separating central versus peripheral RAS.", [["cardiovascular", "ANATOMY", 91, 105], ["heart", "ANATOMY", 126, 131], ["neurological", "ANATOMY", 164, 176], ["brain", "ANATOMY", 396, 401], ["cardiovascular pathologies", "DISEASE", 91, 117], ["heart failure", "DISEASE", 126, 139], ["stroke", "DISEASE", 144, 150], ["neurological affections", "DISEASE", 164, 187], ["Alzheimer's disease", "DISEASE", 193, 212], ["depression", "DISEASE", 214, 224], ["impaired cognition", "DISEASE", 237, 255], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["cardiovascular", "ANATOMICAL_SYSTEM", 91, 105], ["heart", "ORGAN", 126, 131], ["brain", "ORGAN", 396, 401], ["RAS", "GENE_OR_GENE_PRODUCT", 402, 405], ["RAS", "GENE_OR_GENE_PRODUCT", 489, 492], ["ACE2", "PROTEIN", 83, 87], ["peripheral RAS", "PROTEIN", 478, 492], ["central ACE2 in cardiovascular pathologies", "PROBLEM", 75, 117], ["heart failure", "PROBLEM", 126, 139], ["stroke", "PROBLEM", 144, 150], ["neurological affections", "PROBLEM", 164, 187], ["Alzheimer's disease", "PROBLEM", 193, 212], ["depression", "PROBLEM", 214, 224], ["stress and impaired cognition", "PROBLEM", 226, 255], ["New strategies", "PROBLEM", 289, 303], ["the difficulty in separating central versus peripheral RAS", "PROBLEM", 434, 492], ["heart", "ANATOMY", 126, 131], ["failure", "OBSERVATION", 132, 139], ["stroke", "OBSERVATION", 144, 150], ["brain", "ANATOMY", 396, 401], ["central", "ANATOMY_MODIFIER", 463, 470]]], ["The use of transgenic animals with brain-targeted expression of the classic RAS components has proven extremely useful towards solving this issue (Davisson 2003; Lavoie and Sigmund 2003) .", [["brain", "ANATOMY", 35, 40], ["brain", "ORGAN", 35, 40], ["RAS", "GENE_OR_GENE_PRODUCT", 76, 79], ["transgenic animals", "TREATMENT", 11, 29], ["the classic RAS components", "PROBLEM", 64, 90], ["brain", "ANATOMY", 35, 40]]], ["ACE2 is no exception, as it is present both in the brain and the periphery.", [["brain", "ANATOMY", 51, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["brain", "ORGAN", 51, 56], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TEST", 0, 4], ["no exception", "UNCERTAINTY", 8, 20], ["brain", "ANATOMY", 51, 56], ["periphery", "ANATOMY_MODIFIER", 65, 74]]], ["As a first step to separate central and systemic effects of ACE2, we have developed a new transgenic mouse model (bACE2) expressing ACE2 only in the brain and therefore removing the responses associated with activation of peripheral ACE2.", [["brain", "ANATOMY", 149, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["mouse", "ORGANISM", 101, 106], ["bACE2", "ORGANISM", 114, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["brain", "ORGAN", 149, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 233, 237], ["ACE2", "PROTEIN", 60, 64], ["bACE2", "CELL_LINE", 114, 119], ["ACE2", "PROTEIN", 132, 136], ["peripheral ACE2", "PROTEIN", 222, 237], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 101, 106], ["a new transgenic mouse model (bACE2) expressing ACE2 only in the brain", "PROBLEM", 84, 154], ["peripheral ACE2", "TREATMENT", 222, 237], ["central", "ANATOMY_MODIFIER", 28, 35], ["new", "OBSERVATION_MODIFIER", 86, 89], ["transgenic mouse model", "OBSERVATION", 90, 112], ["brain", "ANATOMY", 149, 154], ["peripheral ACE2", "OBSERVATION", 222, 237]]], ["Instead of using CRE/LoxP or shRNA systems that would require the generation and characterization of new transgenic mice, we opted for a simpler and faster strategy by taking advantage of already existing models.", [["CRE", "GENE_OR_GENE_PRODUCT", 17, 20], ["LoxP", "GENE_OR_GENE_PRODUCT", 21, 25], ["mice", "ORGANISM", 116, 120], ["CRE", "DNA", 17, 20], ["LoxP", "DNA", 21, 25], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["CRE/LoxP or shRNA systems", "TREATMENT", 17, 42], ["new transgenic mice", "TREATMENT", 101, 120], ["a simpler and faster strategy", "TREATMENT", 135, 164]]], ["Using genetic complementation, our approach has been to introduce brain-selective expression of the enzyme into an ACE2 nullified background.", [["brain", "ANATOMY", 66, 71], ["brain", "ORGAN", 66, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["enzyme", "PROTEIN", 100, 106], ["ACE2", "PROTEIN", 115, 119], ["the enzyme", "TEST", 96, 106]]], ["Accordingly, by breeding ACE2 -/y mice, lacking the ACE2 gene, with syn-hACE2 mice, expressing the hACE2 gene specifically in the CNS, we were able to generate a new mouse model with \"brain only\" expression of ACE2 (Fig. 2B) .", [["CNS", "ANATOMY", 130, 133], ["brain", "ANATOMY", 184, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["syn-hACE2 mice", "ORGANISM", 68, 82], ["hACE2", "GENE_OR_GENE_PRODUCT", 99, 104], ["CNS", "ANATOMICAL_SYSTEM", 130, 133], ["mouse", "ORGANISM", 166, 171], ["brain", "ORGAN", 184, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 210, 214], ["Fig. 2B", "GENE_OR_GENE_PRODUCT", 216, 223], ["ACE2", "PROTEIN", 25, 29], ["ACE2 gene", "DNA", 52, 61], ["syn-hACE2", "PROTEIN", 68, 77], ["hACE2 gene", "DNA", 99, 109], ["ACE2", "PROTEIN", 210, 214], ["Fig. 2B", "PROTEIN", 216, 223], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 78, 82], ["mouse", "SPECIES", 166, 171], ["mice", "SPECIES", 78, 82], ["mouse", "SPECIES", 166, 171], ["syn-hACE2 mice", "TREATMENT", 68, 82], ["CNS", "ANATOMY", 130, 133]]], ["Consistent with the parent strains, preliminary data indicate that resting hemodynamic parameters are normal in bACE2 mice.", [["mice", "ORGANISM", 118, 122], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["the parent strains", "PROBLEM", 16, 34], ["preliminary data", "TEST", 36, 52], ["resting hemodynamic parameters", "TEST", 67, 97], ["normal", "OBSERVATION", 102, 108]]], ["This new model should be helpful in addressing the participation of peripheral ACE2 in normal and pathophysiologic conditions.", [["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["peripheral ACE2", "PROTEIN", 68, 83], ["peripheral ACE2", "TEST", 68, 83]]], ["Finally, in order to investigate the effects of long-term ACE2 expression on chronic hypertension, we have generated a triple transgenic mouse model (SARA mice, Fig. 2C ) by transposing the syn-hACE2 phenotype onto the R + A + chronically hypertensive mouse background (kind gift from Dr. Curt D. Sigmund, University of Iowa).", [["hypertension", "DISEASE", 85, 97], ["hypertensive", "DISEASE", 239, 251], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["mouse", "ORGANISM", 137, 142], ["SARA mice", "ORGANISM", 150, 159], ["syn-hACE2", "GENE_OR_GENE_PRODUCT", 190, 199], ["R + A", "GENE_OR_GENE_PRODUCT", 219, 224], ["mouse", "ORGANISM", 252, 257], ["ACE2", "PROTEIN", 58, 62], ["syn-hACE2", "PROTEIN", 190, 199], ["mouse", "SPECIES", 137, 142], ["mice", "SPECIES", 155, 159], ["mouse", "SPECIES", 252, 257], ["mouse", "SPECIES", 137, 142], ["mouse", "SPECIES", 252, 257], ["long-term ACE2 expression", "TREATMENT", 48, 73], ["chronic hypertension", "PROBLEM", 77, 97], ["a triple transgenic mouse model", "TREATMENT", 117, 148], ["chronically hypertensive mouse background", "PROBLEM", 227, 268], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["hypertension", "OBSERVATION", 85, 97], ["chronically", "OBSERVATION_MODIFIER", 227, 238], ["hypertensive", "OBSERVATION", 239, 251]]], ["Due to the speciesspecificity of the AGT and renin components, both human genes have to be present for the R + A + mouse to be hypertensive (Merrill et al. 1996) .", [["hypertensive", "DISEASE", 127, 139], ["AGT", "GENE_OR_GENE_PRODUCT", 37, 40], ["renin", "GENE_OR_GENE_PRODUCT", 45, 50], ["human", "ORGANISM", 68, 73], ["R + A", "GENE_OR_GENE_PRODUCT", 107, 112], ["mouse", "ORGANISM", 115, 120], ["AGT", "PROTEIN", 37, 40], ["renin", "PROTEIN", 45, 50], ["human genes", "DNA", 68, 79], ["human", "SPECIES", 68, 73], ["mouse", "SPECIES", 115, 120], ["human", "SPECIES", 68, 73], ["mouse", "SPECIES", 115, 120], ["the AGT and renin components", "PROBLEM", 33, 61], ["hypertensive", "PROBLEM", 127, 139]]], ["These mice develop hypertension early on and are characterized by elevated plasma renin activity and elevated Ang-II levels.", [["plasma", "ANATOMY", 75, 81], ["hypertension", "DISEASE", 19, 31], ["Ang-II", "CHEMICAL", 110, 116], ["mice", "ORGANISM", 6, 10], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["renin", "GENE_OR_GENE_PRODUCT", 82, 87], ["Ang-II", "GENE_OR_GENE_PRODUCT", 110, 116], ["renin", "PROTEIN", 82, 87], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["hypertension", "PROBLEM", 19, 31], ["elevated plasma renin activity", "PROBLEM", 66, 96], ["elevated Ang-II levels", "PROBLEM", 101, 123], ["hypertension", "OBSERVATION", 19, 31], ["elevated", "OBSERVATION_MODIFIER", 66, 74], ["plasma renin activity", "OBSERVATION", 75, 96]]], ["In addition, chronic overproduction of Ang-II has been associated with resetting of the cardiac baroreflex (Merrill et al. 1996) and hemorrhagic stroke Wakisaka et al. 2008) in this model.", [["cardiac", "ANATOMY", 88, 95], ["Ang-II", "CHEMICAL", 39, 45], ["hemorrhagic stroke", "DISEASE", 133, 151], ["Ang-II", "GENE_OR_GENE_PRODUCT", 39, 45], ["cardiac", "ORGAN", 88, 95], ["Ang-II", "PROTEIN", 39, 45], ["chronic overproduction of Ang-II", "PROBLEM", 13, 45], ["hemorrhagic stroke", "PROBLEM", 133, 151], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["overproduction", "OBSERVATION", 21, 35], ["Ang", "OBSERVATION", 39, 42], ["cardiac baroreflex", "ANATOMY", 88, 106], ["hemorrhagic", "OBSERVATION_MODIFIER", 133, 144]]], ["We recently observed that baroreflex sensitivity was also reduced in R + A + mice while ACE2 activity was elevated in the brain (Xia et al. 2007) .", [["brain", "ANATOMY", 122, 127], ["R + A", "GENE_OR_GENE_PRODUCT", 69, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["brain", "ORGAN", 122, 127], ["ACE2", "PROTEIN", 88, 92], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["baroreflex sensitivity", "TEST", 26, 48], ["ACE2 activity", "TEST", 88, 101], ["elevated in the brain", "PROBLEM", 106, 127], ["brain", "ANATOMY", 122, 127]]], ["Therefore, the newly-generated SARA mice constitute a new tool to investigate the ability of central ACE2 in preventing the development of chronic hypertension.", [["hypertension", "DISEASE", 147, 159], ["SARA", "ORGANISM", 31, 35], ["mice", "ORGANISM", 36, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["SARA", "PROTEIN", 31, 35], ["central ACE2", "PROTEIN", 93, 105], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["central ACE2", "TREATMENT", 93, 105], ["chronic hypertension", "PROBLEM", 139, 159], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["hypertension", "OBSERVATION", 147, 159]]], ["In addition, they could represent an interesting model to assess the potential of brain ACE2 in limiting the occurrence of hemorrhagic stroke.New strategies and new toolsWe believe that together, these models will help us to further address the contribution of central ACE2 in buffering the actions of brain and systemic Ang-II on cardiovascular function as well as neurological diseases associated with brain RAS hyperactivity.New strategies and new toolsIn summary, our review of the literature shows that the long-debated physiological relevance of Ang-(1-7) is now substantiated by the identification of an enzyme leading to its formation and its own binding site, all contributing to the formation of a new axis for the RAS.", [["brain", "ANATOMY", 82, 87], ["brain", "ANATOMY", 302, 307], ["cardiovascular", "ANATOMY", 331, 345], ["neurological", "ANATOMY", 366, 378], ["brain", "ANATOMY", 404, 409], ["hemorrhagic stroke", "DISEASE", 123, 141], ["Ang-II", "CHEMICAL", 321, 327], ["neurological diseases", "DISEASE", 366, 387], ["hyperactivity", "DISEASE", 414, 427], ["Ang-(1-7", "CHEMICAL", 552, 560], ["brain", "ORGAN", 82, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 269, 273], ["brain", "ORGAN", 302, 307], ["Ang-II", "GENE_OR_GENE_PRODUCT", 321, 327], ["cardiovascular", "ANATOMICAL_SYSTEM", 331, 345], ["brain", "ORGAN", 404, 409], ["RAS", "GENE_OR_GENE_PRODUCT", 410, 413], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 552, 560], ["RAS", "GENE_OR_GENE_PRODUCT", 725, 728], ["brain ACE2", "PROTEIN", 82, 92], ["ACE2", "PROTEIN", 269, 273], ["RAS", "PROTEIN", 725, 728], ["brain ACE2", "PROBLEM", 82, 92], ["hemorrhagic stroke", "PROBLEM", 123, 141], ["New strategies", "PROBLEM", 142, 156], ["central ACE2", "PROBLEM", 261, 273], ["cardiovascular function", "TEST", 331, 354], ["neurological diseases", "PROBLEM", 366, 387], ["brain RAS hyperactivity", "PROBLEM", 404, 427], ["New strategies", "PROBLEM", 428, 442], ["Ang", "TEST", 552, 555], ["an enzyme", "PROBLEM", 608, 617], ["brain", "ANATOMY", 82, 87], ["ACE2", "OBSERVATION", 88, 92], ["hemorrhagic", "OBSERVATION_MODIFIER", 123, 134], ["stroke", "OBSERVATION", 135, 141], ["brain", "ANATOMY", 302, 307], ["hyperactivity", "OBSERVATION", 414, 427], ["new", "OBSERVATION_MODIFIER", 708, 711]]], ["Evidence is accumulating for the importance of ACE2 as a regulator of this system.", [["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ACE2", "PROTEIN", 47, 51], ["ACE2", "TREATMENT", 47, 51], ["a regulator of this system", "TREATMENT", 55, 81]]], ["Through its ability to degrade Ang-II to Ang-(1-7), ACE2 is able to regulate local Ang-II levels thereby modulating its effects.", [["Ang-II", "CHEMICAL", 31, 37], ["Ang-(1-7", "CHEMICAL", 41, 49], ["Ang-II", "CHEMICAL", 83, 89], ["Ang-II", "GENE_OR_GENE_PRODUCT", 31, 37], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 41, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["Ang-II", "GENE_OR_GENE_PRODUCT", 83, 89], ["Ang-II", "PROTEIN", 31, 37], ["ACE2", "PROTEIN", 52, 56], ["Ang-II", "PROTEIN", 83, 89], ["Ang", "TEST", 41, 44], ["ACE2", "TEST", 52, 56]]], ["It is reasonable to conclude from the above discussion that ACE2 may play a protective role in the brain by balancing the ACE/Ang-II/AT1R axis.", [["brain", "ANATOMY", 99, 104], ["Ang", "CHEMICAL", 126, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["brain", "ORGAN", 99, 104], ["ACE", "GENE_OR_GENE_PRODUCT", 122, 125], ["Ang-II", "GENE_OR_GENE_PRODUCT", 126, 132], ["AT1R", "GENE_OR_GENE_PRODUCT", 133, 137], ["ACE2", "PROTEIN", 60, 64], ["ACE", "PROTEIN", 122, 125], ["Ang-II", "PROTEIN", 126, 132], ["AT1R", "PROTEIN", 133, 137], ["ACE2", "TREATMENT", 60, 64], ["the ACE/Ang-II/AT1R axis", "TREATMENT", 118, 142], ["brain", "ANATOMY", 99, 104]]], ["Disturbance of the balance could alter the levels of Ang-II and contribute to the development of hypertension and other cardiovascular diseases.", [["cardiovascular", "ANATOMY", 120, 134], ["Ang-II", "CHEMICAL", 53, 59], ["hypertension", "DISEASE", 97, 109], ["cardiovascular diseases", "DISEASE", 120, 143], ["Ang-II", "GENE_OR_GENE_PRODUCT", 53, 59], ["cardiovascular", "ANATOMICAL_SYSTEM", 120, 134], ["Ang-II", "PROTEIN", 53, 59], ["hypertension", "PROBLEM", 97, 109], ["other cardiovascular diseases", "PROBLEM", 114, 143], ["hypertension", "OBSERVATION", 97, 109], ["cardiovascular diseases", "OBSERVATION", 120, 143]]], ["The new ACE2/Ang-(1-7)/ Mas axis is present in central areas related to the control of cardiovascular function and therefore provides new possibilities to counter-regulate the effects of Ang-II in the brain, and to develop new strategies for the treatment of cardiovascular and neurological diseases.PerspectivesThe discovery of ACE2 marked an important step in our vision of the RAS and a significant amount of investigators has recently joined the ranks of the \"believers\", as illustrated by recent national and international conferences focusing on this aspect of Angiotensin research.", [["cardiovascular", "ANATOMY", 87, 101], ["brain", "ANATOMY", 201, 206], ["cardiovascular", "ANATOMY", 259, 273], ["neurological", "ANATOMY", 278, 290], ["Ang", "CHEMICAL", 13, 16], ["Ang-II", "CHEMICAL", 187, 193], ["cardiovascular and neurological diseases", "DISEASE", 259, 299], ["Angiotensin", "CHEMICAL", 567, 578], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 13, 21], ["Mas", "GENE_OR_GENE_PRODUCT", 24, 27], ["cardiovascular", "ANATOMICAL_SYSTEM", 87, 101], ["Ang-II", "GENE_OR_GENE_PRODUCT", 187, 193], ["brain", "ORGAN", 201, 206], ["cardiovascular", "ANATOMICAL_SYSTEM", 259, 273], ["ACE2", "GENE_OR_GENE_PRODUCT", 329, 333], ["RAS", "GENE_OR_GENE_PRODUCT", 380, 383], ["Angiotensin", "GENE_OR_GENE_PRODUCT", 567, 578], ["ACE2", "PROTEIN", 8, 12], ["Ang", "PROTEIN", 13, 16], ["Ang-II", "PROTEIN", 187, 193], ["ACE2", "PROTEIN", 329, 333], ["The new ACE2/Ang", "TREATMENT", 0, 16], ["Mas axis", "PROBLEM", 24, 32], ["Ang-II in the brain", "PROBLEM", 187, 206], ["cardiovascular and neurological diseases", "PROBLEM", 259, 299], ["ACE2", "PROBLEM", 329, 333], ["Angiotensin research", "TREATMENT", 567, 587], ["new", "OBSERVATION_MODIFIER", 4, 7], ["axis", "OBSERVATION", 28, 32], ["central", "ANATOMY_MODIFIER", 47, 54], ["cardiovascular function", "OBSERVATION", 87, 110], ["brain", "ANATOMY", 201, 206], ["cardiovascular", "ANATOMY", 259, 273], ["neurological diseases", "OBSERVATION", 278, 299], ["marked", "OBSERVATION_MODIFIER", 334, 340], ["significant", "OBSERVATION_MODIFIER", 390, 401], ["amount", "OBSERVATION_MODIFIER", 402, 408]]], ["Among these questions are: 1/ the importance of ACE2 versus neprilysin in the formation of Ang-(1-7); 2/ the physiological relevance of Ang-I as a substrate for ACE2 in-vivo; 3/ the ability of ACE2 to directly activate signaling pathways, as it has been proposed for ACE; 4/ the effects of ACE2 on other systems (e.g. bradykinin and opioids); and maybe the more important question: 5/ the physiological relevance of ACE2 in \"normal\" conditions.PerspectivesAs new pharmacological and genetic tools are becoming available, it is likely that future therapies will be designed to target ACE2 and will affect the treatment of diseases beyond the cardiovascular system. (hACE2) is driven by a synapsin promoter, and the syn-hACE2 construct was injected into a 1-cell mouse embryo.", [["cardiovascular", "ANATOMY", 641, 655], ["1-cell", "ANATOMY", 754, 760], ["embryo", "ANATOMY", 767, 773], ["Ang-(1-7", "CHEMICAL", 91, 99], ["Ang", "CHEMICAL", 136, 139], ["bradykinin", "CHEMICAL", 318, 328], ["bradykinin", "CHEMICAL", 318, 328], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["neprilysin", "GENE_OR_GENE_PRODUCT", 60, 70], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 91, 99], ["Ang-I", "GENE_OR_GENE_PRODUCT", 136, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 161, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 193, 197], ["ACE", "GENE_OR_GENE_PRODUCT", 267, 270], ["ACE2", "GENE_OR_GENE_PRODUCT", 290, 294], ["bradykinin", "SIMPLE_CHEMICAL", 318, 328], ["opioids", "SIMPLE_CHEMICAL", 333, 340], ["ACE2", "GENE_OR_GENE_PRODUCT", 416, 420], ["ACE2", "GENE_OR_GENE_PRODUCT", 583, 587], ["cardiovascular", "ANATOMICAL_SYSTEM", 641, 655], ["system", "ANATOMICAL_SYSTEM", 656, 662], ["hACE2", "GENE_OR_GENE_PRODUCT", 665, 670], ["synapsin", "GENE_OR_GENE_PRODUCT", 687, 695], ["syn-hACE2", "GENE_OR_GENE_PRODUCT", 714, 723], ["mouse", "ORGANISM", 761, 766], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 767, 773], ["ACE2", "PROTEIN", 48, 52], ["neprilysin", "PROTEIN", 60, 70], ["Ang-I", "PROTEIN", 136, 141], ["ACE2", "PROTEIN", 161, 165], ["ACE2", "PROTEIN", 193, 197], ["ACE2", "PROTEIN", 290, 294], ["ACE2", "PROTEIN", 416, 420], ["ACE2", "PROTEIN", 583, 587], ["hACE2", "DNA", 665, 670], ["synapsin promoter", "DNA", 687, 704], ["syn-hACE2 construct", "DNA", 714, 733], ["mouse", "SPECIES", 761, 766], ["mouse", "SPECIES", 761, 766], ["ACE2 versus neprilysin", "TREATMENT", 48, 70], ["Ang", "TEST", 91, 94], ["ACE2", "TEST", 161, 165], ["ACE2", "TREATMENT", 193, 197], ["ACE", "TREATMENT", 267, 270], ["ACE2 on other systems", "TREATMENT", 290, 311], ["bradykinin and opioids", "TREATMENT", 318, 340], ["future therapies", "TREATMENT", 539, 555], ["diseases", "PROBLEM", 621, 629], ["a synapsin promoter", "TREATMENT", 685, 704], ["the syn-hACE2 construct", "TREATMENT", 710, 733], ["a 1-cell mouse embryo", "TREATMENT", 752, 773], ["diseases", "OBSERVATION", 621, 629], ["cardiovascular system", "ANATOMY", 641, 662]]], ["Transgenic syn-hACE2 mice express hACE2 protein specifically in neurons.", [["neurons", "ANATOMY", 64, 71], ["Transgenic syn-hACE2 mice", "ORGANISM", 0, 25], ["hACE2", "GENE_OR_GENE_PRODUCT", 34, 39], ["neurons", "CELL", 64, 71], ["syn-hACE2", "PROTEIN", 11, 20], ["hACE2 protein", "PROTEIN", 34, 47], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["neurons", "ANATOMY", 64, 71]]], ["(B) \"Brain-only ACE2\" mice (bACE2).", [["Brain", "ANATOMY", 5, 10], ["Brain", "ORGAN", 5, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["mice", "ORGANISM", 22, 26], ["ACE2", "PROTEIN", 16, 20], ["mice", "SPECIES", 22, 26], ["Brain", "ANATOMY", 5, 10]]], ["By breeding ACE2 -/y (white) with the syn-hACE2 line (green), we generated a transgenic mouse model over-expressing ACE2 in the brain while lacking the enzyme in the periphery (black).", [["brain", "ANATOMY", 128, 133], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["syn-hACE2 line", "CELL", 38, 52], ["mouse", "ORGANISM", 88, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["brain", "ORGAN", 128, 133], ["ACE2", "PROTEIN", 12, 16], ["syn-hACE2 line", "CELL_LINE", 38, 52], ["ACE2", "PROTEIN", 116, 120], ["mouse", "SPECIES", 88, 93], ["mouse", "SPECIES", 88, 93], ["breeding ACE2", "TEST", 3, 16], ["the syn-hACE2 line", "TREATMENT", 34, 52], ["expressing ACE2 in the brain", "PROBLEM", 105, 133], ["brain", "ANATOMY", 128, 133], ["periphery", "ANATOMY_MODIFIER", 166, 175]]], ["(C) SARA mice.", [["(C) SARA mice", "ORGANISM", 0, 13], ["SARA", "PROTEIN", 4, 8], ["mice", "SPECIES", 9, 13]]], ["The breeding strategy first consisted in generating double transgenic mice expressing both syn-hACE2 (green) and R + (human renin gene), or A + (human AGT gene) constructs.", [["mice", "ORGANISM", 70, 74], ["syn-hACE2 (green)", "GENE_OR_GENE_PRODUCT", 91, 108], ["R +", "GENE_OR_GENE_PRODUCT", 113, 116], ["human", "ORGANISM", 118, 123], ["renin", "GENE_OR_GENE_PRODUCT", 124, 129], ["A +", "GENE_OR_GENE_PRODUCT", 140, 143], ["human", "ORGANISM", 145, 150], ["AGT", "GENE_OR_GENE_PRODUCT", 151, 154], ["syn-hACE2 (green) and R + (human renin gene", "DNA", 91, 134], ["A + (human AGT gene) constructs", "DNA", 140, 171], ["mice", "SPECIES", 70, 74], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 145, 150], ["mice", "SPECIES", 70, 74], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 145, 150], ["human renin gene", "TEST", 118, 134], ["A + (human AGT gene) constructs", "PROBLEM", 140, 171]]], ["These mice were then bred together to generate the triple transgenic SARA mice (yellow) in which brain-selective overexpression of ACE2 is in a position to counter the hyperactive RAS.", [["brain", "ANATOMY", 97, 102], ["mice", "ORGANISM", 6, 10], ["SARA mice", "ORGANISM", 69, 78], ["brain", "ORGAN", 97, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 131, 135], ["RAS", "GENE_OR_GENE_PRODUCT", 180, 183], ["SARA", "PROTEIN", 69, 73], ["ACE2", "PROTEIN", 131, 135], ["hyperactive RAS", "PROTEIN", 168, 183], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 74, 78], ["the hyperactive RAS", "PROBLEM", 164, 183], ["brain", "ANATOMY", 97, 102], ["selective", "OBSERVATION_MODIFIER", 103, 112], ["overexpression", "OBSERVATION", 113, 127], ["ACE2", "OBSERVATION", 131, 135], ["hyperactive", "OBSERVATION", 168, 179]]]], "e2aded4533c094ee0354db729f9f7925dd79947d": [["INTRODUCTIONWhile N95 filtering facepiece respirators (FFRs) were made for single use operation, the ongoing COVID-19 pandemic has caused a shortage worldwide of these masks.", [["N95 filtering facepiece respirators", "TREATMENT", 18, 53], ["operation", "TREATMENT", 86, 95], ["these masks", "TREATMENT", 162, 173]]], ["COVID-19, caused by the SARS-CoV-2 virus, has been shown to be very contagious and spread through aerosolized droplets.", [["COVID-19", "CHEMICAL", 0, 8], ["SARS-CoV-2 virus", "ORGANISM", 24, 40], ["CoV-2 virus", "SPECIES", 29, 40], ["SARS-CoV-2 virus", "SPECIES", 24, 40], ["COVID", "TEST", 0, 5], ["the SARS-CoV-2 virus", "PROBLEM", 20, 40], ["very contagious", "PROBLEM", 63, 78], ["aerosolized droplets", "TREATMENT", 98, 118], ["aerosolized droplets", "OBSERVATION", 98, 118]]], ["These fine droplets can remain in the air, increasing the risk of contagion to those nearby [1, 2] .", [["fine droplets", "ANATOMY", 6, 19], ["droplets", "OBSERVATION", 11, 19]]], ["This is particularly risky to healthcare workers who work with Covid patients.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77]]], ["In order for an N95 mask to be reused more safely, the mask should be decontaminated of SARS-CoV-2 while maintaining its filtration efficiency and fit factor [3, 4] .", [["SARS", "DISEASE", 88, 92], ["SARS-CoV", "SPECIES", 88, 96], ["an N95 mask", "TREATMENT", 13, 24], ["the mask", "TREATMENT", 51, 59], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96]]], ["Currently, limited information is known about SARS-CoV-2 inactivation.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["SARS", "PROBLEM", 46, 50]]], ["The addition of moisture possibly plays a role in the inactivation of some viruses [5] [6] [7] .", [["5] [6] [7]", "SIMPLE_CHEMICAL", 84, 94], ["some viruses", "PROBLEM", 70, 82]]], ["A study found viral inactivation in 70 o C for 5 minutes [8] while in a buffered solution.", [["A study", "TEST", 0, 7], ["viral inactivation", "PROBLEM", 14, 32], ["a buffered solution", "TREATMENT", 70, 89], ["viral inactivation", "OBSERVATION", 14, 32]]], ["SARS-CoV-2 has also been shown to be inactivated at temperatures of 60-75 o C for 5-30 minutes in various liquid media [9] [10] [11] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["various liquid media", "TREATMENT", 98, 118]]], ["Other enveloped viruses, such as H1N1 and H5N1 Influenza strains have been shown to be inactivated with moist heat at 65 o C and over 50% humidity [5] [6] [7] .", [["H5N1 Influenza strains", "ORGANISM", 42, 64], ["H1N1 and H5N1 Influenza", "SPECIES", 33, 56], ["Other enveloped viruses", "PROBLEM", 0, 23], ["H1N1", "PROBLEM", 33, 37], ["H5N1 Influenza strains", "PROBLEM", 42, 64], ["enveloped", "OBSERVATION_MODIFIER", 6, 15], ["viruses", "OBSERVATION", 16, 23]]], ["These studies also found that dry heat alone was not enough to deactivate H1N1.", [["These studies", "TEST", 0, 13], ["dry heat", "PROBLEM", 30, 38], ["H1N1", "PROBLEM", 74, 78]]], ["While previous studies have looked at the effects of moist heat on N95 FFRs, these were done at substantially lower temperatures of 60-65 o C [5, 7, 12, 13] .", [["previous studies", "TEST", 6, 22], ["N95 FFRs", "TREATMENT", 67, 75]]], ["We also note that recent CDC guidelines have indicated that moist heat is a reasonable method for reusing N95 FFRs.", [["N95 FFRs", "TREATMENT", 106, 114]]], ["The resistance of Clostridium difficile (C. diff.) at elevated temperature and moisture was also studied and found temperatures Figure.", [["Clostridium difficile", "DISEASE", 18, 39], ["Clostridium difficile", "ORGANISM", 18, 39], ["Clostridium difficile", "SPECIES", 18, 39], ["Clostridium difficile", "SPECIES", 18, 39], ["Clostridium difficile", "PROBLEM", 18, 39], ["C. diff", "PROBLEM", 41, 48], ["elevated temperature", "PROBLEM", 54, 74], ["resistance", "OBSERVATION_MODIFIER", 4, 14], ["Clostridium difficile", "OBSERVATION", 18, 39]]], ["1 Figure 1 (a) Each N95 FFR (1) was placed into a plastic container with a paper towel (2) with 500 uL of water.", [["a paper towel", "TREATMENT", 73, 86]]], ["Both the mask (3) and container (4) were labeled with a Sharpie black permanent ink marker, which would allow the mask to be identified by the correct healthcare worker and avoid cross contamination. (b) For testing purposes, the lid of each container was modified to have a temperature and humidity sensor (STH30).INTRODUCTIONof 85 o C found a 5 to 6 log reduction in 15 minutes of heating in a buffer solution [14] .", [["a Sharpie black permanent ink marker", "TREATMENT", 54, 90], ["the mask", "TREATMENT", 110, 118], ["cross contamination", "PROBLEM", 179, 198], ["testing purposes", "TEST", 208, 224], ["a temperature and humidity sensor (STH30)", "TREATMENT", 273, 314], ["heating in a buffer solution", "TREATMENT", 383, 411]]], ["Here we present a scalable method of heating N95 FFRs to 85 o C, in air, with 60-80% humidity.", [["air", "ANATOMY", 68, 71]]], ["We note that during the preparation of this manuscript, another study (with some shared co-authors) was posted on medRxiv on the filtration effects of heating under various humidity conditions and for multiple cycles of mask reuse [15] .", [["another study", "TEST", 56, 69], ["the filtration effects", "TREATMENT", 125, 147], ["heating under various humidity conditions", "TREATMENT", 151, 192], ["multiple cycles of mask reuse", "TREATMENT", 201, 230]]], ["N95 respirators are typically made of meltblown polypropylene fabric.", [["polypropylene", "CHEMICAL", 48, 61], ["N95 respirators", "TREATMENT", 0, 15], ["meltblown polypropylene fabric", "TREATMENT", 38, 68], ["polypropylene fabric", "OBSERVATION", 48, 68]]], ["While this naturally filters out large particles, the efficient filtration of sub-micron sized particles is due electrostatic charge that is created in the mask fabrication process.", [["large particles", "PROBLEM", 33, 48], ["the efficient filtration of sub-micron sized particles", "TREATMENT", 50, 104], ["electrostatic charge", "PROBLEM", 112, 132], ["the mask fabrication process", "TREATMENT", 152, 180], ["large", "OBSERVATION_MODIFIER", 33, 38], ["particles", "OBSERVATION_MODIFIER", 39, 48], ["efficient", "OBSERVATION_MODIFIER", 54, 63], ["filtration", "OBSERVATION", 64, 74], ["electrostatic charge", "OBSERVATION", 112, 132], ["mask fabrication", "OBSERVATION", 156, 172]]], ["If this charge is removed, the mask efficiency plummets, even if there are no visual signs of degradation to the mask.", [["the mask efficiency plummets", "TREATMENT", 27, 55], ["visual signs of degradation", "PROBLEM", 78, 105], ["the mask", "TREATMENT", 109, 117]]], ["Thus it is critical to run filtration tests on any decontamination procedure.INTRODUCTIONThere are many practical considerations which must be taken into account when trying to apply a decontamination method to hospital-scale operations.", [["run filtration tests", "TEST", 23, 43], ["any decontamination procedure", "TREATMENT", 47, 76], ["a decontamination method", "TREATMENT", 183, 207], ["scale operations", "TREATMENT", 220, 236]]], ["Masks should ideally be returned to the same individual for many reasons, including fit and decreased risk of spreading other diseases.", [["Masks", "TREATMENT", 0, 5], ["spreading other diseases", "PROBLEM", 110, 134], ["spreading", "OBSERVATION_MODIFIER", 110, 119]]], ["Avoiding any cross contamination between masks is also important.", [["any cross contamination between masks", "PROBLEM", 9, 46]]], ["Hospitals with limited PPE allocations would also benefit from rapid time turnaround capabilities if there is a critical shortage of N95 FFRs, ideally decontaminating a clinician's mask between shifts.HEATING PROTOCOLHere we place an N95 FFR in a 1.25 quart hard walled polypropylene container (Ziploc medium square).", [["polypropylene", "CHEMICAL", 270, 283], ["limited PPE allocations", "TREATMENT", 15, 38], ["HEATING PROTOCOLHere", "TREATMENT", 201, 221], ["an N95 FFR", "TREATMENT", 231, 241], ["a 1.25 quart hard walled polypropylene container (Ziploc medium square)", "TREATMENT", 245, 316]]], ["This ensures that both the charged layer of the mask and the container are made of the same material, which decreases the likelihood of material incompatibility.", [["the mask", "TREATMENT", 44, 52], ["material incompatibility", "PROBLEM", 136, 160], ["charged", "OBSERVATION_MODIFIER", 27, 34], ["layer", "OBSERVATION_MODIFIER", 35, 40], ["material incompatibility", "OBSERVATION", 136, 160]]], ["We found in our tests that the rigid container is preferable to a bag as it ensures constant volume, leading to a constant humidity and provides protection to the mask in the handling process.", [["a bag", "TREATMENT", 64, 69], ["a constant humidity", "TREATMENT", 112, 131], ["the mask", "TREATMENT", 159, 167]]], ["In each container is added a small (2.5\"x2.5\") paper towel (2-ply), which is wetted with 500(+/-40) uL of water.", [["small", "OBSERVATION_MODIFIER", 29, 34]]], ["The containers are sealed by placing the cover on and then placed in a convection oven (Despatch LAC1-38-8, 3.7 cu.", [["The containers", "TREATMENT", 0, 14], ["a convection oven (Despatch LAC1", "TREATMENT", 69, 101], ["sealed", "OBSERVATION_MODIFIER", 19, 25]]], ["Ft.).", [["Ft", "PROTEIN", 0, 2]]], ["We note that a convection oven produces a stable and uniform temperature throughout the oven, as well as heats the masks and containers quickly due to the driven warm airflow.", [["a convection oven", "TREATMENT", 13, 30], ["heats the masks", "TREATMENT", 105, 120], ["the driven warm airflow", "PROBLEM", 151, 174], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["uniform", "OBSERVATION_MODIFIER", 53, 60], ["temperature", "OBSERVATION_MODIFIER", 61, 72], ["airflow", "OBSERVATION", 167, 174]]], ["We find that the measured oven temperature is stable to less than 1 o C regardless of the number of containers we place into this oven (1-45 containers), Figure 2 .", [["the measured oven temperature", "TEST", 13, 42], ["stable", "OBSERVATION_MODIFIER", 46, 52]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)HEATING PROTOCOLThe copyright holder for this preprint this version posted April 14, 2020. note that a convection oven has no direct line of sight to any radiative heat sources, which would have the potential to damage the masks.", [["CC", "CHEMICAL", 0, 2], ["a convection oven", "TREATMENT", 300, 317], ["any radiative heat sources", "PROBLEM", 349, 375], ["the masks", "TREATMENT", 418, 427], ["med", "ANATOMY", 102, 105]]], ["For testing purposes, the lids of the containers were modified to allow a temperature and humidity sensor (SHT30 DFR0588) inside.", [["testing purposes", "TEST", 4, 20], ["the containers", "TREATMENT", 34, 48], ["a temperature and humidity sensor (SHT30 DFR0588)", "TREATMENT", 72, 121]]], ["We found that the humidity will drop rapidly in the presence of a small hole in the lid.", [["the humidity", "PROBLEM", 14, 26], ["a small hole in the lid", "PROBLEM", 64, 87], ["small", "OBSERVATION_MODIFIER", 66, 71], ["hole", "OBSERVATION", 72, 76], ["lid", "ANATOMY", 84, 87]]], ["The gap between the wires and the lid were thus sealed with 10 minute epoxy with a working temperature of 93 o C. For temperature verification, we also used both a K type thermocouple (readout with a SR630) and an IR thermometer (Fluke 561).", [["K", "CHEMICAL", 164, 165], ["epoxy", "CHEMICAL", 70, 75], ["the wires and the lid", "TREATMENT", 16, 37], ["a working temperature", "TEST", 81, 102], ["temperature verification", "TEST", 118, 142], ["a K type thermocouple", "TREATMENT", 162, 183], ["an IR thermometer", "TREATMENT", 211, 228], ["gap", "OBSERVATION_MODIFIER", 4, 7], ["wires", "OBSERVATION", 20, 25], ["lid", "ANATOMY", 34, 37]]], ["Figure 3 shows the humidity as a function of time within each container as well as the variability of humidity on the volume of water added.", [["the volume of water", "TREATMENT", 114, 133]]], ["We also find that the humidity takes between 10-15 minutes to reach the 60% level.", [["the humidity", "TREATMENT", 18, 30]]], ["This is an important consideration when applying this method as at least 10 additional minutes should be added to the heating cycle to achieve the desired time at target humidity.", [["this method", "TREATMENT", 49, 60], ["the heating cycle", "TREATMENT", 114, 131]]], ["The temperature rises to within 2 o C of the target temperature in a similar time.HEATING PROTOCOLThe containers are placed into the convection oven for 40 minutes.", [["The temperature rises", "PROBLEM", 0, 21], ["HEATING PROTOCOLThe containers", "TREATMENT", 82, 112]]], ["The temperature remained stable to about 1 o C and the humidity was within a range of 60-85%.", [["The temperature", "TEST", 0, 15], ["the humidity", "TEST", 51, 63], ["stable", "OBSERVATION_MODIFIER", 25, 31]]], ["After 40 minutes, the containers were removed from the oven and for each container the lid was opened and rotated 45 degrees and placed back on top of the container, leaving air to naturally flow around Figure.", [["lid", "ORGANISM_SUBDIVISION", 87, 90], ["the containers", "TREATMENT", 18, 32], ["lid", "ANATOMY", 87, 90]]], ["3 Temperature and humidity as a function of water volume for (a) 300uL (b) 500 uL (c) 700uL.", [["a function of water volume", "TREATMENT", 30, 56]]], ["The green shaded region indicated the target humidity range.HEATING PROTOCOL.", [["The green shaded region", "PROBLEM", 0, 23], ["HEATING PROTOCOL", "TREATMENT", 60, 76], ["green shaded", "OBSERVATION", 4, 16], ["target", "OBSERVATION_MODIFIER", 38, 44], ["humidity range", "OBSERVATION", 45, 59]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 14, 2020. the FFR.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["the FFR", "TEST", 273, 280], ["med", "ANATOMY", 102, 105]]], ["This is done while the container is still warm and we find that the processed mask is dry in under 5 minutes and the atmosphere inside the container is the same or slightly below ambient humidity after the lid is resealed.", [["the processed mask", "TREATMENT", 64, 82]]], ["For storage in the container (or a bag, if moved out of the container) the humidity could be further reduced if desired by adding a very inexpensive small desiccant pouch into the container.(which was not certified by peer review)To test whether any degradation of the masks occured, we measure the filtration efficiency after five decontamination cycles.", [["a bag", "TREATMENT", 33, 38], ["the humidity", "TREATMENT", 71, 83], ["a very inexpensive small desiccant pouch", "TREATMENT", 130, 170], ["any degradation of the masks", "PROBLEM", 246, 274], ["the filtration efficiency", "TREATMENT", 295, 320], ["five decontamination cycles", "TREATMENT", 327, 354], ["filtration efficiency", "OBSERVATION", 299, 320]]], ["This number of cycles was chosen as previous reports, which also considered the 3M 1860, have shown that in the absence of any decontamination treatment five cycles of donning can be performed safely before fit tests began to fail consistently [16] .", [["any decontamination treatment", "TREATMENT", 123, 152], ["fit tests", "TEST", 207, 216]]], ["We tested the 3M 1860 1 surgical N95, 3M 8210 Plus N95, Chen Heng V9501 KN95 2 , and a HKYQ N95 3 .", [["HKYQ N95 3", "DNA", 87, 97], ["Chen Heng V9501 KN95", "SPECIES", 56, 76]]], ["We perform quantitative fit test measurements after each decontamination cycle.", [["quantitative fit test measurements", "TEST", 11, 45], ["each decontamination cycle", "TREATMENT", 52, 78]]], ["We used a separate batch of masks for the filtration and fit tests as the masks used for fit testing must be modified to adapt to the fit testing apparatus and are worn by a user.(which was not certified by peer review)After the decontamination cycles the masks are inspected for any qualitative degradation.", [["a separate batch of masks", "TREATMENT", 8, 33], ["the filtration", "TREATMENT", 38, 52], ["fit tests", "TEST", 57, 66], ["the masks", "TREATMENT", 70, 79], ["fit testing", "TEST", 89, 100], ["the decontamination cycles the masks", "TREATMENT", 225, 261], ["any qualitative degradation", "PROBLEM", 280, 307]]], ["The most prominent effect observed is deterioration of the printed labels on the two 3M models.", [["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["effect", "OBSERVATION_MODIFIER", 19, 25], ["deterioration", "OBSERVATION_MODIFIER", 38, 51]]], ["After a single cycle there is noticeable blurring of the text as the ink apparently bleeds into the material.FIT TEST METHODS AND RESULTSThe fit tests were performed with a TSI PortaCount Respirator Fit Tester 8038 using NaCl particles produced by a particle generator.", [["NaCl", "CHEMICAL", 221, 225], ["NaCl", "CHEMICAL", 221, 225], ["noticeable blurring of the text", "PROBLEM", 30, 61], ["bleeds into the material", "PROBLEM", 84, 108], ["fit tests", "TEST", 141, 150], ["a TSI PortaCount Respirator Fit Tester", "TREATMENT", 171, 209], ["NaCl particles", "TREATMENT", 221, 235], ["a particle generator", "TREATMENT", 248, 268], ["noticeable", "OBSERVATION_MODIFIER", 30, 40], ["blurring", "OBSERVATION", 41, 49], ["bleeds", "OBSERVATION", 84, 90], ["particle generator", "OBSERVATION", 250, 268]]], ["Each test was performed by a single user to control for variability in face structure.", [["Each test", "TEST", 0, 9], ["variability in face structure", "PROBLEM", 56, 85]]], ["We used the OSHA modified ambient aerosol Condensation Nuclei Counter (CNC) Quantitative Fit Test for Filtering Facepiece Respirators.", [["the OSHA modified ambient aerosol", "TREATMENT", 8, 41], ["Filtering Facepiece Respirators", "TREATMENT", 102, 133]]], ["This produces a quantitative fit factor score for each of the four test components (bending over, talking, head side to side, head up and down) as well as an overall fit factor computed as the geometric mean of these four scores.", [["head", "ANATOMY", 107, 111], ["head", "ANATOMY", 126, 130], ["head", "ORGANISM_SUBDIVISION", 107, 111], ["head", "ORGANISM_SUBDIVISION", 126, 130], ["head", "ANATOMY", 126, 130]]], ["A passing score is given in each category for a fit factor \u2265100, but any individual category may be failed so long as the overall fit factor is \u2265100 in order to pass the OSHA test.", [["A passing score", "PROBLEM", 0, 15], ["a fit factor", "TEST", 46, 58], ["the OSHA test", "TEST", 166, 179]]], ["Hence they were 9 years expired at the time of testing.", [["testing", "TEST", 47, 54]]], ["As of 4/5/20 the CDC states that model 1860 masks beyond the manufacturer shelf life have been shown to still be in accordance with NIOSH performance standards [17] .", [["the manufacturer shelf life", "TREATMENT", 57, 84]]], ["Our testing is in agreement with these findings.", [["Our testing", "TEST", 0, 11]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 14, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Additionally, the system does not provide a fit factor score greater than 200, and instead gives a maximum possible score of 200+.", [["a fit factor score", "TEST", 42, 60]]], ["Each fit test sequence takes approximately two minutes and 30 seconds.", [["Each fit test sequence", "TEST", 0, 22]]], ["For these tests each mask was punctured and fitted with a metal hose adapter to connect to the PortaCount via 3/16\" ID tubing.", [["these tests each mask", "TREATMENT", 4, 25], ["a metal hose adapter", "TREATMENT", 56, 76], ["ID tubing", "TREATMENT", 116, 125]]], ["Prior to starting each fit test measurement, the user donned the mask and performed a qualitative user seal check to confirm that there were no detectable air leaks when forcefully exhaling.", [["fit test measurement", "TEST", 23, 43], ["the mask", "TREATMENT", 61, 69], ["a qualitative user seal check", "TEST", 84, 113], ["detectable air leaks", "PROBLEM", 144, 164], ["no detectable", "UNCERTAINTY", 141, 154], ["air leaks", "OBSERVATION", 155, 164]]], ["The user then made small adjustments to the fit of the mask based on the results of this seal check.", [["the mask", "TREATMENT", 51, 59], ["this seal check", "TEST", 84, 99]]], ["After each fit test measurement the user doffed the mask to simulate the wear and tear produced through donning and doffing masks.(which was not certified by peer review)The protocol we performed used two masks of each type, one of which was treated as the control, and did not undergo heating, and one mask which went through five decontamination cycles.", [["fit test measurement", "TEST", 11, 31], ["the mask", "TREATMENT", 48, 56], ["tear", "PROBLEM", 82, 86], ["The protocol", "TREATMENT", 170, 182], ["heating", "TREATMENT", 286, 293], ["one mask", "TREATMENT", 299, 307], ["five decontamination cycles", "TREATMENT", 327, 354], ["tear", "OBSERVATION", 82, 86]]], ["Each mask in the test group was fit tested prior to the decontamination cycles to ensure that the mask was not defective.", [["Each mask", "TREATMENT", 0, 9], ["the decontamination cycles", "TREATMENT", 52, 78], ["the mask", "TREATMENT", 94, 102], ["defective", "PROBLEM", 111, 120]]], ["Masks in the test group that passed this initial fit test were then run through the decontamination cycle five times.", [["the decontamination cycle", "TREATMENT", 80, 105]]], ["Between each cycle the test mask was removed from the container and fit tested.", [["the test mask", "TREATMENT", 19, 32]]], ["The control group masks were fit tested six times to correspond to the initial fit test and the fit test the test group masks would receive after each decontamination cycle.", [["The control group masks", "TREATMENT", 0, 23], ["the initial fit test", "TEST", 67, 87], ["the fit test", "TEST", 92, 104], ["the test group masks", "TREATMENT", 105, 125], ["each decontamination cycle", "TREATMENT", 146, 172]]], ["For the test group masks that underwent all five decontamination cycles, we performed three fit tests instead of just one.", [["the test group masks", "TREATMENT", 4, 24], ["all five decontamination cycles", "TREATMENT", 40, 71], ["fit tests", "TEST", 92, 101]]], ["This was done to provide a better sampling of any variance in the user's ability to form a tight seal with the mask and demonstrate whether there had been any degradation at the very end of the cycles.(which was not certified by peer review).", [["the mask", "TREATMENT", 107, 115], ["any degradation", "PROBLEM", 155, 170]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 14, 2020. a The 1860 masks used as a baseline were not expired, while, as previously noted, the masks used for the decontamination cycles were expired by 9 years.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["the masks", "TREATMENT", 355, 364], ["the decontamination cycles", "TREATMENT", 374, 400], ["med", "ANATOMY", 102, 105]]], ["II Filtration testing results.", [["II Filtration testing", "TEST", 0, 21]]], ["Initial filtration performance of 0.26 \u00b5m (mass mean diameter) NaCl at a flow rate of 85 L/min is reported.", [["NaCl", "CHEMICAL", 63, 67], ["NaCl", "CHEMICAL", 63, 67], ["Initial filtration performance", "TEST", 0, 30], ["NaCl", "TEST", 63, 67], ["a flow rate", "TEST", 71, 82]]], ["Filtration efficiency and pressure drop shown for the test group masks is an average of the two masks of each type tested.", [["Filtration efficiency", "PROBLEM", 0, 21], ["pressure drop", "PROBLEM", 26, 39], ["the test group masks", "TREATMENT", 50, 70], ["pressure", "OBSERVATION_MODIFIER", 26, 34], ["drop", "OBSERVATION_MODIFIER", 35, 39]]], ["Testing performed with a TSI Inc. Automated(which was not certified by peer review)Filter Tester 8130A.(which was not certified by peer review)The results of these tests are summarized in Table 1 .", [["Testing", "TEST", 0, 7], ["a TSI", "TEST", 23, 28], ["these tests", "TEST", 158, 169]]], ["The Chen Heng V9501 KN95 and the HKYQ N95 mask both failed the initial qualitative user seal checks, and the fit test.", [["Chen Heng V9501 KN95", "SPECIES", 4, 24], ["the HKYQ N95 mask", "TREATMENT", 29, 46], ["the fit test", "TEST", 105, 117]]], ["As a result, we declined to process these masks through the decontamination cycles and only performed further tests on the control group to determine their fit factor.", [["these masks", "TREATMENT", 36, 47], ["the decontamination cycles", "TREATMENT", 56, 82], ["further tests", "TEST", 102, 115]]], ["The two 3M mask models, 8210 Plus and 1860, both passed the fit test on every trial, and achieved the maximum possible fit factors after five heating cycles.(which was not certified by peer review)There is a trend in which fit tests of the 1860 and to a lesser degree the 8210 Plus which were performed earlier in the experiment showed lower fit factors than those performed later.", [["five heating cycles", "TREATMENT", 137, 156], ["fit tests", "TEST", 223, 232], ["lower fit factors", "PROBLEM", 336, 353]]], ["This is best explained by a training effect as the user gained experience with the particular mask models and identifying potential leaks during user seal checks.", [["the particular mask models", "TREATMENT", 79, 105], ["potential leaks", "PROBLEM", 122, 137], ["user seal checks", "TEST", 145, 161], ["leaks", "OBSERVATION", 132, 137]]], ["This effect is less clear for the other two mask models, as the user was unable to perform a satisfactory user seal check in any test.FILTRATION TESTING METHODS AND RESULTSThe filtration tests were performed with a TSI Inc. Automated Filter Tester 8130A using 0.26 \u00b5m (mass mean diameter) NaCl as the aerosol source under a flow rate of 85 L/min.", [["NaCl", "CHEMICAL", 289, 293], ["NaCl", "CHEMICAL", 289, 293], ["any test", "TEST", 125, 133], ["RESULTSThe filtration tests", "TEST", 165, 192], ["a TSI", "TEST", 213, 218], ["Automated Filter Tester", "TREATMENT", 224, 247], ["\u00b5m (mass mean diameter) NaCl", "TREATMENT", 265, 293], ["a flow rate", "TEST", 322, 333], ["less", "OBSERVATION_MODIFIER", 15, 19], ["clear", "OBSERVATION", 20, 25]]], ["With this system we were able to determine the filtration efficiency for the challenge aerosol and the pressure drop across the mask.", [["the challenge aerosol", "TREATMENT", 73, 94], ["the pressure drop", "TEST", 99, 116], ["the mask", "TREATMENT", 124, 132], ["pressure drop", "OBSERVATION", 103, 116]]], ["For these measurements we report the initial filtration efficiency as opposed to the minimum loaded efficiency, as we do not expect a significant difference in the loading curves for treated vs untreated masks.FILTRATION TESTING METHODS AND RESULTSFor our filtration testing protocol we included one of each mask type in the control group and two of each type in the test group.", [["these measurements", "TEST", 4, 22], ["the initial filtration efficiency", "TREATMENT", 33, 66], ["the loading curves", "TREATMENT", 160, 178], ["untreated masks", "TREATMENT", 194, 209], ["our filtration testing protocol", "TEST", 252, 283], ["each mask type", "TREATMENT", 303, 317]]], ["The test group masks were each put through five heating cycles, while the control group was not heated.", [["The test group masks", "TREATMENT", 0, 20], ["five heating cycles", "TREATMENT", 43, 62]]], ["After the five cycles the masks were all submitted for filtration testing, the results of which are shown in Table 2 .FILTRATION TESTING METHODS AND RESULTSFor all four mask types studied, there was no significant drop between the control group and the test group masks.", [["the five cycles the masks", "TREATMENT", 6, 31], ["filtration testing", "TEST", 55, 73], ["significant drop between the control group", "PROBLEM", 202, 244], ["the test group masks", "TREATMENT", 249, 269], ["no", "UNCERTAINTY", 199, 201], ["significant", "OBSERVATION_MODIFIER", 202, 213], ["drop", "OBSERVATION", 214, 218]]], ["Additionally, all of the masks demonstrated a filtration efficiency significantly above the 95% threshold for N95 respirators.", [["a filtration efficiency", "PROBLEM", 44, 67], ["N95 respirators", "TREATMENT", 110, 125], ["filtration efficiency", "OBSERVATION", 46, 67]]], ["The test group mask results were averaged together, but there were also no individual masks that showed an efficiency below the 95% standard.", [["The test group mask", "TEST", 0, 19], ["efficiency", "OBSERVATION_MODIFIER", 107, 117]]], ["One mask of each type was also run through a 30 minute loading test to simulate the performance change when particles accumulated on the mask during the usage.", [["a 30 minute loading test", "TREATMENT", 43, 67], ["the mask", "TREATMENT", 133, 141]]], ["During this test, the minimum efficiency for all masks remained over the 95% standard.", [["this test", "TEST", 7, 16], ["all masks", "TREATMENT", 45, 54], ["minimum", "OBSERVATION_MODIFIER", 22, 29], ["efficiency", "OBSERVATION_MODIFIER", 30, 40]]], ["While the pressure drop for each mask changed by up to 20%, all masks were still well below the maximum resistance to airflow specified by NIOSH ( [18] 42 CFR 84.180).FILTRATION TESTING METHODS AND RESULTS.", [["the pressure drop", "PROBLEM", 6, 23], ["each mask", "TREATMENT", 28, 37], ["all masks", "TREATMENT", 60, 69], ["CFR", "TEST", 155, 158], ["pressure", "OBSERVATION_MODIFIER", 10, 18], ["drop", "OBSERVATION_MODIFIER", 19, 23], ["maximum resistance", "OBSERVATION", 96, 114]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 14, 2020. . https://doi.org/10.1101/2020.04.09.20059758 doi: medRxiv preprint SCALABILITY With a total cycle time of about 50 minutes, including 10 minutes for loading and unloading the oven, a 3.7 cu ft oven, as was used here, can treat approximately 1,300 masks per 24 hours under constant processing conditions.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["unloading the oven", "TREATMENT", 435, 453], ["a 3.7 cu ft oven", "TREATMENT", 455, 471], ["med", "ANATOMY", 102, 105]]], ["Larger convection ovens are available 4 .", [["Larger convection ovens", "TREATMENT", 0, 23], ["convection ovens", "OBSERVATION", 7, 23]]], ["The equipment needed to implement this method requires the convection oven, containers, paper towels, and a pipette.", [["The equipment", "TREATMENT", 0, 13], ["this method", "TREATMENT", 34, 45], ["the convection oven", "TREATMENT", 55, 74]]], ["This makes such a method accessible to all scales of health services.(which was not certified by peer review)Although the original ink labeling on the masks blurred, the labels we applied to the masks and containers with sharpie were still clear after the five cycles.", [["the masks", "TREATMENT", 191, 200], ["sharpie", "TREATMENT", 221, 228]]], ["This suggests a clear method for ensuring that each mask is always returned to the same user.", [["each mask", "TREATMENT", 47, 56], ["clear", "OBSERVATION_MODIFIER", 16, 21], ["method", "OBSERVATION", 22, 28]]], ["This will be important in healthcare settings both for maintaining good fit, and because this decontamination protocol may not sterilize all potential pathogens on the masks at the temperature chosen.", [["this decontamination protocol", "TREATMENT", 89, 118], ["the masks", "TREATMENT", 164, 173]]], ["Additionally, the ability to label closed containers could both help to protect workers who process masks through a decontamination protocol, and to prevent cross contamination of masks during the process.CONCLUSIONSThis research studied the effect of five cycles of heating to 85 o C for 30 min with a relative humidity of 60-85% on a selection of N95 FFRs.", [["a decontamination protocol", "TREATMENT", 114, 140], ["cross contamination of masks", "TREATMENT", 157, 185], ["a relative humidity", "TEST", 301, 320], ["N95 FFRs", "TREATMENT", 349, 357]]], ["We found that for all of the N95 models we investigated there was no significant difference in filtration efficacy between the test groups of masks and the untreated control masks.", [["significant difference in filtration efficacy", "PROBLEM", 69, 114], ["masks", "TREATMENT", 142, 147], ["the untreated control masks", "TREATMENT", 152, 179], ["no", "UNCERTAINTY", 66, 68], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["difference", "OBSERVATION_MODIFIER", 81, 91]]], ["For the mask models that were able to pass a fit test prior to cycling (3M 1860 and 3M 8210 Plus), there was no measurable degradation of fit after each decontamination cycle, nor relative to the control group masks.", [["the mask models", "TREATMENT", 4, 19], ["a fit test", "TEST", 43, 53], ["measurable degradation of fit", "PROBLEM", 112, 141], ["no", "UNCERTAINTY", 109, 111]]], ["As such, we found that the heating protocol described in this article is compatible with 3M models 1860 and 8210 Plus FFRs.", [["the heating protocol", "TREATMENT", 23, 43]]], ["The Chen Heng V9501 KN95 and HKYQ N95 showed no degradation in the filtration tests, but their fit factor value was in the 4-45 and 5-28 ranges respectively (where 100 is normally considered passing).", [["HKYQ", "CHEMICAL", 29, 33], ["HKYQ N95", "DNA", 29, 37], ["Chen Heng V9501 KN95", "SPECIES", 4, 24], ["HKYQ N95", "TEST", 29, 37], ["degradation", "PROBLEM", 48, 59], ["the filtration tests", "TEST", 63, 83], ["their fit factor value", "TEST", 89, 111], ["no", "UNCERTAINTY", 45, 47], ["degradation", "OBSERVATION_MODIFIER", 48, 59]]], ["Further work is still required to ensure viral inactivation of SARS-CoV-2 on FFRs.", [["SARS", "DISEASE", 63, 67], ["SARS-CoV-2", "ORGANISM", 63, 73], ["FFRs", "CANCER", 77, 81], ["SARS-CoV", "SPECIES", 63, 71], ["viral inactivation of SARS", "PROBLEM", 41, 67], ["CoV", "TEST", 68, 71], ["FFRs", "TREATMENT", 77, 81]]]], "PMC7262110": [["ORNGE DURING COVID-19As of April 30, 2020, Ornge has organized transport for and/or transported 325 patients with either a confirmed case of or under investigation for COVID-19.", [["COVID-19", "CHEMICAL", 168, 176], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["COVID", "TEST", 168, 173]]], ["A total of 52.3% of these were completed by CCLA, 28.9% were completed by FW aircraft, and 16.6% were completed by RW aircraft.", [["CCLA", "CANCER", 44, 48], ["CCLA", "TEST", 44, 48]]], ["Of these, 71% required oxygen therapy, approximately 1% received oxygen by high flow nasal cannula (HFNC), 59% were intubated and being mechanically ventilated, approximately 1% were transported prone, and approximately 1% were transported on extracorporeal membrane oxygenation.", [["nasal", "ANATOMY", 85, 90], ["extracorporeal membrane", "ANATOMY", 243, 266], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 65, 71], ["oxygen", "SIMPLE_CHEMICAL", 23, 29], ["oxygen", "SIMPLE_CHEMICAL", 65, 71], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 85, 98], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 243, 266], ["oxygen therapy", "TREATMENT", 23, 37], ["oxygen", "TREATMENT", 65, 71], ["high flow nasal cannula", "TREATMENT", 75, 98], ["intubated", "TREATMENT", 116, 125], ["extracorporeal membrane oxygenation", "TREATMENT", 243, 278], ["oxygen therapy", "OBSERVATION", 23, 37]]], ["During this time, no staff members tested positive for COVID-19.ORNGE DURING COVID-19On March 11, 2020, the World Health Organization declared a global pandemic.2 On February 28, Ornge activated its pandemic committee.", [["COVID", "TEST", 55, 60], ["a global pandemic", "PROBLEM", 143, 160], ["global", "OBSERVATION_MODIFIER", 145, 151], ["pandemic", "OBSERVATION", 152, 160]]], ["The pandemic committee's priorities include ensuring staff safety, developing surge capacity, and responding to urgent, unconventional requests for assistance.COVID-19 screening and personal protective pquipment ::: Protecting staff physical health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYProtecting our staff has been our top priority.", [["COVID", "TEST", 159, 164]]], ["PTAC offers an online tool to screen for COVID-19.", [["COVID", "TEST", 41, 46]]], ["Ornge decided early during the pandemic to use airborne precautions for all potential COVID-19 cases.", [["airborne precautions", "TREATMENT", 47, 67]]], ["Ornge paramedics are unable to change from droplet to airborne precautions while in an aircraft or vehicle, before performing an aerosol-generating procedure (AGP).COVID-19 screening and personal protective pquipment ::: Protecting staff physical health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYOrnge also procured reusable N95 facemasks (3M 6500) with disposable filters as well as washable water-resistant gowns.", [["AGP", "PROTEIN", 159, 162], ["airborne precautions", "TREATMENT", 54, 74], ["an aerosol-generating procedure", "TREATMENT", 126, 157], ["COVID", "TEST", 164, 169], ["disposable filters", "TREATMENT", 374, 392], ["resistant gowns", "OBSERVATION", 419, 434]]], ["We have not adopted the use of powered air-purifying respirators (PAPRs), because of the increased risk of contamination during doffing,3 and although PAPRs have a higher protective factor compared with N95 respirators, there is no definitive evidence that PAPRs reduce the likelihood of viral transmission in the setting of potential airborne spread.4 Furthermore, significant training burden is required to maintain competency, and there remains difficulty with implementation in the aviation environment.Aircraft/vehicle suitability ::: Protecting staff physical health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYThe Centers for Disease Control and Prevention (CDC) provides guidance on airframe selection for transporting severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus (CoV) patients.5,6 Among other recommendations, the CDC recommends aircraft with front-to-aft cabin air flow and a cabin separate from the cockpit for transporting these infectious patients.", [["acute respiratory syndrome", "DISEASE", 752, 778], ["SARS", "DISEASE", 780, 784], ["Middle East respiratory syndrome (MERS) coronavirus (CoV)", "DISEASE", 790, 847], ["PAPRs", "GENE_OR_GENE_PRODUCT", 151, 156], ["PAPRs", "SIMPLE_CHEMICAL", 257, 262], ["MERS) coronavirus", "ORGANISM", 824, 841], ["CoV", "ORGANISM", 843, 846], ["patients", "ORGANISM", 848, 856], ["patients", "ORGANISM", 1023, 1031], ["PAPRs", "PROTEIN", 151, 156], ["patients", "SPECIES", 848, 856], ["patients", "SPECIES", 1023, 1031], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 790, 841], ["CoV", "SPECIES", 843, 846], ["powered air-purifying respirators", "TREATMENT", 31, 64], ["N95 respirators", "TREATMENT", 203, 218], ["PAPRs", "PROBLEM", 257, 262], ["viral transmission", "PROBLEM", 288, 306], ["potential airborne spread", "PROBLEM", 325, 350], ["significant training burden", "PROBLEM", 366, 393], ["Disease Control", "TREATMENT", 651, 666], ["airframe selection", "TREATMENT", 709, 727], ["transporting severe acute respiratory syndrome", "PROBLEM", 732, 778], ["SARS)", "PROBLEM", 780, 785], ["Middle East respiratory syndrome", "PROBLEM", 790, 822], ["coronavirus", "PROBLEM", 830, 841], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["contamination", "OBSERVATION", 107, 120], ["no definitive evidence", "UNCERTAINTY", 229, 251], ["viral transmission", "OBSERVATION", 288, 306], ["airborne spread", "OBSERVATION", 335, 350], ["significant", "OBSERVATION_MODIFIER", 366, 377], ["severe", "OBSERVATION_MODIFIER", 745, 751], ["acute", "OBSERVATION_MODIFIER", 752, 757], ["respiratory syndrome", "OBSERVATION", 758, 778], ["Middle", "ANATOMY_MODIFIER", 790, 796], ["respiratory syndrome", "OBSERVATION", 802, 822], ["air flow", "OBSERVATION", 942, 950], ["infectious", "OBSERVATION", 1012, 1022]]], ["In aircraft with uncontrolled interior air flow, the CDC suggests that all personnel wear N-95 masks.", [["uncontrolled interior air flow", "PROBLEM", 17, 47], ["uncontrolled", "OBSERVATION_MODIFIER", 17, 29], ["interior", "OBSERVATION_MODIFIER", 30, 38], ["air flow", "OBSERVATION", 39, 47]]], ["Additionally, the CDC offers recommendations for ventilation requirements in hospitals for patient care areas.7 For airborne infection isolation rooms, the CDC recommends a minimum of 6\u201312 total air changes per hour (ACH).7Aircraft/vehicle suitability ::: Protecting staff physical health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYIn our FW aircraft, the cockpit is not separate from the cabin, the air flow is aft-to-front, and the interior cabin air exchange is approximately 10 ACH.", [["airborne infection", "DISEASE", 116, 134], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["ventilation requirements", "TREATMENT", 49, 73], ["the air flow", "TEST", 415, 427], ["air flow", "OBSERVATION", 419, 427], ["cabin air", "OBSERVATION", 462, 471]]], ["For our RW aircraft, cabin air flow varies from 9 to 36 ACH.", [["our RW aircraft", "TEST", 4, 19], ["cabin air flow", "TEST", 21, 35], ["air flow", "OBSERVATION", 27, 35]]], ["All but two of our RW aircraft have a fixed wall installed, resulting in independent cockpit and cabin ventilation.", [["wall", "ANATOMY", 44, 48], ["wall", "TISSUE", 44, 48], ["cabin ventilation", "TREATMENT", 97, 114], ["fixed", "OBSERVATION_MODIFIER", 38, 43], ["wall", "OBSERVATION_MODIFIER", 44, 48], ["independent cockpit", "OBSERVATION", 73, 92], ["cabin ventilation", "OBSERVATION", 97, 114]]], ["Our CCLA assets are capable of 24 ACH per hour and the front driver's compartment is separate from the patient compartment.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["As such, we preferentially transport COVID patients using our CCLA assets.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["our CCLA assets", "TREATMENT", 58, 73]]], ["Our CCLA assets are capable of more than adequate ACH, fewer personnel are exposed to the risk of infection, and the front driver's compartment is separate from the patient compartment.Aircraft/vehicle suitability ::: Protecting staff physical health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYWe have also restricted the use oxygen by high flow nasal cannula (HFNC) to only CCLA assets and temporarily halted the use of noninvasive ventilation (NIV).", [["nasal", "ANATOMY", 365, 370], ["infection", "DISEASE", 98, 107], ["oxygen", "CHEMICAL", 345, 351], ["oxygen", "CHEMICAL", 345, 351], ["patient", "ORGANISM", 165, 172], ["oxygen", "SIMPLE_CHEMICAL", 345, 351], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 365, 378], ["patient", "SPECIES", 165, 172], ["infection", "PROBLEM", 98, 107], ["oxygen", "TREATMENT", 345, 351], ["high flow nasal cannula (HFNC", "TREATMENT", 355, 384], ["noninvasive ventilation", "TREATMENT", 440, 463], ["NIV", "TREATMENT", 465, 468], ["infection", "OBSERVATION", 98, 107]]], ["There is emerging evidence to support the use of HFNC and NIV to prevent mechanical ventilation in COVID-19 patients.8,9 However, there is substantial fear among health care workers about the increased risk of infection transmission from using HFNC and NIV,10 although unsubstantiated with evidence.", [["HFNC", "CHEMICAL", 49, 53], ["infection", "DISEASE", 210, 219], ["HFNC", "CHEMICAL", 49, 53], ["NIV", "CHEMICAL", 58, 61], ["NIV", "CHEMICAL", 253, 256], ["HFNC", "SIMPLE_CHEMICAL", 49, 53], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["HFNC", "TREATMENT", 49, 53], ["NIV", "TREATMENT", 58, 61], ["mechanical ventilation", "TREATMENT", 73, 95], ["infection transmission", "PROBLEM", 210, 232], ["HFNC", "TREATMENT", 244, 248], ["NIV", "TREATMENT", 253, 256], ["mechanical ventilation", "OBSERVATION", 73, 95], ["substantial", "OBSERVATION_MODIFIER", 139, 150], ["infection", "OBSERVATION", 210, 219]]], ["In cases where air transport is required because of geography, Ornge will require these patients to be mechanically ventilated.", [["air", "MULTI-TISSUE_STRUCTURE", 15, 18], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["air transport", "TREATMENT", 15, 28], ["mechanically ventilated", "TREATMENT", 103, 126], ["ventilated", "OBSERVATION", 116, 126]]], ["Ornge will be participating in engineering research trials looking at the risk of droplet and aerosol dispersion using HFNC and NIV in our airframes based on their current airflow dynamics.Ambulance Decontamination ::: Protecting staff physical health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYGiven that SARS-CoV, the virus that causes COVID-19, can live for as long as 72 hours on surfaces,11 decontamination of ambulances is particularly important.", [["HFNC", "CHEMICAL", 119, 123], ["SARS-CoV", "DISEASE", 325, 333], ["NIV", "CHEMICAL", 128, 131], ["SARS-CoV", "ORGANISM", 325, 333], ["SARS-CoV", "SPECIES", 325, 333], ["droplet and aerosol dispersion", "TREATMENT", 82, 112], ["HFNC", "TREATMENT", 119, 123], ["NIV", "TREATMENT", 128, 131], ["SARS", "PROBLEM", 325, 329], ["CoV", "PROBLEM", 330, 333], ["the virus", "PROBLEM", 335, 344]]], ["Decontamination represents a high-risk activity requiring PPE for health care workers.12 For the COVID-19 pandemic, we have now adopted the use of a vaporized hydrogen peroxide disinfection system (Nocospray, Montreal), which minimizes health care worker exposure.Protecting staff mental health ::: MAINTAINING OPERATIONAL READINESS BY ENSURING STAFF SAFETYCommunication has been the touchstone of all our efforts to mitigate the anxiety and mental health consequences of working during this pandemic.", [["hydrogen peroxide", "CHEMICAL", 159, 176], ["anxiety", "DISEASE", 430, 437], ["hydrogen peroxide", "CHEMICAL", 159, 176], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 159, 176], ["Decontamination", "TREATMENT", 0, 15], ["the COVID", "TEST", 93, 102], ["a vaporized hydrogen peroxide disinfection system", "TREATMENT", 147, 196], ["the anxiety", "PROBLEM", 426, 437], ["high-risk activity", "OBSERVATION_MODIFIER", 29, 47]]], ["Finally, after transporting COVID-19 patients, Ornge crews can take an operational pause to decompress and debrief.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Ornge crews", "TREATMENT", 47, 58], ["an operational pause", "TREATMENT", 68, 88], ["decompress", "TREATMENT", 92, 102], ["decompress", "OBSERVATION", 92, 102]]], ["The average duration of an operational pause has been 60 minutes.Northern community surge plan ::: SURGE CAPACITYFor northern communities, Ornge has augmented three remote health care facilities with additional ventilators from our own stockpile.", [["additional ventilators", "TREATMENT", 200, 222], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["Our private air carriers traditionally only transport one patient at a time.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65]]], ["However, we have modified our operating practice to allow for two ventilated patients to be transported in select private air carrier aircraft with our OSRT paramedics.Southern critical care transport ::: SURGE CAPACITYIn Southern Ontario, Ornge has partnered with Toronto Paramedic Services (TPS) to develop a plan for transporting multiple critically ill COVID-19 patients in the TPS ambulance bus (Figure 2).", [["critically ill", "DISEASE", 342, 356], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 366, 374], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 366, 374]]], ["The bus can transport 4 ventilated patients or up to 8 stretcher-bound patients.", [["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 71, 79]]]], "PMC7453919": [["IntroductionLower respiratory tract infection (LRTI) is a common disease in children, and it also brings economic burden to families.", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infection", "DISEASE", 18, 45], ["LRTI", "DISEASE", 47, 51], ["IntroductionLower respiratory tract", "ORGANISM_SUBDIVISION", 0, 35], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["IntroductionLower respiratory tract infection", "PROBLEM", 0, 45], ["a common disease", "PROBLEM", 56, 72], ["respiratory tract", "ANATOMY", 18, 35], ["infection", "OBSERVATION", 36, 45]]], ["The pathogenic microorganisms that caused LRTI mainly include viruses (respiratory syncytial virus, influenza virus, parainfluenza virus, adenovirus, coronavirus, human metapneumovirus, and rhinovirus) and bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus) (Musher & Thorner, 2014).", [["LRTI", "DISEASE", 42, 46], ["respiratory syncytial virus", "DISEASE", 71, 98], ["influenza virus", "DISEASE", 100, 115], ["parainfluenza virus, adenovirus, coronavirus, human metapneumovirus, and rhinovirus)", "DISEASE", 117, 201], ["Streptococcus pneumoniae", "DISEASE", 216, 240], ["Haemophilus influenzae, Staphylococcus aureus", "DISEASE", 242, 287], ["respiratory syncytial virus", "ORGANISM", 71, 98], ["influenza virus", "ORGANISM", 100, 115], ["parainfluenza virus", "ORGANISM", 117, 136], ["adenovirus", "ORGANISM", 138, 148], ["coronavirus", "ORGANISM", 150, 161], ["human", "ORGANISM", 163, 168], ["metapneumovirus", "ORGANISM", 169, 184], ["rhinovirus", "ORGANISM", 190, 200], ["Streptococcus pneumoniae", "ORGANISM", 216, 240], ["Haemophilus influenzae", "ORGANISM", 242, 264], ["Staphylococcus aureus", "ORGANISM", 266, 287], ["respiratory syncytial virus", "SPECIES", 71, 98], ["influenza virus", "SPECIES", 100, 115], ["parainfluenza virus", "SPECIES", 117, 136], ["coronavirus", "SPECIES", 150, 161], ["human", "SPECIES", 163, 168], ["metapneumovirus", "SPECIES", 169, 184], ["rhinovirus", "SPECIES", 190, 200], ["Streptococcus pneumoniae", "SPECIES", 216, 240], ["Haemophilus influenzae", "SPECIES", 242, 264], ["Staphylococcus aureus", "SPECIES", 266, 287], ["respiratory syncytial virus", "SPECIES", 71, 98], ["parainfluenza virus", "SPECIES", 117, 136], ["human metapneumovirus", "SPECIES", 163, 184], ["Streptococcus pneumoniae", "SPECIES", 216, 240], ["Haemophilus influenzae", "SPECIES", 242, 264], ["Staphylococcus aureus", "SPECIES", 266, 287], ["The pathogenic microorganisms", "PROBLEM", 0, 29], ["LRTI", "PROBLEM", 42, 46], ["viruses", "PROBLEM", 62, 69], ["respiratory syncytial virus", "PROBLEM", 71, 98], ["influenza virus", "PROBLEM", 100, 115], ["parainfluenza virus", "PROBLEM", 117, 136], ["adenovirus", "PROBLEM", 138, 148], ["coronavirus", "PROBLEM", 150, 161], ["human metapneumovirus", "PROBLEM", 163, 184], ["rhinovirus", "PROBLEM", 190, 200], ["bacteria", "PROBLEM", 206, 214], ["Streptococcus pneumoniae", "PROBLEM", 216, 240], ["Haemophilus influenzae", "PROBLEM", 242, 264], ["Staphylococcus aureus", "PROBLEM", 266, 287]]], ["LRTI is one of the leading cause of death in children under 5 years old around the world between 1980 and 2016 (GBD 2016 Causes of Death Collaborators, 2017).", [["LRTI", "DISEASE", 0, 4], ["death", "DISEASE", 36, 41], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["LRTI", "PROBLEM", 0, 4], ["death", "PROBLEM", 36, 41]]], ["LRTI in children under 5 years old is mainly caused by virus (Tramper-Stranders, 2018).", [["LRTI", "DISEASE", 0, 4], ["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["LRTI", "PROBLEM", 0, 4]]], ["It was estimated that 56% of healthy children carry Mycoplasma pneumoniae (Meyer Sauteur et al., 2016).", [["Mycoplasma pneumoniae", "DISEASE", 52, 73], ["children", "ORGANISM", 37, 45], ["Mycoplasma pneumoniae", "ORGANISM", 52, 73], ["children", "SPECIES", 37, 45], ["Mycoplasma pneumoniae", "SPECIES", 52, 73], ["Mycoplasma pneumoniae", "SPECIES", 52, 73], ["Mycoplasma pneumoniae", "PROBLEM", 52, 73], ["Mycoplasma pneumoniae", "OBSERVATION", 52, 73]]], ["Both upper and lower respiratory tract infections can be induced by M. pneumoniae.", [["lower respiratory tract", "ANATOMY", 15, 38], ["respiratory tract infections", "DISEASE", 21, 49], ["upper", "ORGANISM_SUBDIVISION", 5, 10], ["lower", "ORGANISM_SUBDIVISION", 15, 20], ["respiratory tract", "ORGANISM_SUBDIVISION", 21, 38], ["M. pneumoniae", "ORGANISM", 68, 81], ["M. pneumoniae", "SPECIES", 68, 81], ["M. pneumoniae", "SPECIES", 68, 81], ["Both upper and lower respiratory tract infections", "PROBLEM", 0, 49], ["M. pneumoniae", "PROBLEM", 68, 81], ["upper", "ANATOMY_MODIFIER", 5, 10], ["lower", "ANATOMY_MODIFIER", 15, 20], ["respiratory tract", "ANATOMY", 21, 38], ["infections", "OBSERVATION", 39, 49], ["pneumoniae", "OBSERVATION", 71, 81]]], ["School-age children and adolescents were the common population of M. pneumoniae infection (Waites et al., 2017).", [["M. pneumoniae infection", "DISEASE", 66, 89], ["children", "ORGANISM", 11, 19], ["adolescents", "ORGANISM", 24, 35], ["M. pneumoniae", "ORGANISM", 66, 79], ["children", "SPECIES", 11, 19], ["adolescents", "SPECIES", 24, 35], ["M. pneumoniae", "SPECIES", 66, 79], ["M. pneumoniae", "SPECIES", 66, 79], ["M. pneumoniae infection", "PROBLEM", 66, 89], ["pneumoniae", "OBSERVATION_MODIFIER", 69, 79], ["infection", "OBSERVATION", 80, 89]]], ["However, it has been observed that respiratory tract infections caused by M. pneumoniae are increasing among children younger than 5 years old (Sun et al., 2015).", [["respiratory tract", "ANATOMY", 35, 52], ["respiratory tract infections", "DISEASE", 35, 63], ["M. pneumoniae", "DISEASE", 74, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["M. pneumoniae", "ORGANISM", 74, 87], ["children", "ORGANISM", 109, 117], ["M. pneumoniae", "SPECIES", 74, 87], ["children", "SPECIES", 109, 117], ["M. pneumoniae", "SPECIES", 74, 87], ["respiratory tract infections", "PROBLEM", 35, 63], ["M. pneumoniae", "PROBLEM", 74, 87], ["respiratory tract", "ANATOMY", 35, 52], ["infections", "OBSERVATION", 53, 63], ["pneumoniae", "OBSERVATION", 77, 87], ["increasing", "OBSERVATION_MODIFIER", 92, 102]]], ["Elevated white blood cell is a useful parameter in the diagnosis of bacterial infections (Lavoignet et al., 2019).", [["white blood cell", "ANATOMY", 9, 25], ["bacterial infections", "DISEASE", 68, 88], ["white blood cell", "CELL", 9, 25], ["white blood cell", "CELL_TYPE", 9, 25], ["Elevated white blood cell", "PROBLEM", 0, 25], ["bacterial infections", "PROBLEM", 68, 88], ["white blood cell", "OBSERVATION", 9, 25], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["infections", "OBSERVATION", 78, 88]]], ["However, normal or decreased leukocyte counts do not exclude bacterial infection.", [["leukocyte", "ANATOMY", 29, 38], ["bacterial infection", "DISEASE", 61, 80], ["leukocyte", "CELL", 29, 38], ["decreased leukocyte counts", "PROBLEM", 19, 45], ["bacterial infection", "PROBLEM", 61, 80], ["normal", "OBSERVATION", 9, 15], ["decreased", "OBSERVATION_MODIFIER", 19, 28], ["leukocyte counts", "OBSERVATION", 29, 45], ["do not exclude", "UNCERTAINTY", 46, 60], ["bacterial", "OBSERVATION_MODIFIER", 61, 70], ["infection", "OBSERVATION", 71, 80]]], ["Community acquired pneumonia caused by M. pneumoniae and virus have similar clinical symptoms, such as fever, muscle pain, weakness, dry cough.", [["muscle", "ANATOMY", 110, 116], ["pneumonia", "DISEASE", 19, 28], ["fever", "DISEASE", 103, 108], ["muscle pain", "DISEASE", 110, 121], ["weakness", "DISEASE", 123, 131], ["dry cough", "DISEASE", 133, 142], ["M. pneumoniae", "ORGANISM", 39, 52], ["muscle", "ORGAN", 110, 116], ["M. pneumoniae", "SPECIES", 39, 52], ["M. pneumoniae", "SPECIES", 39, 52], ["Community acquired pneumonia", "PROBLEM", 0, 28], ["M. pneumoniae", "PROBLEM", 39, 52], ["virus", "PROBLEM", 57, 62], ["similar clinical symptoms", "PROBLEM", 68, 93], ["fever", "PROBLEM", 103, 108], ["muscle pain", "PROBLEM", 110, 121], ["weakness", "PROBLEM", 123, 131], ["dry cough", "PROBLEM", 133, 142], ["pneumonia", "OBSERVATION", 19, 28], ["pneumoniae", "OBSERVATION", 42, 52], ["muscle", "ANATOMY", 110, 116], ["weakness", "OBSERVATION", 123, 131], ["dry", "OBSERVATION_MODIFIER", 133, 136], ["cough", "OBSERVATION", 137, 142]]], ["The white blood cell counts of viral infection is normal in most cases, as well as M. pneumoniae infection.", [["white blood cell", "ANATOMY", 4, 20], ["viral infection", "DISEASE", 31, 46], ["M. pneumoniae infection", "DISEASE", 83, 106], ["white blood cell", "CELL", 4, 20], ["M. pneumoniae", "ORGANISM", 83, 96], ["M. pneumoniae", "SPECIES", 83, 96], ["M. pneumoniae", "SPECIES", 83, 96], ["The white blood cell counts", "TEST", 0, 27], ["viral infection", "PROBLEM", 31, 46], ["M. pneumoniae infection", "PROBLEM", 83, 106], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46], ["normal", "OBSERVATION", 50, 56], ["most cases", "OBSERVATION_MODIFIER", 60, 70], ["pneumoniae", "OBSERVATION_MODIFIER", 86, 96], ["infection", "OBSERVATION", 97, 106]]], ["It is difficult to distinguish M. pneumoniae from virus-induced LRTI (Sharma et al., 2017).IntroductionRapid identification of pathogens is helpful for the treatment of LRTI.", [["LRTI", "DISEASE", 64, 68], ["LRTI", "DISEASE", 169, 173], ["M. pneumoniae", "ORGANISM", 31, 44], ["M. pneumoniae", "SPECIES", 31, 44], ["M. pneumoniae", "SPECIES", 31, 44], ["M. pneumoniae", "PROBLEM", 31, 44], ["virus", "PROBLEM", 50, 55], ["pathogens", "PROBLEM", 127, 136], ["LRTI", "PROBLEM", 169, 173], ["pneumoniae", "OBSERVATION", 34, 44], ["LRTI", "OBSERVATION_MODIFIER", 64, 68], ["pathogens", "OBSERVATION", 127, 136], ["LRTI", "OBSERVATION", 169, 173]]], ["Early identification of viral infection can avoid overuse of antibiotics.", [["viral infection", "DISEASE", 24, 39], ["viral infection", "PROBLEM", 24, 39], ["antibiotics", "TREATMENT", 61, 72], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39]]], ["The specificity of culture is high, but it takes a long time.", [["culture", "TEST", 19, 26]]], ["The sensitivity of serological diagnosis depends on the time of sample collection (Waites et al., 2017).", [["sample", "ANATOMY", 64, 70], ["serological diagnosis", "TEST", 19, 40], ["sample collection", "TEST", 64, 81]]], ["The polymerase-chain-reaction (PCR) detection technology improves the sensitivity of pathogen identification, but PCR is expensive (GBD 2016 Lower Respiratory Infections Collaborators, 2018).", [["Respiratory Infections", "DISEASE", 147, 169], ["The polymerase", "TEST", 0, 14], ["pathogen identification", "TEST", 85, 108], ["PCR", "TEST", 114, 117], ["Respiratory", "ANATOMY", 147, 158], ["Infections", "OBSERVATION", 159, 169]]], ["However, PCR is unable to identify all pathogens.", [["PCR", "TEST", 9, 12], ["all pathogens", "PROBLEM", 35, 48], ["pathogens", "OBSERVATION", 39, 48]]], ["Jain and colleagues used PCR technology to detect the pathogens in 2,259 community-acquired pneumonia patients, and 62% of the patients still could not identify the pathogens (Jain et al., 2015).", [["pneumonia", "DISEASE", 92, 101], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 127, 135], ["PCR technology", "TEST", 25, 39], ["the pathogens", "PROBLEM", 50, 63], ["acquired pneumonia", "PROBLEM", 83, 101], ["the pathogens", "PROBLEM", 161, 174], ["pneumonia", "OBSERVATION", 92, 101]]], ["Possible causes include unable to get lower respiratory tract specimen, application of antibiotics before specimen collection, insensitivity of diagnostic tests to known pathogens, lack of detection of other recognized pathogens, unidentified pathogens and noninfectious factors.", [["lower respiratory tract specimen", "ANATOMY", 38, 70], ["specimen", "ANATOMY", 106, 114], ["respiratory tract", "ORGANISM_SUBDIVISION", 44, 61], ["noninfectious factors", "PROTEIN", 257, 278], ["lower respiratory tract specimen", "PROBLEM", 38, 70], ["antibiotics", "TREATMENT", 87, 98], ["specimen collection", "TEST", 106, 125], ["diagnostic tests", "TEST", 144, 160], ["known pathogens", "PROBLEM", 164, 179], ["other recognized pathogens", "PROBLEM", 202, 228], ["unidentified pathogens", "PROBLEM", 230, 252], ["noninfectious factors", "PROBLEM", 257, 278], ["respiratory tract", "ANATOMY", 44, 61], ["pathogens", "OBSERVATION", 219, 228], ["noninfectious", "OBSERVATION_MODIFIER", 257, 270]]], ["Some biological indicators help to predict the pathogen categories of infectious diseases.", [["infectious diseases", "DISEASE", 70, 89], ["infectious diseases", "PROBLEM", 70, 89], ["infectious", "OBSERVATION", 70, 80]]], ["Procalcitonin and C-reactive protein were considered to be biomarkers of bacterial infection in LRTI (Katz, Sartoni & Williams, 2019; Schuetz et al., 2017; IIrwin et al., 2017).Introduction\u03b22-MG is a nonglycosylated protein (11.6 kDa), which is found on the surface of almost all nucleated cells (Cunningham et al., 1973; Becker & Reeke, 1985). \u03b22-MG is part of major histocompatibility complex class I that play a pivotal role in the adaptive immune system (Wieczorek et al., 2017).", [["surface", "ANATOMY", 258, 265], ["cells", "ANATOMY", 290, 295], ["bacterial infection", "DISEASE", 73, 92], ["LRTI", "DISEASE", 96, 100], ["Introduction\u03b22-MG", "CHEMICAL", 177, 194], ["\u03b22-MG", "CHEMICAL", 345, 350], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 18, 36], ["surface", "CELLULAR_COMPONENT", 258, 265], ["cells", "CELL", 290, 295], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 345, 350], ["major histocompatibility complex class I", "GENE_OR_GENE_PRODUCT", 362, 402], ["Procalcitonin", "PROTEIN", 0, 13], ["C-reactive protein", "PROTEIN", 18, 36], ["MG", "PROTEIN", 192, 194], ["nonglycosylated protein", "PROTEIN", 200, 223], ["11.6 kDa", "PROTEIN", 225, 233], ["nucleated cells", "CELL_TYPE", 280, 295], ["\u03b22", "PROTEIN", 345, 347], ["MG", "PROTEIN", 348, 350], ["major histocompatibility complex class I", "PROTEIN", 362, 402], ["Procalcitonin", "TEST", 0, 13], ["C-reactive protein", "TEST", 18, 36], ["bacterial infection", "PROBLEM", 73, 92], ["a nonglycosylated protein", "TEST", 198, 223], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["infection", "OBSERVATION", 83, 92], ["nucleated cells", "OBSERVATION", 280, 295]]], ["It was found that cytotoxic T cells were absent in \u03b22-MG deficient mice (Zijlstra et al., 1990).", [["cytotoxic T cells", "ANATOMY", 18, 35], ["cytotoxic T cells", "CELL", 18, 35], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 51, 56], ["mice", "ORGANISM", 67, 71], ["cytotoxic T cells", "CELL_TYPE", 18, 35], ["mice", "SPECIES", 67, 71], ["cytotoxic T cells", "PROBLEM", 18, 35], ["cytotoxic", "OBSERVATION_MODIFIER", 18, 27]]], ["Cytotoxic T cells activation occurs in viral infections (David et al., 2019).", [["Cytotoxic T cells", "ANATOMY", 0, 17], ["viral infections", "DISEASE", 39, 55], ["Cytotoxic T cells", "CELL", 0, 17], ["Cytotoxic T cells", "CELL_TYPE", 0, 17], ["Cytotoxic T cells activation", "PROBLEM", 0, 28], ["viral infections", "PROBLEM", 39, 55], ["viral infections", "OBSERVATION", 39, 55]]], ["It has been found that abnormally high serum \u03b22-microglobulin (\u03b22-MG) levels are associated with several viral infections, such as human immunodeficiency virus, Epstein-Barr virus and cytomegalovirus (Zipeto et al., 2018; Lamelin et al., 1982; Norfolk, Barnard & Child, 1984).IntroductionIs there a better biomarker to identify viral infection in LRTI?", [["serum", "ANATOMY", 39, 44], ["\u03b22-MG", "CHEMICAL", 63, 68], ["viral infections", "DISEASE", 105, 121], ["human immunodeficiency virus", "DISEASE", 131, 159], ["Epstein-Barr virus and cytomegalovirus", "DISEASE", 161, 199], ["viral infection", "DISEASE", 328, 343], ["LRTI", "DISEASE", 347, 351], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 45, 61], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 63, 68], ["human immunodeficiency virus", "ORGANISM", 131, 159], ["Epstein-Barr virus", "ORGANISM", 161, 179], ["cytomegalovirus", "ORGANISM", 184, 199], ["human immunodeficiency virus", "SPECIES", 131, 159], ["Barr virus", "SPECIES", 169, 179], ["human immunodeficiency virus", "SPECIES", 131, 159], ["Epstein-Barr virus", "SPECIES", 161, 179], ["abnormally high serum \u03b22", "PROBLEM", 23, 47], ["microglobulin", "TEST", 48, 61], ["MG) levels", "TEST", 66, 76], ["several viral infections", "PROBLEM", 97, 121], ["human immunodeficiency virus", "PROBLEM", 131, 159], ["Epstein-Barr virus", "PROBLEM", 161, 179], ["cytomegalovirus", "PROBLEM", 184, 199], ["viral infection in LRTI", "PROBLEM", 328, 351], ["abnormally", "OBSERVATION_MODIFIER", 23, 33], ["high", "OBSERVATION_MODIFIER", 34, 38], ["associated with", "UNCERTAINTY", 81, 96], ["several", "OBSERVATION_MODIFIER", 97, 104], ["viral infections", "OBSERVATION", 105, 121], ["Barr virus", "OBSERVATION", 169, 179], ["viral", "OBSERVATION_MODIFIER", 328, 333], ["infection", "OBSERVATION", 334, 343], ["LRTI", "OBSERVATION", 347, 351]]], ["We retrospectively studied the serum levels of \u03b22-MG in patients with LRTI caused by respiratory syncytial virus, influenza A virus, influenza B virus M. pneumonia and Streptococcus pneumonia.", [["serum", "ANATOMY", 31, 36], ["\u03b22-MG", "CHEMICAL", 47, 52], ["LRTI", "DISEASE", 70, 74], ["respiratory syncytial virus", "DISEASE", 85, 112], ["influenza A virus", "DISEASE", 114, 131], ["influenza B", "DISEASE", 133, 144], ["M. pneumonia", "DISEASE", 151, 163], ["Streptococcus pneumonia", "DISEASE", 168, 191], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 47, 52], ["patients", "ORGANISM", 56, 64], ["respiratory syncytial virus", "ORGANISM", 85, 112], ["influenza A virus", "ORGANISM", 114, 131], ["influenza B virus", "ORGANISM", 133, 150], ["M. pneumonia", "ORGANISM", 151, 163], ["Streptococcus pneumonia", "ORGANISM", 168, 191], ["patients", "SPECIES", 56, 64], ["respiratory syncytial virus", "SPECIES", 85, 112], ["influenza A virus", "SPECIES", 114, 131], ["influenza B virus", "SPECIES", 133, 150], ["M. pneumonia", "SPECIES", 151, 163], ["Streptococcus pneumonia", "SPECIES", 168, 191], ["respiratory syncytial virus", "SPECIES", 85, 112], ["influenza A virus", "SPECIES", 114, 131], ["M. pneumonia", "SPECIES", 151, 163], ["the serum levels", "TEST", 27, 43], ["LRTI", "PROBLEM", 70, 74], ["respiratory syncytial virus", "PROBLEM", 85, 112], ["influenza A virus", "PROBLEM", 114, 131], ["influenza B virus M. pneumonia", "PROBLEM", 133, 163], ["Streptococcus pneumonia", "PROBLEM", 168, 191], ["respiratory", "ANATOMY", 85, 96], ["syncytial virus", "OBSERVATION", 97, 112], ["pneumonia", "OBSERVATION", 154, 163], ["Streptococcus", "OBSERVATION_MODIFIER", 168, 181], ["pneumonia", "OBSERVATION", 182, 191]]], ["In this study, the distribution difference of \u03b22-MG in viral infection and bacterial infection was analyzed.", [["\u03b22-MG", "CHEMICAL", 46, 51], ["viral infection", "DISEASE", 55, 70], ["bacterial infection", "DISEASE", 75, 94], ["\u03b22-MG", "SIMPLE_CHEMICAL", 46, 51], ["viral", "ORGANISM", 55, 60], ["\u03b22", "PROTEIN", 46, 48], ["this study", "TEST", 3, 13], ["\u03b22", "TREATMENT", 46, 48], ["viral infection", "PROBLEM", 55, 70], ["bacterial infection", "PROBLEM", 75, 94], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 61, 70], ["bacterial", "OBSERVATION_MODIFIER", 75, 84], ["infection", "OBSERVATION", 85, 94]]], ["We discussed the theoretical basis of \u03b22-MG in distinguishing viral infection from bacterial infection.", [["\u03b22-MG", "CHEMICAL", 38, 43], ["viral infection", "DISEASE", 62, 77], ["bacterial infection", "DISEASE", 83, 102], ["\u03b22-MG", "SIMPLE_CHEMICAL", 38, 43], ["viral infection", "PROBLEM", 62, 77], ["bacterial infection", "PROBLEM", 83, 102], ["viral infection", "OBSERVATION", 62, 77], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["infection", "OBSERVATION", 93, 102]]], ["It was expected that the detection of \u03b22-MG may provide help for the management of respiratory tract infection diseases, and antibiotic management.Study design and participants ::: MethodsWe reviewed the electronic medical records of all hospitalized children with a single pathogen of LRTI from Yancheng Third People\u2019s Hospital, Yancheng, China, between January 1, 2016 and December 31, 2019.", [["respiratory tract", "ANATOMY", 83, 100], ["\u03b22-MG", "CHEMICAL", 38, 43], ["respiratory tract infection", "DISEASE", 83, 110], ["LRTI", "DISEASE", 286, 290], ["\u03b22-MG", "SIMPLE_CHEMICAL", 38, 43], ["tract", "ORGANISM_SUBDIVISION", 95, 100], ["children", "ORGANISM", 251, 259], ["participants", "SPECIES", 164, 176], ["children", "SPECIES", 251, 259], ["the detection", "TEST", 21, 34], ["\u03b22-MG", "TREATMENT", 38, 43], ["the management", "TREATMENT", 65, 79], ["respiratory tract infection diseases", "PROBLEM", 83, 119], ["antibiotic management", "TREATMENT", 125, 146], ["respiratory tract", "ANATOMY", 83, 100], ["infection", "OBSERVATION", 101, 110]]], ["The LRTI in this study consisted of acute bronchitis and community-acquired pneumonia.", [["LRTI", "DISEASE", 4, 8], ["bronchitis", "DISEASE", 42, 52], ["pneumonia", "DISEASE", 76, 85], ["The LRTI", "TEST", 0, 8], ["this study", "TEST", 12, 22], ["acute bronchitis", "PROBLEM", 36, 52], ["community-acquired pneumonia", "PROBLEM", 57, 85], ["LRTI", "OBSERVATION", 4, 8], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["bronchitis", "OBSERVATION", 42, 52], ["pneumonia", "OBSERVATION", 76, 85]]], ["The diagnosis of LRTI is based on the following criteria: diagnosis of acute bronchitis according to persistent cough less than 3 weeks and lack of radiologically visible infiltrates in lungs or other underlying lung disease.", [["lungs", "ANATOMY", 186, 191], ["lung", "ANATOMY", 212, 216], ["LRTI", "DISEASE", 17, 21], ["bronchitis", "DISEASE", 77, 87], ["cough", "DISEASE", 112, 117], ["lung disease", "DISEASE", 212, 224], ["lungs", "ORGAN", 186, 191], ["lung", "ORGAN", 212, 216], ["LRTI", "PROBLEM", 17, 21], ["acute bronchitis", "PROBLEM", 71, 87], ["persistent cough", "PROBLEM", 101, 117], ["radiologically visible infiltrates in lungs", "PROBLEM", 148, 191], ["other underlying lung disease", "PROBLEM", 195, 224], ["LRTI", "OBSERVATION", 17, 21], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["bronchitis", "OBSERVATION", 77, 87], ["persistent", "OBSERVATION_MODIFIER", 101, 111], ["cough", "OBSERVATION", 112, 117], ["visible", "OBSERVATION_MODIFIER", 163, 170], ["infiltrates", "OBSERVATION", 171, 182], ["lungs", "ANATOMY", 186, 191], ["lung", "ANATOMY", 212, 216], ["disease", "OBSERVATION", 217, 224]]], ["Diagnosis of community-acquired pneumonia according to fever, lung radiologically visible infiltrates, cough, sputum production, shortness of breath, abnormal breath sounds and rales in auscultation of lung.", [["lung", "ANATOMY", 62, 66], ["sputum", "ANATOMY", 110, 116], ["lung", "ANATOMY", 202, 206], ["pneumonia", "DISEASE", 32, 41], ["fever", "DISEASE", 55, 60], ["cough", "DISEASE", 103, 108], ["shortness of breath", "DISEASE", 129, 148], ["abnormal breath sounds", "DISEASE", 150, 172], ["lung", "ORGAN", 62, 66], ["lung", "ORGAN", 202, 206], ["community-acquired pneumonia", "PROBLEM", 13, 41], ["fever", "PROBLEM", 55, 60], ["lung radiologically visible infiltrates", "PROBLEM", 62, 101], ["cough", "PROBLEM", 103, 108], ["sputum production", "PROBLEM", 110, 127], ["shortness of breath", "PROBLEM", 129, 148], ["abnormal breath sounds", "PROBLEM", 150, 172], ["rales in auscultation of lung", "PROBLEM", 177, 206], ["pneumonia", "OBSERVATION", 32, 41], ["lung", "ANATOMY", 62, 66], ["radiologically", "OBSERVATION_MODIFIER", 67, 81], ["visible", "OBSERVATION_MODIFIER", 82, 89], ["infiltrates", "OBSERVATION", 90, 101], ["cough", "OBSERVATION", 103, 108], ["abnormal", "OBSERVATION_MODIFIER", 150, 158], ["breath sounds", "OBSERVATION", 159, 172], ["rales", "OBSERVATION", 177, 182], ["lung", "ANATOMY", 202, 206]]], ["Pathogens include respiratory syncytial virus, influenza A virus, influenza B virus, M. pneumonia and Streptococcus pneumonia.", [["respiratory syncytial virus", "DISEASE", 18, 45], ["influenza A virus", "DISEASE", 47, 64], ["influenza B", "DISEASE", 66, 77], ["M. pneumonia", "DISEASE", 85, 97], ["Streptococcus pneumonia", "DISEASE", 102, 125], ["respiratory syncytial virus", "ORGANISM", 18, 45], ["influenza A virus", "ORGANISM", 47, 64], ["influenza B virus", "ORGANISM", 66, 83], ["M. pneumonia", "ORGANISM", 85, 97], ["Streptococcus pneumonia", "ORGANISM", 102, 125], ["respiratory syncytial virus", "SPECIES", 18, 45], ["influenza A virus", "SPECIES", 47, 64], ["influenza B virus", "SPECIES", 66, 83], ["M. pneumonia", "SPECIES", 85, 97], ["Streptococcus pneumonia", "SPECIES", 102, 125], ["respiratory syncytial virus", "SPECIES", 18, 45], ["influenza A virus", "SPECIES", 47, 64], ["influenza B virus", "SPECIES", 66, 83], ["M. pneumonia", "SPECIES", 85, 97], ["Pathogens", "PROBLEM", 0, 9], ["respiratory syncytial virus", "PROBLEM", 18, 45], ["influenza A virus", "PROBLEM", 47, 64], ["influenza B virus", "PROBLEM", 66, 83], ["M. pneumonia", "PROBLEM", 85, 97], ["Streptococcus pneumonia", "PROBLEM", 102, 125], ["respiratory syncytial virus", "OBSERVATION", 18, 45], ["pneumonia", "OBSERVATION", 88, 97], ["Streptococcus", "OBSERVATION_MODIFIER", 102, 115], ["pneumonia", "OBSERVATION", 116, 125]]], ["Blood samples, sputum samples and nasopharynx swabs were collected and sent to the laboratory for pathogen detection within 24 h after admission.Study design and participants ::: MethodsInclusion criteria: (1) Children suffered from LRTI.", [["Blood samples", "ANATOMY", 0, 13], ["sputum samples", "ANATOMY", 15, 29], ["nasopharynx swabs", "ANATOMY", 34, 51], ["LRTI", "DISEASE", 233, 237], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["sputum samples", "ORGANISM_SUBSTANCE", 15, 29], ["nasopharynx swabs", "ORGANISM_SUBSTANCE", 34, 51], ["Children", "ORGANISM", 210, 218], ["participants", "SPECIES", 162, 174], ["Children", "SPECIES", 210, 218], ["Blood samples", "TEST", 0, 13], ["sputum samples", "TEST", 15, 29], ["nasopharynx swabs", "TEST", 34, 51], ["pathogen detection", "TEST", 98, 116], ["LRTI", "PROBLEM", 233, 237], ["nasopharynx", "ANATOMY", 34, 45], ["LRTI", "OBSERVATION", 233, 237]]], ["(2) There was only one pathogen causing LRTI.", [["LRTI", "DISEASE", 40, 44], ["LRTI", "PROBLEM", 40, 44], ["pathogen", "OBSERVATION", 23, 31], ["LRTI", "OBSERVATION", 40, 44]]], ["(3) Pathogens included M. pneumoniae, respiratory syncytial virus, influenza A virus, influenza B virus, Streptococcus pneumoniae.", [["respiratory syncytial virus", "DISEASE", 38, 65], ["influenza A virus", "DISEASE", 67, 84], ["influenza B", "DISEASE", 86, 97], ["Streptococcus pneumoniae", "DISEASE", 105, 129], ["M. pneumoniae", "ORGANISM", 23, 36], ["respiratory syncytial virus", "ORGANISM", 38, 65], ["influenza A virus", "ORGANISM", 67, 84], ["influenza B virus", "ORGANISM", 86, 103], ["Streptococcus pneumoniae", "ORGANISM", 105, 129], ["M. pneumoniae", "SPECIES", 23, 36], ["respiratory syncytial virus", "SPECIES", 38, 65], ["influenza A virus", "SPECIES", 67, 84], ["influenza B virus", "SPECIES", 86, 103], ["Streptococcus pneumoniae", "SPECIES", 105, 129], ["M. pneumoniae", "SPECIES", 23, 36], ["respiratory syncytial virus", "SPECIES", 38, 65], ["influenza A virus", "SPECIES", 67, 84], ["influenza B virus", "SPECIES", 86, 103], ["Streptococcus pneumoniae", "SPECIES", 105, 129], ["Pathogens", "PROBLEM", 4, 13], ["M. pneumoniae", "PROBLEM", 23, 36], ["respiratory syncytial virus", "PROBLEM", 38, 65], ["influenza A virus", "PROBLEM", 67, 84], ["influenza B virus", "PROBLEM", 86, 103], ["Streptococcus pneumoniae", "PROBLEM", 105, 129], ["respiratory", "ANATOMY", 38, 49], ["syncytial virus", "OBSERVATION", 50, 65], ["Streptococcus pneumoniae", "OBSERVATION", 105, 129]]], ["(4) \u03b22-MG is often used as an index to evaluate renal function (Wong et al., 2016).", [["renal", "ANATOMY", 48, 53], ["\u03b22-MG", "CHEMICAL", 4, 9], ["\u03b22-MG", "SIMPLE_CHEMICAL", 4, 9], ["renal", "ORGAN", 48, 53], ["an index", "TEST", 27, 35], ["renal", "ANATOMY", 48, 53]]], ["The renal function of earlier infants is immature until the age of 8\u201312 months is close to that of adults (Kearns et al., 2003).", [["renal", "ANATOMY", 4, 9], ["renal", "ORGAN", 4, 9], ["infants", "ORGANISM", 30, 37], ["infants", "SPECIES", 30, 37], ["renal", "ANATOMY", 4, 9]]], ["Therefore, children were included in this study between 1 and 5 years old.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19]]], ["The age of the child was based on the date of birth and the date of hospitalization.", [["child", "ORGANISM", 15, 20]]], ["(5) Serum \u03b22-MG had been detected in the acute stage of LRTI.Study design and participants ::: MethodsExclusion criteria: (1) Children had primary immunodeficiency disease or kidney disease.", [["Serum", "ANATOMY", 4, 9], ["kidney", "ANATOMY", 175, 181], ["LRTI", "DISEASE", 56, 60], ["primary immunodeficiency disease", "DISEASE", 139, 171], ["kidney disease", "DISEASE", 175, 189], ["Serum", "ORGANISM_SUBSTANCE", 4, 9], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 10, 15], ["Children", "ORGANISM", 126, 134], ["kidney", "ORGAN", 175, 181], ["\u03b22", "PROTEIN", 10, 12], ["participants", "SPECIES", 78, 90], ["Children", "SPECIES", 126, 134], ["Serum \u03b22", "TEST", 4, 12], ["LRTI", "PROBLEM", 56, 60], ["primary immunodeficiency disease", "PROBLEM", 139, 171], ["kidney disease", "PROBLEM", 175, 189], ["acute stage", "OBSERVATION_MODIFIER", 41, 52], ["LRTI", "OBSERVATION", 56, 60], ["immunodeficiency disease", "OBSERVATION", 147, 171], ["kidney", "ANATOMY", 175, 181], ["disease", "OBSERVATION", 182, 189]]], ["(2) Immunodepressant was used in the last 2 weeks.Study design and participants ::: MethodsThis study was approved by the ethics committee of the Yancheng Third People\u2019s Hospital (Approval Number: 2019100).", [["participants", "SPECIES", 67, 79], ["Immunodepressant", "TREATMENT", 4, 20], ["Methods", "TREATMENT", 84, 91], ["This study", "TEST", 91, 101]]], ["Individual informed consent was waived by the ethics committee of the Yancheng Third People\u2019s Hospital because the study was considered to pose the least risk to participants.Pathogen detection ::: MethodsViral infection: The diagnosis of respiratory syncytial virus, influenza A virus and influenza B virus infection were based on antigen detection or PCR nucleic acid detection of nasopharynx swab samples.", [["nasopharynx swab samples", "ANATOMY", 383, 407], ["MethodsViral infection", "DISEASE", 198, 220], ["respiratory syncytial virus", "DISEASE", 239, 266], ["influenza A virus", "DISEASE", 268, 285], ["influenza B virus infection", "DISEASE", 290, 317], ["nucleic acid", "CHEMICAL", 357, 369], ["respiratory syncytial virus", "ORGANISM", 239, 266], ["influenza A virus", "ORGANISM", 268, 285], ["influenza B virus", "ORGANISM", 290, 307], ["nasopharynx swab samples", "CANCER", 383, 407], ["participants", "SPECIES", 162, 174], ["influenza A virus", "SPECIES", 268, 285], ["influenza B virus", "SPECIES", 290, 307], ["respiratory syncytial virus", "SPECIES", 239, 266], ["influenza A virus", "SPECIES", 268, 285], ["influenza B virus", "SPECIES", 290, 307], ["the study", "TEST", 111, 120], ["Pathogen detection", "TEST", 175, 193], ["MethodsViral infection", "PROBLEM", 198, 220], ["respiratory syncytial virus", "PROBLEM", 239, 266], ["influenza A virus", "PROBLEM", 268, 285], ["influenza B virus infection", "PROBLEM", 290, 317], ["antigen detection", "TEST", 332, 349], ["PCR nucleic acid detection", "TEST", 353, 379], ["nasopharynx swab samples", "TEST", 383, 407], ["infection", "OBSERVATION", 211, 220], ["respiratory", "ANATOMY", 239, 250], ["syncytial virus", "OBSERVATION", 251, 266], ["nasopharynx", "ANATOMY", 383, 394]]], ["M. pneumoniae infection: During hospitalization, the serum immunoglobulin M antibody of M. pneumoniae changed from negative to positive.", [["serum", "ANATOMY", 53, 58], ["M. pneumoniae infection", "DISEASE", 0, 23], ["M. pneumoniae", "ORGANISM", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 59, 73], ["M. pneumoniae", "ORGANISM", 88, 101], ["serum immunoglobulin M antibody", "PROTEIN", 53, 84], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "SPECIES", 88, 101], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "SPECIES", 88, 101], ["M. pneumoniae infection", "PROBLEM", 0, 23], ["the serum immunoglobulin M antibody", "TEST", 49, 84], ["M. pneumoniae", "PROBLEM", 88, 101], ["pneumoniae", "OBSERVATION_MODIFIER", 3, 13], ["infection", "OBSERVATION", 14, 23]]], ["Streptococcus pneumoniae infection: Sputum cultures or blood cultures were positive.Statistical analysis ::: MethodsCategorical variables were described by frequencies and percentage.", [["Sputum cultures", "ANATOMY", 36, 51], ["blood cultures", "ANATOMY", 55, 69], ["Streptococcus pneumoniae infection", "DISEASE", 0, 34], ["Streptococcus pneumoniae", "ORGANISM", 0, 24], ["Sputum cultures", "CELL", 36, 51], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae infection", "PROBLEM", 0, 34], ["Sputum cultures", "TEST", 36, 51], ["blood cultures", "TEST", 55, 69], ["MethodsCategorical variables", "PROBLEM", 109, 137], ["pneumoniae", "OBSERVATION_MODIFIER", 14, 24], ["infection", "OBSERVATION", 25, 34]]], ["Continuous variables features were expressed by mean \u00b1 standard deviation or interquartile ranges.", [["mean \u00b1 standard deviation or interquartile ranges", "PROBLEM", 48, 97]]], ["The difference between the two groups of continuous variables is analyzed by student\u2019s t-test. \u03c72-test was used to compare the difference of count data in different groups.", [["\u03c72", "DNA", 95, 97], ["student\u2019s t-test", "TEST", 77, 93], ["\u03c72-test", "TEST", 95, 102], ["count data", "TEST", 141, 151], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Due to the different age distribution of different diseases, subgroup analysis of \u03b22-MG was carried out according to age.", [["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 82, 87], ["\u03b22", "PROTEIN", 82, 84], ["different diseases", "PROBLEM", 41, 59], ["subgroup analysis", "TEST", 61, 78], ["\u03b22-MG", "TREATMENT", 82, 87], ["different diseases", "OBSERVATION", 41, 59]]], ["All analysis were performed through SPSS 24 software.General characteristics of patients ::: ResultsWe collected 475 children with LRTI caused by single pathogen (Fig. 1).", [["LRTI", "DISEASE", 131, 135], ["patients", "ORGANISM", 80, 88], ["children", "ORGANISM", 117, 125], ["patients", "SPECIES", 80, 88], ["children", "SPECIES", 117, 125], ["All analysis", "TEST", 0, 12], ["LRTI", "PROBLEM", 131, 135]]], ["There were 155 cases of respiratory syncytial virus infection, 142 cases of influenza A virus infection, 67 cases of influenza B virus infection, 97 cases of M. pneumoniae infection and 14 cases of Streptococcus pneumonia infection.", [["respiratory syncytial virus infection", "DISEASE", 24, 61], ["influenza A virus infection", "DISEASE", 76, 103], ["influenza B virus infection", "DISEASE", 117, 144], ["M. pneumoniae infection", "DISEASE", 158, 181], ["Streptococcus pneumonia infection", "DISEASE", 198, 231], ["respiratory syncytial virus", "ORGANISM", 24, 51], ["influenza A virus", "ORGANISM", 76, 93], ["influenza B virus", "ORGANISM", 117, 134], ["M. pneumoniae", "ORGANISM", 158, 171], ["Streptococcus pneumonia", "ORGANISM", 198, 221], ["influenza A virus", "SPECIES", 76, 93], ["influenza B virus", "SPECIES", 117, 134], ["M. pneumoniae", "SPECIES", 158, 171], ["Streptococcus pneumonia", "SPECIES", 198, 221], ["respiratory syncytial virus", "SPECIES", 24, 51], ["influenza A virus", "SPECIES", 76, 93], ["influenza B virus", "SPECIES", 117, 134], ["M. pneumoniae", "SPECIES", 158, 171], ["respiratory syncytial virus infection", "PROBLEM", 24, 61], ["influenza A virus infection", "PROBLEM", 76, 103], ["influenza B virus infection", "PROBLEM", 117, 144], ["M. pneumoniae infection", "PROBLEM", 158, 181], ["Streptococcus pneumonia infection", "PROBLEM", 198, 231], ["respiratory syncytial virus", "OBSERVATION", 24, 51], ["pneumoniae", "OBSERVATION_MODIFIER", 161, 171], ["infection", "OBSERVATION", 172, 181], ["Streptococcus", "OBSERVATION_MODIFIER", 198, 211], ["pneumonia", "OBSERVATION", 212, 221]]], ["The epidemiological and clinical characteristics of patients were shown in Table 1.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["Blood urea nitrogen and serum creatinine were in normal range in all cases.", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 24, 29], ["urea nitrogen", "CHEMICAL", 6, 19], ["creatinine", "CHEMICAL", 30, 40], ["urea", "CHEMICAL", 6, 10], ["nitrogen", "CHEMICAL", 11, 19], ["creatinine", "CHEMICAL", 30, 40], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urea", "SIMPLE_CHEMICAL", 6, 10], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["creatinine", "SIMPLE_CHEMICAL", 30, 40], ["Blood urea nitrogen", "TEST", 0, 19], ["serum creatinine", "TEST", 24, 40], ["normal range", "OBSERVATION", 49, 61]]], ["Age distribution of children infected with different pathogens was analyzed.", [["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28], ["different pathogens", "PROBLEM", 43, 62]]], ["In the younger group (1 year old \u2264 age < 3 years old), it is mainly 78.6% of children affected by respiratory syncytial virus, 52.1% of children affected by influenza A virus and 78.6% of children affected by Streptococcus pneumonia.", [["respiratory syncytial virus", "DISEASE", 98, 125], ["influenza A virus", "DISEASE", 157, 174], ["Streptococcus pneumonia", "DISEASE", 209, 232], ["children", "ORGANISM", 77, 85], ["respiratory syncytial virus", "ORGANISM", 98, 125], ["children", "ORGANISM", 136, 144], ["influenza A virus", "ORGANISM", 157, 174], ["children", "ORGANISM", 188, 196], ["Streptococcus pneumonia", "ORGANISM", 209, 232], ["children", "SPECIES", 77, 85], ["children", "SPECIES", 136, 144], ["influenza A virus", "SPECIES", 157, 174], ["children", "SPECIES", 188, 196], ["respiratory syncytial virus", "SPECIES", 98, 125], ["influenza A virus", "SPECIES", 157, 174], ["respiratory syncytial virus", "PROBLEM", 98, 125], ["influenza A virus", "PROBLEM", 157, 174], ["Streptococcus pneumonia", "PROBLEM", 209, 232], ["respiratory", "ANATOMY", 98, 109], ["syncytial virus", "OBSERVATION", 110, 125], ["Streptococcus", "OBSERVATION_MODIFIER", 209, 222], ["pneumonia", "OBSERVATION", 223, 232]]], ["In the older group (3 years old \u2264 age < 5 years old), it is mainly 80.4% of children affected by M. pneumoniae and 62.7% of children affected by influenza B virus.Characteristics of \u03b22-microglobulin in patients ::: ResultsTable 2 shows the characteristics of \u03b22-MG in different pathogenic groups.", [["M. pneumoniae", "DISEASE", 97, 110], ["influenza B", "DISEASE", 145, 156], ["\u03b22-MG", "CHEMICAL", 259, 264], ["children", "ORGANISM", 76, 84], ["M. pneumoniae", "ORGANISM", 97, 110], ["children", "ORGANISM", 124, 132], ["influenza B virus", "ORGANISM", 145, 162], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 182, 198], ["patients", "ORGANISM", 202, 210], ["\u03b22-MG", "SIMPLE_CHEMICAL", 259, 264], ["\u03b22", "PROTEIN", 182, 184], ["\u03b22", "PROTEIN", 259, 261], ["children", "SPECIES", 76, 84], ["M. pneumoniae", "SPECIES", 97, 110], ["children", "SPECIES", 124, 132], ["influenza B virus", "SPECIES", 145, 162], ["patients", "SPECIES", 202, 210], ["M. pneumoniae", "SPECIES", 97, 110], ["influenza B virus", "SPECIES", 145, 162], ["pneumoniae", "PROBLEM", 100, 110], ["influenza B virus", "PROBLEM", 145, 162], ["\u03b22", "PROBLEM", 259, 261], ["pneumoniae", "OBSERVATION", 100, 110], ["influenza", "OBSERVATION", 145, 154]]], ["In the younger group as well as the older group, the concentration of serum \u03b22-MG in respiratory syncytial virus infection, influenza A virus infection and influenza B virus infection were significantly increased compared to that in M. pneumoniae infection.", [["serum", "ANATOMY", 70, 75], ["\u03b22-MG", "CHEMICAL", 76, 81], ["respiratory syncytial virus infection", "DISEASE", 85, 122], ["influenza A virus infection", "DISEASE", 124, 151], ["influenza B", "DISEASE", 156, 167], ["infection", "DISEASE", 174, 183], ["M. pneumoniae infection", "DISEASE", 233, 256], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 76, 81], ["respiratory syncytial virus", "ORGANISM", 85, 112], ["influenza A virus", "ORGANISM", 124, 141], ["influenza B virus", "ORGANISM", 156, 173], ["M. pneumoniae", "ORGANISM", 233, 246], ["serum \u03b22", "PROTEIN", 70, 78], ["respiratory syncytial virus", "SPECIES", 85, 112], ["influenza A virus", "SPECIES", 124, 141], ["influenza B virus", "SPECIES", 156, 173], ["M. pneumoniae", "SPECIES", 233, 246], ["respiratory syncytial virus", "SPECIES", 85, 112], ["influenza A virus", "SPECIES", 124, 141], ["influenza B virus", "SPECIES", 156, 173], ["M. pneumoniae", "SPECIES", 233, 246], ["serum \u03b22", "TEST", 70, 78], ["respiratory syncytial virus infection", "PROBLEM", 85, 122], ["influenza A virus infection", "PROBLEM", 124, 151], ["influenza B virus infection", "PROBLEM", 156, 183], ["M. pneumoniae infection", "PROBLEM", 233, 256], ["respiratory", "ANATOMY", 85, 96], ["syncytial virus", "OBSERVATION", 97, 112], ["increased", "OBSERVATION_MODIFIER", 203, 212], ["pneumoniae", "OBSERVATION_MODIFIER", 236, 246], ["infection", "OBSERVATION", 247, 256]]], ["There were only three cases of lower respiratory tract infection with Streptococcus pneumoniae in children between 3 and 5 years old, so there was no statistical comparison.", [["lower respiratory tract", "ANATOMY", 31, 54], ["respiratory tract infection", "DISEASE", 37, 64], ["Streptococcus pneumoniae", "DISEASE", 70, 94], ["lower", "ORGANISM_SUBDIVISION", 31, 36], ["respiratory tract", "ORGANISM_SUBDIVISION", 37, 54], ["Streptococcus pneumoniae", "ORGANISM", 70, 94], ["children", "ORGANISM", 98, 106], ["Streptococcus pneumoniae", "SPECIES", 70, 94], ["children", "SPECIES", 98, 106], ["Streptococcus pneumoniae", "SPECIES", 70, 94], ["lower respiratory tract infection", "PROBLEM", 31, 64], ["Streptococcus pneumoniae", "PROBLEM", 70, 94], ["lower", "ANATOMY_MODIFIER", 31, 36], ["respiratory tract", "ANATOMY", 37, 54], ["infection", "OBSERVATION", 55, 64], ["Streptococcus pneumoniae", "OBSERVATION", 70, 94]]], ["The concentration of serum \u03b22-microglobulin was 1.67 mg/L, 1.69 mg/L and 1.51 mg/L, respectively.", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 27, 43], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["The \u03b22-MG concentration in viral infection group was compared with that in Streptococcus pneumoniae infection group.", [["\u03b22-MG", "CHEMICAL", 4, 9], ["viral infection", "DISEASE", 27, 42], ["Streptococcus pneumoniae infection", "DISEASE", 75, 109], ["\u03b22-MG", "SIMPLE_CHEMICAL", 4, 9], ["Streptococcus pneumoniae", "ORGANISM", 75, 99], ["\u03b22", "PROTEIN", 4, 6], ["Streptococcus pneumoniae", "SPECIES", 75, 99], ["Streptococcus pneumoniae", "SPECIES", 75, 99], ["The \u03b22-MG concentration", "TREATMENT", 0, 23], ["viral infection group", "PROBLEM", 27, 48], ["Streptococcus pneumoniae infection group", "PROBLEM", 75, 115], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["infection", "OBSERVATION", 33, 42], ["Streptococcus pneumoniae", "OBSERVATION", 75, 99]]], ["The \u03b22-MG concentration was significantly increased in respiratory syncytial virus group, influenza A virus group and influenza B virus group (Table 3).", [["\u03b22-MG", "CHEMICAL", 4, 9], ["respiratory syncytial virus", "DISEASE", 55, 82], ["influenza A virus", "DISEASE", 90, 107], ["influenza B", "DISEASE", 118, 129], ["\u03b22-MG", "SIMPLE_CHEMICAL", 4, 9], ["respiratory syncytial virus", "ORGANISM", 55, 82], ["influenza A virus", "ORGANISM", 90, 107], ["influenza B virus", "ORGANISM", 118, 135], ["\u03b22", "PROTEIN", 4, 6], ["syncytial virus group", "SPECIES", 67, 88], ["influenza A virus group", "SPECIES", 90, 113], ["influenza B virus group", "SPECIES", 118, 141], ["respiratory syncytial virus", "SPECIES", 55, 82], ["influenza A virus", "SPECIES", 90, 107], ["influenza B virus", "SPECIES", 118, 135], ["The \u03b22-MG concentration", "TREATMENT", 0, 23], ["respiratory syncytial virus group", "PROBLEM", 55, 88], ["influenza A virus group", "PROBLEM", 90, 113], ["influenza", "PROBLEM", 118, 127], ["respiratory", "ANATOMY", 55, 66], ["syncytial virus", "OBSERVATION", 67, 82]]], ["The serum \u03b22-MG level was significantly different between the younger group and the older group in the LRTI caused by influenza A virus (Table 4).DiscussionIn our research, children with LRTI caused by respiratory syncytial virus, influenza A virus and influenza B virus had higher levels of serum \u03b22-MG than children with LRTI caused by M. pneumoniae.", [["serum", "ANATOMY", 4, 9], ["serum", "ANATOMY", 292, 297], ["LRTI", "DISEASE", 103, 107], ["influenza A virus", "DISEASE", 118, 135], ["LRTI", "DISEASE", 187, 191], ["respiratory syncytial virus", "DISEASE", 202, 229], ["influenza A virus", "DISEASE", 231, 248], ["influenza B", "DISEASE", 253, 264], ["LRTI", "DISEASE", 323, 327], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 10, 15], ["influenza A virus", "ORGANISM", 118, 135], ["children", "ORGANISM", 173, 181], ["respiratory syncytial virus", "ORGANISM", 202, 229], ["influenza A virus", "ORGANISM", 231, 248], ["influenza B virus", "ORGANISM", 253, 270], ["serum", "ORGANISM_SUBSTANCE", 292, 297], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 298, 303], ["children", "ORGANISM", 309, 317], ["M. pneumoniae", "ORGANISM", 338, 351], ["\u03b22", "PROTEIN", 10, 12], ["influenza A virus", "SPECIES", 118, 135], ["children", "SPECIES", 173, 181], ["respiratory syncytial virus", "SPECIES", 202, 229], ["influenza A virus", "SPECIES", 231, 248], ["influenza B virus", "SPECIES", 253, 270], ["children", "SPECIES", 309, 317], ["M. pneumoniae", "SPECIES", 338, 351], ["influenza A virus", "SPECIES", 118, 135], ["respiratory syncytial virus", "SPECIES", 202, 229], ["influenza A virus", "SPECIES", 231, 248], ["influenza B virus", "SPECIES", 253, 270], ["M. pneumoniae", "SPECIES", 338, 351], ["The serum \u03b22-MG level", "TEST", 0, 21], ["influenza A virus", "PROBLEM", 118, 135], ["LRTI", "PROBLEM", 187, 191], ["respiratory syncytial virus", "PROBLEM", 202, 229], ["influenza A virus", "PROBLEM", 231, 248], ["influenza B virus", "PROBLEM", 253, 270], ["serum \u03b22", "TEST", 292, 300], ["LRTI", "PROBLEM", 323, 327], ["M. pneumoniae", "PROBLEM", 338, 351], ["LRTI", "OBSERVATION", 103, 107], ["influenza", "OBSERVATION", 118, 127], ["respiratory syncytial", "ANATOMY", 202, 223], ["pneumoniae", "OBSERVATION", 341, 351]]], ["The results suggest that serum \u03b22-MG may be helpful to distinguish M. pneumoniae infection from viral infection in LRTI.", [["serum", "ANATOMY", 25, 30], ["\u03b22-MG", "CHEMICAL", 31, 36], ["M. pneumoniae infection", "DISEASE", 67, 90], ["viral infection", "DISEASE", 96, 111], ["LRTI", "DISEASE", 115, 119], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 31, 36], ["M. pneumoniae", "ORGANISM", 67, 80], ["M. pneumoniae", "SPECIES", 67, 80], ["M. pneumoniae", "SPECIES", 67, 80], ["serum \u03b22", "TEST", 25, 33], ["M. pneumoniae infection", "PROBLEM", 67, 90], ["viral infection in LRTI", "PROBLEM", 96, 119], ["pneumoniae", "OBSERVATION", 70, 80], ["viral", "OBSERVATION_MODIFIER", 96, 101], ["infection", "OBSERVATION", 102, 111]]], ["Tamura et al. (2008) found that urine \u03b22-MG increased in children with refractory M. pneumoniae pneumonia. \u03b22-MG freely passes through the glomerular filtration barrier.", [["urine", "ANATOMY", 32, 37], ["glomerular", "ANATOMY", 139, 149], ["\u03b22-MG", "CHEMICAL", 38, 43], ["M. pneumoniae pneumonia", "DISEASE", 82, 105], ["\u03b22-MG", "CHEMICAL", 107, 112], ["urine", "ORGANISM_SUBSTANCE", 32, 37], ["\u03b22-MG", "SIMPLE_CHEMICAL", 38, 43], ["children", "ORGANISM", 57, 65], ["M. pneumoniae", "ORGANISM", 82, 95], ["\u03b22-MG", "SIMPLE_CHEMICAL", 107, 112], ["glomerular filtration barrier", "TISSUE", 139, 168], ["\u03b22", "PROTEIN", 107, 109], ["children", "SPECIES", 57, 65], ["M. pneumoniae", "SPECIES", 82, 95], ["M. pneumoniae", "SPECIES", 82, 95], ["urine", "TEST", 32, 37], ["refractory M. pneumoniae pneumonia", "PROBLEM", 71, 105], ["the glomerular filtration barrier", "TREATMENT", 135, 168], ["refractory", "OBSERVATION_MODIFIER", 71, 81], ["pneumoniae", "OBSERVATION_MODIFIER", 85, 95], ["pneumonia", "OBSERVATION", 96, 105], ["glomerular", "ANATOMY", 139, 149], ["filtration", "OBSERVATION", 150, 160]]], ["Urinary \u03b22-MG increased when serum \u03b22-MG level exceeded renal threshold.", [["Urinary", "ANATOMY", 0, 7], ["serum", "ANATOMY", 29, 34], ["renal", "ANATOMY", 56, 61], ["\u03b22-MG", "CHEMICAL", 35, 40], ["Urinary", "ORGANISM_SUBSTANCE", 0, 7], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 8, 13], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 35, 40], ["renal", "ORGAN", 56, 61], ["Urinary", "TEST", 0, 7], ["serum \u03b22", "TEST", 29, 37], ["MG level", "TEST", 38, 46], ["renal threshold", "TEST", 56, 71], ["renal", "ANATOMY", 56, 61]]], ["It was found that macrophages infected with influenza A virus could temporarily increase the expression of \u03b22-MG (Keskinen et al., 1997).", [["macrophages", "ANATOMY", 18, 29], ["macrophages", "CELL", 18, 29], ["influenza A virus", "ORGANISM", 44, 61], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 107, 112], ["macrophages", "CELL_TYPE", 18, 29], ["\u03b22", "PROTEIN", 107, 109], ["influenza A virus", "SPECIES", 44, 61], ["influenza A virus", "SPECIES", 44, 61], ["macrophages", "PROBLEM", 18, 29], ["influenza A virus", "PROBLEM", 44, 61], ["macrophages", "OBSERVATION", 18, 29]]], ["Our results suggest that the concentration of \u03b22-MG increased significantly in children with viral LRTI.DiscussionWe analyzed virus groups and Streptococcus pneumoniae group between 1 and 3 years old.", [["\u03b22-MG", "CHEMICAL", 46, 51], ["viral LRTI", "DISEASE", 93, 103], ["\u03b22-MG", "SIMPLE_CHEMICAL", 46, 51], ["children", "ORGANISM", 79, 87], ["Streptococcus pneumoniae", "ORGANISM", 143, 167], ["children", "SPECIES", 79, 87], ["Streptococcus pneumoniae group", "SPECIES", 143, 173], ["Streptococcus pneumoniae", "SPECIES", 143, 167], ["the concentration of \u03b22", "TREATMENT", 25, 48], ["viral LRTI", "PROBLEM", 93, 103], ["analyzed virus groups", "PROBLEM", 117, 138], ["Streptococcus pneumoniae", "PROBLEM", 143, 167], ["viral LRTI", "OBSERVATION", 93, 103]]], ["The serum \u03b22-MG level of respiratory syncytial virus group, influenza A virus group and influenza B virus group were higher than that of the Streptococcus pneumoniae group.", [["serum", "ANATOMY", 4, 9], ["\u03b22-MG", "CHEMICAL", 10, 15], ["respiratory syncytial virus", "DISEASE", 25, 52], ["influenza B", "DISEASE", 88, 99], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 10, 15], ["respiratory syncytial virus", "ORGANISM", 25, 52], ["influenza A virus", "ORGANISM", 60, 77], ["influenza B virus", "ORGANISM", 88, 105], ["Streptococcus pneumoniae", "ORGANISM", 141, 165], ["serum \u03b22", "PROTEIN", 4, 12], ["syncytial virus group", "SPECIES", 37, 58], ["influenza A virus group", "SPECIES", 60, 83], ["influenza B virus group", "SPECIES", 88, 111], ["Streptococcus pneumoniae group", "SPECIES", 141, 171], ["respiratory syncytial virus", "SPECIES", 25, 52], ["influenza A virus", "SPECIES", 60, 77], ["influenza B virus", "SPECIES", 88, 105], ["Streptococcus pneumoniae", "SPECIES", 141, 165], ["The serum \u03b22", "TEST", 0, 12], ["respiratory syncytial virus group", "PROBLEM", 25, 58], ["influenza A virus group", "PROBLEM", 60, 83], ["influenza B virus group", "PROBLEM", 88, 111], ["the Streptococcus pneumoniae group", "PROBLEM", 137, 171], ["respiratory syncytial", "ANATOMY", 25, 46], ["Streptococcus pneumoniae", "OBSERVATION", 141, 165]]], ["Previous studies had found that the increased concentration of serum \u03b22-MG was related to human cytomegalovirus, Epstein-Barr virus, hepatitis C virus and hepatitis B virus (Fabbri et al., 2011; Grywalska et al., 2015; Dlouhy et al., 2017; Deveci et al., 2020).", [["serum", "ANATOMY", 63, 68], ["\u03b22-MG", "CHEMICAL", 69, 74], ["hepatitis C", "DISEASE", 133, 144], ["hepatitis B", "DISEASE", 155, 166], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 69, 74], ["human", "ORGANISM", 90, 95], ["cytomegalovirus", "ORGANISM", 96, 111], ["Epstein-Barr virus", "ORGANISM", 113, 131], ["hepatitis C virus", "ORGANISM", 133, 150], ["hepatitis B virus", "ORGANISM", 155, 172], ["human", "SPECIES", 90, 95], ["hepatitis C virus", "SPECIES", 133, 150], ["hepatitis B virus", "SPECIES", 155, 172], ["human cytomegalovirus", "SPECIES", 90, 111], ["Epstein-Barr virus", "SPECIES", 113, 131], ["hepatitis C virus", "SPECIES", 133, 150], ["hepatitis B virus", "SPECIES", 155, 172], ["Previous studies", "TEST", 0, 16], ["the increased concentration of serum \u03b22", "PROBLEM", 32, 71], ["human cytomegalovirus", "PROBLEM", 90, 111], ["Barr virus", "PROBLEM", 121, 131], ["hepatitis C virus", "PROBLEM", 133, 150], ["hepatitis B virus", "PROBLEM", 155, 172], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["concentration", "OBSERVATION_MODIFIER", 46, 59], ["cytomegalovirus", "OBSERVATION", 96, 111], ["Barr virus", "OBSERVATION", 121, 131]]], ["The level of serum \u03b22-MG was increased in patients with human immunodeficiency virus, and its concentration changes reflected the progress of the disease (Chitra, Bakthavatsalam & Palvannan, 2011).", [["serum", "ANATOMY", 13, 18], ["\u03b22-MG", "CHEMICAL", 19, 24], ["human immunodeficiency virus", "DISEASE", 56, 84], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 19, 24], ["patients", "ORGANISM", 42, 50], ["human immunodeficiency virus", "ORGANISM", 56, 84], ["serum \u03b22", "PROTEIN", 13, 21], ["patients", "SPECIES", 42, 50], ["human", "SPECIES", 56, 61], ["immunodeficiency virus", "SPECIES", 62, 84], ["human immunodeficiency virus", "SPECIES", 56, 84], ["serum \u03b22", "TEST", 13, 21], ["human immunodeficiency virus", "PROBLEM", 56, 84], ["its concentration changes", "PROBLEM", 90, 115], ["the disease", "PROBLEM", 142, 153], ["Chitra, Bakthavatsalam & Palvannan", "TREATMENT", 155, 189], ["immunodeficiency virus", "OBSERVATION", 62, 84]]], ["Overall, serum \u03b22-MG may be more specific in the identification of viral infection.DiscussionCorrelation analysis showed that the serum \u03b22-MG level decreased with the increase of gestational age in normal fetuses (Hu et al., 2014).", [["serum", "ANATOMY", 9, 14], ["serum", "ANATOMY", 130, 135], ["fetuses", "ANATOMY", 205, 212], ["\u03b22-MG", "CHEMICAL", 15, 20], ["viral infection", "DISEASE", 67, 82], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 15, 20], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 136, 141], ["fetuses", "ORGAN", 205, 212], ["\u03b22", "PROTEIN", 136, 138], ["serum \u03b22", "TEST", 9, 17], ["viral infection", "PROBLEM", 67, 82], ["Correlation analysis", "TEST", 93, 113], ["the serum \u03b22", "TEST", 126, 138], ["MG level", "TEST", 139, 147], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["infection", "OBSERVATION", 73, 82], ["increase", "OBSERVATION_MODIFIER", 167, 175], ["normal fetuses", "OBSERVATION", 198, 212]]], ["We analyzed the relationship between serum \u03b22-MG level and age in children with LRTI.", [["serum", "ANATOMY", 37, 42], ["LRTI", "DISEASE", 80, 84], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 43, 48], ["children", "ORGANISM", 66, 74], ["\u03b22", "PROTEIN", 43, 45], ["children", "SPECIES", 66, 74], ["LRTI", "PROBLEM", 80, 84], ["LRTI", "OBSERVATION", 80, 84]]], ["We only observed that serum \u03b22-MG level was significantly reduced in older children with LRTI caused by influenza A virus.", [["serum", "ANATOMY", 22, 27], ["LRTI", "DISEASE", 89, 93], ["influenza A virus", "DISEASE", 104, 121], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 28, 33], ["children", "ORGANISM", 75, 83], ["influenza A virus", "ORGANISM", 104, 121], ["children", "SPECIES", 75, 83], ["influenza A virus", "SPECIES", 104, 121], ["influenza A virus", "SPECIES", 104, 121], ["serum \u03b22", "TEST", 22, 30], ["MG level", "TEST", 31, 39], ["LRTI", "PROBLEM", 89, 93], ["influenza A virus", "PROBLEM", 104, 121], ["influenza", "OBSERVATION", 104, 113]]], ["In the case of infection, whether the concentration of serum \u03b22-MG was affected by age needs further study.DiscussionThere are some obvious limitations in our study, and the results may be biased.", [["serum", "ANATOMY", 55, 60], ["infection", "DISEASE", 15, 24], ["\u03b22-MG", "CHEMICAL", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 61, 66], ["serum \u03b22", "PROTEIN", 55, 63], ["infection", "PROBLEM", 15, 24], ["serum \u03b22", "TEST", 55, 63], ["further study", "TEST", 93, 106], ["our study", "TEST", 155, 164], ["infection", "OBSERVATION", 15, 24]]], ["First, this retrospective study collected a small number of samples.", [["samples", "ANATOMY", 60, 67], ["samples", "CANCER", 60, 67], ["this retrospective study", "TEST", 7, 31], ["small", "OBSERVATION_MODIFIER", 44, 49]]], ["Second, although we had screened cases with a single pathogen infection, the limitations of clinical pathogen detection may be combined with other undetected pathogens.", [["pathogen infection", "DISEASE", 53, 71], ["a single pathogen infection", "PROBLEM", 44, 71], ["clinical pathogen detection", "PROBLEM", 92, 119], ["other undetected pathogens", "PROBLEM", 141, 167], ["infection", "OBSERVATION", 62, 71], ["pathogens", "OBSERVATION", 158, 167]]], ["Third, the vast majority of the bacterial cases in this study were of M. pneumoniae, therefore the generalisability of these findings to other bacterial infections is limited.", [["bacterial infections", "DISEASE", 143, 163], ["M. pneumoniae", "ORGANISM", 70, 83], ["M. pneumoniae", "SPECIES", 70, 83], ["M. pneumoniae", "SPECIES", 70, 83], ["the bacterial cases", "PROBLEM", 28, 47], ["this study", "TEST", 51, 61], ["M. pneumoniae", "PROBLEM", 70, 83], ["other bacterial infections", "PROBLEM", 137, 163], ["pneumoniae", "OBSERVATION", 73, 83], ["bacterial", "OBSERVATION_MODIFIER", 143, 152], ["infections", "OBSERVATION", 153, 163]]], ["Fourth, we did not perform any multivariate linear regression models to see if viral/non-viral atiology was an independent predictor of higher \u03b22-MG levels, after including possible confounders such as age, creatinine/urea nitrogen levels, gender, C-reactive protein, white blood cell.", [["white blood cell", "ANATOMY", 268, 284], ["creatinine", "CHEMICAL", 207, 217], ["urea nitrogen", "CHEMICAL", 218, 231], ["creatinine", "CHEMICAL", 207, 217], ["urea", "CHEMICAL", 218, 222], ["nitrogen", "CHEMICAL", 223, 231], ["non-viral", "ORGANISM", 85, 94], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 143, 148], ["creatinine", "SIMPLE_CHEMICAL", 207, 217], ["urea", "SIMPLE_CHEMICAL", 218, 222], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 248, 266], ["white blood cell", "CELL", 268, 284], ["\u03b22", "PROTEIN", 143, 145], ["C-reactive protein", "PROTEIN", 248, 266], ["white blood cell", "CELL_TYPE", 268, 284], ["viral/non-viral atiology", "PROBLEM", 79, 103], ["creatinine", "TEST", 207, 217], ["urea nitrogen levels", "TEST", 218, 238], ["gender", "TEST", 240, 246], ["C-reactive protein", "PROBLEM", 248, 266], ["white blood cell", "TEST", 268, 284], ["reactive protein", "OBSERVATION", 250, 266]]], ["Fifth, we lack analysis of healthy children.ConclusionsIn a retrospective analysis of the children with lower respiratory tract infection, we found that serum \u03b22-MG levels in respiratory syncytial virus, influenza A virus, and influenza B virus groups were higher than M. pneumoniae group and Streptococcus pneumoniae group.", [["lower respiratory tract", "ANATOMY", 104, 127], ["serum", "ANATOMY", 153, 158], ["respiratory tract infection", "DISEASE", 110, 137], ["\u03b22-MG", "CHEMICAL", 159, 164], ["respiratory syncytial virus", "DISEASE", 175, 202], ["influenza A", "DISEASE", 204, 215], ["influenza B", "DISEASE", 227, 238], ["children", "ORGANISM", 35, 43], ["children", "ORGANISM", 90, 98], ["lower", "ORGANISM_SUBDIVISION", 104, 109], ["respiratory tract", "ORGANISM_SUBDIVISION", 110, 127], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 159, 164], ["respiratory syncytial virus", "ORGANISM", 175, 202], ["influenza A virus", "ORGANISM", 204, 221], ["influenza B virus", "ORGANISM", 227, 244], ["M. pneumoniae", "ORGANISM", 269, 282], ["Streptococcus pneumoniae", "ORGANISM", 293, 317], ["children", "SPECIES", 35, 43], ["children", "SPECIES", 90, 98], ["respiratory syncytial virus", "SPECIES", 175, 202], ["influenza A virus", "SPECIES", 204, 221], ["influenza B virus", "SPECIES", 227, 244], ["M. pneumoniae group", "SPECIES", 269, 288], ["Streptococcus pneumoniae group", "SPECIES", 293, 323], ["respiratory syncytial virus", "SPECIES", 175, 202], ["influenza A virus", "SPECIES", 204, 221], ["influenza B virus", "SPECIES", 227, 244], ["M. pneumoniae", "SPECIES", 269, 282], ["Streptococcus pneumoniae", "SPECIES", 293, 317], ["a retrospective analysis", "TEST", 58, 82], ["lower respiratory tract infection", "PROBLEM", 104, 137], ["serum \u03b22", "TEST", 153, 161], ["MG levels", "TEST", 162, 171], ["respiratory syncytial virus", "PROBLEM", 175, 202], ["influenza A virus", "PROBLEM", 204, 221], ["influenza B virus groups", "PROBLEM", 227, 251], ["Streptococcus pneumoniae group", "PROBLEM", 293, 323], ["respiratory tract", "ANATOMY", 110, 127], ["infection", "OBSERVATION", 128, 137], ["respiratory syncytial", "ANATOMY", 175, 196], ["Streptococcus pneumoniae", "OBSERVATION", 293, 317]]], ["Hence we infer that serum \u03b22-MG may play an important role in the prediction of viral LRTI in children.", [["serum", "ANATOMY", 20, 25], ["\u03b22-MG", "CHEMICAL", 26, 31], ["LRTI", "DISEASE", 86, 90], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 26, 31], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102]]], ["It may provide a basis for avoiding antibiotic abuse.", [["antibiotic abuse", "TREATMENT", 36, 52]]], ["The molecular biological mechanism of \u03b22-MG needs further verification and exploration.", [["\u03b22-MG", "CHEMICAL", 38, 43], ["\u03b22-MG", "GENE_OR_GENE_PRODUCT", 38, 43], ["\u03b22", "PROTEIN", 38, 40], ["further verification", "TEST", 50, 70], ["exploration", "TEST", 75, 86]]]], "PMC7126582": [["IntroductionRecently, graphical techniques have emerged as a powerful tool for the visualization and analysis of complicated biological systems.", [["the visualization", "TEST", 79, 96], ["complicated biological systems", "PROBLEM", 113, 143]]], ["These methods can provide an intuitive picture and help people gain useful insights.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["For instance, various graphic schemes have been successfully used to study enzyme-catalyzed system (King and Altman, 1956; Chou et al., 1979; Chou, 1980; Chou and Forsen, 1980, Chou and Forsen, 1981; Chou and Liu, 1981; Cornish-Bowden, 1979; Myers and Palmer, 1985; Zhou and Deng, 1984; Chou, 1989, Chou, 1990; Lin and Neet, 1990; Kuzmic et al., 1992; Andraos, 2008), protein folding kinetics (Chou, 1990, Chou, 1993), condon usage (Chou and Zhang, 1992; Zhang and Chou, 1994), HIV reverse transcriptase inhibition mechanisms (see Althaus et al., 1993a, Althaus et al., 1993b, Althaus et al., 1993c, as well as a review article, Chou et al., 1994), and base frequency distribution in the anti-sense strands (Chou et al., 1996).", [["reverse transcriptase", "PROTEIN", 482, 503], ["Andraos", "TEST", 352, 359]]], ["Recently, the images of cellular automata were also used to represent biological sequences (Xiao et al., 2005a, Xiao et al., 2005b), predict protein subcellular location (Xiao et al., 2006a, Xiao et al., 2006b), investigate HBV virus gene missense mutation (Xiao et al., 2005a, Xiao et al., 2005b) and HBV viral infections (Xiao et al., 2006a, Xiao et al., 2006b), predicting protein structural classes (Xiao et al., 2008) and G-protein-coupled receptor functional classes (Xiao et al., 2009), as well as analyze the fingerprint of SARS coronavirus (Wang et al., 2005; Gao et al., 2006).", [["cellular", "ANATOMY", 24, 32], ["subcellular", "ANATOMY", 149, 160], ["viral infections", "DISEASE", 306, 322], ["SARS coronavirus", "DISEASE", 532, 548], ["cellular", "CELL", 24, 32], ["HBV virus", "ORGANISM", 224, 233], ["HBV", "ORGANISM", 302, 305], ["G-protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 427, 453], ["SARS coronavirus", "ORGANISM", 532, 548], ["G-protein-coupled receptor", "PROTEIN", 427, 453], ["HBV virus", "SPECIES", 224, 233], ["HBV", "SPECIES", 302, 305], ["SARS coronavirus", "SPECIES", 532, 548], ["the images of cellular automata", "TEST", 10, 41], ["HBV virus gene missense mutation", "PROBLEM", 224, 256], ["HBV viral infections", "PROBLEM", 302, 322], ["Xiao et al.", "TEST", 344, 355], ["predicting protein structural classes", "PROBLEM", 365, 402], ["Xiao et al.", "TEST", 404, 415], ["G", "TEST", 427, 428], ["protein", "TEST", 429, 436], ["SARS coronavirus", "PROBLEM", 532, 548], ["cellular automata", "OBSERVATION", 24, 41]]], ["Graphic approaches have been also used recently to examine the similarities/dissimilarities among the coding sequences of different species (Qi et al., 2007; Qi and Qi, 2007, Qi and Qi, 2009; Qi and Fan, 2007; Yao et al., 2006), analyze the network structure of the amino acid metabolism (Shikata et al., 2007), and study cellular signaling networks (Diao et al., 2007).IntroductionAnother useful graphic method, radar chart, has been used to illustrate differences in amino acid compositions to predict protein subcellular localization (Chou and Elrod, 1999).", [["cellular", "ANATOMY", 322, 330], ["subcellular", "ANATOMY", 512, 523], ["amino acid", "CHEMICAL", 266, 276], ["amino acid", "CHEMICAL", 469, 479], ["amino acid", "CHEMICAL", 266, 276], ["amino acid", "CHEMICAL", 469, 479], ["amino acid", "AMINO_ACID", 266, 276], ["cellular", "CELL", 322, 330], ["amino acid", "AMINO_ACID", 469, 479], ["the amino acid metabolism", "PROBLEM", 262, 287], ["amino acid compositions", "TREATMENT", 469, 492]]], ["In Sorimachi and Okayasu (2004), 23 eubacteria was classified (11 Gram-positive and 12 Gram-negative eubacteria) into two groups, \u201cS-Type\u201d represented by Staphylococcus aureus and \u201cE-Type\u201d represented by Escherichia coli, based on their patterns of amino acid compositions by radar charts determined from the complete genome.", [["Staphylococcus aureus", "DISEASE", 154, 175], ["amino acid", "CHEMICAL", 249, 259], ["amino acid", "CHEMICAL", 249, 259], ["Gram-", "GENE_OR_GENE_PRODUCT", 66, 71], ["Gram", "GENE_OR_GENE_PRODUCT", 87, 91], ["Staphylococcus aureus", "ORGANISM", 154, 175], ["Escherichia coli", "ORGANISM", 204, 220], ["amino acid", "AMINO_ACID", 249, 259], ["Staphylococcus aureus", "SPECIES", 154, 175], ["Escherichia coli", "SPECIES", 204, 220], ["Staphylococcus aureus", "SPECIES", 154, 175], ["Escherichia coli", "SPECIES", 204, 220], ["Gram", "TEST", 87, 91], ["Type\u201d", "PROBLEM", 133, 138], ["Staphylococcus aureus", "PROBLEM", 154, 175], ["Type\u201d", "PROBLEM", 183, 188], ["Escherichia coli", "PROBLEM", 204, 220], ["amino acid compositions", "TREATMENT", 249, 272], ["radar charts", "TEST", 276, 288], ["Staphylococcus aureus", "OBSERVATION", 154, 175], ["Escherichia coli", "OBSERVATION", 204, 220]]], ["The study shows that amino acid compositions are useful values to investigate genomic structures and biological evolution.IntroductionIn this paper, we introduce a new approach to investigate the 23 eubacteria studied by Sorimachi and Okayasu (2004).", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["The study", "TEST", 0, 9], ["amino acid compositions", "TREATMENT", 21, 44], ["a new approach", "TREATMENT", 162, 176]]], ["The method consists of two parts: (i) PN-curve, a 3D graphical representation of DNA sequences presented in our earlier study (Qi and Fan, 2007) and (ii) principal components analysis (PCA), a projection method to analyze data set and reduce it from high dimensional space.", [["DNA", "CELLULAR_COMPONENT", 81, 84], ["DNA sequences", "DNA", 81, 94], ["DNA sequences", "TEST", 81, 94], ["our earlier study", "TEST", 108, 125], ["a projection method", "TREATMENT", 191, 210], ["high dimensional", "OBSERVATION_MODIFIER", 250, 266]]], ["Here, we firstly obtain a 16-dimension vector set of dual nucleotides by PN-curve from the complete genome of organism.", [["nucleotides", "CHEMICAL", 58, 69], ["dual nucleotides", "TREATMENT", 53, 69]]], ["Each vector of the set corresponds to a single gene of genome.", [["genome", "OBSERVATION", 55, 61]]], ["Then the 16-dimension vector set is reduced to 2-dimension by PCA.", [["16-dimension vector set", "DNA", 9, 32], ["the 16-dimension vector set", "TREATMENT", 5, 32], ["reduced", "OBSERVATION_MODIFIER", 36, 43], ["PCA", "ANATOMY", 62, 65]]], ["The 2D graphical representation based on the 2-dimension vector set is proposed to investigate the classification patters among different organisms.PN-curve and its applications ::: MethodsPN-curve is a 3D graphical representation of DNA sequences presented in our earlier study (Qi and Fan, 2007).", [["DNA", "CELLULAR_COMPONENT", 234, 237], ["DNA sequences", "DNA", 234, 247], ["The 2D graphical representation", "TEST", 0, 31], ["the 2-dimension vector set", "TREATMENT", 41, 67], ["PN", "TREATMENT", 148, 150], ["DNA sequences", "TEST", 234, 247], ["our earlier study", "TEST", 261, 278]]], ["It consider a consider a 4\u00d74 matrix in which the rows and columns are assigned to pairs of nucleotides (PNs)ATGCAAAATAGACTTATTTGTCGGAGTGGGCCCACTCGCCGiven an arbitrary DNA primary sequence, the PN-curve can be generated by the following map \u03c6:\u03c6(gigi+1)={(1,(AA)i,i)ifgigi+1=AA(2,(AT)i,i)ifgigi+1=AT(3,(AG)i,i)ifgigi+1=AG(4,(AC)i,i)ifgigi+1=AC(5,(TA)i,i)ifgigi+1=TA(6,(TT)i,i)ifgigi+1=TT(7,(TG)i,i)ifgigi+1=TG(8,(TC)i,i)ifgigi+1=TC(9,(GA)i,i)ifgigi+1=GA(10,(GT)i,i)ifgigi+1=GT(11,(GG)i,i)ifgigi+1=GG(12,(GC)i,i)ifgigi+1=GC(13,(CA)i,i)ifgigi+1=CA(14,(CT)i,i)ifgigi+1=CT(15,(CG)i,i)ifgigi+1=CG(16,(CC)i,i)ifgigi+1=CCwhere (AA)i, (AT)i, (AG)i, (AC)i,\u2026, (CG)i and (CC)i are the cumulative occurrence numbers of AA, AT, AG, AC,\u2026, CG and CC, respectively, in the subsequence from the first base to the nth base in the sequence.", [["AA", "CHEMICAL", 705, 707], ["CC", "CHEMICAL", 730, 732], ["nucleotides", "CHEMICAL", 91, 102], ["\u03c6:\u03c6(gigi+1)={(1,(AA)i,i)ifgigi+1=AA(2,(AT)i,i)ifgigi+1=AT(3,(AG)i,i)ifgigi+1=AG(4,(AC)i,i)ifgigi+1=AC(5,(TA)i,i)ifgigi+1=TA(6,(TT)i,i)ifgigi+1=TT(7,(TG)i,i)ifgigi+1=TG(8,(TC)i,i)ifgigi+1=TC(9,(GA)i,i)ifgigi+1=GA(10,(GT)i,i)ifgigi+1=GT(11,(GG)i,i)ifgigi+1=GG(12,(GC)i,i)ifgigi+1=GC(13,(CA)i,i)ifgigi+1=CA(14,(CT)i,i)ifgigi+1=CT", "CHEMICAL", 240, 566], ["CG(16,(CC)i,i)ifgigi", "CHEMICAL", 587, 607], ["CCwhere (AA)i, (AT)i, (AG)i, (AC)i", "CHEMICAL", 610, 644], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["ifgigi+1=AA(2,(AT)i,i)ifgigi+1=AT(3,(AG)i,i)ifgigi+1=AG(4,(AC)i", "SIMPLE_CHEMICAL", 264, 327], ["5,(TA)i,i)ifgigi+1=TA(6,(TT)i,i)ifgigi+1=TT(7,(TG)i", "SIMPLE_CHEMICAL", 342, 393], ["ifgigi+1=TG(8,(TC)i,i)ifgigi+1=TC(9,(GA)i", "SIMPLE_CHEMICAL", 396, 437], ["ifgigi+1=GA(10,(GT)i", "SIMPLE_CHEMICAL", 440, 460], ["ifgigi+1=GT(11,(GG)i,i)ifgigi+1=GG(12,(GC)i,i)ifgigi+1=GC(13,(CA)i,i)ifgigi+1=CA(14,(CT)i,i)ifgigi+1=CT(15,(CG)i,i)ifgigi+1=CG(16,(CC)i,i)ifgigi+1=CCwhere (AA)i, (AT)i, (AG)i, (AC)i", "SIMPLE_CHEMICAL", 463, 644], ["(CG)i", "SIMPLE_CHEMICAL", 648, 653], ["AA", "SIMPLE_CHEMICAL", 705, 707], ["DNA primary sequence", "DNA", 167, 187], ["a 4\u00d74 matrix", "TREATMENT", 23, 35], ["nucleotides (PNs)", "TREATMENT", 91, 108], ["an arbitrary DNA primary sequence", "TREATMENT", 154, 187], ["the PN-curve", "TREATMENT", 189, 201], ["map", "TEST", 236, 239], ["gigi+1)={(1", "TEST", 244, 255], [",(AA)", "TEST", 255, 260], ["i", "TEST", 260, 261], ["ifgigi+1=AA(", "TEST", 264, 276], ["i", "TEST", 282, 283], ["ifgigi+1=AT(", "TEST", 286, 298], ["ifgigi+1=AG(", "TEST", 308, 320], ["ifgigi+1=AC(", "TEST", 330, 342], ["ifgigi+1=TA(6", "TEST", 352, 365], ["TT)i", "TEST", 367, 371], ["ifgigi+1=TT(", "TEST", 374, 386], ["TG", "TEST", 389, 391], [")i", "TEST", 391, 393], ["ifgigi+1=TG(", "TEST", 396, 408], [",(TC", "TEST", 409, 413], ["ifgigi+1=TC(", "TEST", 418, 430], ["ifgigi+1=GA(", "TEST", 440, 452], ["GT)i", "TEST", 456, 460], ["ifgigi+1=GT(11", "TEST", 463, 477], ["GG", "TEST", 479, 481], ["GC", "TEST", 502, 504], ["ifgigi+1=GC", "TEST", 509, 520], ["CA", "TEST", 525, 527], ["i", "TEST", 528, 529], ["ifgigi+1=CA(", "TEST", 532, 544], ["CT", "TEST", 548, 550], ["i", "TEST", 551, 552], ["CT", "TEST", 564, 566], ["CG", "TEST", 571, 573], ["ifgigi", "TEST", 578, 584], ["CG", "TEST", 587, 589], ["ifgigi", "TEST", 601, 607], ["\u2026", "TEST", 645, 646], ["CG", "TEST", 649, 651], ["AA", "TEST", 705, 707], ["AG", "TEST", 713, 715], ["AC", "TEST", 717, 719], ["CG", "TEST", 723, 725], ["base", "ANATOMY_MODIFIER", 782, 786], ["nth", "ANATOMY_MODIFIER", 794, 797], ["base", "ANATOMY_MODIFIER", 798, 802]]], ["Unlike important geometry curve Z (Zhang, 1997) and Z\u2032 (Zhang and Zhang, 2004), PN-curve is not unique because of the 16! different combinations about 16 kinds of PNs.", [["PNs", "ANATOMY", 163, 166], ["PNs", "CELL", 163, 166], ["PNs", "PROBLEM", 163, 166], ["16 kinds", "OBSERVATION_MODIFIER", 151, 159]]], ["However, we are only interested in PN-curve as numerical parameters that may extract characteristics of DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 104, 107], ["DNA sequences", "DNA", 104, 117], ["numerical parameters", "TEST", 47, 67], ["DNA sequences", "TEST", 104, 117]]], ["Here, the different combinations attach no impact on the extracted numerical parameters.PN-curve and its applications ::: MethodsFor a given gene or genome, there is a cumulative PN-profile or PN-curve corresponding to it.", [["PN", "TREATMENT", 88, 90], ["Methods", "TREATMENT", 122, 129], ["a cumulative PN", "TEST", 166, 181]]], ["The PN-curve or the cumulative PN-profile is used interchangeably in this paper.", [["The PN-curve", "TREATMENT", 0, 12], ["the cumulative PN-profile", "TREATMENT", 16, 41]]], ["Note that the essence of cumulative PN-profile is to display the variations of the PN content along a gene or genome.", [["genome", "CELLULAR_COMPONENT", 110, 116], ["cumulative PN", "TEST", 25, 38], ["the PN content", "PROBLEM", 79, 93], ["PN content", "OBSERVATION", 83, 93]]], ["The derivative of PN-curve with respect to the PN content is used to construct 16-component vectors related with the cumulative PN content.", [["PN", "SIMPLE_CHEMICAL", 47, 49], ["PN", "SIMPLE_CHEMICAL", 128, 130], ["The derivative of PN-curve", "TREATMENT", 0, 26], ["the PN content", "TREATMENT", 43, 57], ["the cumulative PN content", "TREATMENT", 113, 138], ["PN content", "OBSERVATION", 128, 138]]], ["The 16-component vector consists of the percentage of 16 kinds of PNs: AA, AT, AG, AC,\u2026, CG and CC.PN-curve and its applications ::: MethodsFor a given gene, there is a 16-component vector to reveal the patterns of PN compositions.", [["PNs", "ANATOMY", 66, 69], ["CC", "CHEMICAL", 96, 98], ["PNs", "CELL", 66, 69], ["AA", "SIMPLE_CHEMICAL", 71, 73], ["AG", "SIMPLE_CHEMICAL", 79, 81], ["PN", "SIMPLE_CHEMICAL", 215, 217], ["16-component vector", "DNA", 4, 23], ["16-component vector", "DNA", 169, 188], ["PNs", "TEST", 66, 69], ["AA", "TEST", 71, 73], ["AG", "TEST", 79, 81], ["AC", "TEST", 83, 85], ["CG", "TEST", 89, 91], ["PN", "TREATMENT", 99, 101], ["Methods", "TREATMENT", 133, 140], ["PN compositions", "TREATMENT", 215, 230], ["AA", "ANATOMY", 71, 73], ["PN compositions", "OBSERVATION", 215, 230]]], ["As for genome of an organism, there are thousands of genes.", [["an organism", "PROBLEM", 17, 28], ["organism", "OBSERVATION", 20, 28]]], ["It is not practical that the cluster tendency of patterns is only based on a single pattern derived from a single gene.", [["cluster", "OBSERVATION_MODIFIER", 29, 36], ["tendency", "OBSERVATION_MODIFIER", 37, 45]]], ["There are two normal ways to know the tendency of genome: (i) all genes are linked each other into a very long sequence, and a 16-component vector by cumulative PN-profile is used to represent the cluster pattern of PN compositions; (ii) each gene is used to generate a corresponding 16-component vector by PN-profile, and the average of all vectors illustrates the cluster pattern.", [["16-component vector", "DNA", 127, 146], ["16-component vector", "DNA", 284, 303], ["a 16-component vector", "TREATMENT", 125, 146], ["PN compositions", "TREATMENT", 216, 231], ["two", "OBSERVATION_MODIFIER", 10, 13], ["normal", "OBSERVATION", 14, 20], ["cluster pattern", "OBSERVATION", 366, 381]]], ["So we use dimension reduction method to uncover the more detail hid in all vectors.Dimension reduction method based on principal components analysis ::: MethodsPrincipal components analysis (Jackson and Wiley, 1991) is a projection method to analyze data set and reduce it from high dimensional space to few hidden variables while keeping information on its variability.", [["dimension reduction method", "TREATMENT", 10, 36], ["Dimension reduction method", "TREATMENT", 83, 109]]], ["It and its many expanded methods have been successfully applied to the resolution of some problems (Costa et al., 2009; Du et al., 2006).", [["some problems", "PROBLEM", 85, 98], ["many", "OBSERVATION_MODIFIER", 11, 15], ["expanded", "OBSERVATION", 16, 24], ["resolution", "OBSERVATION_MODIFIER", 71, 81]]], ["Since the patterns in 16-component vectors of genome of an organism can be hard to find in high dimension space, where graphical representation is not available, the possibility of grouping the variability in few variables is an important step to visualize and consequently uncover the information.", [["16-component vectors", "DNA", 22, 42], ["an organism", "PROBLEM", 56, 67], ["high dimension", "OBSERVATION_MODIFIER", 91, 105]]], ["In Wang et al. (2008), an effective dimension-reducing approach was introduced for predicting membrane protein types.", [["membrane", "ANATOMY", 94, 102], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["membrane protein types", "PROTEIN", 94, 116], ["an effective dimension-reducing approach", "TREATMENT", 23, 63], ["predicting membrane protein types", "PROBLEM", 83, 116]]], ["Here, we reduce 16-dimension vector to 2-dimension by using PCA.", [["PCA", "TREATMENT", 60, 63], ["PCA", "ANATOMY", 60, 63]]], ["Then we give the 2D graphical representation of the patterns of PN compositions and utilize the representation to intuitively observe the evolution patters among different organisms.Dimension reduction method based on principal components analysis ::: MethodsWe now give the simple description of PCA.", [["PN compositions", "TREATMENT", 64, 79], ["Dimension reduction method", "TREATMENT", 182, 208], ["PCA", "TREATMENT", 297, 300]]], ["Assume that the mean of sample X={xi}i=1n of space RD is x_=1n\u2211i=1nxi.", [["1nxi", "PROTEIN", 65, 69], ["sample", "TEST", 24, 30], ["xi}i", "TEST", 34, 38], ["space RD", "TEST", 45, 53]]], ["Write the singular value decomposition of covariance matrix \u03a3 as \u03a3=U\u2227UT, where \u03a3=E(x-x_)(x-x_)T. Matrix U is orthogonal matrix.", [["matrix", "CELLULAR_COMPONENT", 120, 126], ["covariance matrix", "TEST", 42, 59], ["UT", "TEST", 69, 71], ["orthogonal matrix", "OBSERVATION", 109, 126]]], ["Diagonal matrix \u2227 is made up of the eigenvalues of \u03a3, where \u2227=diag(\u03bb1,\u2026,\u03bbD) and \u03bb1\u2265\u22ef\u2265\u03bbD.", [["diag", "TEST", 62, 66], ["\u2026", "TEST", 70, 71], ["\u03bb", "TEST", 80, 81]]], ["The principle component transformation is UT(X-X_).", [["X-X_", "GENE_OR_GENE_PRODUCT", 45, 49], ["principle", "OBSERVATION_MODIFIER", 4, 13], ["component", "OBSERVATION_MODIFIER", 14, 23], ["transformation", "OBSERVATION", 24, 38]]], ["Then a new data set Y={yi}i=1n is obtained by Y=UT(X-X_).", [["X-X_", "SIMPLE_CHEMICAL", 51, 55], ["a new data set Y", "TEST", 5, 21]]], ["The mean and covariance matrix of Y are 0 and diagonal matrix \u2227, respectively.", [["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Now we ignore the components of lesser significance and leave out some important components.", [["lesser", "OBSERVATION_MODIFIER", 32, 38]]], ["Then the final data set will have fewer dimensions than the original.", [["fewer", "OBSERVATION_MODIFIER", 34, 39], ["dimensions", "OBSERVATION_MODIFIER", 40, 50]]], ["The final data set has only two dimensions by choosing only the first two eigenvectors.Genomic data used for this study ::: MethodsComplete genome sequences were downloaded from NCBI GenBank (ftp://ftp.ncbi.nih.gov/genomes/Bacteria/).", [["MethodsComplete genome sequences", "DNA", 124, 156], ["NCBI GenBank", "DNA", 178, 190], ["this study", "TEST", 109, 119], ["MethodsComplete genome sequences", "TEST", 124, 156]]], ["Here, the analysis of genomes was performed by some bacteria consisting of 11 Gram-positive and 12 Gram-negative bacteria (Sorimachi and Okayasu, 2004).", [["Gram", "GENE_OR_GENE_PRODUCT", 78, 82], ["Gram", "GENE_OR_GENE_PRODUCT", 99, 103], ["the analysis", "TEST", 6, 18], ["some bacteria", "PROBLEM", 47, 60], ["Gram", "TEST", 78, 82], ["Gram", "TEST", 99, 103], ["negative bacteria", "OBSERVATION_MODIFIER", 104, 121]]], ["The genome sequences used for this study are summarized in Table 1.Calculations ::: ApplicationsDual nucleotide contents at various base positions were computationally calculated by PN-curve.", [["nucleotide", "CHEMICAL", 101, 111], ["nucleotide", "CHEMICAL", 101, 111], ["genome sequences", "DNA", 4, 20], ["this study", "TEST", 30, 40], ["Dual nucleotide contents", "TREATMENT", 96, 120], ["PN", "TEST", 182, 184]]], ["As for a sequence, a 16-dimension vector related to dual nucleotide contents is generated by PN-curve.", [["nucleotide", "CHEMICAL", 57, 67], ["nucleotide", "CHEMICAL", 57, 67], ["16-dimension vector", "DNA", 21, 40], ["a sequence", "TEST", 7, 17], ["a 16-dimension vector", "TREATMENT", 19, 40], ["dual nucleotide contents", "TEST", 52, 76]]], ["In order to visualize and uncover the information hidden in the vector set, we reduce 16-dimension vector to 2-dimension by using PCA.", [["PCA", "TREATMENT", 130, 133]]], ["Then we give the 2D graphical representation of the patterns of PN compositions and utilize the representation to intuitively observe the evolution patters among different organisms.", [["PN compositions", "TREATMENT", 64, 79]]], ["A program named as \u201cGenomePNs.pl\u201d is designed to generate 16-dimension vector set of complete genome.", [["genome", "OBSERVATION", 94, 100]]], ["The input of the perl program is file \u201c*.ffn\u201d from NCBI GenBank.", [["ffn", "DNA", 41, 44], ["NCBI GenBank", "DNA", 51, 63]]], ["Its output is a file called as \u201cpercentage_PNs.txt\u201d.", [["output", "OBSERVATION_MODIFIER", 4, 10]]], ["The other program, \u201cDimReductionAnaly.m\u201d, is a matlab program used to reduce 16-dimension vector set to 2-dimension by using PCA algorithm and visualize the 2-dimension vector set.", [["a matlab program", "TREATMENT", 45, 61], ["PCA algorithm", "TEST", 125, 138]]], ["Its input is \u201cpercentage_PNs.txt\u201d and the output is a 2-dimension graphic representation.Results ::: ApplicationsThe patterns of dual nucleotide compositions based on the complete genomes of various eubacteria in Table 1 are 2-dimension dot-cluster graphs, as shown in Fig. 1.Results ::: ApplicationsTo characterize the pattern of dual nucleotide compositions and to classify eubacteria, we focused on particular dot-cluster.", [["nucleotide", "CHEMICAL", 134, 144], ["nucleotide", "CHEMICAL", 336, 346], ["nucleotide", "CHEMICAL", 134, 144], ["nucleotide", "CHEMICAL", 336, 346], ["the output", "TEST", 38, 48], ["dual nucleotide compositions", "TREATMENT", 129, 157], ["dual nucleotide compositions", "TREATMENT", 331, 359], ["eubacteria", "PROBLEM", 376, 386], ["output", "OBSERVATION_MODIFIER", 42, 48], ["various eubacteria", "OBSERVATION", 191, 209]]], ["A close look to Fig. 1 shows that dot-cluster in some graphs is mainly grouped into two clusters while those dots in other graphs is mainly grouped into one cluster.", [["dot-cluster", "DNA", 34, 45], ["some graphs", "PROBLEM", 49, 60]]], ["Concentrations of dot-cluster changed markedly two main groups: \u201cS-Type\u201d represented by S. aureus and \u201cE-Type\u201d represented by E. coli.", [["S. aureus", "ORGANISM", 88, 97], ["E. coli", "ORGANISM", 126, 133], ["S. aureus", "SPECIES", 88, 97], ["E. coli", "SPECIES", 126, 133], ["S. aureus", "SPECIES", 88, 97], ["E. coli", "SPECIES", 126, 133], ["Type\u201d", "PROBLEM", 67, 72], ["S. aureus", "PROBLEM", 88, 97], ["E. coli", "PROBLEM", 126, 133], ["aureus", "OBSERVATION", 91, 97], ["E. coli", "OBSERVATION", 126, 133]]], ["Here, concentrations of dot clusters are mainly inside Region I in \u201cS-Type\u201d whereas they are mainly inside Region II in \u201cE-Type\u201d.", [["concentrations of dot clusters", "PROBLEM", 6, 36]]], ["The two groups are separated from each other by these dot-clusters.Results ::: ApplicationsBy using PCA algorithm, eubacteria is classified into two groups, \u201cS-Type\u201d and \u201cE-Type\u201d, based on the dual nucleotides compositions calculated from the complete genome.", [["nucleotides", "CHEMICAL", 198, 209], ["PCA algorithm", "TREATMENT", 100, 113], ["eubacteria", "PROBLEM", 115, 125], ["the dual nucleotides compositions", "TEST", 189, 222], ["complete genome", "OBSERVATION", 243, 258]]], ["According to the relative location between main clusters, \u201cS-Type\u201d can be classified into two subgroups: (i) one subgroup includes the bacteria, S. aureus Mu50, Str. pyogenes M1, B. subtilis, R. prowazekii, C. perfringens 13 and B. burgdorferi.", [["S. aureus Mu50", "ORGANISM", 145, 159], ["Str. pyogenes M1", "ORGANISM", 161, 177], ["B. subtilis", "ORGANISM", 179, 190], ["R. prowazekii", "ORGANISM", 192, 205], ["C. perfringens 13", "ORGANISM", 207, 224], ["B. burgdorferi", "ORGANISM", 229, 243], ["S. aureus", "SPECIES", 145, 154], ["Str. pyogenes", "SPECIES", 161, 174], ["B. subtilis", "SPECIES", 179, 190], ["R. prowazekii", "SPECIES", 192, 205], ["C. perfringens", "SPECIES", 207, 221], ["B. burgdorferi", "SPECIES", 229, 243], ["S. aureus", "SPECIES", 145, 154], ["Str. pyogenes M1", "SPECIES", 161, 177], ["B. subtilis", "SPECIES", 179, 190], ["R. prowazekii", "SPECIES", 192, 205], ["C. perfringens", "SPECIES", 207, 221], ["B. burgdorferi", "SPECIES", 229, 243], ["the bacteria", "PROBLEM", 131, 143], ["S. aureus Mu50", "PROBLEM", 145, 159], ["Str. pyogenes M1", "PROBLEM", 161, 177], ["C. perfringens", "PROBLEM", 207, 221], ["bacteria", "OBSERVATION", 135, 143], ["aureus", "OBSERVATION", 148, 154]]], ["Concentration of dots of them is mainly in the left dot-clusters and (ii) the other consists of the following, L. monocytogenes, C. jejuni, M. pulmonis, H. pylori J99, H. influenzae, M. genitalium and H. pylori 26695.", [["left dot-clusters", "ANATOMY", 47, 64], ["L. monocytogenes", "ORGANISM", 111, 127], ["C. jejuni", "ORGANISM", 129, 138], ["M. pulmonis", "ORGANISM", 140, 151], ["H. pylori J99", "ORGANISM", 153, 166], ["H. influenzae", "ORGANISM", 168, 181], ["M. genitalium", "ORGANISM", 183, 196], ["H. pylori 26695", "ORGANISM", 201, 216], ["L. monocytogenes", "SPECIES", 111, 127], ["C. jejuni", "SPECIES", 129, 138], ["M. pulmonis", "SPECIES", 140, 151], ["H. pylori", "SPECIES", 153, 162], ["H. influenzae", "SPECIES", 168, 181], ["M. genitalium", "SPECIES", 183, 196], ["H. pylori", "SPECIES", 201, 210], ["L. monocytogenes", "SPECIES", 111, 127], ["C. jejuni", "SPECIES", 129, 138], ["M. pulmonis", "SPECIES", 140, 151], ["H. pylori", "SPECIES", 153, 162], ["H. influenzae", "SPECIES", 168, 181], ["M. genitalium", "SPECIES", 183, 196], ["H. pylori 26695", "SPECIES", 201, 216], ["L. monocytogenes", "TEST", 111, 127], ["C. jejuni", "PROBLEM", 129, 138], ["M. pulmonis", "PROBLEM", 140, 151], ["H. pylori", "TEST", 153, 162], ["H. influenzae", "PROBLEM", 168, 181], ["M. genitalium", "PROBLEM", 183, 196], ["H. pylori", "PROBLEM", 201, 210], ["dots", "OBSERVATION_MODIFIER", 17, 21], ["left", "ANATOMY_MODIFIER", 47, 51], ["monocytogenes", "OBSERVATION", 114, 127], ["jejuni", "ANATOMY", 132, 138], ["pulmonis", "ANATOMY", 143, 151]]], ["Concentration of dots of these bacteria is mainly in the right dot-clusters.", [["right dot-clusters", "ANATOMY", 57, 75], ["these bacteria", "PROBLEM", 25, 39], ["dots", "OBSERVATION_MODIFIER", 17, 21], ["bacteria", "OBSERVATION", 31, 39], ["right", "ANATOMY_MODIFIER", 57, 62]]], ["The first subgroup includes those bacteria whose dots are classified into two clusters.", [["those bacteria", "PROBLEM", 28, 42]]], ["They are E. coli, S. typhi, V. cholerae and Y. pestis.", [["E. coli", "ORGANISM", 9, 16], ["S. typhi", "ORGANISM", 18, 26], ["V. cholerae", "ORGANISM", 28, 39], ["Y. pestis", "ORGANISM", 44, 53], ["E. coli", "SPECIES", 9, 16], ["S. typhi", "SPECIES", 18, 26], ["V. cholerae", "SPECIES", 28, 39], ["Y. pestis", "SPECIES", 44, 53], ["E. coli", "SPECIES", 9, 16], ["S. typhi", "SPECIES", 18, 26], ["V. cholerae", "SPECIES", 28, 39], ["Y. pestis", "SPECIES", 44, 53], ["E. coli", "PROBLEM", 9, 16], ["E. coli", "OBSERVATION", 9, 16], ["typhi", "OBSERVATION_MODIFIER", 21, 26], ["pestis", "OBSERVATION", 47, 53]]], ["They are M. tuberculosis, M. leprae, N. meningitides, T. pallidum, M. pneumoniae and U. urealyticum, respectively.", [["tuberculosis", "DISEASE", 12, 24], ["M. tuberculosis", "ORGANISM", 9, 24], ["M. leprae", "ORGANISM", 26, 35], ["N. meningitides", "ORGANISM", 37, 52], ["T. pallidum", "ORGANISM", 54, 65], ["M. pneumoniae", "ORGANISM", 67, 80], ["U. urealyticum", "ORGANISM", 85, 99], ["M. tuberculosis", "SPECIES", 9, 24], ["M. leprae", "SPECIES", 26, 35], ["N. meningitides", "SPECIES", 37, 52], ["T. pallidum", "SPECIES", 54, 65], ["M. pneumoniae", "SPECIES", 67, 80], ["U. urealyticum", "SPECIES", 85, 99], ["M. tuberculosis", "SPECIES", 9, 24], ["M. leprae", "SPECIES", 26, 35], ["N. meningitides", "SPECIES", 37, 52], ["T. pallidum", "SPECIES", 54, 65], ["M. pneumoniae", "SPECIES", 67, 80], ["U. urealyticum", "SPECIES", 85, 99], ["T. pallidum", "PROBLEM", 54, 65], ["pneumoniae", "PROBLEM", 70, 80], ["U. urealyticum", "PROBLEM", 85, 99], ["tuberculosis", "OBSERVATION", 12, 24], ["pallidum", "ANATOMY", 57, 65], ["pneumoniae", "OBSERVATION", 70, 80], ["urealyticum", "OBSERVATION", 88, 99]]], ["The above results show that bacteria in Table 1 are grouped into two classes: S. aureus \u201cS-Type\u201d and E. coli \u201cE-Type\u201d, based on their genomic structures.", [["S. aureus", "ORGANISM", 78, 87], ["E. coli", "ORGANISM", 101, 108], ["S. aureus", "SPECIES", 78, 87], ["E. coli", "SPECIES", 101, 108], ["S. aureus", "SPECIES", 78, 87], ["E. coli", "SPECIES", 101, 108], ["bacteria", "PROBLEM", 28, 36], ["S. aureus \u201cS", "TEST", 78, 90], ["Type\u201d", "PROBLEM", 91, 96], ["E. coli", "TEST", 101, 108], ["Type\u201d", "PROBLEM", 112, 117], ["bacteria", "OBSERVATION", 28, 36], ["aureus", "OBSERVATION", 81, 87], ["E. coli", "OBSERVATION_MODIFIER", 101, 108]]], ["As Okayasu and Sorimachi (2009) reported both types \u201cS-Type\u201d and \u201cE-Type\u201d, the above species were classified further into their subgroups based on amino acid compositions or codon usages.", [["amino acid", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 147, 157], ["amino acid", "AMINO_ACID", 147, 157], ["the above species", "PROBLEM", 75, 92], ["amino acid compositions", "TREATMENT", 147, 170], ["codon usages", "TREATMENT", 174, 186]]], ["Similar results have also been obtained by Sorimachi and Okayasu (2004).DiscussionBy using data derived from dual nucleotides based on complete genomes, our studies are applicable to analyze genomic structures and provide their 2-dimension graphic representation by PCA algorithm.", [["nucleotides", "CHEMICAL", 114, 125], ["dual nucleotides", "TREATMENT", 109, 125], ["our studies", "TEST", 153, 164], ["PCA algorithm", "TEST", 266, 279]]], ["Then the method is used to investigate the dual nucleotide compositions of 11 Gram-positive and 12 Gram-negative eubacteria in Table 1.DiscussionThe amino acid compositions of the eubacteria of Table 1 have been studied by Sorimachi and Okayasu (2004).", [["nucleotide", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 149, 159], ["nucleotide", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 149, 159], ["Gram", "GENE_OR_GENE_PRODUCT", 78, 82], ["amino acid", "AMINO_ACID", 149, 159], ["Gram", "PROTEIN", 99, 103], ["the dual nucleotide compositions", "TEST", 39, 71], ["Gram", "TEST", 78, 82], ["Gram", "TEST", 99, 103], ["The amino acid compositions", "TREATMENT", 145, 172]]], ["Their research results show that these eubacteria were classified into two groups, \u201cS-Type\u201d represented by S. aureus and \u201cE-Type\u201d represented by E. coli.", [["S. aureus", "ORGANISM", 107, 116], ["E. coli", "ORGANISM", 145, 152], ["S. aureus", "SPECIES", 107, 116], ["E. coli", "SPECIES", 145, 152], ["S. aureus", "SPECIES", 107, 116], ["E. coli", "SPECIES", 145, 152], ["these eubacteria", "PROBLEM", 33, 49], ["S. aureus", "PROBLEM", 107, 116], ["E. coli", "PROBLEM", 145, 152], ["aureus", "OBSERVATION", 110, 116], ["E. coli", "OBSERVATION", 145, 152]]], ["Similarly, we also classified these eubacteria into two groups, \u201cS-Type\u201d and \u201cE-Type\u201d, according to particular dot-cluster derived from complete genomes data by PCA.", [["PCA", "ANATOMY", 161, 164]]], ["Compared with the research results of Sorimachi and Okayasu, our results show some diversity in three eubacteria: H. influenzae, M. pneumoniae and U. urealyticum.", [["U. urealyticum", "DISEASE", 147, 161], ["H. influenzae", "ORGANISM", 114, 127], ["M. pneumoniae", "ORGANISM", 129, 142], ["U. urealyticum", "ORGANISM", 147, 161], ["H. influenzae", "SPECIES", 114, 127], ["M. pneumoniae", "SPECIES", 129, 142], ["U. urealyticum", "SPECIES", 147, 161], ["H. influenzae", "SPECIES", 114, 127], ["M. pneumoniae", "SPECIES", 129, 142], ["U. urealyticum", "SPECIES", 147, 161], ["H. influenzae", "PROBLEM", 114, 127], ["M. pneumoniae", "PROBLEM", 129, 142], ["U. urealyticum", "PROBLEM", 147, 161], ["urealyticum", "OBSERVATION", 150, 161]]], ["Here, H. influenzae belong to \u201cS-Type\u201d while M. pneumoniae and U. urealyticum are \u201cE-Type\u201d.", [["H. influenzae", "ORGANISM", 6, 19], ["M. pneumoniae", "ORGANISM", 45, 58], ["U. urealyticum", "ORGANISM", 63, 77], ["H. influenzae", "SPECIES", 6, 19], ["M. pneumoniae", "SPECIES", 45, 58], ["U. urealyticum", "SPECIES", 63, 77], ["H. influenzae", "SPECIES", 6, 19], ["M. pneumoniae", "SPECIES", 45, 58], ["U. urealyticum", "SPECIES", 63, 77], ["H. influenzae", "TEST", 6, 19], ["pneumoniae", "PROBLEM", 48, 58], ["U. urealyticum", "TEST", 63, 77], ["urealyticum", "OBSERVATION", 66, 77]]], ["We do not think that the diversity imply some failure in our approach or Sorimachi and Okayasu's scheme.", [["some failure", "PROBLEM", 41, 53], ["Sorimachi", "TREATMENT", 73, 82], ["some", "OBSERVATION_MODIFIER", 41, 45], ["failure", "OBSERVATION", 46, 53]]], ["The proportion of diversity is low, only 13%.", [["proportion", "OBSERVATION_MODIFIER", 4, 14], ["diversity", "OBSERVATION_MODIFIER", 18, 27], ["low", "OBSERVATION_MODIFIER", 31, 34]]], ["Looked by statistics viewpoint, the diversity is acceptable.DiscussionThe present study demonstrates that dual nucleotide compositions are useful values to investigate genomic structures and biological evolution.", [["nucleotide", "CHEMICAL", 111, 121], ["nucleotide", "CHEMICAL", 111, 121], ["The present study", "TEST", 70, 87], ["dual nucleotide compositions", "TREATMENT", 106, 134], ["acceptable", "OBSERVATION_MODIFIER", 49, 59]]], ["The more similar the structures of dot-cluster are the more similar the organisms are.", [["dot-cluster", "GENE_OR_GENE_PRODUCT", 35, 46], ["more similar", "OBSERVATION_MODIFIER", 4, 16]]], ["That is to say, the structures between evolutionary closely related species are more similar, while those between evolutionary disparate species are larger.", [["evolutionary disparate species", "PROBLEM", 114, 144], ["species", "OBSERVATION_MODIFIER", 68, 75], ["more similar", "OBSERVATION_MODIFIER", 80, 92], ["disparate", "OBSERVATION_MODIFIER", 127, 136], ["species", "OBSERVATION", 137, 144], ["larger", "OBSERVATION_MODIFIER", 149, 155]]], ["Closely observing Fig. 1, we find that in \u201cS-Type\u201d the more similar species groups are the following: S. aureus Mu50, S. pyogenes M1 and B. subtilis; L. monocytogenes, H. pylori J99, H. influenzae and H. pylori 26695.", [["S. aureus Mu50", "ORGANISM", 102, 116], ["S. pyogenes M1", "ORGANISM", 118, 132], ["B. subtilis", "ORGANISM", 137, 148], ["L. monocytogenes", "ORGANISM", 150, 166], ["H. pylori J99", "ORGANISM", 168, 181], ["H. influenzae", "ORGANISM", 183, 196], ["H. pylori 26695", "ORGANISM", 201, 216], ["S. aureus", "SPECIES", 102, 111], ["S. pyogenes", "SPECIES", 118, 129], ["B. subtilis", "SPECIES", 137, 148], ["L. monocytogenes", "SPECIES", 150, 166], ["H. pylori", "SPECIES", 168, 177], ["H. influenzae", "SPECIES", 183, 196], ["H. pylori", "SPECIES", 201, 210], ["S. aureus", "SPECIES", 102, 111], ["S. pyogenes", "SPECIES", 118, 129], ["B. subtilis", "SPECIES", 137, 148], ["L. monocytogenes", "SPECIES", 150, 166], ["H. pylori J99", "SPECIES", 168, 181], ["H. influenzae", "SPECIES", 183, 196], ["H. pylori 26695", "SPECIES", 201, 216], ["S. aureus", "PROBLEM", 102, 111], ["S. pyogenes M1", "PROBLEM", 118, 132], ["B. subtilis", "PROBLEM", 137, 148], ["L. monocytogenes", "PROBLEM", 150, 166], ["H. pylori J99", "PROBLEM", 168, 181], ["H. influenzae", "PROBLEM", 183, 196], ["H. pylori", "PROBLEM", 201, 210], ["aureus", "OBSERVATION", 105, 111], ["L. monocytogenes", "OBSERVATION", 150, 166]]], ["In \u201cE-Type\u201d the more similar species groups are the following: E. coli, S. typhi, Y. pestis; M. tuberculosis, M. leprae, T. pallidum and U. urealyticum.", [["M. tuberculosis", "DISEASE", 93, 108], ["U. urealyticum", "DISEASE", 137, 151], ["E. coli", "ORGANISM", 63, 70], ["S. typhi", "ORGANISM", 72, 80], ["Y. pestis", "ORGANISM", 82, 91], ["M. tuberculosis", "ORGANISM", 93, 108], ["M. leprae", "ORGANISM", 110, 119], ["T. pallidum", "ORGANISM", 121, 132], ["U. urealyticum", "ORGANISM", 137, 151], ["E. coli", "SPECIES", 63, 70], ["S. typhi", "SPECIES", 72, 80], ["Y. pestis", "SPECIES", 82, 91], ["M. tuberculosis", "SPECIES", 93, 108], ["M. leprae", "SPECIES", 110, 119], ["T. pallidum", "SPECIES", 121, 132], ["U. urealyticum", "SPECIES", 137, 151], ["E. coli", "SPECIES", 63, 70], ["S. typhi", "SPECIES", 72, 80], ["Y. pestis", "SPECIES", 82, 91], ["M. tuberculosis", "SPECIES", 93, 108], ["M. leprae", "SPECIES", 110, 119], ["T. pallidum", "SPECIES", 121, 132], ["U. urealyticum", "SPECIES", 137, 151], ["E. coli", "PROBLEM", 63, 70], ["tuberculosis", "OBSERVATION", 96, 108], ["urealyticum", "OBSERVATION", 140, 151]]]], "PMC7305492": [["Global impact of COVID-19 ::: IntroductionThe lockdown due to COVID-19 has several ramifications to the society.", [["COVID-19", "CHEMICAL", 62, 70], ["COVID-19", "CHEMICAL", 17, 25], ["COVID-19", "DNA", 62, 70], ["COVID", "TEST", 17, 22], ["COVID", "TEST", 62, 67], ["society", "OBSERVATION", 104, 111]]], ["It has resulted in a major financial crisis resulting in the \u2018Great Recession\u2019 (Ruckert and Labont\u00e9, 2014).", [["a major financial crisis", "PROBLEM", 19, 43], ["major", "OBSERVATION_MODIFIER", 21, 26], ["financial crisis", "OBSERVATION", 27, 43], ["Great", "OBSERVATION_MODIFIER", 62, 67], ["Recession", "OBSERVATION", 68, 77]]], ["The disproportionate effects of COVID-19 predominantly in underprivileged communities are a reflection of inequality and social exclusion that exist in our society at large (Kim and Bostwick, 2020).", [["COVID", "TEST", 32, 37], ["disproportionate", "OBSERVATION_MODIFIER", 4, 20]]], ["It has impacted all forms of education globally.", [["impacted", "OBSERVATION_MODIFIER", 7, 15], ["all forms", "OBSERVATION_MODIFIER", 16, 25]]], ["However, several other countries struggle with this mode primarily because of lack of infrastructure, guidance, and poverty.", [["infrastructure", "OBSERVATION", 86, 100]]], ["These will have a severe bearing on the future generation.SARS-CoV-2 ::: IntroductionIntermediate hosts have a special role in the transmission of SARS-CoV-2 based on the following evidences: (i) COVID-19 was associated with seafood and wildlife market in Wuhan (Huang et al., 2020); (ii) SARS-CoV-2 is believed to have originated from the bats (Lu et al., 2020); and (iii) Coronaviruses closely related to SARS-CoV-2 have been isolated from Malayan or Sunda pangolins in China (Lam et al., 2020).", [["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 147, 151], ["SARS", "DISEASE", 407, 411], ["SARS-CoV-2", "ORGANISM", 147, 157], ["SARS-CoV-2", "ORGANISM", 289, 299], ["SARS-CoV-2", "ORGANISM", 407, 417], ["CoV-2", "SPECIES", 412, 417], ["SARS-CoV", "SPECIES", 147, 155], ["SARS-CoV", "SPECIES", 407, 415], ["a severe bearing", "PROBLEM", 16, 32], ["Coronaviruses", "PROBLEM", 374, 387], ["SARS", "PROBLEM", 407, 411], ["severe", "OBSERVATION_MODIFIER", 18, 24]]], ["Genetic analysis has identified 103 commonly circulating strains of SARS-CoV-2; all of which recently shifted to infecting humans (Sen et al., 2020).", [["SARS", "DISEASE", 68, 72], ["SARS-CoV-2", "ORGANISM", 68, 78], ["humans", "ORGANISM", 123, 129], ["humans", "SPECIES", 123, 129], ["SARS-CoV", "SPECIES", 68, 76], ["humans", "SPECIES", 123, 129], ["Genetic analysis", "TEST", 0, 16], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76]]], ["Based on two single nucleotide polymorphism (SNPs), the strains have been classified into two types: L (T28,144 is in the codon of Leucine) and S (C28,144 is in the codon of Serine) types.SARS-CoV-2 ::: IntroductionThe virus is easily spread by speech droplets airborne from symptomatic and asymptomatic carriers (Stadnytskyi et al., 2020).", [["SARS", "DISEASE", 188, 192], ["Leucine", "CHEMICAL", 131, 138], ["Serine", "CHEMICAL", 174, 180], ["Leucine", "AMINO_ACID", 131, 138], ["two single nucleotide polymorphism (SNPs", "TREATMENT", 9, 49], ["the strains", "PROBLEM", 52, 63], ["The virus", "PROBLEM", 215, 224], ["symptomatic and asymptomatic carriers", "PROBLEM", 275, 312]]], ["Risk factors to COVID-19 may include household plumbing, large family cluster, overcrowding, male sex, comorbidities like hypertension, bullous pemphigoid and pemphigus vulgaris patients, cancer patients, renal disease, glutathione deficiency, race, and socioeconomic status (Rodriguez-Lonebear et al., 2020; Ikitimur et al., 2020; Zemlin and Wiese, 2020; Escalera-Antezana et al., 2020; Carugno et al., 2020; Bhargava et al., 2020; Tian et al., 2020; Polonikov, 2020).SARS-CoV-2 ::: IntroductionSARS-CoV-2 possess a positive sense RNA genome expressing open reading frames that encodes both structural and non-structural proteins (Satarker and Nampoothiri, 2020).", [["cancer", "ANATOMY", 188, 194], ["renal", "ANATOMY", 205, 210], ["hypertension", "DISEASE", 122, 134], ["bullous pemphigoid", "DISEASE", 136, 154], ["pemphigus vulgaris", "DISEASE", 159, 177], ["cancer", "DISEASE", 188, 194], ["renal disease", "DISEASE", 205, 218], ["glutathione", "CHEMICAL", 220, 231], ["SARS", "DISEASE", 469, 473], ["glutathione", "CHEMICAL", 220, 231], ["patients", "ORGANISM", 178, 186], ["cancer", "CANCER", 188, 194], ["patients", "ORGANISM", 195, 203], ["renal", "ORGAN", 205, 210], ["glutathione", "SIMPLE_CHEMICAL", 220, 231], ["IntroductionSARS-CoV-2", "ORGANISM", 484, 506], ["CoV", "DNA", 501, 504], ["positive sense RNA genome", "DNA", 517, 542], ["open reading frames", "DNA", 554, 573], ["structural and non-structural proteins", "PROTEIN", 592, 630], ["2020", "PROTEIN", 658, 662], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 195, 203], ["pemphigus vulgaris", "SPECIES", 159, 177], ["Risk factors", "PROBLEM", 0, 12], ["hypertension", "PROBLEM", 122, 134], ["bullous pemphigoid", "PROBLEM", 136, 154], ["pemphigus vulgaris", "PROBLEM", 159, 177], ["cancer", "PROBLEM", 188, 194], ["renal disease", "PROBLEM", 205, 218], ["glutathione deficiency", "PROBLEM", 220, 242], ["IntroductionSARS", "TEST", 484, 500], ["a positive sense RNA genome", "PROBLEM", 515, 542], ["large", "OBSERVATION_MODIFIER", 57, 62], ["hypertension", "OBSERVATION", 122, 134], ["bullous", "OBSERVATION_MODIFIER", 136, 143], ["pemphigoid", "OBSERVATION", 144, 154], ["pemphigus", "OBSERVATION", 159, 168], ["renal", "ANATOMY", 205, 210], ["disease", "OBSERVATION", 211, 218], ["glutathione deficiency", "OBSERVATION", 220, 242], ["non-structural proteins", "OBSERVATION", 607, 630]]], ["The genome length is approximately 29.8 kb (Chen et al., 2020).", [["length", "OBSERVATION_MODIFIER", 11, 17], ["29.8 kb", "OBSERVATION_MODIFIER", 35, 42]]], ["Like other coronaviruses, SARS-CoV-2 is an enveloped virus.", [["SARS", "DISEASE", 26, 30], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV-2", "SPECIES", 26, 36], ["other coronaviruses", "PROBLEM", 5, 24], ["SARS", "PROBLEM", 26, 30], ["an enveloped virus", "PROBLEM", 40, 58], ["coronaviruses", "OBSERVATION", 11, 24], ["enveloped", "OBSERVATION_MODIFIER", 43, 52], ["virus", "OBSERVATION", 53, 58]]], ["The key structural proteins include spike (S) (Dong et al., 2020a), nucleocapsid (N) (SoRelle et al., 2020), membrane (M) (Hu et al., 2003), and envelope (E) proteins (Tilocca et al., 2020).", [["membrane", "ANATOMY", 109, 117], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 145, 157], ["envelope (E) proteins", "PROTEIN", 145, 166], ["Hu et al.", "TEST", 123, 132]]], ["The envelope is composed of M and E proteins.", [["M and E proteins", "PROTEIN", 28, 44], ["M and E proteins", "PROBLEM", 28, 44]]], ["The fact that the virus is enveloped makes it susceptible to commonly used detergent and ethanol.SARS-CoV-2 ::: IntroductionThe virus entry among the members of Coronaviridae family is a highly conserved process that is mediated by the homotrimer and glycosylated S protein (Wrapp et al., 2020; Ou et al., 2020; Millet and Whittaker, 2015).", [["ethanol", "CHEMICAL", 89, 96], ["SARS", "DISEASE", 97, 101], ["ethanol", "CHEMICAL", 89, 96], ["ethanol", "SIMPLE_CHEMICAL", 89, 96], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 161, 174], ["glycosylated S protein", "GENE_OR_GENE_PRODUCT", 251, 273], ["Coronaviridae family", "PROTEIN", 161, 181], ["homotrimer", "PROTEIN", 236, 246], ["glycosylated S protein", "PROTEIN", 251, 273], ["the virus", "PROBLEM", 14, 23], ["virus", "OBSERVATION", 18, 23]]], ["The envelope is studded with 5\u20137 nm of S protein.", [["S protein", "PROTEIN", 39, 48]]], ["Conformational changes to S protein is triggered as soon as receptor binding domain (RBD) within the S1 subunit of S protein interacts with the host cell receptor molecule, angiotensin-converting enzyme 2 (ACE2) (Li, 2016).", [["cell", "ANATOMY", 149, 153], ["angiotensin", "CHEMICAL", 173, 184], ["S protein", "GENE_OR_GENE_PRODUCT", 115, 124], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 144, 162], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 173, 204], ["ACE2", "GENE_OR_GENE_PRODUCT", 206, 210], ["S protein", "PROTEIN", 26, 35], ["receptor binding domain", "PROTEIN", 60, 83], ["RBD", "PROTEIN", 85, 88], ["S1 subunit", "PROTEIN", 101, 111], ["S protein", "PROTEIN", 115, 124], ["host cell receptor molecule", "PROTEIN", 144, 171], ["angiotensin-converting enzyme 2", "PROTEIN", 173, 204], ["ACE2", "PROTEIN", 206, 210], ["Conformational changes to S protein", "PROBLEM", 0, 35], ["receptor binding domain (RBD)", "PROBLEM", 60, 89], ["angiotensin", "TEST", 173, 184], ["enzyme", "TEST", 196, 202], ["host cell", "OBSERVATION", 144, 153]]], ["Receptor binding stabilize the binding by shedding of the S1 subunit and transition of the S2 subunit (Walls et al., 2017).", [["S2", "GENE_OR_GENE_PRODUCT", 91, 93], ["S1 subunit", "PROTEIN", 58, 68], ["S2 subunit", "PROTEIN", 91, 101], ["Receptor binding", "PROBLEM", 0, 16], ["S2", "ANATOMY", 91, 93]]], ["The S2 subunit of S protein facilitates internalization of the virus (Lau et al., 2020).", [["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["S protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["S2 subunit", "PROTEIN", 4, 14], ["S protein", "PROTEIN", 18, 27], ["the virus", "PROBLEM", 59, 68]]], ["Apart from its role in the virus entry process, it represents a target for antibody-mediated neutralization as it is highly immunogenic; all of which make a good target to design vaccine and therapies.Clinical manifestations of SARS-CoV-2 infection ::: IntroductionThe first manifestation of the SARS-CoV-2 infection are ageusia and anosmia in the patients with COVID-19 infection (Passarelli et al., 2020).", [["SARS-CoV-2 infection", "DISEASE", 228, 248], ["SARS-CoV-2 infection", "DISEASE", 296, 316], ["ageusia", "DISEASE", 321, 328], ["anosmia", "DISEASE", 333, 340], ["COVID-19", "CHEMICAL", 362, 370], ["infection", "DISEASE", 371, 380], ["SARS-CoV-2", "ORGANISM", 228, 238], ["SARS-CoV-2", "ORGANISM", 296, 306], ["patients", "ORGANISM", 348, 356], ["patients", "SPECIES", 348, 356], ["SARS-CoV", "SPECIES", 228, 236], ["SARS-CoV-2", "SPECIES", 296, 306], ["antibody-mediated neutralization", "TREATMENT", 75, 107], ["design vaccine", "TREATMENT", 172, 186], ["therapies", "TREATMENT", 191, 200], ["SARS", "PROBLEM", 228, 232], ["the SARS", "PROBLEM", 292, 300], ["CoV-2 infection", "PROBLEM", 301, 316], ["ageusia", "PROBLEM", 321, 328], ["anosmia", "PROBLEM", 333, 340], ["COVID-19 infection", "PROBLEM", 362, 380], ["virus", "OBSERVATION", 27, 32], ["neutralization", "OBSERVATION", 93, 107], ["SARS", "OBSERVATION", 228, 232], ["infection", "OBSERVATION", 239, 248], ["infection", "OBSERVATION", 371, 380]]], ["The other common manifestations are fever, cough, dyspnea, and myalgias and/or fatigue in COVID-19 patients (Meo et al., 2020).", [["fever", "DISEASE", 36, 41], ["cough", "DISEASE", 43, 48], ["dyspnea", "DISEASE", 50, 57], ["myalgias", "DISEASE", 63, 71], ["fatigue", "DISEASE", 79, 86], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["fever", "PROBLEM", 36, 41], ["cough", "PROBLEM", 43, 48], ["dyspnea", "PROBLEM", 50, 57], ["myalgias", "PROBLEM", 63, 71], ["fatigue", "PROBLEM", 79, 86], ["fever", "OBSERVATION", 36, 41], ["myalgias", "OBSERVATION", 63, 71]]], ["However, it is not limited to the above symptoms alone.", [["the above symptoms", "PROBLEM", 30, 48]]], ["The other symptoms may include the following:(i)Ataxia, headache, dizziness, and loss of consciousness, which suggest a potential for neural involvement (Baig and Sanders, 2020).(ii)Diarrhea (de Souza et al., 2020).(iii)Subacute thyroiditis (SAT) (Brancatella et al., 2020).(iv)Nausea and vomiting (Song et al., 2020).(v)In severe case, there may be acute respiratory distress syndrome or even multi-organ failure (Li et al., 2020).(vi)Skin manifestations like rashes on the back of trunk, and urticaria (Tammaro et al., 2020).", [["neural", "ANATOMY", 134, 140], ["respiratory", "ANATOMY", 356, 367], ["multi-organ", "ANATOMY", 394, 405], ["Skin", "ANATOMY", 436, 440], ["back", "ANATOMY", 475, 479], ["trunk", "ANATOMY", 483, 488], ["Ataxia", "DISEASE", 48, 54], ["headache", "DISEASE", 56, 64], ["dizziness", "DISEASE", 66, 75], ["loss of consciousness", "DISEASE", 81, 102], ["Diarrhea", "DISEASE", 182, 190], ["thyroiditis", "DISEASE", 229, 240], ["SAT", "DISEASE", 242, 245], ["Nausea", "DISEASE", 278, 284], ["vomiting", "DISEASE", 289, 297], ["respiratory distress syndrome", "DISEASE", 356, 385], ["multi-organ failure", "DISEASE", 394, 413], ["rashes", "DISEASE", 461, 467], ["urticaria", "DISEASE", 494, 503], ["Skin", "ORGAN", 436, 440], ["trunk", "ORGANISM_SUBDIVISION", 483, 488], ["The other symptoms", "PROBLEM", 0, 18], ["Ataxia", "PROBLEM", 48, 54], ["headache", "PROBLEM", 56, 64], ["dizziness", "PROBLEM", 66, 75], ["loss of consciousness", "PROBLEM", 81, 102], ["Diarrhea", "PROBLEM", 182, 190], ["Subacute thyroiditis (SAT)", "PROBLEM", 220, 246], ["Nausea", "PROBLEM", 278, 284], ["vomiting", "PROBLEM", 289, 297], ["acute respiratory distress syndrome", "PROBLEM", 350, 385], ["multi-organ failure", "PROBLEM", 394, 413], ["Skin manifestations", "PROBLEM", 436, 455], ["rashes on the back of trunk", "PROBLEM", 461, 488], ["urticaria", "PROBLEM", 494, 503], ["Subacute", "OBSERVATION_MODIFIER", 220, 228], ["thyroiditis", "OBSERVATION", 229, 240], ["may be", "UNCERTAINTY", 343, 349], ["acute", "OBSERVATION_MODIFIER", 350, 355], ["respiratory distress", "OBSERVATION", 356, 376], ["multi-organ", "ANATOMY", 394, 405], ["failure", "OBSERVATION", 406, 413], ["Skin", "ANATOMY", 436, 440], ["manifestations", "OBSERVATION", 441, 455], ["rashes", "OBSERVATION", 461, 467], ["back", "ANATOMY", 475, 479], ["trunk", "ANATOMY", 483, 488], ["urticaria", "ANATOMY", 494, 503]]]]}